0001104659-15-076246.txt : 20151109 0001104659-15-076246.hdr.sgml : 20151109 20151105161142 ACCESSION NUMBER: 0001104659-15-076246 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151105 DATE AS OF CHANGE: 20151105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: THERAVANCE INC CENTRAL INDEX KEY: 0001080014 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943265960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30319 FILM NUMBER: 151200751 BUSINESS ADDRESS: STREET 1: 951 GATEWAY BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502389600 MAIL ADDRESS: STREET 1: 951 GATEWAY BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MEDICINE INC DATE OF NAME CHANGE: 20000302 10-Q 1 a15-17874_110q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 000-30319

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		94-3265960
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

951 Gateway Boulevard

South San Francisco, CA 94080

(Address of Principal Executive Offices)

(650) 238-9600

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer x		Accelerated filer o

Non-accelerated filer o		Smaller reporting company o
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

The number of shares of registrant’s common stock outstanding on October 30, 2015 was 117,425,815.

Table of Contents

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements
Condensed Consolidated Balance Sheets as of September 30, 2015 (unaudited) and December 31, 2014	3
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2015 and 2014 (unaudited)	4
Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2015 and 2014 (unaudited)	5
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2015 and 2014 (unaudited)	6
Notes to Condensed Consolidated Financial Statements (unaudited)	7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3. Quantitative and Qualitative Disclosures About Market Risk	25

Item 4. Controls and Procedures	25

PART II. OTHER INFORMATION

Item 1A. Risk Factors	26

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	39

Item 6. Exhibits	40

Signatures	41
Exhibits

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

THERAVANCE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

	September 30,			December 31,
	2015			2014
	(unaudited)			*
Assets
Current assets:
Cash and cash equivalents	$	78,746		$	96,800
Short-term marketable securities	127,446			143,698
Related party receivables from collaborative arrangements	16,947			10,550
Prepaid expenses and other current assets	615			1,134
Total current assets	223,754			252,182
Marketable securities	—			42,856
Property and equipment, net	248			324
Capitalized fees paid to a related party, net	197,824			208,191
Other assets	15,805			18,101
Total assets	$	437,631		$	521,654

Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable	$	154		$	—
Payable to Theravance Biopharma, Inc.	—			1,056
Accrued personnel-related expenses	1,392			1,959
Accrued interest payable	6,390			7,551
Other accrued liabilities	2,457			2,108
Deferred revenue	885			1,082
Total current liabilities	11,278			13,756
Convertible subordinated notes, due 2023	255,109			255,109
Non-recourse notes, due 2029	488,976			470,527
Deferred rent	100			105
Other long-term liabilities	1,847			1,718
Deferred revenue	3,320			3,788
Commitments and contingencies (Notes 3, 6, and 9)
Stockholders’ deficit:
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding	—			—
Common stock: $0.01 par value, 200,000 shares authorized, 117,575 and 116,445 shares issued as of September 30, 2015 and December 31, 2014, respectively	1,176			1,164
Treasury stock: 150 shares as of September 30, 2015 and December 31, 2014	(3,263		)	(3,263		)
Additional paid-in capital	1,375,805			1,452,504
Accumulated other comprehensive income (loss)	11			(87		)
Accumulated deficit	(1,696,728		)	(1,673,667		)
Total stockholders’ deficit	(322,999		)	(223,349		)

Total liabilities and stockholders’ deficit	$	437,631		$	521,654

See accompanying notes to condensed consolidated financial statements.

* Condensed consolidated balance sheet as of December 31, 2014 has been derived from audited consolidated financial statements.

Table of Contents

THERAVANCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2015			2014			2015			2014

Royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of $3,455 and $3,233 for the three months ended September 30, 2015 and 2014 and $10,367 and $7,611 for the nine months ended September 30, 2015 and 2014	$	13,341		$	729		$	30,449		$	342
Revenue from collaborative arrangements from a related party, net	221			270			664			811
Total net revenue	13,562			999			31,113			1,153

Operating expenses:
Research and development	547			1,909			1,897			6,721
General and administrative	4,581			8,632			14,929			28,491
Total operating expenses	5,128			10,541			16,826			35,212

Income (loss) from operations	8,434			(9,542		)	14,287			(34,059		)

Other income (expense), net	(45		)	255			1,117			335
Interest income	90			93			291			446
Interest expense	(13,063		)	(12,355		)	(38,756		)	(24,326		)
Loss from continuing operations before income taxes	(4,584		)	(21,549		)	(23,061		)	(57,604		)
Income tax expense (benefit)	—			(278		)	—			—
Loss from continuing operations, net of tax	(4,584		)	(21,271		)	(23,061		)	(57,604		)

Loss from discontinued operations (Notes 1 and 11)	—			—			—			(94,934		)
Net loss	$	(4,584	)	$	(21,271	)	$	(23,061	)	$	(152,538	)

Basic and diluted net loss per share:
Continuing operations, net of tax	$	(0.04	)	$	(0.19	)	$	(0.20	)	$	(0.52	)
Discontinued operations	—			—			—			(0.85		)
Basic and diluted net loss per share	$	(0.04	)	$	(0.19	)	$	(0.20	)	$	(1.37	)

Cash dividend declared per common share	$	0.25		$	0.25		$	0.75		$	0.25

Shares used to compute basic and diluted net loss per share	115,787			113,100			115,381			111,306

See accompanying notes to condensed consolidated financial statements.

Table of Contents

THERAVANCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2015			2014			2015			2014

Net loss	$	(4,584	)	$	(21,271	)	$	(23,061	)	$	(152,538	)

Other comprehensive income:
Unrealized gain (loss) on marketable securities, net	21			(3,903		)	1,302			(359		)
Less: Realized gain on marketable securities, net	—			—			(1,204		)	—
Comprehensive loss	$	(4,563	)	$	(25,174	)	$	(22,963	)	$	(152,897	)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

THERAVANCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2015			2014
Cash flows from operating activities
Net loss	$	(23,061	)	$	(152,538	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	10,449			8,720
Stock-based compensation	5,223			26,013
Amortization of premium on short-term investments	526			1,539
Interest added to the principal balance of the non-recourse term notes due 2029	18,449			—
Realized gain on sale of marketable securities, net	(1,204		)	—
Amortization of debt issuance costs	2,296			1,550
Other non-cash items	(2		)	(2		)
Changes in operating assets and liabilities:
Accounts receivable	—			74
Receivables from collaborative arrangements	(6,397		)	(833		)
Prepaid expenses and other current assets	519			(52		)
Inventories	—			(1,908		)
Other assets	—			561
Accounts payable	154			(7,122		)
Payable to Theravance Biopharma, Inc., net	(1,056		)	(16,166		)
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	(851		)	71
Accrued interest payable	(1,161		)	16,667
Deferred rent	(5		)	224
Deferred revenue	(665		)	(2,911		)
Net cash provided by (used in) operating activities	3,214			(126,113		)

Cash flows from investing activities
Purchases of property and equipment	(6		)	(556		)
Purchases of marketable securities	(86,523		)	(228,899		)
Maturities of marketable securities	89,311			292,666
Sales of marketable securities	57,098			5,000
Capitalized fees paid to a related party	—			(125,000		)
Payments received on notes receivable	—			140
Net cash provided by (used in) investing activities	59,880			(56,649		)

Cash flows from financing activities
Payments of cash dividends to stockholders	(87,144		)	(28,338		)
Proceeds from issuances of common stock, net	5,996			35,629
Cash and cash equivalents contributed to Theravance Biopharma, Inc.	—			(277,541		)
Change in restricted cash	—			(5,600		)
Proceeds from issuances of notes payable, net of debt issuance costs	—			434,677
Net cash (used in) provided by financing activities	(81,148		)	158,827

Net decrease in cash and cash equivalents	(18,054		)	(23,935		)
Cash and cash equivalents at beginning of period	96,800			143,510

Cash and cash equivalents at end of period	$	78,746		$	119,575

Supplemental disclosure of cash flow information
Cash paid for interest	$	19,169		$	6,109

Supplemental disclosure of noncash information
Contribution of net assets, excluding cash and cash equivalents to Theravance Biopharma, Inc.	$	—		$	125,337
Conversion of convertible subordinated notes into common stock	$	—		$	32,391
Guarantee issued in connection with the Spin-Off (Note 9)	$	—		$	1,300

See accompanying notes to condensed consolidated financial statements.

Table of Contents

THERAVANCE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Description of Operations and Summary of Significant Accounting Policies

Description of Operations

Theravance, Inc. (“Theravance”, the “Company”, or “we” and other similar pronouns) is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Theravance’s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Theravance and GSK. Under the Long-Acting Beta 2 Agonist (“LABA”) Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the “GSK Agreements”), Theravance is eligible to receive the associated royalty revenues from RELVAR ® /BREO ® ELLIPTA ® , ANORO® ELLIPTA ® and if approved and commercialized, VI monotherapy. Theravance is also entitled to 15% of any future payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (“TRC”), relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta 2 Agonist (“MABA”) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement (“LABA Collaboration”), which has been assigned to TRC other than RELVAR ®/BREO ® ELLIPTA ® , ANORO® ELLIPTA ® and VI monotherapy.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In our opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive loss and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2015 or any other period.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (“SEC”) on February 27, 2015.

Business Separation

On June 1, 2014, we separated our biopharmaceutical research and drug development operations from our late-stage partnered respiratory assets by transferring our research and drug development operations into our then wholly-owned subsidiary, Theravance Biopharma, Inc. (“Theravance Biopharma”). We contributed $393.0 million of cash, cash equivalents and marketable securities to Theravance Biopharma and all outstanding shares of Theravance Biopharma were then distributed to Theravance stockholders as a pro-rata dividend distribution on June 2, 2014 by issuing one ordinary share of Theravance Biopharma for every 3.5 shares of our common stock to stockholders of record on May 15, 2014 (the “Spin-Off”). The Spin-Off resulted in Theravance Biopharma becoming an independent, publicly traded company.

The results of operations for the former research and drug development operations conducted by us and by Theravance Biopharma until June 1, 2014 are included as part of this report as discontinued operations for the three and nine months ended September 30, 2014. Refer to Note 11 “Discontinued Operations” for further information.

Variable Interest Entities

We evaluate our ownership, contractual and other interest in entities to determine if they are variable interest entities (“VIE”), whether we have a variable interest in those entities and the nature and extent of those interests. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. We consolidate the financial results of TRC, which we have determined to be a VIE, because we have the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. The financial position and results of operations of TRC are not material for the periods presented.

Table of Contents

Recently Issued Accounting Pronouncements Not Yet Adopted

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), requiring an entity to recognize the amount of revenue to which it expects to be entitled to in exchange for the transfer of promised goods or services to customers. The new standard will replace nearly all existing revenue recognition guidance under GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date by one year. Thus, the new standard will be effective for us beginning January 1, 2018, at which time we may adopt the new standard under either the full retrospective method or the modified retrospective method. Early adoption on or after January 1, 2017 would be permitted. We are currently evaluating the effect that the new standard will have on our consolidated financial statements and related disclosures.

In April 2015, the FASB issued ASU 2015-03, Interest — Imputation of Interest, to simplify the presentation of debt issuance costs. This standard amends existing guidance to require the presentation of debt issuance costs associated with term loans in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It will be effective for us on January 1, 2016, with early adoption permitted. We plan to adopt ASU 2015-03 on January 1, 2016. Upon adoption of ASU 2015-03, we will apply the guidance retrospectively to all periods presented and classify our debt issuance costs, which are currently included in other assets in the condensed consolidated financial statements, as a deduction to our long-term debt.

2. Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less Restricted Stock Awards (“RSAs”) subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common shares had been issued for other dilutive securities.

For the three and nine months ended September 30, 2015 and 2014, diluted and basic net loss per common share were identical since potential common shares were excluded from the calculation, as their effect was anti-dilutive.

Anti-Dilutive Securities

The following common equivalent shares were not included in the computation of diluted net loss per share because their effect was anti-dilutive:

	Three Months Ended September 30,		Nine Months Ended September 30,
(In thousands)	2015 (1)	2014	2015 (2)	2014
Outstanding options and awards granted under equity incentive plan and employee stock purchase plan	5,070	6,771	5,459	6,218
Unvested RSAs	1,489	1,782	1,738	1,782
Shares issuable upon conversion of convertible subordinated notes	12,904	12,100	12,904	12,100
	19,463	20,653	20,101	20,100

(1) Includes 4.0 million options, 0.3 million restricted stock units, and 0.8 million unvested RSAs retained by former employees who were transferred to Theravance Biopharma in connection with the Spin-Off during the three months ended September 30, 2015. Subsequent to the Spin-Off, stock-based compensation expense associated with the awards held by Theravance Biopharma employees granted prior to the Spin-Off is recognized by Theravance Biopharma.

(2) Includes 4.2 million options, 0.4 million restricted stock units, and 1.0 million unvested RSAs retained by former employees who were transferred to Theravance Biopharma in connection with the Spin-Off during the nine months ended September 30, 2015. Subsequent to the Spin-Off, stock-based compensation expense associated with the awards held by Theravance Biopharma employees granted prior to the Spin-Off is recognized by Theravance Biopharma.

Table of Contents

3. Collaborative Arrangements

Net Revenue from Collaborative Arrangements

Net revenue from collaborative arrangements from continuing operations relates to our collaborative arrangement with GSK. Net revenue from other collaborative arrangements is reflected as discontinued operations in the condensed consolidated statements of operations. Refer to Notes 1 and 11, “Description of Operations and Summary of Significant Accounting Policies” and “Discontinued Operations” for further information.

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2015			2014			2015			2014
Royalties from a related party	$	16,796		$	3,962		$	40,816		$	7,953
Less: amortization of capitalized fees paid to a related party	(3,455		)	(3,233		)	(10,367		)	(7,611		)
Royalty revenue	13,341			729			30,449			342
Strategic alliance - MABA program	221			270			664			811
Total net revenue from GSK	$	13,562		$	999		$	31,113		$	1,153

LABA Collaboration

As a result of the launch and approval of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® in the U.S., Japan and Europe, in accordance with the GSK Agreements, we were obligated to pay milestone fees to GSK totaling $220.0 million, all of which was paid as of December 31, 2014. Although we have no further milestone payment obligations to GSK, we continue to have ongoing development and commercialization activities under the GSK Agreements that are expected to continue over the life of the agreements. The milestone fees paid to GSK were recognized as capitalized fees paid to a related party, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product.

We are entitled to receive annual royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion. Sales of single-agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO® ELLIPTA®, royalties are upward tiering and range from 6.5% to 10%.

Amortization expense resulting from the milestone fees paid to GSK, which are recognized as capitalized fees paid to a related party, is a non-cash reduction to royalty revenue. In periods when amortization expense exceeded amounts recognized for royalty revenue, negative revenue was reported in our condensed consolidated statements of operations.

Agreements Entered into with GSK in Connection with the Spin-Off

On March 3, 2014, in contemplation of the Spin-Off, we, Theravance Biopharma and GSK entered into a series of agreements, including amendments to the GSK Agreements, clarifying how the companies would implement the Spin-Off and operate following the Spin-Off. Pursuant to a three-way master agreement, by and among us, Theravance Biopharma and GSK, we agreed to sell a certain number of Theravance Biopharma shares withheld from a taxable dividend of Theravance Biopharma shares to GSK. After such Theravance Biopharma shares were sent to the transfer agent, we agreed to purchase the Theravance Biopharma shares from the transfer agent, rather than have them sold on the open market, in order to satisfy tax withholdings. GSK had a right to purchase these shares of Theravance Biopharma from us, but this right expired unexercised. During the nine months ended September 30, 2015, we sold all 436,802 ordinary shares of Theravance Biopharma that we held as of December 31, 2014. Refer to Note 4 “Available-for-Sale Securities and Fair Value Measurements” for further information.

GSK Contingent Payments and Revenue

The potential future contingent payments receivable related to the MABA program of $363.0 million are not deemed substantive milestones due to the fact that the achievement of the event underlying the payment predominantly relates to GSK’s performance of future development, manufacturing and commercialization activities for product candidates after licensing the program.

Table of Contents

4. Available-for-Sale Securities and Fair Value Measurements

Available-for-Sale Securities

The classification of available-for-sale securities in the condensed consolidated balance sheets is as follows:

(In thousands)	September 30, 2015		December 31, 2014
Cash and cash equivalents	$	76,077	$	95,090
Short-term marketable securities	127,446		143,698
Marketable securities	—		42,856
Total	$	203,523	$	281,644

The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:

	September 30, 2015
(In thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
U.S. government securities	$	7,503	$	3	$	—		$	7,506
U.S. government agencies	69,965		9		(2		)	69,972
Corporate notes	27,485		3		(2		)	27,486
Commercial paper	54,702		—		—			54,702
Money market funds	43,857		—		—			43,857
Total	$	203,512	$	15	$	(4	)	$	203,523

	December 31, 2014
(In thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Other Than Temporary Impairment Loss			Estimated Fair Value
U.S. government securities	$	30,019	$	24	$	—		$	—		$	30,043
U.S. government agencies	34,756		6		(12		)	—			34,750
Corporate notes	80,880		5		(110		)	—			80,775
Commercial paper	34,469		—		—			—			34,469
Ordinary shares of Theravance Biopharma	10,269		—		—			(3,752		)	6,517
Money market funds	95,090		—		—			—			95,090
Total	$	285,483	$	35	$	(122	)	$	(3,752	)	$	281,644

As of September 30, 2015, all of the available-for-sale securities had contractual maturities within one year and the weighted average duration of marketable securities was approximately three months. We do not intend to sell the investments that are in an unrealized loss position, and it is unlikely that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. We have determined that the gross unrealized losses on our marketable securities as of September 30, 2015 were temporary in nature. As of September 30, 2015, all marketable securities with unrealized losses have been in a loss position for less than twelve months.

During the nine months ended September 30, 2015, we recognized a gain of $1.2 million from the sale of all of the ordinary shares of Theravance Biopharma that we held as of December 31, 2014, which is included in other income (expense), net in the condensed consolidated statement of operations. In addition, we sold other available-for-sale securities totaling $49.4 million, and the related realized gains and losses were not significant during the nine months ended September 30, 2015.

Table of Contents

Fair Value Measurements

Our available-for-sale securities are measured at fair value on a recurring basis and our debt is carried at the amortized cost basis. The estimated fair values were as follows:

	Estimated Fair Value Measurements as of September 30, 2015 Using:
Types of Instruments	Quoted Price in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In thousands)	Level 1		Level 2		Level 3		Total
Assets
U.S. government securities	$	7,506	$	—	$	—	$	7,506
U.S. government agencies	—		69,972		—		69,972
Corporate notes	—		27,486		—		27,486
Commercial paper	—		54,702		—		54,702
Money market funds	43,857		—		—		43,857
Total assets measured at estimated fair value	$	51,363	$	152,160	$	—	$	203,523
Liabilities
Convertible subordinated notes due 2023	$	—	$	169,362	$	—	$	169,362
Non-recourse notes due 2029	—		464,527		—		464,527
Total fair value of liabilities	$	—	$	633,889	$	—	$	633,889

	Estimated Fair Value Measurements as of December 31, 2014 Using:
Types of Instruments	Quoted Price in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In thousands)	Level 1		Level 2		Level 3		Total
Assets
U.S. government securities	$	30,043	$	—	$	—	$	30,043
U.S. government agencies	—		34,750		—		34,750
Corporate notes	—		80,775		—		80,775
Commercial paper	—		34,469		—		34,469
Ordinary shares of Theravance Biopharma	6,517		—		—		6,517
Money market funds	95,090		—		—		95,090
Total assets measured at estimated fair value	$	131,650	$	149,994	$	—	$	281,644
Liabilities
Convertible subordinated notes due 2023	$	—	$	197,095	$	—	$	197,095
Non-recourse notes due 2029	—		456,411		—		456,411
Total fair value of liabilities	$	—	$	653,506	$	—	$	653,506

The fair value of our marketable securities classified within Level 2 were derived from observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications.

The fair value of our convertible subordinated notes due 2023 and non-recourse notes due 2029 is based on recent trading prices of the instruments, if applicable, or pricing models that utilize current observable market characteristics for similar types of instruments.

Table of Contents

5. Capitalized Fees Paid to a Related Party

Capitalized fees paid to a related party, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:

September 30, 2015

December 31, 2014

Weighted

Average

Remaining

Amortization

Gross

Net

Gross

Net

Period

Carrying

Accumulated

Carrying

Accumulated

Carrying

(In thousands)

(Years)

Value

Amortization

Value

Amortization

Value

Approval and launch related milestone payments under the LABA Collaboration

14.4

220,000

(22,176

)

197,824

220,000

(11,809

)

208,191

These milestone fees are being amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization expense recorded as a reduction in revenue from collaborative arrangements. Additional information regarding these milestone fees is included in Note 3, “Collaborative Arrangements”. Amortization expense for the three and nine months ended September 30, 2015 was $3.5 million and $10.4 million, respectively. Amortization expense for the three and nine months ended September 30, 2014 was $3.2 million and $7.6 million, respectively. As of September 30, 2015, the remaining estimated amortization expense is $3.5 million for 2015, $13.8 million for each of the years from 2016 to 2020, and $125.3 million thereafter.

6. Stock-Based Compensation

Equity Incentive Plan

The 2012 Equity Incentive Plan (the “2012 Plan”) provides for the granting of incentive stock options, nonstatutory stock options, RSAs, restricted stock units (“RSUs”) and stock appreciation rights to employees, non-employee directors and consultants. As of September 30, 2015, the total shares remaining available for issuance under the 2012 Plan were 3,200,521.

Employee Stock Purchase Plan

Under the 2004 Employee Stock Purchase Plan (the “ESPP”), our employees may purchase common stock through payroll deductions at a price equal to 85% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The ESPP provides for consecutive and overlapping offering periods of 24 months in duration, with each offering period composed of four consecutive six-month purchase periods. The purchase periods end on either May 15 or November 15. ESPP contributions are limited to a maximum of 15% of an employee’s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period is 2,500. An employee may not purchase shares with a value greater than $25,000 in any calendar year.

As of September 30, 2015, total shares remaining available for issuance under the ESPP were 278,971.

Performance-Contingent RSAs

Since 2011, the Compensation Committee of our Board of Directors (the “Compensation Committee”) have approved grants of performance-contingent RSAs to senior management and a non-executive officer. Generally, these awards have dual triggers of vesting based upon the achievement of certain performance goals by a pre-specified date, as well as a requirement for continued employment. Recognition of stock-based compensation expense begins when the performance goals are deemed probable of achievement.

Included in these performance-contingent RSAs is the grant of 1,290,000 special long-term retention and incentive performance-contingent RSAs to senior management in 2011. The awards have dual triggers of vesting based upon the achievement of certain performance conditions over a six-year timeframe from 2011 through December 31, 2016 and require continued employment. As of March 31, 2014, we determined that the achievement of the requisite performance conditions for vesting of the first tranche of these awards was probable and the total stock-based compensation expense of $7.0 million for the first tranche was fully recognized through May 2014. In connection with the Spin-Off, our Compensation Committee approved the modification of the remaining tranches related to these awards as the performance conditions associated with the remaining portions of these awards were unlikely to be consistent with the new strategies of each company following the Spin-Off. The modification acknowledged the Spin-Off and

Table of Contents

permitted recognition of achievement of certain of the original performance conditions that were met prior to the Spin-Off, triggering service-based vesting for a portion of the equity awards, for which $3.8 million was recognized by us during the twelve-month period that commenced in June 2014. The remaining 63,000 RSAs for which service-based vesting was not triggered at the time of the Spin-Off remain subject to new performance conditions (as well as the original service conditions). In addition, the RSAs for which both the performance and service-based conditions were not achieved prior to the Spin-Off were entitled to the pro rata dividend distribution made by Theravance on June 2, 2014 of one ordinary share of Theravance Biopharma for every 3.5 shares of Theravance common stock subject to their awards, which will also be subject to the same new performance and service conditions as the original RSAs to which they relate. As of September 30, 2015, we determined that the achievement of the requisite performance conditions was not probable and, as a result, no compensation cost was recognized for the remaining equity awards.

Stock-Based Compensation Expense

Stock-based compensation expense is included in the condensed consolidated statements of operations as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2015		2014		2015		2014
Research and development	$	220	$	1,357	$	687	$	2,589
General and administrative	1,248		3,375		4,536		11,795
Stock-based compensation from continuing operations	1,468		4,732		5,223		14,384
Stock-based compensation from discontinued operations	—		—		—		11,629
Total stock-based compensation expense	$	1,468	$	4,732	$	5,223	$	26,013

As of September 30, 2015, unrecognized compensation expense, net of expected forfeitures for awards expected to vest, was as follows: $1.7 million related to unvested stock options; $2.1 million related to unvested RSUs; and $9.1 million related to unvested RSAs (including performance-contingent RSAs for which the performance milestones were determined to be probable of achievement).

At the time of the Spin-Off, all outstanding stock options, RSUs and RSAs held by former employees and directors, who transferred to Theravance Biopharma, were retained by them. As the vesting of these options and awards is based on continuing employment or service with Theravance Biopharma, all stock-based compensation expense associated with these options and awards is recognized by Theravance Biopharma.

Valuation Assumptions

No options were granted for the three and nine months ended September 30, 2015.

The range of assumptions used to estimate fair value of employee stock options granted during the three and nine months ended September 30, 2014 was as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2014		2014
Risk-free interest rate	1.97%		1.64%-2.05%
Expected term (in years)	6		5-6
Volatility	58%		52%-60%
Dividend yield	4%		4%
Weighted-average estimated fair value of stock options granted	$	13.23	$	15.92

7. Long-Term Debt

Our long-term debt consists of:

(In thousands)	September 30, 2015		December 31, 2014
Convertible Subordinated Notes due 2023	$	255,109	$	255,109
Non-Recourse Notes Payable due 2029	488,976		470,527
Total Long-Term Debt	$	744,085	$	725,636

Table of Contents

Convertible Subordinated Notes Due 2023

In January 2013, we completed an underwritten public offering of $287.5 million aggregate principal amount of unsecured convertible subordinated notes, which will mature on January 15, 2023 (the “2023 Notes”). The financing raised proceeds, net of debt issuance costs, of approximately $281.2 million, less $36.8 million to purchase two privately-negotiated capped call option transactions in connection with the issuance of the notes. The 2023 Notes bear interest at the rate of 2.125% per year that is payable semi-annually in arrears in cash on January 15 and July 15 of each year, beginning on July 15, 2013.

The 2023 Notes were convertible, at the option of the holder, into shares of our common stock at an initial conversion rate of 35.9903 shares per $1,000 principal amount of the 2023 Notes, subject to adjustment in certain circumstances, which represents an initial conversion price of approximately $27.79 per share. Following the Spin-Off of Theravance Biopharma, a number of adjustments to the initial conversion rate have been made as described below. Holders of the 2023 Notes will be able to require us to repurchase some or all of their notes upon the occurrence of a Change of Control or a Termination of Trading (as contractually defined) following the original issuance of the 2023 Notes at 100% of the principal amount of the notes being repurchased plus accrued and unpaid interest. We may not redeem the 2023 Notes prior to their stated maturity date.

In connection with the offering of the 2023 Notes, we entered into two privately-negotiated capped call option transactions with a single counterparty. The capped call option transaction is an integrated instrument consisting of a call option on our common stock purchased by us with a strike price equal to the initial conversion price of $27.79 per share for the underlying number of shares and a cap price of $38.00 per share, both of which are subject to adjustments consistent with the 2023 Notes. The cap component is economically equivalent to a call option sold by us for the underlying number of shares with an initial strike price of $38.00 per share. As an integrated instrument, the settlement of the capped call coincides with the due date of the convertible debt. Upon settlement, we would receive from our hedge counterparty a number of shares of our common shares that would range from zero, if the stock price was below $27.79 per share, to a maximum of 2,779,659 shares, if the stock price is above $38.00 per share. However, if the market price of our common stock, as measured under the terms of the capped call transactions, exceeds $38.00 per share, there is no incremental anti-dilutive benefit from the capped call.

In accordance with the agreement for the 2023 Notes, the conversion rate was adjusted as a result of the completion of the Spin-Off of Theravance Biopharma. The conversion rate was adjusted based on the conversion rate immediately prior to the record date for the Spin-Off and the average of the stock dividend distributed to our common stockholders and our stock prices. This resulted in an adjusted conversion rate of 46.9087 shares per $1,000 principal amount of the 2023 Notes, which represents an adjusted conversion price of approximately $21.32 per share. As a result of the conversion rate adjustment, the capped call strike price and cap price were also adjusted accordingly to $21.32 and $29.16, respectively. On July 15, 2014, certain holders of the 2023 Notes converted their notes into 1,519,402 shares of our common stock at the adjusted conversion price of $21.32 per share. In connection with the partial conversion of the 2023 Notes, we received 149,645 shares of our common stock from our capped call option counterparty and the shares of common stock received were recorded as treasury stock.

In connection with the payments of subsequent cash dividends through September 30, 2015, the adjusted conversion rate with respect to our 2023 Notes was further adjusted from 46.9087 shares of our common stock per $1,000 principal amount of the 2023 Notes to 50.5818 shares of our common stock per $1,000 principal amount of the 2023 Notes, which represents an adjusted conversion price of approximately $19.77 per share. As a result of the conversion rate adjustment, the capped call strike price and cap price were also adjusted accordingly to $19.77 and $27.04.

Non-Recourse Notes Due 2029

In April 2014, we entered into certain note purchase agreements relating to the private placement of $450.0 million aggregate principal amount of non-recourse fixed rate term notes due 2029 (the “2029 Notes”) issued by our wholly-owned subsidiary.

The 2029 Notes are secured by a security interest in a segregated bank account established to receive 40% of royalties due to us under the LABA Collaboration with GSK commencing on April 1, 2014 and ending upon the earlier of full repayment of principal or May 15, 2029. The amounts in the segregated bank account can only be used to make interest and principal payments on the 2029 Notes. As of September 30, 2015, the balance of the segregated bank account was not material.

The 2029 Notes bear an annual interest rate of 9%, with interest and principal paid quarterly beginning November 15, 2014. The 2029 Notes may be redeemed at any time prior to maturity, in whole or in part, at specified redemption premiums. Prior to May 15, 2016, in the event that the specified portion of royalties received in a quarter is less than the interest accrued for the quarter, the principal amount of the 2029 Notes will increase by the interest shortfall amount for that period. Since issuance, $39.0 million of interest expense has been added to the principal balance of the 2029 Notes, of which $5.6 million and $18.4 million was added during the three and nine months ended September 30, 2015. No interest expense was added to the principal during the three and nine months

Table of Contents

ended September 30, 2014. Since the principal and interest payments on the 2029 Notes are based on royalties from GSK for product sales recorded, which will vary from quarter to quarter and are unknown to us, the 2029 Notes may be repaid prior to the final maturity date in May 2029.

In connection with the sale of the 2029 Notes, we incurred approximately $15.3 million in debt issuance costs, which are being amortized to interest expense over the estimated life of the 2029 Notes.

8. Shareholders’ Deficit

For the nine months ended September 30, 2015, options to purchase 111,156 shares of our common stock were exercised at a weighted-average exercise price of $13.75 per share, for total cash proceeds of approximately $1.5 million. For the nine months ended September 30, 2014, options to purchase 1,127,000 shares of our common stock were exercised at a weighted-average exercise price of $14.09 per share, for total cash proceeds of approximately $15.9 million.

During the nine months ended September 30, 2015, GSK purchased 424,081 shares of our common stock pursuant to its periodic “top-up” rights under our Amended and Restated Governance Agreement, dated as of June 4, 2004, as amended, among us, GSK and certain GSK affiliates (the “Governance Agreement”), for an aggregate purchase price of approximately $6.5 million. GSK’s periodic “top-up” rights terminated with the expiration of the Governance Agreement in September 2015.

9. Commitments and Contingencies

Lease Guarantee

Upon the Spin-Off, our facility leases in South San Francisco, California were assigned to Theravance Biopharma. However, if Theravance Biopharma were to default on its lease obligations, we would be held liable by the landlord and thus, we have in substance guaranteed the lease payments for these facilities. We would also be responsible for lease-related payments including utilities, property taxes, and common area maintenance, which may be as much as the actual lease payments. As of September 30, 2015, the total remaining lease payments, which run through May 2020, were $29.1 million. The carrying value of this lease guarantee was $1.3 million as of September 30, 2015 and is reflected in other long-term liabilities in our condensed consolidated balance sheet.

Special Long-Term Retention and Incentive Cash Awards Program

In 2011, we granted special long-term retention and incentive cash bonus awards to certain employees. The awards have dual triggers of vesting based upon the achievement of certain performance conditions over a six-year timeframe from 2011 through December 31, 2016 and continued employment.

As of March 31, 2014, we determined that the achievement of the requisite performance conditions for the first tranche of these awards was probable and, as a result, $9.1 million of cash bonus expense was recognized for the three months ended March 31, 2014, the majority of which is included in discontinued operations in the condensed consolidated statements of operations. In May 2014, the total cash bonus of $9.5 million for the first tranche was paid.

In connection with the Spin-Off, the Compensation Committee approved the modification of the remaining tranches related to these awards as the performance conditions associated with the remaining portions of these awards were unlikely to be consistent with the new strategies of each company following the Spin-Off. The modification acknowledged the Spin-Off and permitted recognition of achievement of certain of the original performance conditions that were met prior to the Spin-Off, triggering service-based vesting for a portion of the cash awards. The amount due by us under these modified cash bonus awards of $0.5 million was fully paid in June 2015. The remaining tranches of the cash awards were forfeited.

Table of Contents

10. Income Taxes

We did not record a provision for income taxes for the three and nine months ended September 30, 2015. The deferred tax assets remain fully offset by a valuation allowance or uncertain tax position liabilities.

As a part of the overall Spin-Off transaction on June 1, 2014, certain assets that were transferred by us to Theravance Biopharma resulted in taxable transfers pursuant to Section 367 of the Internal Revenue Code of 1986, as amended (the “Code”), or other applicable provisions of the Code and Treasury Regulations. The taxable gain attributable to the transfer of the certain assets to Theravance Biopharma was the excess of the fair market value of each asset transferred over our adjusted tax basis in such asset. The U.S. federal income tax gain on transfer of the assets to Theravance Biopharma was approximately $400 million. This taxable income was substantially offset by our net operating loss from 2014 and carryforwards from prior years resulting in a net impact of zero to income tax expenses during the nine months ended September 30, 2014.

11. Discontinued Operations

On June 1, 2014, we separated our research and drug development businesses from our late-stage partnered respiratory assets. For further information on the Spin-Off, refer to Note 1 “Description of Operations and Summary of Significant Accounting Policies”. The significant components of the research and drug development operations, which are presented as discontinued operations on the condensed consolidated statements of operations, were as follows:

	Nine Months Ended September 30,
(In thousands)	2015		2014
Net revenues (1)	$	—	$	3,129
Loss from discontinued operations (2)	—		(94,934		)

There was no impact of the discontinued operations after the Spin-Off to our revenues and expenses for the three months ended September 30, 2015 and 2014.

(1) Net revenues primarily consist of revenue from collaborative arrangements and product sales. Revenue from collaborative arrangements was recognized from our agreement with R-Pharm CJSC, which was transferred to Theravance Biopharma as a part of the Spin-Off. Product sales were generated from sales of VIBATIV® in the U.S. through a limited number of distributors, and title and risk of loss transfer upon receipt by these distributors. VIBATIV® was transferred to Theravance Biopharma as part of the Spin-Off. Healthcare providers ordered VIBATIV® through these distributors. Commencing in the first quarter of 2014, revenue on the sale of VIBATIV® was recorded on a sell-through basis, once the distributors sold the product to healthcare providers. Product sales were recorded net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns and other deductions.

(2) Included in the loss from discontinued operations for the three and nine months ended September 30, 2014 are reimbursements of research and development costs from our former collaborative arrangements, excluding GSK, which we accounted for as reductions to research and development expense. Reimbursement of research and development costs from discontinued operations from our collaborative arrangements was zero and $0.1 million for the three and nine months ended September 30, 2014. In addition, the loss from discontinued operations includes the additional stock-based compensation and cash bonus expense recognized due to the achievement of performance conditions under a special long-term retention and incentive equity and cash bonus awarded to certain employees in 2011. Refer to Note 6 “Stock-Based Compensation” and Note 9 “Commitment and Contingencies” for further information.

12. Subsequent Events

On October 28, 2015, we announced the acceleration of our capital return plan with a $150 million share repurchase program effective through the end of 2016 approved by our Board of Directors, replacing our quarterly dividend. As a component of the share repurchase plan, on October 30, 2015, we commenced a “modified Dutch auction” tender offer to purchase up to $75 million of our common stock, at a price per share of not less than $8.50 and not greater than $9.25, which will be contingent upon satisfaction of customary conditions.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

The information in this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve substantial risks, uncertainties and assumptions. All statements contained herein that are not of historical fact, including, without limitation, statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, intentions, expectations, goals and objectives, may be forward-looking statements. The words “anticipates,” “believes,” “could,” “designed,” “estimates,” “expects,” “goal,” “intends,” “may,” “objective,” “plans,” “projects,” “pursue,” “will,” “would” and similar expressions (including the negatives thereof) are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, expectations or objectives disclosed in our forward-looking statements and the assumptions underlying our forward-looking statements may prove incorrect. Therefore, you should not place undue reliance on our forward-looking statements. Actual results or events could materially differ from the plans, intentions, expectations and objectives disclosed in the forward-looking statements that we make. Factors that we believe could cause actual results or events to differ materially from our forward-looking statements include, but are not limited, to those discussed below in “Risk Factors” in Item 1A of Part II and in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Item 2 of Part I. All forward-looking statements in this document are based on information available to us as of the date hereof and we assume no obligation to update any such forward-looking statements on account of new information, future events or otherwise, except as required by law.

OVERVIEW

Executive Summary

Theravance, Inc. (“Theravance”, the “Company” or “we” and other similar pronouns) is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Theravance’s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Theravance and GSK. Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein collectively as the “GSK Agreements”), Theravance is eligible to receive the associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and if approved and commercialized, VI monotherapy. Theravance is also entitled to 15% of any future payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (“TRC”), relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (“MABA”) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement, which has been assigned to TRC other than RELVAR®/BREO®ELLIPTA®, ANORO® ELLIPTA® and VI monotherapy.

We have designed our company structure and organization to be tailored to our more focused activities following the Spin-Off, including managing our respiratory assets with GSK, the commercial and developmental obligations associated with the GSK Agreements, intellectual property, licensing operations, business development activities and providing for certain essential reporting and management functions of a public company. As of September 30, 2015, we had 13 employees. Our revenues currently consist of royalties and potential milestone payments, if any, from our respiratory partnership agreements with GSK.

Financial Highlights

For the nine months ended September 30, 2015, our net loss from our continuing operations was $23.1 million, a decrease of $34.5 million from $57.6 million for the nine months ended September 30, 2014. The decrease was primarily due to an increase in our royalty revenues, decrease in research and development expenses, and lower employee-related expenses, including stock-based

Table of Contents

compensation expense, as a result of decreased operations and headcount post Spin-Off, offset by an increase in interest expense from our non-recourse notes payable due 2029 (the “2029 Notes”). Cash, cash equivalents, and marketable securities, totaled $206.2 million as of September 30, 2015, a decrease of $77.1 million from December 31, 2014. The decrease was primarily due to payments of cash dividends of $87.1 million, partially offset by net proceeds of $6.0 million received from issuances of our common stock and cash provided by operations of $3.2 million.

Recent Developments

Declaration and Payment of Cash Dividends

On February 20, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on March 12, 2015. A total of $28.8 million was paid to our stockholders on March 31, 2015. On April 24, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on June 12, 2015. A total of $29.2 million was paid to our stockholders on June 30, 2015. On July 24, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on September 10, 2015. A total of $29.1 million was paid to our stockholders on September 30, 2015. Unvested RSAs and certain unvested RSUs as of the record date are also entitled to dividends, which will only be paid when the RSAs and such RSUs vest and are released. In connection with the payments of the cash dividends during the nine months ended September 30, 2015, the conversion rate with respect to our 2.125% Convertible Subordinated Notes due 2023 (the “2023 Notes”) was further adjusted in total from 48.3294 shares of our common stock per $1,000 principal amount of the 2023 Notes at December 31, 2014 to 50.5818 shares of our common stock per $1,000 principal amount of the 2023 Notes at September 30, 2015, which represents an adjusted conversion price of approximately $19.77 per share. As a result of the conversion rate adjustment, the capped call strike price and cap price were also adjusted accordingly to $19.77 and $27.04.

Share Repurchase Plan

On October 28, 2015, we announced the acceleration of our capital return plan with a $150 million share repurchase program effective through the end of 2016 approved by our Board of Directors, replacing our quarterly dividend. We currently intend to repurchase our shares under the program through a combination of the tender offer referred to below and, open market purchases, and may also repurchase shares through private transactions, exchange offers, additional tender offers or other means. The repurchase program will be funded using our working capital.

Our announcement of our share repurchase program does not obligate us to repurchase any specific dollar amount or number of shares of common stock. We will determine when, if and how to proceed with any repurchase transactions under the program, as well as the amount of any such repurchase transactions, based upon, among other things, the results of the tender offer and our evaluation of our liquidity and capital needs (including for strategic and other opportunities), our business, results of operations, and financial position and prospects, general financial, economic and market conditions, prevailing market prices for our shares of common stock, corporate, regulatory and legal requirements, and other conditions and factors deemed relevant by our management and Board of Directors from time to time. The share repurchase program may be suspended or discontinued at any time. There can be no assurance as to the actual volume of any share repurchases in any given period or over the term of the program or as to the manner or terms of any such repurchases.

On October 30, 2015, we commenced a “modified Dutch auction” tender offer to purchase up to $75 million of our common stock, at a price per share of not less than $8.50 and not greater than $9.25. The tender offer is contingent upon satisfaction of customary conditions. Repurchases under the tender offer will be part of our share repurchase program. As of October 29, 2015, we had approximately 117.4 million shares outstanding. We intend to fund the tender offer and related expenses with available cash and cash equivalents.

The information above relating to the tender offer is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any shares of our common stock. The solicitation and offer to buy our common stock is being made only pursuant to the Offer to Purchase, and the related Letter of Transmittal. Stockholders and investors are urged to read our Tender Offer Statement on Schedule TO, that we filed with the SEC in connection with the tender offer, including the Offer to Purchase, the related Letter of Transmittal and the other offer materials and exhibits thereto, as well as any amendments or supplements to the Schedule TO that we file with the SEC, because they contain important information, including various terms and conditions of the tender offer.

Table of Contents

Program Highlights

· Theravance paid a cash dividend of $0.25 per share on September 30, 2015 to stockholders of record as of the close of business on September 10, 2015.

· In the third quarter of 2015, net sales of RELVAR®/BREO® ELLIPTA® by GSK were $97.8 million, comprised of $40.4 million in the U.S. market (an increase of 44 percent from the prior quarter in the U.S.) and $57.4 million in non-U.S. markets (a smaller increase of 7 percent from the prior quarter primarily due to slower summer sales in Europe and Japan).

· As of September 30, 2015, RELVAR®/BREO® ELLIPTA® has been approved in 73 countries for marketing and has been launched in 42 countries.

· In the third quarter of 2015, sales of ANORO® ELLIPTA® by GSK were $32.7 million, an increase of approximately 38 percent compared to the prior quarter. Sales were $22.0 million in the U.S. market (an increase of 23 percent from the prior quarter) and $10.7 million in non-U.S. markets (an increase of 82% from the prior quarter).

· As of September 30, 2015, ANORO® ELLIPTA® has been approved in 61 countries for marketing and has been launched in 33 countries.

Collaborative Arrangements with GSK

LABA Collaboration

As a result of the launch and approval of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® in the U.S., Japan and Europe, we were obligated to pay milestone fees to GSK totaling $220.0 million, which we have paid in their entirety in 2014. Although we have no further milestone payment obligations to GSK pursuant to the LABA Collaboration Agreement, we continue to have ongoing development and commercialization activities under the GSK Agreements that are expected to continue over the life of the agreements. The milestone fees paid to GSK were recognized as capitalized fees paid to a related party, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product.

We are entitled to receive annual royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion. Sales of single-agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA collaboration, such as ANORO™ ELLIPTA™, royalties are upward tiering and range from 6.5% to 10%.

2004 Strategic Alliance

In March 2004, we entered into our Strategic Alliance Agreement with GSK where GSK received an option to license exclusive development and commercialization rights to product candidates from certain of our discovery programs on pre-determined terms and on an exclusive, worldwide basis. Upon GSK’s decision to license a program, GSK is responsible for funding all future development, manufacturing and commercialization activities for product candidates in that program. In addition, GSK is obligated to use diligent efforts to develop and commercialize product candidates from any program that it licenses. If the program is successfully advanced through development by GSK, we are entitled to receive clinical, regulatory and commercial milestone payments and royalties on any sales of medicines developed from the program. For a detailed discussion of our alliance with GSK, see Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 27, 2015.

Agreements Entered into with GSK in Connection with the Spin-Off

The amendments to the GSK Agreements did not change the economics or royalty rates under the GSK Agreements, though the assignment of the Strategic Alliance Agreement and portions of the LABA Collaboration Agreement to TRC do change how the

Table of Contents

economics are allocated between Theravance Biopharma and us. The amendments to the GSK Agreements do provide that upon regulatory approval in either the U.S. or the European Union of FF/UMEC/VI or a MABA in combination with FF, GSK’s diligent efforts obligations as to commercialization matters under the GSK Agreements will have the objective of focusing on the best interests of patients and maximizing the net value of the overall portfolio of products under the GSK Agreements. As such, GSK’s commercialization efforts may have the effect of reducing the overall value of our remaining interests in the GSK Agreements after the Spin-Off.

Purchases of Common Stock by GSK

Prior to 2015, affiliates of GSK purchased an aggregate of 31.6 million shares of our common stock. During the nine months ended September 30, 2015, GSK purchased 424,081 shares of our common stock pursuant to its periodic “top-up” rights under our Amended and Restated Governance Agreement, dated as of June 4, 2004, as amended, among us, GSK and certain GSK affiliates (the “Governance Agreement”), for an aggregate purchase price of approximately $6.5 million. GSK’s periodic “top-up” rights terminated with the expiration of the Governance Agreement in September 2015. As of October 30, 2015, GSK beneficially owned approximately 27% of our outstanding capital stock.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

During the nine months ended September 30, 2015, there were no significant changes to our critical accounting policies and estimates. Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 27, 2015 provides a more complete discussion of our critical accounting policies and estimates.

Results of Operations

Net Revenue

Total net revenue from continuing operations, as compared to the prior year periods, was as follows:

	Three Months Ended September 30,						Change					Nine Months Ended September 30,						Change
(In thousands)	2015			2014			$			%		2015			2014			$			%
Royalties from a related party	$	16,796		$	3,962		$	12,834		324	%	$	40,816		$	7,953		$	32,863		413	%
Less: amortization of capitalized fees paid to a related party	(3,455		)	(3,233		)	(222		)	7		(10,367		)	(7,611		)	(2,756		)	36
Royalty revenue	13,341			729			12,612			*		30,499			342			30,107			*
Strategic alliance - MABA program	221			270			(49		)	(18	)	664			811			(147		)	(18	)
Total net revenue from GSK	$	13,562		$	999		$	12,563		*	%	$	31,113		$	1,153		$	29,960		*	%

*Not meaningful

Total net revenue increased for the three and nine months ended September 30, 2015 compared to the same periods a year ago. The increases are primarily due to higher sales of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® not having been commercially launched until April 2014 and the approval in April 2015 of BREO® ELLIPTA® (FF/VI) as a once-daily inhaled treatment of asthma in patients aged 18 years and older in the U.S. Royalty revenue is reduced by amortization expense for capitalized fees paid to a related party.

Table of Contents

Research & Development

Research and development expenses from continuing operations, as compared to the prior year periods, were as follows:

	Three Months Ended September 30,				Change					Nine Months Ended September 30,				Change
(In thousands)	2015		2014		$			%		2015		2014		$			%
Research and development expenses	$	547	$	1,909	$	(1,362	)	(71	)%	$	1,897	$	6,721	$	(4,824	)	(72	)%

Research and development expenses decreased for the three and nine months ended September 30, 2015 compared to the same periods a year ago primarily due to fewer allocated costs as our ongoing operations are significantly smaller as a result of the Spin-Off in June 2014 and lower stock-based compensation expense. Stock-based compensation expense was higher during the three and nine months ended September 30, 2014 due to the achievement of performance conditions under a specified long-term retention and incentive equity awarded to certain employees in 2011. Currently, our research and development expenses are primarily due to expenses related to the late-stage partnered respiratory assets with GSK.

General & Administrative

General and administrative expenses from continuing operations, as compared to the prior periods, were as follows:

	Three Months Ended September 30,				Change					Nine Months Ended September 30,				Change
(In thousands)	2015		2014		$			%		2015		2014		$			%
General and administrative expenses	$	4,581	$	8,632	$	(4,051	)	(47	)%	$	14,929	$	28,491	$	(13,562	)	(48	)%

General and administrative expenses decreased for the three and nine months ended September 30, 2015 compared to the same periods a year ago primarily due to lower stock-based compensation expense and employee-related costs. For the three and nine months ended September 30, 2014, stock-based compensation expense and employee-related costs were higher primarily due to the probable achievement of performance conditions under a special long-term retention and incentive equity and cash bonus awarded to certain employees in 2011.

We structured our organization to be tailored to our more focused activities following the Spin-Off, including managing our respiratory assets with GSK, the commercial and developmental obligations associated with the GSK Agreements, intellectual property, licensing operations, business development activities and providing for certain essential reporting and management functions of a public company.

Other Income (Expense), net and Interest Income

Other income (expense), net and interest income, as compared to the prior year periods, were as follows:

	Three Months Ended September 30,					Change					Nine Months Ended September 30,				Change
(In thousands)	2015			2014		$			%		2015		2014		$			%
Other income (expense), net	$	(45	)	$	255	$	(300	)	(118	)%	$	1,117	$	335	$	782		233	%
Interest income	90			93		(3		)	(3	)	291		446		(155		)	(35	)

Other income (expense), net increased for the nine months ended September 30, 2015 compared to the same period in 2014 primarily related to a realized gain of $1.2 million on the sale of all of the ordinary shares of Theravance Biopharma that we held as of December 31, 2014 in the first quarter of 2015.

Interest income decreased for the three and nine months ended September 30, 2015 as compared to the same periods a year ago primarily due to lower average cash balances resulting from the cash contribution to Theravance Biopharma in June 2014.

Interest Expense

Interest expense, as compared to the prior year periods, was as follows:

Table of Contents

	Three Months Ended September 30,				Change				Nine Months Ended September 30,				Change
(In thousands)	2015		2014		$		%		2015		2014		$		%
Interest expense	$	13,063	$	12,355	$	708	6	%	$	38,756	$	24,326	$	14,430	59	%

Interest expense increased for the three and nine months ended September 30, 2015 compared to the same periods a year ago primarily due to the issuance of our 2029 Notes in April 2014, and a subsequent increase of $39.0 million to the outstanding principal balance from interest short falls. See “Liquidity” section below for further information.

Discontinued Operations

On June 1, 2014, we separated our research and drug development businesses from our late-stage partnered respiratory assets. The significant components of the research and drug development operations, which are presented as discontinued operations on the condensed consolidated statements of operations, were as follows:

	Nine Months Ended September 30,
(In thousands)	2015		2014
Net revenue	$	—	$	3,129
Loss from discontinued operations	—		94,934

There was no impact of the discontinued operations after the Spin-Off to our revenues and expenses for the three months ended September 30, 2015 and 2014.

Net revenues for the nine months ended September 30, 2014 includes revenue from collaborative arrangements with R-Pharm CJSC, which was transferred to Theravance Biopharma as a part of the Spin-Offs and products sales from sales of VIBATIV® in the U.S. for which revenue recognition commenced in the first quarter of 2014 which was transferred to Theravance Biopharma as a part of the Spin-Off.

Loss from discontinued operations for the nine months ended September 30, 2014 primarily relates to research and development expenses incurred prior to June 1, 2014 in addition to external legal and accounting fees in connection with our separation strategy and the additional stock-based compensation and cash bonus expense recognized due to the achievement of performance conditions under a special long-term retention and incentive equity and cash bonus awarded to certain employees in 2011, both of which we started to incur in 2013.

Liquidity and Capital Resources

Liquidity

Since our inception, we have financed our operations primarily through private placements and public offerings of equity and debt securities and payments received under collaborative arrangements. In 2015, we have also received royalty payments from GSK from sales of RELVAR®/ BREO® ELLIPTA®, which was launched in the fourth quarter of 2013, and from ANORO® ELLIPTA®, which was launched during 2014. As of September 30, 2015, we had $206.2 million in cash, cash equivalents, and marketable securities.

As discussed above under “Recent Developments ” on October 28, 2015, we announced that our Board of Directors approved a $150 million share repurchase program, and on October 30, 2015, we commenced a “modified Dutch auction” tender offer to purchase up to $75 million of our common stock, at a price per share of not less than $8.50 and not greater than $9.25. As discussed above, there can be no assurance as to the actual volume of any share repurchases in any given period or over the term of the program or as to the manner or terms of any such repurchases.

On February 20, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on March 12, 2015. On April 24, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on June 12, 2015. On July 24, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on September 10, 2015. During the three and nine months ended September 30, 2015, we paid $29.1 million and $87.1 million of dividends in cash.

Table of Contents

On June 1, 2014, we contributed $393.0 million of cash, cash equivalents and marketable securities to Theravance Biopharma as initial funds for their operations, based on anticipated operating plans and financial forecasts at the separation date. Although our cash on hand was reduced as a result of the Spin-Off, our operating expenses have decreased significantly as our ongoing operations are significantly smaller due to our focus on royalty management activities. As a result of the reduction in our operations, we believe that cash from future royalty revenues, net of operating expenses, debt service and cash on hand, will be sufficient to fund our operations for at least the next twelve months.

In April 2014, we entered into certain note purchase agreements relating to the private placement of $450.0 million aggregate principal amount of non-recourse 9% fixed rate term notes due 2029 (“2029 Notes”). The 2029 Notes are secured exclusively by a security interest in a segregated bank account established to receive 40% of the royalties from global net sales occurring on or after April 1, 2014 and ending upon the earlier of full repayment of principal or May 15, 2029 due to us under the LABA Collaboration Agreement with GSK. Prior to May 15, 2016, in the event that the specified portion of royalties received in a quarter is less than the interest accrued for the quarter, the principal amount of the 2029 Notes will increase by the interest shortfall amount for that period. As of September 30, 2015, interest expense of $39.0 million has been added to the principal balance of the 2029 Notes. From the net proceeds of the offering of approximately $434.7 million, we established a milestone payment reserve account to fund 40% of any future milestone payments that could become payable under the LABA Collaboration Agreement with GSK. As of September 30, 2015, the balance of the milestone reserve account was zero as we have fulfilled our obligation related to the milestone payments during the fourth quarter of 2014. We incurred approximately $15.3 million in debt issuance costs, which are being amortized to interest expense over the estimated life of the 2029 Notes.

Adequacy of cash resources to meet future needs

We believe that our cash, cash equivalents and marketable securities will be sufficient to meet our anticipated operating needs, including the funding of the share repurchase program discussed above, for at least the next twelve months based upon current operating plans and financials forecasts. If our current operating plans and financial forecasts change, we may require additional funding sooner in the form of public or private equity offerings or debt financings or may need to reduce or stop our quarterly dividend. Furthermore, if in our view favorable financing opportunities arise, we may seek additional funding at any time. However, future financing may not be available in amounts or on terms acceptable to us, if at all. This could leave us without adequate financial resources to fund our operations as currently planned. In addition, we regularly explore debt restructuring and/or reduction alternatives, including through tender offers, redemptions, repurchases or otherwise, all consistent with the terms of our debt agreements.

Cash Flows

Cash flows, as compared to the prior year periods, were as follows:

	Nine Months Ended September 30,
(In thousands)	2015			2014			Change
Net cash provided by (used in) operating activities	$	3,214		$	(126,113	)	$	129,327
Net cash provided by (used in) investing activities	59,880			(56,649		)	116,529
Net cash (used in) provided by financing activities	(81,148		)	158,827			(239,975		)

Cash Flows from Operating Activities

Cash provided by or used in operating activities is primarily driven by net loss, excluding the effect of non-cash charges and net changes in our operating assets and liabilities.

Net cash provided by operating activities for the nine months ended September 30, 2015 of $3.2 million was primarily due to:

· $34.4 million provided by receipt of royalties from a related party and revenue from collaborative arrangements, after adjusting for a $6.4 million increase in receivables from collaborative arrangements and $0.7 million decrease in deferred revenue;

· $11.5 million used for operating expenses, after adjusting for $5.2 million of non-cash related items, consisting primarily of stock-based compensation expense;

· $19.2 million used for interest payments on convertible subordinated notes, due 2023 and non-recourse notes, due 2029; and

· $0.9 million used to decrease accrued personnel-related expenses due to the timing of payments.

Net cash used in operating activities for the nine months ended September 30, 2014 of $126.1 million was primarily due to:

Table of Contents

· $114.7 million used for operating expenses, after adjusting for non-cash related items of $37.8 million consisting primarily of stock-based compensation expense of $26.0 million and depreciation and amortization expenses of $8.7 million and amortization on premium of marketable securities of $1.5 million and amortization of debt issuance cost of $1.6 million;

· $16.2 million decrease in payable to Theravance Biopharma;

· $16.7 million used for interest accruals on convertible subordinated notes, due 2023 and non-recourse notes, due 2029;

· $1.9 million used to increase inventories;

· $7.1 million decrease in accounts payable primarily due to the timing of payments and our ongoing operations being significantly smaller due to the Spin-Off; and

· $2.9 million provided by decrease in deferred revenue.

Cash Flows from Investing Activities

Net cash provided by investing activities for the nine months ended September 30, 2015 of $59.9 million was primarily due to $146.4 million of proceeds received from the sale of marketable securities and maturities of marketable securities, partially offset by $86.5 million in purchases of marketable securities.

Net cash provided by investing activities for the nine months ended September 30, 2014 of $56.6 million was primarily due to $125.0 million used for registrational and launch-related milestone payments to GSK, partially offset by $68.8 million from the sale and maturities of marketable securities, net of purchases.

Cash Flows from Financing Activities

Net cash used in financing activities for the nine months ended September 30, 2015 of $81.1 million was primarily due to $87.1 million of cash dividends paid to our stockholders, offset by $6.0 million of net proceeds received from the issuance of our common stock.

Net cash provided by financing activities for the nine months ended September 30, 2014 of $158.8 million was primarily due to net proceeds of $434.7 million received from the private placement of our 2029 Notes and $35.6 million received from the issuances of our common stock, partially offset by $277.5 million of cash and cash equivalents contributed to Theravance Biopharma as a result of the Spin-Off and payments of cash dividends of $28.3 million to our stockholders.

Off-Balance Sheet Arrangements

Commitments and Contingencies

We indemnify our officers and directors for certain events or occurrences, subject to certain limits. We may be subject to contingencies that may arise from matters such as product liability claims, legal proceedings, shareholder suits and tax matters, as such, we are unable to estimate the potential exposure related to these indemnification agreements. We have not recognized any liabilities relating to these agreements as of September 30, 2015.

Special Long-Term Retention and Incentive Cash Awards Program

In 2011, we granted special long-term retention and incentive RSAs to members of senior management and special long-term retention and incentive cash bonus awards to certain employees. The awards have dual triggers of vesting based upon the achievement of certain performance conditions over a six-year timeframe from 2011 through December 31, 2016 and continued employment.

In connection with the Spin-Off, the Compensation Committee of our Board of Directors approved the modification of the remaining tranches related to these awards as the performance conditions associated with the remaining portions of these awards were unlikely to be consistent with the new strategies of each company following the Spin-Off. The modification acknowledged the Spin-

Table of Contents

Off and permitted recognition of achievement of certain of the original performance conditions that were met prior to the Spin-Off, triggering service-based vesting for a portion of the cash and equity awards. Stock-based compensation expense of $3.8 million associated with this portion of the equity awards after the modification was recognized by us during the twelve-month period that commenced in June 2014. The remaining 63,000 RSAs for which service-based vesting was not triggered at the time of the Spin-Off remain subject to new performance conditions (as well as the original service conditions). In addition, the RSAs for which both the performance and service-based conditions were not achieved prior to the Spin-Off were entitled to the pro rata dividend distribution made by Theravance on June 2, 2014 of one ordinary share of Theravance Biopharma for every 3.5 shares of Theravance common stock subject to their awards. The Theravance Biopharma shares will be subject to the same new performance and service conditions as the original RSAs to which they relate. The amount due by us under the modified cash bonus awards of $0.5 million is fully paid in June 2015 and the remaining tranches of the cash bonus awards were forfeited.

Contractual Obligations and Commercial Commitments

There have been no significant changes in our payments due under contractual obligations, compared to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014.

Item 3. Quantitative and Qualitative Disclosure about Market Risk

During the nine months ended September 30, 2015, there have been no significant changes in our market risk or how our market risk is managed compared to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures.

We conducted an evaluation as of September 30, 2015, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, which are defined under SEC rules as controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Securities Exchange Act of 1934 (“Exchange Act”) is recorded, processed, summarized and reported within required time periods. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance levels.

Limitations on the Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within Theravance have been detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1A. Risk Factors

Risks Related to our Business

For the foreseeable future we will derive all of our royalty revenues from GSK and our future success depends on GSK’s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK.

Pursuant to the GSK Agreements, GSK is responsible for the development and commercialization of products in the partnered respiratory programs. Through September 30, 2015, sales of both BREO ® ELLIPTA ® and especially ANORO® ELLIPTA® by GSK have been significantly below our expectations which resulted in a decline in our stock price. Although we may receive milestone payments from GSK if certain development milestones are achieved in our MABA program, we believe that royalty revenues from BREO ® ELLIPTA ® and ANORO® ELLIPTA® will represent the majority of our future revenues from GSK. The amount and timing of revenue from such royalties and milestones is unknown and highly uncertain. Our future success depends upon the performance by GSK of its commercial obligations under the GSK Agreements. We have no control over GSK’s marketing and sales efforts, and GSK might not be successful, which would harm our business and cause the price of our securities to fall.

The amount of royalties and milestone payments, if any, we receive will depend on many factors, including the following:

· the extent and effectiveness of the sales and marketing and distribution support GSK provides our partnered products;

· market acceptance and demand for our partnered products;

· the competitive landscape of generic and branded products and developing therapies that compete with our partnered products, including other products owned by GSK (such as Advair®) but which are not partnered with us and pricing pressure in the respiratory markets targeted by our partnered products;

· the size of the market for our partnered products;

· decisions as to the timing of product launches, pricing and discounts;

· GSK’s ability to expand the indications for which our partnered products can be marketed;

· a satisfactory efficacy and safety profile as demonstrated in a broad patient population;

· acceptance of, and ongoing satisfaction with, our partnered products by the medical community, patients receiving therapy and third party payors;

· the ability of patients to be able to afford our partnered products or obtain health care coverage that covers our partnered products;

· safety concerns in the marketplace for respiratory therapies in general and with our partnered products in particular;

· regulatory developments relating to the manufacture or continued use of our partnered products;

· the requirement to conduct additional post-approval studies or trials for our partnered products;

· GSK’s ability to successfully achieve development milestones with respect to our partnered MABA program;

· GSK’s ability to obtain regulatory approval of our partnered products in additional countries; or

· the unfavorable outcome of any potential litigation relating to our partnered products.

Table of Contents

Reduced prices and reimbursement rates due to the actions of governments, payors, or competition or other healthcare cost containment initiatives such as restrictions on use, may negatively impact royalties generated under the GSK Agreements.

The continuing efforts of governments, pharmaceutical benefit management organizations (PBMs), insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care has adversely affected the price, market access, and total revenues of BREO ® ELLIPTA ® and ANORO® ELLIPTA® and may continue to adversely affect them in the future. In addition, we have experienced and expect to continue to experience increased competitive activity which has resulted in lower overall prices for our products.

The Patient Protection and Affordable Care Act and other legislative or regulatory requirements or potential legislative or regulatory actions regarding healthcare and insurance matters, along with the trend toward managed healthcare in the United States (U.S.), could adversely influence the purchase of healthcare products and reduce demand and prices for our partnered products. This could harm GSK’s ability to market our partnered products and significantly reduce future revenues. For example, when GSK launched BREO® ELLIPTA® for the treatment of COPD in the U.S. in October 2013, GSK experienced significant challenges gaining coverage at some of the largest PBMs, healthcare payors, and providers and lower overall prices than expected. Recent actions by U.S. PBMs in particular have increased discount levels for respiratory products resulting in lower net sales pricing realized for products in our collaboration. Further, if the ongoing Phase 3b studies with FF/VI do not show improved outcomes relative to the standard of care, obtaining payor coverage for RELVAR®/BREO® ELLIPTA® could become more difficult in the future. In addition, in certain foreign markets, the pricing of prescription drugs is subject to government control and reimbursement may in some cases be unavailable. We believe that pricing pressures will continue and may increase. This may make it difficult for GSK to sell our partnered products a price acceptable to us or GSK or to generate revenues in-line with our analysts’ or investors’ expectations, which may cause the price of our securities to fall.

If the commercialization of RELVAR ® /BREO ® ELLIPTA ® or ANORO® ELLIPTA® in the countries in which they have received regulatory approval encounters any delays or adverse developments, or perceived delays or adverse developments, or if sales or payor coverage do not meet investor, analyst or our expectations, our business will be harmed, and the price of our securities could fall.

Under the GSK Agreements, GSK has full responsibility for commercialization of RELVAR ® / BREO ® ELLIPTA ® and ANORO® ELLIPTA®. GSK has launched RELVAR ® / BREO ® ELLIPTA ® in a number of countries including the United States (U.S.), Canada, Japan, the United Kingdom, and Germany among others. The commercial launch of both products has been below our expectations primarily due to lower overall pricing levels in the U.S. and a longer timeframes to obtain payor coverage. For example, GSK recently stated that it has experienced more restrictive formulary access and lower net pricing in the U.S. respiratory market than it expected, which may indicate broader weakness in the respiratory markets targeted by RELVAR ® / BREO ® ELLIPTA ® and ANORO® ELLIPTA®. As a result, a number of analysts have adjusted their sales forecasts downward from previous projections. Any further delays or adverse developments or perceived additional delays or adverse developments with respect to the commercialization of RELVAR ® / BREO ® ELLIPTA ® and ANORO® ELLIPTA® including if sales or payor coverage do not meet investor, analyst or our expectations, will significantly harm our business and the price of our securities could fall.

If GSK’s commercialization efforts to market BREO® ELLIPTA® for asthma encounters any delays or adverse developments, or perceived delays or adverse developments, or if sales or payor coverage do not meet investor, analyst or our expectations, our business will be harmed, and the price of our securities could fall.

On April 30, 2015, the U.S. Food and Drug Administration (“FDA”) approved BREO® ELLIPTA® (FF/VI) as a once-daily inhaled treatment for asthma in patients aged 18 years and older in the U.S. If GSK’s commercialization efforts to market BREO® ELLIPTA® for asthma in the U.S. encounters any delays or adverse developments, or perceived delays or adverse developments, or if sales or payor coverage do not meet investor, analyst or our expectations, our business will be harmed, and the price of our securities could fall.

Any adverse change in FDA policy or guidance regarding the use of LABAs to treat asthma may significantly harm our business and the price of our securities could fall.

On February 18, 2010, the FDA announced that LABAs should not be used alone in the treatment of asthma and it will require manufacturers to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medicines. The FDA now requires that the product labels for LABA medicines reflect, among other things, that the use of LABAs is contraindicated without the use of an asthma controller medication such as an inhaled corticosteroid, that LABAs should only be used long-term in patients whose asthma cannot be adequately controlled on asthma controller medications, and that LABAs should be used for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved. In addition, in March 2010, the FDA held an Advisory Committee to discuss the design of medical

Table of Contents

research studies (known as “clinical trial design”) to evaluate serious asthma outcomes (such as hospitalizations, a procedure using a breathing tube known as intubation, or death) with the use of LABAs in the treatment of asthma in adults, adolescents, and children. Further, in April 2011, the FDA announced that to further evaluate the safety of LABAs, it is requiring the manufacturers of currently marketed LABAs to conduct additional randomized, double-blind, controlled clinical trials comparing the addition of LABAs to inhaled corticosteroids versus inhaled corticosteroids alone. Results from these post-marketing studies are expected in 2017. It is unknown at this time what, if any, effect these or future FDA actions will have on the prospects for FF/VI. The current uncertainty regarding the FDA’s position on LABAs for the treatment of asthma and the lack of consensus expressed at the March 2010 Advisory Committee may result in the FDA requiring additional asthma clinical trials in the U.S. for FF/VI and increase the overall risk of FF/VI for the treatment of asthma in the U.S. We cannot predict the extent to which new FDA policy or guidance might significantly impede the discovery, development, production and marketing of FF/VI. Any adverse change in FDA policy or guidance regarding the use of LABAs to treat asthma may significantly harm our business and the price of our securities could fall.

Any adverse developments to the regulatory status of either RELVAR ® /BREO ® ELLIPTA ® or ANORO® ELLIPTA® in the countries in which they have received regulatory approval including labeling restrictions, safety findings, or any other limitation to usage, will harm our business and may cause the price of our securities to fall.

Although RELVAR®/BREO® ELLIPTA® or ANORO® ELLIPTA® are approved and marketed in a number of countries, it is possible that adverse changes to the regulatory status of these products could occur in the event new safety issues are identified, treatment guidelines are changed, or new studies fail to demonstrate product benefits. A number of notable pharmaceutical products have experienced adverse developments during commercialization that have resulted in the product being withdrawn, approved uses being limited, or new warnings being included. In the event that any adverse regulatory change was to occur to any of our products, our business will be harmed and the price of our securities will fall.

Any adverse developments or results or perceived adverse developments or results with respect to the ongoing studies for FF/VI in asthma or COPD, for UMEC/VI in COPD, or any future studies will significantly harm our business and the price of our securities could fall, and if regulatory authorities in those countries in which approval has not yet been granted determine that the Phase 3 programs for FF/VI in asthma or COPD or the Phase 3 programs for UMEC/VI for COPD do not demonstrate adequate safety and efficacy, the continued development of FF/VI or UMEC/VI or both may be significantly delayed, they may not be approved by these regulatory authorities, and even if approved it may be subject to restrictive labeling, any of which will harm our business, and the price of our securities could fall.

Although we have announced the completion of, and reported certain top-line data from, the Phase 3 registrational program for FF/VI in COPD and asthma, a number of additional studies of FF/VI are underway. For example, in September 2015, GSK and we announced that the Study to Understand Mortality and MorbidITy” (SUMMIT) did not meet its primary endpoints. Any adverse developments or perceived adverse developments with respect to any prior, current or future studies in these programs will significantly harm our business and the price of our securities could fall.

Although the FDA, the European Medicines Agency, the Japanese Ministry of Health, Labour and Welfare and Health Canada have approved ANORO® ELLIPTA®, it has not yet been approved in other countries.

Any adverse developments or results or perceived adverse developments or results with respect to other pending or future regulatory submissions for the FF/VI program or the UMEC/VI program will significantly harm our business and the price of our securities could fall. Examples of such adverse developments include, but are not limited to:

· not every study, nor every dose in every study, in the Phase 3 programs for FF/VI achieved its primary endpoint and regulatory authorities may determine that additional clinical studies are required;

· safety, efficacy or other concerns arising from clinical or non-clinical studies in these programs having to do with the LABA VI, which is a component of FF/VI and UMEC/VI;

· analysts adjusting their sales forecasts downward from previous projections based on results or interpretations of results of prior, current or future studies;

· safety, efficacy or other concerns arising from clinical or non-clinical studies in these programs;

· regulatory authorities determining that the Phase 3 programs in asthma or in COPD raise safety concerns or do not demonstrate adequate efficacy; or

Table of Contents

· any change in FDA policy or guidance regarding the use of LABAs to treat asthma or the use of LABAs combined with a LAMA to treat COPD.

If the FDA or other applicable regulatory authorities approve generic products, including but not limited generic forms of Advair®, that compete with RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® the royalties payable to us pursuant to the LABA Collaboration Agreement will be less than anticipated, which in turn would harm our business and the price of our securities could fall.

Once an NDA or marketing authorization application outside the United States is approved, the product covered thereby becomes a “listed drug” that can, in turn, be cited by potential competitors in support of approval of an Abbreviated New Drug Application (“ANDA”) in the United States. Agency regulations and other applicable regulations and policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes in the United States and in nearly every pharmaceutical market around the world. Numerous companies like Mylan N.V. and Teva Pharmaceuticals Industries Ltd. have publicly stated their intentions to bring generic forms of the ICS/LABA drug Advair®, when certain patents covering the Advair® delivery device expire in 2016. Mylan N.V. has recently announced the completion of their Phase III studies for their generic Advair program, and expressed their intention to file their ANDA with the FDA before the end of 2015. These manufacturers might only be required to conduct a relatively inexpensive study to show that their product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use, or labeling, as the branded product and that the generic product is bioequivalent to the branded product, meaning it is absorbed in the body at the same rate and to the same extent. These generic equivalents, which must meet the same quality standards as branded products, may be significantly less costly to bring to market, and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product and products that may compete with such branded product is typically lost to the generic product. Accordingly, introduction of generic products that compete against ICS/LABA products, like RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, would materially adversely impact our future royalty revenue, profitability and cash flows. We cannot yet ascertain what impact these generic products and any future approved generic products will have on any sales of RELVAR®/BREO® ELLIPTA® or ANORO® ELLIPTA®, if approved.

RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® face substantial competition for their intended uses in the targeted markets from products discovered, developed, launched and commercialized both by GSK and by other pharmaceutical companies, which could cause the royalties payable to us pursuant to the LABA Collaboration Agreement to be less than expected, which in turn would harm our business and the price of our securities could fall.

GSK has responsibility for obtaining regulatory approval, launching and commercializing RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® for their intended uses in the targeted markets around the world. While these products have received regulatory approval and been launched and commercialized in the U.S. and certain other targeted markets, the products face substantial competition from existing products previously developed and commercialized both by GSK and by other competing pharmaceutical companies and can expect to face additional competition from new products that are discovered, developed and commercialized by the same pharmaceutical companies and other competitors going forward. For example, sales of Advair®, GSK’s approved medicine for both COPD and asthma, continue to be significantly greater than sales of RELVAR®/BREO® ELLIPTA®, and GSK has indicated publicly that it intends to continue commercializing Advair®.

Many of the pharmaceutical companies competing in respiratory markets are international in scope with substantial financial, technical and personnel resources that permit them to discover, develop, obtain regulatory approval and commercialize new products in a highly efficient and low cost manner at competitive prices to consumers. In addition, many of these competitors have substantial commercial infrastructures that facilitate commercializing their products in a highly efficient and low cost manner at competitive prices to consumers. The market for products developed for the treatment of COPD and asthma continues to experience significant innovation and reduced cost in bringing products to market over time, including generic forms of existing products developed for the treatment of COPD and asthma. As an example, Boehringer Ingelheim recently obtained approval for its LABA/LAMA combination product Spiolto® Respimat®, which was launched in 2015. In September 2015, Boehringer Ingelheim obtained FDA approval for Spiriva for the long-term, once-daily, maintenance treatment of asthma in patients 12 years of age and older. In addition, Novartis obtained FDA approval for a combination COPD treatment, which Novartis plans to launch in the first quarter of 2016 under the tradename Utibron Neohaler. There can be no assurance that RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® will not be replaced by new products that are deemed more effective at lower cost to consumers. The ability of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® to succeed and achieve the anticipated level of sales depends on the commercial and development performance of GSK to achieve and maintain a competitive advantage over other products with the same intended use in the targeted markets.

Table of Contents

If sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® are less than anticipated because of existing or future competition in the markets in which they are commercialized, including competition from existing and new products that are perceived as lower cost or more effective, our royalty payments will be less than anticipated, which in turn would harm our business and the price of our securities could fall.

We and GSK are developing UMEC/VI/FF (LAMA/LABA/ICS) and MABA/FF as potential triple combination treatments for COPD and, potentially, asthma. As a result of the Spin-Off, most of our economic rights in these programs were assigned to Theravance Biopharma. If these programs are successful and GSK and the respiratory market in general views triple combination therapy as significantly more beneficial than existing therapies, including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, our business could be harmed, and the price of our securities could fall.

Under our LABA Collaboration Agreement with GSK, we and GSK are exploring various paths to create triple therapy respiratory medications. The use of triple therapy is supported by the GOLD (“Global initiative for chronic Obstructive Lung Disease”) guidelines in high-risk patients with severe COPD and a high risk of exacerbations. One potential triple therapy path is the combination of UMEC/VI (two separate bronchodilators) and FF (an inhaled corticosteroid), to be administered via the ELLIPTA ® dry powder inhaler, referred to as UMEC/VI/FF or the “closed triple.” Prior to the Spin-Off, we were entitled to receive 100% of any royalties payable under the GSK Agreements arising from sales of UMEC/VI/FF (as well as MABA and MABA/FF) if such products were successfully developed, approved and commercialized. In July 2014, we and GSK announced the initiation of a large, global Phase 3 study for the closed triple in patients with COPD. If this Phase 3 study (or any other closed triple Phase 3 studies that may be initiated in the future) is successful, GSK and the respiratory market in general may view this triple combination therapy as significantly more beneficial than existing therapies, including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. In such event the commercialization of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® could be adversely affected, which in turn could result in lower royalties to us. Furthermore, if the closed triple (or MABA /FF) receives regulatory approval in either the U.S. or the EU, GSK’s diligent efforts obligations regarding commercialization matters will have the objective of focusing on the best interests of patients and maximizing the net value of the overall portfolio of products under the GSK Agreements. Since GSK’s commercialization efforts following such regulatory approval will be guided by a portfolio approach across products in which we have retained our full interest and also products in which we now have only a small portion of our former interest, GSK’s commercialization efforts may have the effect of reducing the overall value of our remaining interests in the GSK Agreements in the future. As a result of the transactions effected by the Spin-Off, however, we are now only entitled to receive 15% of any contingent payments and royalties payable by GSK from sales of FF/UMEC/VI (and MABA, and MABA/FF) while Theravance Biopharma receives 85% of those same payments.

On June 2, 2014, we completed the separation of our businesses into two independent, publicly traded companies by separating our late-stage partnered respiratory assets from our biopharmaceutical operations; the lengthy, complicated process to separate the two businesses has diverted the attention of our management and employees, and has increased our professional services expenses in 2014 and in the early part of 2015.

On April 25, 2013, we announced our intention to separate our businesses into two independent, publicly traded companies. On August 1, 2013, the company to be spun-off, Theravance Biopharma, filed a preliminary Form 10 with the SEC, and subsequent amendments throughout 2013 and the spring of 2014. The Spin-Off was completed on June 2, 2014. Theravance continues to be responsible for all development and commercial activities under the GSK Agreements. Theravance is eligible to receive the associated royalty revenues from FF/VI (RELVAR®/BREO® ELLIPTA®), UMEC/VI (ANORO® ELLIPTA®) and potentially VI monotherapy and 15% of the aggregate potential royalty revenues payable to Theravance Respiratory Company, LLC from UMEC/VI/FF, MABA, and MABA/FF and other products that may be developed under the GSK Agreements. Theravance Biopharma is now a separate and independent publicly traded biopharmaceutical company focusing on the discovery, development and commercialization of small-molecule medicines in areas of significant unmet medical need.

Upon the Spin-Off, our facility leases in South San Francisco, California were assigned to Theravance Biopharma. However, if Theravance Biopharma were to default on its lease obligations, we would be held liable by the landlord and thus, we have in substance guaranteed the lease payments for these facilities. We would also be responsible for lease-related payments including utilities, property taxes, and common area maintenance, which may be as much as the actual lease payments. As of September 30, 2015, the total remaining lease payments, which run through May 2020, were $29.1 million. In the event that Theravance Biopharma defaults on such obligations, our business and results of operations may be materially harmed.

In conjunction with the Spin-Off of Theravance Biopharma, on March 3, 2014, we, Theravance Biopharma and GSK entered into a series of agreements clarifying how the companies would implement the separation and operate following the Spin-Off. We, Theravance Biopharma and GSK entered into a three-way master agreement providing for GSK’s consent to the Spin-Off provided certain conditions were met. We and GSK also entered into amendments of the GSK Agreements. The master agreement and the other agreements are all currently effective.

Table of Contents

The amendments to the GSK Agreements do not change the royalty rates or other economic terms. The amendments do provide that GSK’s diligent efforts obligations regarding commercialization matters under both agreements will change upon regulatory approval in either the U.S. or the EU of UMEC/VI/FF or a MABA combined with FF. Upon such regulatory approval, GSK’s diligent efforts obligations as to commercialization matters under the GSK Agreements will have the objective of focusing on the best interests of patients and maximizing the net value of the overall portfolio of products under the GSK Agreements. Since GSK’s commercialization efforts following such regulatory approval will be guided by a portfolio approach across products in which we have retained our full interest and also products in which we now have only a small portion of our former interest, GSK’s commercialization efforts may have the effect of reducing the overall value of our remaining interests in the GSK Agreements in the future.

We cannot assure you that we will not undertake additional restructuring activities, that the business separation will succeed in meeting our objectives and increasing stockholder value, or that the actual results will not differ materially from the results that we anticipate.

We have incurred and may continue to incur significant expenditures for professional services in connection with the business separation and our post-separation operations, including financial advisory, accounting and legal fees.

Under the terms of a separation and distribution agreement entered into between us and Theravance Biopharma, Theravance Biopharma will indemnify us from (i) all debts, liabilities and obligations transferred to Theravance Biopharma in connection with the Spin-Off (including its failure to pay, perform or otherwise promptly discharge any such debts, liabilities or obligations after the Spin-Off), (ii) any misstatement or omission of a material fact in its information statement filed with the SEC, resulting in a misleading statement and (iii) any breach by it of certain agreements entered into between the parties in connection with the Spin-Off. Theravance Biopharma’s ability to satisfy these indemnities, if called upon to do so, will depend upon its future financial strength and if we are not able to collect on indemnification rights from Theravance Biopharma, our financial condition may be harmed.

We may not be able to utilize all of our net operating loss carryforwards.

We have net operating loss carryforwards and other significant U.S. tax attributes that we believe could offset otherwise taxable income in the U.S. As a part of the overall Spin-Off transaction, the transfer of certain assets by us to Theravance Biopharma and our distribution of Theravance Biopharma ordinary shares resulted in taxable transfers pursuant to applicable provisions of the Internal Revenue Code of 1986, as amended (the “Code”) and Treasury Regulations. The taxable gain recognized by us attributable to the transfer of certain assets to Theravance Biopharma will generally equal the excess of the fair market value of each asset transferred over our adjusted tax basis in such asset. Although we will not recognize any gain with respect to the cash we transferred to Theravance Biopharma, we may recognize substantial gain based on the fair market value of the other assets (other than cash) transferred to Theravance Biopharma. The determination of the fair market value of these assets is subjective and could be subject to adjustments or future challenge by the Internal Revenue Service (“IRS”), which could result in an increase in the amount of gain realized by us as a result of the transfer. Our U.S. federal income tax resulting from any gain recognized upon the transfer of our assets to Theravance Biopharma (including any increased U.S. federal income tax that may result from a subsequent determination of higher fair market values for the transferred assets), may be reduced by our net operating loss carryforward. The net operating loss carryforwards available in any year to offset our net taxable income will be reduced following a more than 50% change in ownership during any period of 36 consecutive months (an “ownership change”) as determined under the Internal Revenue Code of 1986 (the “Code”). As of December 31, 2014, we have conducted an analysis to determine whether an ownership change had occurred since inception through December 31, 2014, and concluded that we had undergone two ownership changes in prior years. We have approximately $1.4 billion of net operating loss carryforward available to us as of December 31, 2014. We currently expect our net operating losses to be fully available to offset current year net taxable income after taking into account the taxable nature of the Spin-Off. With respect to our remaining net operating losses of approximately $1.2 billion as of December 31, 2014, there may be certain annual limitations for utilization based on the above-described ownership change provisions. In addition, we may not be able to have sufficient future taxable income prior to their expiration because net operating losses have carryforward periods. Future changes in federal and state tax laws pertaining to net operating loss carryforwards may also cause limitations or restrictions from us claiming such net operating losses. If the net operating loss carryforwards become unavailable to us or are fully utilized, our future taxable income will not be shielded from federal and state income taxation absent certain U.S. federal and state tax credits, and the funds otherwise available for general corporate purposes would be reduced.

The Spin-Off resulted in substantial changes in our Board, management, and employees. If we fail to hire and effectively integrate new executive officers into our organization, the future development and commercialization of our product candidates may suffer, harming future regulatory approvals, sales of our product candidates or our results of operations.

Since the Spin-Off, substantially all of our directors and senior management team has changed. Our current board and management team has only been working together for a relatively short period of time. In addition, Rick E. Winningham resigned as

Table of Contents

our President and Chief Executive Officer effective as of August 15, 2014 and as Chairman of our Board and as a director effective as of October 30, 2014. Since the Spin-Off, we have appointed Michael W. Aguiar as our Chief Executive Officer and as a member of our Board, appointed Eric d’Esparbes as our Chief Financial Officer and appointed Michael E. Faerm as our Chief Business Officer. We expect to continue to expand our management team in the future. Our future performance will depend significantly on our ability to successfully integrate our new directors into our Board and our new Chief Executive Officer, Chief Financial Officer, Chief Business Officer and other recently and subsequently hired executive officers into our management team, and on those individuals’ ability to develop and maintain an effective working relationship. Our failure to integrate recently and subsequently appointed directors and executive officers, including our new Chief Executive Officer, Chief Financial Officer and Chief Business Officer, with other members of management could result in inefficiencies in the conduct of our business, which can adversely affect our results of operations.

If any product candidates in any respiratory program partnered with GSK are not approved by regulatory authorities or are determined to be unsafe or ineffective in humans, our business will be adversely affected and the price of our securities could fall.

The FDA must approve any new medicine before it can be marketed and sold in the U.S. Our partner GSK must provide the FDA and similar foreign regulatory authorities with data from preclinical and clinical studies that demonstrate that the product candidates are safe and effective for a defined indication before they can be approved for commercial distribution. GSK will not obtain this approval for a partnered product candidate unless and until the FDA approves a NDA. The processes by which regulatory approvals are obtained from the FDA to market and sell a new product are complex, require a number of years and involve the expenditure of substantial resources. In order to market medicines in foreign countries, separate regulatory approvals must be obtained in each country. The approval procedure varies among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Conversely, failure to obtain approval in one or more country may make approval in other countries more difficult.

Clinical studies involving product candidates partnered with GSK may reveal that those candidates are ineffective, inferior to existing approved medicines, unacceptably toxic, or that they have other unacceptable side effects. In addition, the results of preclinical studies do not necessarily predict clinical success, and larger and later-stage clinical studies may not produce the same results as earlier-stage clinical studies.

Frequently, product candidates that have shown promising results in early preclinical or clinical studies have subsequently suffered significant setbacks or failed in later clinical or non-clinical studies. In addition, clinical and non-clinical studies of potential products often reveal that it is not possible or practical to continue development efforts for these product candidates. If these studies are substantially delayed or fail to prove the safety and effectiveness of product candidates in development partnered with GSK, GSK may not receive regulatory approval for such product candidates and our business and financial condition will be materially harmed and the price of our securities may fall.

Several well-publicized Complete Response letters issued by the FDA and safety-related product withdrawals, suspensions, post-approval labeling revisions to include boxed warnings and changes in approved indications over the last several years, as well as growing public and governmental scrutiny of safety issues, have created a conservative regulatory environment. The implementation of new laws and regulations and revisions to FDA clinical trial design guidance have increased uncertainty regarding the approvability of a new drug. Further, there are additional requirements for approval of new drugs, including advisory committee meetings for new chemical entities, and formal risk evaluation and mitigation strategy at the FDA’s discretion. These laws, regulations, additional requirements and changes in interpretation could cause non-approval or further delays in the FDA’s review and approval of any product candidates in any respiratory program partnered with GSK.

Even if product candidates in any respiratory program partnered with GSK receive regulatory approval, as is the case with RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, commercialization of such products may be adversely affected by regulatory actions and oversight.

Even if GSK receives regulatory approval for product candidates in any respiratory program partnered with GSK, this approval may include limitations on the indicated uses for which GSK can market the medicines or the patient population that may utilize the medicines, which may limit the market for the medicines or put GSK at a competitive disadvantage relative to alternative therapies. These restrictions make it more difficult to market the approved products.

For example, at the joint meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA regarding the sNDA for BREO® ELLIPTA® as a treatment for asthma, the advisory committee recommended that a large LABA safety trial with BREO® ELLIPTA® should be required in adults and in 12-17 year olds, similar to

Table of Contents

the ongoing LABA safety trials being conducted as an FDA Post-Marketing Requirement by each of the manufacturers of LABA containing asthma treatments.

In addition, the manufacturing, labeling, packaging, adverse event reporting, advertising, promotion and recordkeeping for the approved product remain subject to extensive and ongoing regulatory requirements. If we or GSK become aware of previously unknown problems with an approved product in the U.S. or overseas or at contract manufacturers’ facilities, a regulatory authority may impose restrictions on the product, the contract manufacturers or on GSK, including requiring it to reformulate the product, conduct additional clinical studies, change the labeling of the product, withdraw the product from the market or require the contract manufacturer to implement changes to its facilities. GSK is also subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies as well as governmental authorities in those foreign countries in which any of the product candidates in any respiratory program partnered with GSK are approved for commercialization. The Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal and state statutes and regulations govern to varying degrees the research, development, manufacturing and commercial activities relating to prescription pharmaceutical products, including non-clinical and clinical testing, approval, production, labeling, sale, distribution, import, export, post-market surveillance, advertising, dissemination of information and promotion. Any failure to maintain regulatory approval will limit GSK’s ability to commercialize the product candidates in any respiratory program partnered with GSK, which would materially and adversely affect our business and financial condition and which may cause the price of our securities to fall.

We have incurred operating losses in each year since our inception and will continue to incur losses until royalties from the sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® exceed total expenses, including interest expenses, and our revenues and operating results will likely fluctuate in future periods.

From mid-1997 until the Spin-Off, we were engaged in discovering and developing compounds and product candidates and we never generated sufficient revenue from the sale of medicines or royalties on sales by our partners to achieve sustained profitability. As of September 30, 2015, we had an accumulated deficit of approximately $1.7 billion. Although we expect to have a substantial reduction in our expenses in future periods as a result of the Spin-Off, we will continue to incur losses until royalties from the sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® exceed total expenses, including interest expenses, and our revenues and operating results will likely fluctuate from period to period. We are uncertain when or if we will be able to achieve or sustain profitability. Failure to become and remain profitable would adversely affect the price of our securities, our ability to return capital to stockholders and continue operations.

We may not be successful in our efforts to expand our portfolio of royalty generating products.

In the future, we may choose to acquire rights to one or more additional royalty generating products. However, we may be unable to license or acquire rights to suitable royalty generating products for a number of reasons. In particular, the licensing and acquisition of pharmaceutical product rights is a competitive area. Several more established companies are also pursuing strategies to license or acquire rights to royalty generating products. These established companies may have a competitive advantage over us. Other factors that may prevent us from licensing or otherwise acquiring rights to suitable royalty generating products include the following:

· we may be unable to license or acquire the rights on terms that would allow us to make an appropriate return from the product;

· companies that perceive us to be their competitors may be unwilling to assign or license their product rights to us; or

· we may be unable to identify suitable royalty generating products.

If we are unable to acquire or license rights to suitable royalty generating product candidates, our business may suffer.

We have a significant amount of debt including Convertible Subordinated Notes and Non-Recourse Notes that are senior in capital structure and cash flow, respectively, to our common stockholders. Satisfying the obligations relating to our debt could adversely affect the amount or timing of distributions to our stockholders.

As of September 30, 2015, we had approximately $744.1 million in total long-term debt outstanding, comprised primarily of $255.1 million in principal that remains outstanding under our 2.125% Convertible Subordinated Notes due 2023 (the “2023 Notes”) and $489.0 million in principal that remains outstanding under our 9% Fixed Rate Royalty term notes due 2029 (the “2029 Notes” and with the 2023 Notes, the “Notes”). The 2023 Notes are unsecured debt and are not redeemable by us prior to the maturity date. Holders of the Notes may require us to purchase all or any portion of their Notes at 100% of their principal amount, plus any unpaid interest, upon a fundamental change. A fundamental change is generally defined to include a merger involving us, an acquisition of a

Table of Contents

majority of our outstanding common stock, and the change of a majority of our board without the approval of the board. In addition, to the extent we pursue and complete a monetization transaction, the structure of such transaction may qualify as a fundamental change under the Notes, which could trigger the put rights of the holders of the Notes, in which case we would be required to use a portion of the net proceeds from such transaction to repurchase any Notes put to us. Our 2029 Notes have rights to 40% of all royalty payments received from GSK related to RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and VI monotherapy until the notes are paid in full.

Satisfying the obligations of this debt could adversely affect the amount or timing of any distributions to our stockholders. We may choose to satisfy repurchase, or refinance this debt through public or private equity or debt financings if we deem such financings available on favorable terms. If any or all of the Convertible Subordinated Notes are not converted into shares of our common stock before the maturity date, we will have to pay the holders the full aggregate principal amount of the Notes then outstanding. If the Fixed Rate Royalty are not refinanced or paid in full, then they will receive 40% of all future economics associated with RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and VI monotherapy, until the notes are paid in full. Any of the above payments could have a material adverse effect on our cash position. If we fail to satisfy these obligations, it may result in a default under the indenture, which could result in a default under certain of our other debt instruments, if any. Any such default would harm our business and the price of our securities could fall.

If we lose key management personnel, or if we fail to retain our key employees, our ability to manage our business will be impaired.

Following the Spin-Off, we have a much smaller management team and very few employees. We are highly dependent on principal members of our management team and a small group of key employees to operate our business. Our company is located in northern California, which is headquarters to many other biotechnology and biopharmaceutical companies and many academic and research institutions. As a result, competition for certain skilled personnel in our market remains intense. None of our employees have employment commitments for any fixed period of time and they all may leave our employment at will. If we fail to retain our qualified personnel or replace them when they leave, we may be unable to continue our business operations, which may cause the price of our securities to fall.

We rely and will continue to rely on outsourcing arrangements for many of our activities, including financial reporting and accounting and human resources.

We currently have only thirteen full-time employees and, as a result, we rely, and expect to continue to rely, on outsourcing arrangements for a significant portion of our activities, including financial reporting and accounting and human resources, as well as for certain functions as a public company. We may have limited control over these third parties and we cannot guarantee that they will perform their obligations in an effective and timely manner.

As we continue to develop our business, our mix of assets and our sources of income may require that we register with the SEC as an “investment company” in accordance with the Investment Company Act of 1940.

We have not been and have no current intention to register as an “investment company” under the Investment Company Act of 1940, or the 40 Act, because we believe the nature of our assets and the sources of our income currently exclude us from the definition of an investment company pursuant to Sections (3)(a)(1)(A), (3)(a)(1)(C) under the 40 Act and Rule 270.3a-1 of Title 17 of the Code of Federal Regulations. Accordingly, we are not currently subject to the provisions of the 40 Act, such as compliance with the 40 Act’s registration and reporting requirements, capital structure requirements, affiliate transaction restrictions, conflict of interest rules, requirements for disinterested directors, and other substantive provisions. Generally, to avoid being a company that is an “investment company” under the 40 Act, it must both: (a) not be or hold itself out as being engaged primarily in the business of investing, reinvesting or trading in securities, and (b) either (i) not be engaged or propose to engage in the business of investing in securities or own or propose to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis or (ii) not have more than 45% of the value of its total assets (exclusive of Government securities and cash items) consist of or more than 45% of its net income after taxes (for the last four fiscal quarters combined) be derived from securities. In addition, we would not be an “investment company” if an exception, exemption, or safe harbor under the 40 Act applies.

We monitor our assets and income for compliance with the tests under the 40 Act and seek to conduct our business activities to ensure that we do not fall within its definitions of “investment company.” If we were to become an “investment company” and be subject to the strictures of the 40 Act, the restrictions imposed by the 40 Act would likely require changes in the way we do business and add significant administrative burdens to our operations. In order to ensure that we do not fall within the 40 Act, we may need to take various actions which we might otherwise not pursue. These actions may include restructuring the Company and/or modifying our mixture of assets and income.

Specifically, our mixture of debt vs. royalty assets is important to our classification as an “investment company” or not. In this regard, while we currently believe that none of the definitions of “investment company” apply to us, we may in the future rely on an

Table of Contents

exception under the 40 Act provided by Section 3(c)(5)(A). To qualify for Section 3(c)(5)(A), as interpreted by the staff of the SEC, we would be required to have at least 55% of our total assets in “notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services” (or Qualifying Assets). In a no-action letter issued to Royalty Pharma on August 13, 2010, the staff stated that royalty interests are Qualifying Assets under this exception. If the SEC or its staff in the future adopts a contrary interpretation or otherwise restricts the conclusions in the staff’s no-action letter such that our royalty interests are no longer Qualifying Assets for purposes of Section 3(c)(5)(A), we could be required to register under the 40 Act.

The rules and interpretations of the SEC and the courts, relating to the definition of “investment company” are highly complex in numerous respects. While we currently intend to conduct our operations so that we will not be deemed an investment company, we can give no assurances that we will not determine it to be in the Company’s and our stockholders’ interest to register as an “investment company”, not be deemed an “investment company” and not be required to register under the 40 Act.

Risks Related to our Alliance with GSK

Because all our current and projected revenues are derived from products under the GSK Agreements, disputes with GSK could harm our business and cause the price of our securities to fall.

All of our current and projected revenues are derived from products under the GSK Agreements. Any action or inaction by either GSK or us that results in a material dispute, allegation of breach, litigation, arbitration, or significant disagreement between the parties may be interpreted negatively by the market or by our investors, could harm our business and cause the price of our securities to fall. Examples of these kinds of issues include but are not limited to non-performance of contractual obligations and allegations of non-performance, disagreements over the relative marketing and sales efforts for our partnered products and other GSK respiratory products, disputes over public statements, and similar matters. In addition, while we obtained GSK’s consent to the Spin-Off as structured, GSK could decide to challenge various aspects of our post-Spin-Off operation of Theravance Respiratory Company, LLC (“TRC”), the limited liability company jointly owned by us and Theravance Biopharma as violating or allowing it to terminate the GSK Agreements. Although we believe our operation of TRC fully complies with the GSK Agreements and applicable law, there can be no assurance that we would prevail against any such claims by GSK. Moreover, regardless of the merit of any claims by GSK, we may incur significant cost and diversion of resources in defending them. In addition, any market or investor uncertainty about the respiratory programs partnered with GSK or the enforceability of the GSK Agreements could result in significant reduction in the market price of our securities and other material harm to our business.

Because GSK is a strategic partner as well as a significant stockholder, it may take actions that in certain cases are materially harmful to both our business or to our other stockholders.

Although GSK beneficially owns approximately 27% of our outstanding capital stock as of October 30, 2015, it is also a strategic partner with rights and obligations under the GSK Agreements that cause its interests to differ from the interests of us and our other stockholders. In particular, GSK has a substantial respiratory product portfolio in addition to the partnered products that are covered by the GSK Agreements. GSK may make respiratory product portfolio decisions or statements about its portfolio which may be, or may be perceived to be, harmful to the respiratory products partnered with us. For example, GSK could promote its non-GSK/Theravance respiratory products, delay or terminate the development or commercialization of the respiratory programs covered by the GSK Agreements, or take other actions, such as making public statements, that have a negative effect on our stock price. In this regard and by way of example, sales of Advair®, GSK’s approved medicine for both COPD and asthma, continue to be significantly greater than sales of RELVAR®/BREO® ELLIPTA®, and GSK has indicated publicly that it intends to continue commercializing Advair®. Also, given the potential future royalty payments GSK may be obligated to pay under the GSK Agreements, GSK may seek to acquire us to reduce those payment obligations. The timing of when GSK may seek to acquire us could potentially be when it possesses information regarding the status of drug programs covered by the GSK Agreements that has not been publicly disclosed and is not otherwise known to us. As a result of these differing interests, GSK may take actions that it believes are in its best interest but which might not be in the best interests of either us or our other stockholders. In addition, upon regulatory approval of UMEC/VI/FF or a MABA/ICS in either the U.S. or the EU, GSK’s diligent efforts obligations as to commercialization matters under the GSK Agreements will have the objective of focusing on the best interests of patients and maximizing the net value of the overall portfolio of products under the GSK Agreements. Since GSK’s commercialization efforts following such regulatory approval will be guided by a portfolio approach across products in which we have retained our full interest and also products in which we now have only a portion of our former interest, GSK’s commercialization efforts may have the effect of reducing the overall value of our remaining interests in the products covered by the GSK Agreements in the future. In addition, following the expiration of our governance agreement with GSK in September 2015, GSK is no longer subject to the restrictions thereunder regarding the voting of the shares of our capital stock owned by it.

Table of Contents

GSK has also indicated to us that it believes its consent may be required before we can engage in certain royalty monetization transactions with third parties, which may inhibit our ability to engage in these transactions.

In the course of our discussions with GSK concerning the Spin-Off of Theravance Biopharma, GSK indicated to us that it believes that its consent may be required before we can engage in certain transactions designed to monetize the future value of royalties that may be payable to us from GSK under the GSK Agreements. GSK has informed us that it believes that there may be certain covenants included in these types of transactions that might violate certain provisions of the GSK Agreements. Although we believe that we can structure royalty monetization transactions in a manner that fully complies with the requirements of the GSK Agreements without GSK’s consent, a third party in a proposed monetization transaction may nonetheless insist that we obtain GSK’s consent for the transaction or re-structure the transaction on less favorable terms. We have obtained GSK’s agreement that (i) we may grant certain pre-agreed covenants in connection with monetization of our interests in RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and vilanterol monotherapy and portions of our interests in TRC, and (ii) it will not unreasonably withhold its consent to our requests to grant other covenants, provided, among other conditions, that in each case, the covenants are not granted in favor of pharmaceutical or biotechnology company with a product either being developed or commercialized for the treatment of respiratory disease. If we seek GSK’s consent to grant covenants other than pre-agreed covenants, we may not be able to obtain GSK’s consent on reasonable terms, or at all. If we proceed with a royalty monetization transaction that is not otherwise covered by the GSK Agreement without GSK’s consent, GSK could request that its consent be obtained or seek to enjoin or otherwise challenge the transaction as violating or allowing it to terminate the GSK Agreements. Regardless of the merit of any claims by GSK, we would incur significant cost and diversion of resources in defending against GSK’s claims or asserting our own claims and GSK may seek concessions from us in order to provide its consent. Any uncertainty about whether or when we could engage in a royalty monetization transaction, the potential impact on the enforceability of the GSK Agreements or the loss of potential royalties from the respiratory programs partnered with GSK, could impair our ability to pursue a return of capital strategy for our stockholders ahead of our receipt of significant royalties from GSK, result in significant reduction in the market price of our securities and cause other material harm to our business.

GSK’s ownership of a significant percentage of our stock and its ability to acquire additional shares of our stock may create conflicts of interest, and may inhibit our management’s ability to continue to operate our business in the manner in which it is currently being operated.

As of October 31, 2015, GSK beneficially owned approximately 27% of our outstanding capital stock. As such, GSK could have substantial influence in the election of our directors, delay or prevent a transaction in which stockholders might receive a premium over the prevailing market price for their shares and have significant control over certain changes in our business. Moreover, if GSK does not participate in the tender offer we commenced on October 30, 2015, it will further concentrate its ownership of Theravance.

The procedures previously governing and restricting GSK offers to our stockholders to acquire outstanding voting stock and the restrictions regarding the voting of shares of our capital stock owned by it terminated upon the expiration of the governance agreement on September 1, 2015.

Further, pursuant to our Certificate of Incorporation, we renounce our interest in and waive any claim that a corporate or business opportunity taken by GSK constitutes a corporate opportunity of ours unless such corporate or business opportunity is expressly offered to one of our directors who is a director, officer or employee of GSK, primarily in his or her capacity as one of our directors.

GSK’s significant ownership position may deter or prevent efforts by other companies to acquire us, which could prevent our stockholders from realizing a control premium.

As of October 31, 2015, GSK beneficially owned approximately 27% of our outstanding capital stock. As a result of GSK’s significant ownership, other companies may be less inclined to pursue an acquisition of us and therefore we may not have the opportunity to be acquired in a transaction that stockholders might otherwise deem favorable, including transactions in which our stockholders might realize a substantial premium for their shares. If GSK does not participate in the tender offer we commenced on October 30, 2015, it will further concentrate its ownership of Theravance.

GSK could sell or transfer a substantial number of shares of our common stock, which could depress the price of our securities or result in a change in control of our company.

GSK is not subject to any contractual restrictions with us on its ability to sell or transfer our common stock on the open market, in privately negotiated transactions or otherwise, and these sales or transfers could create substantial declines in the price of our

Table of Contents

securities or, if these sales or transfers were made to a single buyer or group of buyers, could contribute to a transfer of control of our company to a third party. Sales by GSK of a substantial number of shares, or the expectation of such sales, could cause a significant reduction in the market price of our common stock.

Risks Related to Legal and Regulatory Uncertainty

If the efforts of our partner, GSK, to protect the proprietary nature of the intellectual property related to products in any respiratory program partnered with GSK are not adequate, the future commercialization of any such product could be delayed, limited or prevented, which would materially harm our business and the price of our securities could fall.

To the extent the intellectual property protection of products in any respiratory program partnered with GSK are successfully challenged or encounter problems with the U.S. Patent and Trademark Office or other comparable agencies throughout the world, the commercialization of these products could be delayed, limited or prevented. Any challenge to the intellectual property protection of a late-stage development asset or approved product arising from any respiratory program partnered with GSK could harm our business and cause the price of our securities to fall.

Our commercial success depends in part on products in any respiratory program partnered with GSK not infringing the patents and proprietary rights of third parties. Third parties may assert that these products are using their proprietary rights without authorization. In addition, third parties may obtain patents in the future and claim that use of GSK’s technologies infringes upon these patents. Furthermore, parties making claims against GSK may obtain injunctive or other equitable relief, which could effectively block GSK’s ability to further develop or commercialize one or more of the product candidates or products in any respiratory program partnered with GSK.

In the event of a successful claim of infringement against GSK, it may have to pay substantial damages, obtain one or more licenses from third parties or pay royalties. In addition, even in the absence of litigation, GSK may need to obtain licenses from third parties to advance its research or allow commercialization of the products. GSK may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, GSK would be unable to further develop and commercialize one or more of the products, which could harm our business significantly. In addition, in the future GSK could be required to initiate litigation to enforce its proprietary rights against infringement by third parties. Prosecution of these claims to enforce its rights against others would involve substantial litigation expenses. If GSK fails to effectively enforce its proprietary rights related to our partnered respiratory programs against others, our business will be harmed, and the price of our securities could fall.

Risks Related to Ownership of our Common Stock

The price of our securities has been extremely volatile and may continue to be so, and purchasers of our securities could incur substantial losses.

The price of our securities has been extremely volatile and may continue to be so. Between January 1, 2015 and September 30, 2015, the high and low sales prices of our common stock as reported on The NASDAQ Global Select Market varied between $6.36 and $21.16 per share. The stock market in general and the market for biotechnology and biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the companies’ operating performance, in particular during the last several years. The following factors, in addition to the other risk factors described in this section, may also have a significant impact on the market price of our securities:

· any adverse developments or results or perceived adverse developments or results with respect to the commercialization of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® with GSK, including, without limitation, if payor coverage is lower than anticipated or if sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® are less than anticipated because of pricing pressure in the respiratory markets targeted by our partnered products or existing or future competition in the markets in which they are commercialized, including competition from existing and new products that are perceived as lower cost or more effective, and our royalty payments are less than anticipated;

· any positive developments or results or perceived positive developments or results with respect to the development of UMEC/VI/FF with GSK, including, without limitation if the new Phase 3 study (or any other closed triple Phase 3 studies that may be initiated in the future) is successful and GSK and the respiratory market in general view this triple combination therapy as significantly more beneficial than existing therapies, including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®;

· any adverse developments or results or perceived adverse developments or results with respect to the on-going development of FF/VI with GSK, including, without limitation, any difficulties or delays encountered with the regulatory path for

Table of Contents

FF/VI or any indication from clinical or non-clinical studies, including the large Phase 3b program, that FF/VI is not safe or efficacious or does not sufficiently differentiate itself from alternative therapies;

· any adverse developments or results or perceived adverse developments or results with respect to the on-going development of UMEC/VI with GSK, including, without limitation, any difficulties or delays encountered with regard to the regulatory path for UMEC/VI, any indication from clinical or non-clinical studies that UMEC/VI is not safe or efficacious;

· any adverse developments or perceived adverse developments in the field of LABAs, including any change in FDA policy or guidance (such as the pronouncement in February 2010 warning that LABAs should not be used alone in the treatment of asthma and related labeling requirements, the impact of the March 2010 FDA Advisory Committee discussing LABA clinical trial design to evaluate serious asthma outcomes or the FDA’s April 2011 announcement that manufacturers of currently marketed LABAs conduct additional clinical studies comparing the addition of LABAs to inhaled corticosteroids versus inhaled corticosteroids alone);

· the occurrence of a fundamental change triggering a put right of the holders of the Notes or our inability, or perceived inability, to satisfy the obligations under the Notes when they become due;

· our incurrence of expenses in any particular quarter that are different than market expectations;

· the extent to which GSK advances (or does not advance) FF/VI, UMEC/VI, UMEC/VI/FF, VI monotherapy and the MABA program through development into commercialization in all indications in all major markets;

· any adverse developments or perceived adverse developments with respect to our relationship with GSK, including, without limitation, disagreements that may arise between us and GSK;

· announcements regarding GSK generally;

· announcements of patent issuances or denials, technological innovations or new commercial products by GSK;

· publicity regarding actual or potential study results or the outcome of regulatory review relating to products under development by GSK;

· regulatory developments in the U.S. and foreign countries;

· economic and other external factors beyond our control;

· sales of stock by us or by our stockholders, including sales by certain of our employees and directors whether or not pursuant to selling plans under Rule 10b5-1 of the Securities Exchange Act of 1934;

· relative illiquidity in the public market for our common stock (our three largest stockholders other than GSK collectively owned approximately 27% of our outstanding capital stock as of October 30, 2015 based on our review of publicly available filings); and

· potential sales or purchases of our capital stock by GSK.

We may be unable to or elect not to continue returning capital to our stockholders.

We have a corporate goal of returning capital to stockholders and have paid quarterly dividends during the 3rd and 4th quarters of 2014 and during the first three quarters of 2015. On October 28, 2015, we announced the acceleration of our capital return plan with a $150 million share repurchase program approved by our Board of Directors, replacing our quarterly dividend. We currently intend to repurchase our shares through the end of 2016 through a combination of the tender offer which commenced on October 30, 2015 and, open market purchases, and may also repurchase shares through private transactions, exchange offers, additional tender offers or other means. The repurchase program will be funded using our working capital. Our announcement of our share repurchase program does not obligate us to repurchase any specific dollar amount or number of shares of common stock. We will determine when, if and how to proceed with any repurchase transactions under the program, as well as the amount of any such repurchase transactions, based upon, among other things, the results of the tender offer and our evaluation of our liquidity and capital needs (including for strategic and other opportunities), our business, results of operations, and financial position and prospects, general

Table of Contents

financial, economic and market conditions, prevailing market prices for our shares of common stock, corporate, regulatory and legal requirements, and other conditions and factors deemed relevant by our management and Board of Directors from time to time. The share repurchase program may be suspended or discontinued at any time. There can be no assurance as to the actual volume of any share repurchases in any given period or over the term of the program or as to the manner or terms of any such repurchases.

The payment of, or continuation of, capital returns to stockholders is at the discretion of our board of directors and is dependent upon our financial condition, results of operations, capital requirements, general business conditions, tax treatment of capital returns, potential future contractual restrictions contained in credit agreements and other agreements and other factors deemed relevant by our board of directors. Future capital returns may also be affected by, among other factors: our views on potential future capital requirements for investments in acquisitions and our working capital and debt maintenance requirements; legal risks; stock repurchase programs; changes in federal and state income tax laws or corporate laws; and changes to our business model. Our capital returns may change from time to time, and we cannot provide assurance that we will continue to provide any particular amounts. A reduction, change or suspension in our capital returns programs could have a negative effect on our stock price.

Concentration of ownership will limit your ability to influence corporate matters.

As of October 30, 2015, GSK beneficially owned approximately 27% of our outstanding capital stock and our directors, executive officers and investors affiliated with these individuals beneficially owned approximately 1% of our outstanding capital stock. Based on our review of publicly available filings as of October 30, 2015, our three largest stockholders other than GSK collectively owned approximately 42% of our outstanding capital stock. These stockholders could control the outcome of actions taken by us that require stockholder approval, including a transaction in which stockholders might receive a premium over the prevailing market price for their shares. If certain of our large stockholders do not participate in the tender offer we commenced on October 30, 2015, it will further concentrate their ownership of Theravance. In addition, following the expiration of the governance agreement in September 2015, GSK is no longer subject to the restrictions thereunder regarding the voting of the shares of our capital stock owned by it.

Anti-takeover provisions in our charter and bylaws and in Delaware law could prevent or delay a change in control of our company.

Provisions of our Certificate of Incorporation and Bylaws may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions include:

· requiring supermajority stockholder voting to effect certain amendments to our Certificate of Incorporation and Bylaws;

· restricting the ability of stockholders to call special meetings of stockholders;

· prohibiting stockholder action by written consent; and

· establishing advance notice requirements for nominations for election to the Board or for proposing matters that can be acted on by stockholders at meetings.

In addition, some provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On March 5, 2015, May 11, 2015 and August 12, 2015, we completed the sale of 92,674, 85,579 and 245,828 shares of our common stock to Glaxo Group Limited, an affiliate of GSK, at a price of $18.06, $16.00 and $14.18, respectively, per share, resulting in aggregate gross proceeds of $6.5 million before deducting transaction expenses. Neither we nor the affiliate of GSK engaged any investment advisors with respect to the sale and no underwriting discounts or commissions were paid or will be paid to any party in connection with the sale. We issued and sold the shares in reliance upon an exemption from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

Table of Contents

Item 6. Exhibits

(a) Index to Exhibits

Exhibit Number	Description	Form	Incorporated by Reference Filing Date/Period End Date
3.3	Amended and Restated Certificate of Incorporation	S-1	7/26/04

3.4	Certificate of Amendment of Restated Certificate of Incorporation	10-Q	3/31/07

3.5	Amended and Restated Bylaws (as amended by the board of directors April 25, 2007)	10-Q	9/30/08

3.6	Amended and Restated Bylaws (as amended by the board of directors October 22, 2015)	8-K	10/28/15

4.1	Specimen certificate representing the common stock of the registrant	10-K	12/31/06

4.4	Indenture dated as of January 24, 2013 by and between Theravance, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee	8-K	1/25/13

4.5	Form of 2.125% Convertible Subordinated Note Due 2023 (included in Exhibit 4.4)

10.64	First Amendment to 2029 Severance Plan	8-K (filed as Exhibit 10.2)	7/29/15

31.1	Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended

31.2	Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended

32	Certifications Pursuant to 18 U.S.C. Section 1350

101	Financial statements from the quarterly report on Form 10-Q of the Company for the three and nine months ended September 30, 2015 (unaudited), formatted in XBRL: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Loss, (iv) the Condensed Consolidated Statements of Cash Flows and (iv) the Notes to the Condensed Consolidated Financial Statements

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Theravance, Inc.


Date: November 5, 2015	/s/ Michael W. Aguiar
	Michael W. Aguiar
	Chief Executive Officer
	(principal executive officer)

Date: November 5, 2015	/s/ Eric d’Esparbes
	Eric d’Esparbes
	Senior Vice President, Finance and Chief Financial Officer (principal financial and principal accounting officer)

EX-31.1 2 a15-17874_1ex31d1.htm EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Michael W. Aguiar, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Theravance, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2015	/s/ Michael W. Aguiar
	Michael W. Aguiar
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 a15-17874_1ex31d2.htm EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Eric d’Esparbes, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Theravance, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2015	/s/ Eric d’Esparbes
	Eric d’Esparbes
	Senior Vice President, Finance and
	Chief Financial Officer
	(Principal Financial Officer)

EX-32 4 a15-17874_1ex32.htm EX-32

Exhibit 32

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael W. Aguiar, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Theravance, Inc. on Form 10-Q for the nine months ended September 30, 2015 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition of Theravance, Inc. at the end of the periods covered by such Quarterly Report on Form 10-Q and results of operations of Theravance, Inc. for the periods covered by such Quarterly Report on Form 10-Q.

Date: November 5, 2015	By:	/s/ Michael W. Aguiar
		Michael W. Aguiar
		Chief Executive Officer

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Eric d’Esparbes, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Theravance, Inc. on Form 10-Q for the nine months ended September 30, 2015 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition of Theravance, Inc. at the end of the periods covered by such Quarterly Report on Form 10-Q and results of operations of Theravance, Inc. for the periods covered by such Quarterly Report on Form 10-Q.

Date: November 5, 2015	By:	/s/ Eric d’Esparbes
		Eric d’Esparbes
		Senior Vice President, Finance and Chief Financial Officer

EX-101.INS 5 thrx-20150930.xml XBRL INSTANCE DOCUMENT 0001080014 thrx:ModifiedDutchAuctionTenderOfferMember us-gaap:SubsequentEventMember 2015-10-30 0001080014 thrx:ShareRepurchaseProgramApprovedOctober2015Member us-gaap:SubsequentEventMember 2015-10-28 0001080014 us-gaap:EmployeeStockMember 2015-09-30 0001080014 thrx:EquityIncentivePlan2012Member 2015-09-30 0001080014 thrx:PerformanceContingentMember us-gaap:RestrictedStockMember thrx:SpecialLongTermRetentionAwards2011Member 2011-12-31 0001080014 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0001080014 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0001080014 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0001080014 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0001080014 thrx:PerformanceContingentMember us-gaap:RestrictedStockMember thrx:SpecialLongTermRetentionAwards2011Member 2015-09-30 0001080014 thrx:PerformanceContingentMember us-gaap:RestrictedStockMember thrx:SpecialLongTermRetentionAwards2011Member 2011-01-01 2011-12-31 0001080014 thrx:Percent9FixedRateTermNotesDue2029Member 2015-09-30 0001080014 thrx:Percent9FixedRateTermNotesDue2029Member 2014-12-31 0001080014 us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001080014 us-gaap:CommonStockMember 2014-01-01 2014-09-30 0001080014 thrx:IssuerOtherThanTheravanceBiopharmaMember 2015-01-01 2015-09-30 0001080014 thrx:Percent2.125ConvertibleDebtMember thrx:PrivatelyNegotiatedCappedCallOptionMember 2015-01-01 2015-09-30 0001080014 thrx:Percent2.125ConvertibleDebtMember thrx:PrivatelyNegotiatedCappedCallOptionMember 2014-06-30 2014-06-30 0001080014 thrx:TheravanceBiopharmaMember us-gaap:PropertyLeaseGuaranteeMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent9FixedRateTermNotesDue2029Member 2015-09-30 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent9FixedRateTermNotesDue2029Member 2015-09-30 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent9FixedRateTermNotesDue2029Member 2015-09-30 0001080014 us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent9FixedRateTermNotesDue2029Member 2015-09-30 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent9FixedRateTermNotesDue2029Member 2014-12-31 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent9FixedRateTermNotesDue2029Member 2014-12-31 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent9FixedRateTermNotesDue2029Member 2014-12-31 0001080014 us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent9FixedRateTermNotesDue2029Member 2014-12-31 0001080014 thrx:Percent9FixedRateTermNotesDue2029Member thrx:GSKMember 2015-07-01 2015-09-30 0001080014 thrx:Percent9FixedRateTermNotesDue2029Member thrx:GSKMember 2015-01-01 2015-09-30 0001080014 thrx:Percent9FixedRateTermNotesDue2029Member thrx:GSKMember 2014-07-01 2014-09-30 0001080014 thrx:Percent9FixedRateTermNotesDue2029Member thrx:GSKMember 2014-04-01 2015-09-30 0001080014 thrx:Percent9FixedRateTermNotesDue2029Member thrx:GSKMember 2014-01-01 2014-09-30 0001080014 us-gaap:PropertyLeaseGuaranteeMember 2015-09-30 0001080014 thrx:TheravanceBiopharmaMember 2015-01-01 2015-09-30 0001080014 us-gaap:RestrictedStockUnitsRSUMember 2015-09-30 0001080014 us-gaap:RestrictedStockMember 2015-09-30 0001080014 us-gaap:EmployeeStockOptionMember 2015-09-30 0001080014 thrx:Percent2.125ConvertibleDebtMember thrx:PrivatelyNegotiatedCappedCallOptionMember 2013-01-31 2013-01-31 0001080014 thrx:Percent2.125ConvertibleDebtMember thrx:PrivatelyNegotiatedCappedCallOptionMember 2015-09-30 0001080014 thrx:Percent2.125ConvertibleDebtMember thrx:PrivatelyNegotiatedCappedCallOptionMember 2014-06-30 0001080014 us-gaap:DeferredBonusMember 2011-01-01 2011-12-31 0001080014 us-gaap:DeferredBonusMember 2014-05-31 0001080014 us-gaap:DeferredBonusMember 2014-01-01 2014-03-31 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2015-09-30 0001080014 us-gaap:FairValueMeasurementsNonrecurringMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2014-12-31 0001080014 us-gaap:FairValueMeasurementsNonrecurringMember 2014-12-31 0001080014 thrx:Percent2.125ConvertibleDebtMember 2015-01-01 2015-09-30 0001080014 thrx:Percent2.125ConvertibleDebtMember 2014-06-30 2014-06-30 0001080014 thrx:Percent2.125ConvertibleDebtMember 2013-01-01 2013-01-31 0001080014 thrx:Percent2.125ConvertibleDebtMember us-gaap:CommonStockMember 2014-07-15 0001080014 thrx:Percent2.125ConvertibleDebtMember 2014-06-30 0001080014 thrx:Percent2.125ConvertibleDebtMember 2013-01-31 0001080014 thrx:Percent2.125ConvertibleDebtMember us-gaap:CommonStockMember 2014-07-15 2014-07-15 0001080014 thrx:Percent2.125ConvertibleDebtMember 2015-09-30 0001080014 thrx:Percent2.125ConvertibleDebtMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent2.125ConvertibleDebtMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent2.125ConvertibleDebtMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent2.125ConvertibleDebtMember 2015-09-30 0001080014 us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent2.125ConvertibleDebtMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent2.125ConvertibleDebtMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent2.125ConvertibleDebtMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent2.125ConvertibleDebtMember 2014-12-31 0001080014 us-gaap:FairValueMeasurementsNonrecurringMember thrx:Percent2.125ConvertibleDebtMember 2014-12-31 0001080014 2015-07-24 2015-07-24 0001080014 2015-04-24 2015-04-24 0001080014 2015-02-20 2015-02-20 0001080014 2014-09-30 0001080014 2013-12-31 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-09-30 0001080014 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2015-09-30 0001080014 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0001080014 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-09-30 0001080014 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2015-09-30 0001080014 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001080014 us-gaap:USTreasuryAndGovernmentMember 2015-09-30 0001080014 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0001080014 us-gaap:ShortTermInvestmentsMember 2015-09-30 0001080014 us-gaap:MoneyMarketFundsMember 2015-09-30 0001080014 us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001080014 us-gaap:CorporateNoteSecuritiesMember 2015-09-30 0001080014 us-gaap:CommercialPaperMember 2015-09-30 0001080014 us-gaap:CashAndCashEquivalentsMember 2015-09-30 0001080014 thrx:MarketableSecuritiesMember 2015-09-30 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2014-12-31 0001080014 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2014-12-31 0001080014 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2014-12-31 0001080014 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2014-12-31 0001080014 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001080014 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001080014 us-gaap:ShortTermInvestmentsMember 2014-12-31 0001080014 us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001080014 us-gaap:CashAndCashEquivalentsMember 2014-12-31 0001080014 thrx:MarketableSecuritiesMember 2014-12-31 0001080014 us-gaap:RestrictedStockUnitsRSUMember 2015-07-01 2015-09-30 0001080014 us-gaap:RestrictedStockMember 2015-07-01 2015-09-30 0001080014 us-gaap:RestrictedStockMember 2015-07-01 2015-09-30 0001080014 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001080014 us-gaap:ConvertibleSubordinatedDebtMember 2015-07-01 2015-09-30 0001080014 thrx:EquityIncentivePlansAndESPPMember 2015-07-01 2015-09-30 0001080014 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-09-30 0001080014 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001080014 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001080014 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001080014 us-gaap:ConvertibleSubordinatedDebtMember 2015-01-01 2015-09-30 0001080014 thrx:EquityIncentivePlansAndESPPMember 2015-01-01 2015-09-30 0001080014 us-gaap:RestrictedStockMember 2014-07-01 2014-09-30 0001080014 us-gaap:ConvertibleSubordinatedDebtMember 2014-07-01 2014-09-30 0001080014 thrx:EquityIncentivePlansAndESPPMember 2014-07-01 2014-09-30 0001080014 us-gaap:RestrictedStockMember 2014-01-01 2014-09-30 0001080014 us-gaap:ConvertibleSubordinatedDebtMember 2014-01-01 2014-09-30 0001080014 thrx:EquityIncentivePlansAndESPPMember 2014-01-01 2014-09-30 0001080014 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2015-07-01 2015-09-30 0001080014 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2015-07-01 2015-09-30 0001080014 us-gaap:SegmentDiscontinuedOperationsMember 2015-07-01 2015-09-30 0001080014 us-gaap:SegmentContinuingOperationsMember 2015-07-01 2015-09-30 0001080014 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2015-01-01 2015-09-30 0001080014 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2015-01-01 2015-09-30 0001080014 us-gaap:SegmentDiscontinuedOperationsMember 2015-01-01 2015-09-30 0001080014 us-gaap:SegmentContinuingOperationsMember 2015-01-01 2015-09-30 0001080014 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2014-07-01 2014-09-30 0001080014 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2014-07-01 2014-09-30 0001080014 us-gaap:SegmentContinuingOperationsMember 2014-07-01 2014-09-30 0001080014 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2014-01-01 2014-09-30 0001080014 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2014-01-01 2014-09-30 0001080014 us-gaap:SegmentContinuingOperationsMember 2014-01-01 2014-09-30 0001080014 thrx:PerformanceContingentMember us-gaap:RestrictedStockMember thrx:SpecialLongTermRetentionAwards2011Member 2014-01-01 2014-05-31 0001080014 thrx:PerformanceContingentMember us-gaap:RestrictedStockMember thrx:SpecialLongTermRetentionAwards2011Member 2014-06-01 2014-06-30 0001080014 us-gaap:MinimumMember thrx:ModifiedDutchAuctionTenderOfferMember us-gaap:SubsequentEventMember 2015-10-30 2015-10-30 0001080014 us-gaap:MaximumMember thrx:ModifiedDutchAuctionTenderOfferMember us-gaap:SubsequentEventMember 2015-10-30 2015-10-30 0001080014 thrx:GSKMember us-gaap:CommonStockMember thrx:GovernanceAgreementMember 2015-01-01 2015-09-30 0001080014 us-gaap:EmployeeStockMember 2015-01-01 2015-09-30 0001080014 thrx:Percent9FixedRateTermNotesDue2029Member thrx:GSKMember 2014-04-30 0001080014 thrx:GSKMember thrx:LABACollaborationAndStrategicAllianceAgreementMember 2015-01-01 2015-09-30 0001080014 thrx:Percent2.125ConvertibleDebtMember us-gaap:CallOptionMember us-gaap:MinimumMember 2013-01-31 2013-01-31 0001080014 thrx:Percent2.125ConvertibleDebtMember us-gaap:CallOptionMember us-gaap:MaximumMember 2013-01-31 2013-01-31 0001080014 thrx:Percent2.125ConvertibleDebtMember thrx:PrivatelyNegotiatedCappedCallOptionMember 2013-01-31 0001080014 us-gaap:DeferredBonusMember 2014-05-01 2014-05-31 0001080014 thrx:TheravanceBiopharmaMember us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001080014 thrx:Percent2.125ConvertibleDebtMember us-gaap:PutOptionMember 2013-01-31 2013-01-31 0001080014 thrx:Percent2.125ConvertibleDebtMember 2013-01-31 2013-01-31 0001080014 2014-06-01 2014-06-01 0001080014 2014-06-02 2014-06-02 0001080014 thrx:GSKMember thrx:BifunctionalMuscarinicAntagonistBeta2AgonistMember thrx:StrategicAllianceAgreementMember 2015-07-01 2015-09-30 0001080014 thrx:GSKMember thrx:BifunctionalMuscarinicAntagonistBeta2AgonistMember thrx:StrategicAllianceAgreementMember 2015-01-01 2015-09-30 0001080014 thrx:GSKMember thrx:BifunctionalMuscarinicAntagonistBeta2AgonistMember thrx:StrategicAllianceAgreementMember 2014-07-01 2014-09-30 0001080014 thrx:GSKMember thrx:BifunctionalMuscarinicAntagonistBeta2AgonistMember thrx:StrategicAllianceAgreementMember 2014-01-01 2014-09-30 0001080014 us-gaap:SegmentDiscontinuedOperationsMember 2014-07-01 2014-09-30 0001080014 us-gaap:SegmentDiscontinuedOperationsMember 2014-01-01 2014-09-30 0001080014 thrx:GSKMember thrx:BifunctionalMuscarinicAntagonistBeta2AgonistMember 2015-09-30 0001080014 thrx:GSKMember us-gaap:MinimumMember thrx:LABACollaborationMember 2015-01-01 2015-09-30 0001080014 thrx:GSKMember us-gaap:MaximumMember thrx:LABACollaborationMember 2015-01-01 2015-09-30 0001080014 2015-09-30 0001080014 us-gaap:USTreasuryAndGovernmentMember 2014-12-31 0001080014 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2014-12-31 0001080014 us-gaap:MoneyMarketFundsMember 2014-12-31 0001080014 us-gaap:EquitySecuritiesMember 2014-12-31 0001080014 us-gaap:CorporateNoteSecuritiesMember 2014-12-31 0001080014 us-gaap:CommercialPaperMember 2014-12-31 0001080014 2014-12-31 0001080014 thrx:GSKMember thrx:LABACollaborationMember 2015-07-01 2015-09-30 0001080014 thrx:GSKMember 2015-07-01 2015-09-30 0001080014 2015-07-01 2015-09-30 0001080014 thrx:GSKMember thrx:LABACollaborationMember 2015-01-01 2015-09-30 0001080014 thrx:GSKMember 2015-01-01 2015-09-30 0001080014 thrx:GSKMember thrx:LABACollaborationMember 2014-07-01 2014-09-30 0001080014 thrx:GSKMember 2014-07-01 2014-09-30 0001080014 2014-07-01 2014-09-30 0001080014 thrx:GSKMember thrx:LABACollaborationMember 2014-01-01 2014-09-30 0001080014 thrx:GSKMember 2014-01-01 2014-09-30 0001080014 2014-01-01 2014-09-30 0001080014 thrx:GSKMember thrx:LABACollaborationMember 2015-09-30 0001080014 thrx:GSKMember thrx:LABACollaborationMember 2014-12-31 0001080014 2015-10-30 0001080014 2015-01-01 2015-09-30 iso4217:USD thrx:item iso4217:USD xbrli:shares thrx:item xbrli:pure iso4217:USD xbrli:shares false --12-31 Q3 2015 2015-09-30 10-Q 0001080014 117425815 Yes Large Accelerated Filer THERAVANCE INC 11809000 22176000 7611000 7611000 7600000 3233000 3233000 3200000 10367000 10367000 10400000 3455000 3455000 3500000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   4. Available-for-Sale Securities and Fair Value Measurements   Available-for-Sale Securities   The classification of available-for-sale securities in the condensed consolidated balance sheets is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:68.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2015 </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2014 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;background-color: #CCEEFF;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76,077  </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,090  </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;padding:0pt;"> Short-term marketable securities </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,446  </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>143,698  </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;background-color: #CCEEFF;padding:0pt;"> Marketable securities </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,856  </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>203,523  </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,644  </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> </table></div>   The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:38.96%;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2015 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:38.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Amortized Cost </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Gross Unrealized Gains </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Gross Unrealized Losses </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Estimated Fair Value </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.96%;background-color: #CCEEFF;padding:0pt;"> U.S. government securities </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,503 </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3 </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,506 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.96%;padding:0pt;"> U.S. government agencies </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,965 </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2 </td> <td valign="bottom" style="width:02.58%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,972 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.96%;background-color: #CCEEFF;padding:0pt;"> Corporate notes </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,485 </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3 </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2 </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,486 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.96%;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54,702 </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54,702 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.96%;background-color: #CCEEFF;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,857 </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,857 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.96%;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>203,512 </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15 </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4 </td> <td valign="bottom" style="width:02.58%;"> ) </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>203,523 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.96%;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:31.96%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="14" valign="bottom" style="width:64.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2014 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Amortized Cost </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Gross Unrealized Gains </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Gross Unrealized Losses </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other Than Temporary Impairment Loss </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Estimated Fair Value </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.96%;background-color: #CCEEFF;padding:0pt;"> U.S. government securities </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,019 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,043 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.96%;padding:0pt;"> U.S. government agencies </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,756 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12 </td> <td valign="bottom" style="width:02.68%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,750 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.96%;background-color: #CCEEFF;padding:0pt;"> Corporate notes </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,880 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(110 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,775 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.96%;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,469 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,469 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.96%;background-color: #CCEEFF;padding:0pt;"> Ordinary shares of Theravance Biopharma </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,269 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,752 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,517 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.96%;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,090 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,090 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.96%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.96%;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>285,483 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(122 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,752 </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,644 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of September 30, 2015, all of the available-for-sale securities had contractual maturities within one year and the weighted average duration of marketable securities was approximately three months. We do not intend to sell the investments that are in an unrealized loss position, and it is unlikely that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. We have determined that the gross unrealized losses on our marketable securities as of September 30, 2015 were temporary in nature. As of September 30, 2015, all marketable securities with unrealized losses have been in a loss position for less than twelve months.   During the nine months ended September 30, 2015, we recognized a gain of $1.2 million from the sale of all of the ordinary shares of Theravance Biopharma that we held as of December 31, 2014, which is included in other income (expense), net in the condensed consolidated statement of operations. In addition, we sold other available-for-sale securities totaling $49.4 million, and the related realized gains and losses were not significant during the nine months ended September 30, 2015.   Fair Value Measurements   Our available-for-sale securities are measured at fair value on a recurring basis and our debt is carried at the amortized cost basis. The estimated fair values were as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Estimated Fair Value Measurements as of September 30, 2015 Using: </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> Types of Instruments </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Quoted Price in Active Markets for Identical Assets </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Other Observable Inputs </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Unobservable Inputs </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Assets </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> U.S. government securities </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,506  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,506  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> U.S. government agencies </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,972  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,972  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Corporate notes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,486  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,486  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54,702  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54,702  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,857  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,857  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Total assets measured at estimated fair value </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51,363  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>152,160  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>203,523  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Liabilities </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Convertible subordinated notes due 2023 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169,362  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169,362  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Non-recourse notes due 2029 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>464,527  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>464,527  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Total fair value of liabilities </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>633,889  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>633,889  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Estimated Fair Value Measurements as of December 31, 2014 Using: </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> Types of Instruments </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Quoted Price in Active Markets for Identical Assets </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Other Observable Inputs </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Unobservable Inputs </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Assets </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> U.S. government securities </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,043  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,043  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> U.S. government agencies </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,750  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,750  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Corporate notes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,775  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,775  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,469  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,469  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Ordinary shares of Theravance Biopharma </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,517  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,517  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,090  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,090  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Total assets measured at estimated fair value </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131,650  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>149,994  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,644  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Liabilities </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Convertible subordinated notes due 2023 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>197,095  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>197,095  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Non-recourse notes due 2029 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>456,411  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>456,411  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Total fair value of liabilities </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>653,506  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>653,506  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   The fair value of our marketable securities classified within Level 2 were derived from observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications.   The fair value of our convertible subordinated notes due 2023 and non-recourse notes due 2029 is based on recent trading prices of the instruments, if applicable, or pricing models that utilize current observable market characteristics for similar types of instruments. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div> 3752000 0 0 3752000 0 0 0 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   Business Separation   On June 1, 2014, we separated our biopharmaceutical research and drug development operations from our late-stage partnered respiratory assets by transferring our research and drug development operations into our then wholly-owned subsidiary, Theravance Biopharma, Inc. (“Theravance Biopharma”). We contributed $393.0 million of cash, cash equivalents and marketable securities to Theravance Biopharma and all outstanding shares of Theravance Biopharma were then distributed to Theravance stockholders as a pro-rata dividend distribution on June 2, 2014 by issuing one ordinary share of Theravance Biopharma for every 3.5 shares of our common stock to stockholders of record on May 15, 2014 (the “Spin-Off”). The Spin-Off resulted in Theravance Biopharma becoming an independent, publicly traded company.   The results of operations for the former research and drug development operations conducted by us and by Theravance Biopharma until June 1, 2014 are included as part of this report as discontinued operations for the three and nine months ended September 30, 2014. Refer to Note 11 “Discontinued Operations” for further information. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div> 125300000 3500000 13800000 13800000 13800000 13800000 13800000 220000000 220000000 208191000 208191000 197824000 197824000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   5. Capitalized Fees Paid to a Related Party   Capitalized fees paid to a related party, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td colspan="10" valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2015 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2014 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;padding:0pt;"> Amortization </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Net </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Net </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;padding:0pt;"> Period </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Carrying </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Accumulated </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Carrying </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Carrying </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Accumulated </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Carrying </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (Years) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Value </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Amortization </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Value </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Value </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Amortization </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:15.16%;background-color: #CCEEFF;padding:0pt;"> Approval and launch related milestone payments under the LABA Collaboration </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14.4 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220,000 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,176 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>197,824 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220,000 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,809 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;"> )   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>208,191 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   These milestone fees are being amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization expense recorded as a reduction in revenue from collaborative arrangements. Additional information regarding these milestone fees is included in Note 3, “Collaborative Arrangements”. Amortization expense for the three and nine months ended September 30, 2015 was $3.5 million and $10.4 million, respectively. Amortization expense for the three and nine months ended September 30, 2014 was $3.2 million and $7.6 million, respectively. As of September 30, 2015, the remaining estimated amortization expense is $3.5 million for 2015, $13.8 million for each of the years from 2016 to 2020, and $125.3 million thereafter. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div> P14Y4M24D 0.10 0.065 363000000 220000000 100000 0 0.15 0.05 3000000000 811000 811000 270000 270000 664000 664000 221000 221000 0.286 393000000 1.00 1056000 0 400000000 0 436802 500000 P3M P1Y 2 2779659 0 125000000 0 0.15 0.40 10550000 16947000 342000 342000 729000 729000 30449000 30449000 13341000 13341000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:68.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2015 </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2014 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;background-color: #CCEEFF;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76,077  </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,090  </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;padding:0pt;"> Short-term marketable securities </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,446  </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>143,698  </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;background-color: #CCEEFF;padding:0pt;"> Marketable securities </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,856  </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>203,523  </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,644  </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.96%;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td colspan="10" valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2015 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2014 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;padding:0pt;"> Amortization </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Net </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Net </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;padding:0pt;"> Period </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Carrying </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Accumulated </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Carrying </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Carrying </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Accumulated </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> Carrying </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:15.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (Years) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Value </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Amortization </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Value </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Value </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Amortization </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Value </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:15.16%;background-color: #CCEEFF;padding:0pt;"> Approval and launch related milestone payments under the LABA Collaboration </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14.4 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220,000 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,176 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>197,824 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220,000 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,809 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;"> )   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>208,191 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:49.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three Months Ended September 30, </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Nine Months Ended September 30, </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;"> Royalties from a related party </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.78%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,796 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,962 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,816 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,953 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:49.00%;padding:0pt;"> Less: amortization of capitalized fees paid to a related party </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,455 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,233 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,367 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,611 </td> <td valign="bottom" style="width:01.00%;"> ) </td> </tr> <tr> <td valign="top" style="width:49.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;"> Royalty revenue </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,341 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,449 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>342 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:49.00%;padding:0pt;"> Strategic alliance - MABA program </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>221 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>270 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>664 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>811 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:49.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;"> Total net revenue from GSK </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.78%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,562 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>999 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,113 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,153 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:49.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div> P24M 25000 0.15 2500 4 P6M 424081 6500000 9.25 8.50 3800000 7000000 125337000 0

154000

-87000

11000

1452504000

1375805000

26013000

14384000

11629000

11795000

2589000

4732000

3375000

1357000

5223000

4536000

687000

1468000

1248000

220000

1550000

2296000

20100000

6218000

12100000

1782000

20653000

6771000

12100000

1782000

20101000

5459000

12904000

4200000

1738000

1000000

400000

19463000

5070000

12904000

4000000

1489000

800000

300000

521654000

437631000

252182000

223754000

281644000

42856000

95090000

34469000

80775000

6517000

281644000

95090000

143698000

34750000

30043000

131650000

149994000

34469000

80775000

6517000

95090000

34750000

30043000

6517000

95090000

30043000

34469000

80775000

34750000

203523000

76077000

54702000

27486000

203523000

43857000

127446000

69972000

7506000

51363000

152160000

54702000

27486000

43857000

69972000

7506000

43857000

7506000

54702000

27486000

69972000

35000

5000

6000

24000

15000

3000

9000

3000

122000

110000

12000

4000

2000

285483000

34469000

80880000

10269000

95090000

34756000

30019000

203512000

54702000

27485000

43857000

69965000

7503000

143698000

127446000

42856000

143510000

119575000

96800000

78746000

-23935000

-18054000

0.25

0.75

0.25

0.01

200000000

116445000

117575000

1164000

1176000

-152897000

-25174000

-22963000

-4563000

197095000

169362000

255109000

1519402

-32391000

27.79

21.32

19.77

35.9903

46.9087

50.5818

287500000

450000000

653506000

633889000

0.02125

0.09

9100000

9500000

P6Y

105000

100000

1082000

885000

3788000

3320000

8720000

10449000

38.00

29.16

27.04

36800000

-94934000

3129000

87100000

29100000

-1.37

-0.19

-0.20

-0.04

1959000

1392000

1700000

9100000

2100000

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Estimated Fair Value Measurements as of September 30, 2015 Using: </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> Types of Instruments </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Quoted Price in Active Markets for Identical Assets </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Other Observable Inputs </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Unobservable Inputs </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Assets </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> U.S. government securities </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,506  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,506  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> U.S. government agencies </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,972  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,972  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Corporate notes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,486  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,486  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54,702  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54,702  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,857  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,857  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Total assets measured at estimated fair value </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51,363  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>152,160  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>203,523  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Liabilities </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Convertible subordinated notes due 2023 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169,362  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169,362  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Non-recourse notes due 2029 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>464,527  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>464,527  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Total fair value of liabilities </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>633,889  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>633,889  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Estimated Fair Value Measurements as of December 31, 2014 Using: </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> Types of Instruments </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Quoted Price in Active Markets for Identical Assets </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Other Observable Inputs </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Unobservable Inputs </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Assets </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> U.S. government securities </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,043  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,043  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> U.S. government agencies </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,750  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,750  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Corporate notes </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,775  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,775  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,469  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,469  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Ordinary shares of Theravance Biopharma </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,517  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,517  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,090  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,090  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Total assets measured at estimated fair value </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131,650  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>149,994  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,644  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Liabilities </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Convertible subordinated notes due 2023 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>197,095  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>197,095  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Non-recourse notes due 2029 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>456,411  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>456,411  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Total fair value of liabilities </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>653,506  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>653,506  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

1200000

1204000

28491000

8632000

14929000

4581000

1300000

-57604000

-21271000

-23061000

-4584000

-57604000

-21549000

-23061000

-4584000

-0.52

-0.19

-0.20

-0.04

-94934000

-0.85

0.00

-278000

-7122000

154000

-74000

71000

-851000

-224000

5000

-2911000

-665000

-16166000

-1056000

16667000

-1161000

1908000

-561000

833000

6397000

52000

-519000

39000000

18449000

18400000

5600000

24326000

12355000

38756000

13063000

6109000

19169000

7551000

6390000

1539000

526000

446000

93000

291000

90000

521654000

437631000

1300000

13756000

11278000

725636000

744085000

158827000

-81148000

-56649000

59880000

-126113000

3214000

-152538000

-21271000

-23061000

-4584000

456411000

464527000

35212000

10541000

16826000

5128000

-34059000

-9542000

14287000

8434000

29100000

27.79

21.32

19.77

18101000

15805000

1204000

-359000

-3903000

1302000

21000

2108000

2457000

1718000

1847000

2000

335000

255000

1117000

-45000

277541000

28338000

87144000

228899000

86523000

556000

6000

0.01

230000

1134000

615000

281200000

434677000

35629000

5996000

-5600000

140000

292666000

89311000

5000000

57098000

49400000

15900000

1500000

324000

248000

6721000

1909000

1897000

547000

-1673667000

-1696728000

1153000

999000

31113000

13562000

7953000

3962000

40816000

16796000

470527000

488976000

26013000

5223000

P6Y

63000

0.04

P6Y

P5Y

P6Y

0.58

0.60

0.52

0.0197

0.0205

0.0164

1290000

3200521

278971

15.92

13.23

0.85

14.09

13.75

-223349000

-322999000

1127000

111156

150000000

75000000

150000

149645

3263000

15300000

111306000

113100000

115381000

115787000

Condensed consolidated balance sheet as of December 31, 2014 has been derived from audited consolidated financial statements.

EX-101.SCH 6 thrx-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Collaborative Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Details 2) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Capitalized Fees Paid to a Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Description of Operations and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Available-for-Sale Securities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Capitalized Fees Paid to a Related Party link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Shareholders' Deficit link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Capitalized Fees Paid to a Related Party (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Stock-Based Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Stock-Based Compensation (Details 3) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Shareholders' Deficit (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Commitments and Contingencies (Details 2) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 thrx-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 8 thrx-20150930_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Document and Entity Information Statement [Table] Statement [Line Items] Statement Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Available-for-sale Securities, Debt Securities, Current Short-term marketable securities Represents the amount receivable from collaboration partners under the collaborative arrangement. Receivables from Collaboration Partners Related party receivables from collaborative arrangements Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Available-for-sale Securities, Debt Securities, Noncurrent Marketable securities Property, Plant and Equipment, Net Property and equipment, net Represents capitalized fees paid to a related party, net. Capitalized Fees Paid To A Related Party Net Capitalized fees paid to a related party, net Net Carrying Value Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Deficit Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Carrying amount as of the balance sheet date of obligations due to certain related party. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer). Due to A Related Party Two Current Payable to Theravance Biopharma, Inc. Employee-related Liabilities, Current Accrued personnel-related expenses Interest Payable, Current Accrued interest payable Other Liabilities, Current Other accrued liabilities Deferred Revenue, Current Deferred revenue Liabilities, Current Total current liabilities Convertible Subordinated Debt, Noncurrent Convertible subordinated notes, due 2023 Secured Long-term Debt, Noncurrent Non-recourse notes, due 2029 Deferred Rent Credit, Noncurrent Deferred rent Other Liabilities, Noncurrent Other long-term liabilities Deferred Revenue, Noncurrent Deferred revenue Commitments and Contingencies. Commitments and contingencies (Notes 3, 6 and 9) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' deficit: Shareholders' Deficit Preferred Stock, Value, Issued Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding Common stock value oustanding Common stock: $0.01 par value, 200,000 shares authorized, 117,575 and 116,445 shares issued as of September 30, 2015 and December 31, 2014, respectively Treasury Stock, Value Treasury stock: 150 shares as of September 30, 2015 and December 31, 2014 Additional Paid in Capital, Common Stock Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' deficit Liabilities and Equity Total liabilities and stockholders' deficit Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Treasury Stock, Number of Shares Held Treasury stock held CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Represents revenue net of amortization expense for capitalized fees paid to a related party during the period from the leasing or otherwise lending to a related party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. An example of property from which royalties may be derived includes patents. Royalty Revenue from Related Party Net Royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of $3,455 and $3,233 for the three months ended September 30, 2015 and 2014 and $10,367 and $7,611 for the nine months ended september 30, 2015 and 2014 Royalty revenue Revenue earned under collaborative arrangements from upfront payments and contingent payments. Collaborative Arrangements, Revenue Revenue from Collaborative Arrangements Revenue from collaborative arrangements from a related party, net Revenues Total revenue Total net revenue Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Income (loss) from operations Other Nonoperating Income (Expense) Other income (expense), net Investment Income, Net Interest income Interest Expense Interest expense Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss from continuing operations before income taxes Income Tax Expense (Benefit) Income tax expenses Income tax expense (benefit) Income (Loss) from Continuing Operations Attributable to Parent Loss from continuing operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Loss from discontinued operations (Notes 1 and 11) Net Income (Loss) Available to Common Stockholders, Basic Net loss Net loss Net Loss per Share Basic and diluted net loss per share: Income (Loss) from Continuing Operations, Per Basic and Diluted Share Continuing operations, net of tax (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share Discontinued operations (in dollars per share) Earnings Per Share, Basic and Diluted Basic and diluted net loss per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Cash dividends declared per common share (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Shares used to compute basic and diluted net loss per share (in shares) Represents the amortization of capitalized fees paid to a related party. Amortization Of Capitalized Fees Paid To Related Party Less: amortization of capitalized fees paid to a related party Amortization of capitalized fees paid to a related party CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive income: Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gain (loss) on marketable securities, net Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Less: Realized gain on marketable securities, net Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Share-based Compensation Stock-based compensation Investment Income, Amortization of Premium Amortization of premium on short-term investments Interest added to the principal balance of the non-recourse term notes due 2029 Interest amount added to principal balance Realized gain on sale marketable securities, net Realized gain on sale of marketable securities, net Amortization of debt issuance costs Other Noncash Income (Expense) Other non-cash items Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Account receivable Increase (Decrease) in Other Receivables Receivables from collaborative arrangements Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Inventories Inventories Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Due to Affiliates, Current Payable to Theravance Biopharma, Inc., net Increase (Decrease) in Accrued Liabilities Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities Increase (Decrease) in Interest Payable, Net Accrued interest payable Increase (Decrease) in Deferred Charges Deferred rent Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Available-for-sale Securities Purchases of marketable securities Proceeds from Sale and Maturity of Available-for-sale Securities Maturities of marketable securities Proceeds from Sale of Available-for-sale Securities Sales of marketable securities Proceeds from sale of available-for-sale securities Represents the cash outflow associated with payments for capitalized fees paid to a related party. Payments For Capitalized Fees Paid To A Related Party Capitalized fees paid to a related party Proceeds from Sale and Collection of Notes Receivable Payments received on notes receivable Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities Payments of cash dividends to stockholders Payments of cash dividends to stockholders Proceeds from Issuance of Common Stock Proceeds from issuances of common stock, net Payments of Distributions to Affiliates Cash and cash equivalents contributed to Theravance Biopharma, Inc. Proceeds from (Repayments of) Restricted Cash, Financing Activities Change in restricted cash Proceeds from Debt, Net of Issuance Costs Proceeds from issuances of note payable, net of debt issuance costs Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information Interest Paid Cash paid for interest Noncash Investing and Financing Items [Abstract] Supplemental disclosure of noncash information Transfer of net assets to another entity resulting from noncash or partial noncash business separation. Transfer of Net Assets Business Separation Contribution of net assets, excluding cash and cash equivalents to Theravance Biopharma, Inc. Debt Conversion, Original Debt, Amount Conversion of convertible subordinated notes into common stock Liabilities Assumed Guarantee issued in connection with the Spin-Off (Note 9) Description of Operations and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Description of Operations and Summary of Significant Accounting Policies Earnings Per Share [Text Block] Net Loss per Share Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Collaborative Arrangements No definition available. Available-for-Sale Securities and Fair Value Measurements The entire disclosure for available-for-sale securities and fair value measurements. Available For Sale Securities And Fair Value Measurements [Disclosure Text Block] Available-for-Sale Securities and Fair Value Measurements No definition available. Capitalized Fees Paid to a Related Party The entire disclosure for capitalized fees paid to a related party. Capitalized Fees Paid To A Related Party Text Block Capitalized Fees Paid to a Related Party Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Long-Term Debt. Long-term Debt [Text Block] Long-Term Debt Shareholders' Deficit Stockholders' Equity Note Disclosure [Text Block] Shareholders' Deficit Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Income Taxes Income Tax Disclosure [Text Block] Income Taxes Discontinued Operations. Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Disclosure of accounting policy for business separation. Business Separation Policy [Policy Text Block] Business Separation Consolidation, Variable Interest Entity, Policy [Policy Text Block] Variable Interest Entities New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Not Yet Adopted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of anti-dilutive securities Tabular disclosure of the revenue recognized through amortization of the deferred upfront fees and milestone payments received by the entity under the collaboration and strategic alliance agreements related to long-acting beta-2 agonist (LABA) products during the period. Schedule of Collaborative Arrangements Upfront Fees and Milestone Payments Revenue Recognized LABA [Table Text Block] Schedule of net revenue recognized under GSK Agreements Tabular disclosure of the classification of available-for-sale securities in the consolidated balance sheet. Schedule of Available for Sale Securities Classification Table [Text Block] Schedule of available-for-sale securities Available-for-sale Securities [Table Text Block] Schedule of amortized cost and estimated fair values for available-for-sale securities Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of estimated fair values Tabular disclosure of capitalized fees paid to a related party. Schedule Of Capitalized Fees Paid To A Related Party Table Text Block Schedule of capitalized fees paid to a related party Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of allocation of stock-based compensation expense included in the condensed consolidated statements of operations Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used to estimate the fair value of employee stock options granted Schedule of Long-term Debt Instruments [Table Text Block] Schedule of long-term debt Disposal Groups, Including Discontinued Operations [Table Text Block] Schedule of discontinued operations presented on the condensed consolidated statements of operations Information related to various accounting policies of the entity. Summary of Significant Accounting Policies [Table] Counterparty Name [Axis] Repurchase Agreement Counterparty Name [Domain] Counterparty Name [Domain] Represents GSK, with whom the entity has agreements and arrangements, such as those for developing and commercializing different products. G S K [Member] GSK Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Represents the entity's LABA collaboration and Strategic Alliance agreements. L A B A Collaboration And Strategic Alliance Agreement [Member] LABA collaboration and Strategic Alliance agreements No definition available. Summary of Significant Accounting Policies [Line Items] Description of Operations and Summary of Significant Accounting Policies Represents the percentage of economic interest in any future payments made under the agreements. Percentage of Economic Interest on Future Payments Under Agreements Percentage of economic interest in any future payments made under the agreements Business Separation [Abstract] Business Separation Value of cash, cash equivalents and marketable securities contributed to another entity due to business separation activities. Contribution of Cash and Cash Equivalents and Marketable Securities in Business Separation Cash, cash equivalents and marketable securities contributed to Theravance Biopharma Represents the number of common stock distributed as form of dividend for each common stock held by parent company associated with the separation from parent company on completion of spin-off. Common Stock Stock Dividend Ratio Number of shares of Theravance Biopharma issued for every share of Theravance Number of ordinary shares of Theravance Biopharma issued for every share of Theravance Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Represents information pertaining to options, Equity Incentive Plans and Employee Stock Purchase Plans. Equity Incentive Plans And E S P P [Member] Outstanding options and awards granted under equity incentive plan and ESPP Convertible Subordinated Debt [Member] Shares issuable upon conversion of convertible subordinated notes Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities (in shares) Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Represents the collaboration with GSK to develop and commercialize once-daily LABA products and combination products RELOVAIR. L A B A Collaboration [Member] Long-acting beta agonist (LABA) collaboration Represents the strategic alliance with GSK for initiating three new full discovery programs and giving GSK option to license exclusive development and commercialization rights of products. Strategic Alliance Agreement [Member] 2004 Strategic alliance Products and Services [Axis] Products And Services [Domain] Products and Services [Domain] EX-101.PRE 9 thrx-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 10 thrx-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT XML 11 R39.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - Lease payments guarantee $ in Millions	Sep. 30, 2015 USD ($)
Operating Leases
Estimated fair value of the guarantee	$ 1.3
Theravance Biopharma
Operating Leases
Total lease payments	$ 29.1

EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`":.94^Q4T!0%<2K MTMWDT3N>>Y-QSJ:G=T^.PFAENCY,BS9&=\)8J%LR*I3649^4F?5&Q73KY\RI M>J'FQ,1DA&^7BE3&K!5AT;A/61EUEG_V,8G"?5A)8HFJX, M\:FCL,U_K;PZ7]!,/73Q1\8O[Z[TU`TUH=7NQ>IRE;J$]-NT2&KXEL/FPJ^2 M:9.'YOKYAQ7Y_I?/LO$2EZ:[\.I1;Q@L=S:F?"Z-TOVV43U:O[BW=O&?VX3R M4S74C)U/A3[J+;LD%=\D-;#4^D_>KSNEMIZ^99@+=_A1M,I3YRY+D.UY\-?1`#&TX[A,2/<@B0'!(D1P628Q\DQP%(CD.0'$<@.8Y!P902P,$%`````@`)HYE1TAU!>[%````*P(```L` M``!?.0Q M(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?'5$Q^#*G*_=ITJK$"2+8CCVG! MD4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,41Y26M#;3"&>6X9MY M6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO+0O]C^AY%.!)T:'B M1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_V/P"4$L#!!0````(`":.94>[ MF$,ZMP$``*X:```:````>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V<`94`*S=LU1MH8*`$^I/.&/7NK2P,_LP7%R3?IDW;Y,R[ M:)XTTT4;R_EC.%7IT+6Q/O1Q\M:JV$?TK)X[89CK$-( MT9U/&H+8!MX;@M`&[AR"V`;N'8+0!OX>BM0&_EZ*U`;R5] M:Z./;8[>"O16CMX*]%:.W@KT5H[>"O16CMX*]%:.W@KT5H[>"O16CMX&]#:. MW@;T-H[>!O0VTEX)VBSAZ&U`;^/H;4!OX^AM0&_CZ&U`;^/H;4!OX^AM0&_C MZ.V!WIZCMP=Z>X[>'NCM.7I[H+2I>04;5-4(X?ET(F5&-6[GTQ&+!8@A$ MO,Z`:Z_=:MUZL-7`$TB:^<%IP^^;*(,\3UE,-1/#T:+^?&">::&.UQ1OH2DC'W_<5^+)Y#*9'K3OF[A M[U""O;WP#31A?#FC3"J_O]&]#<1:R)U,&UU7I43$1G3U%.'Y5(/,J0*SO&ML MJ&24ZP91["]NVXTB;&&UZS176OJ_A7Q6*P"M^M[!:)=E;'G-NGZW8Q&X.D9Z MA\S\7=F.\C:6B.D4U'0QHU+_IU+8G/:%Z'8:I>SW+@CE"1EQC>U('G@1"L4K ME^2P&DXGP6@2C@*"JW`Z?@@&$6[N!^/!9#@B-3B=*IPPPK_'T:0&YTL-SFT- MSE0[(`Q[.B%:$$I^ M0NKFA%K$S\U[;,2$F-D%7)UNJ['@RV8$,B,!S+7;GRG`2J0)CI9/",-+P-Q( MC)8Q;2M@JSL4V-M8$QYCAD[&`X]%!B2BVQ.`@*G8>EEC-J_BN0^ZGBOXLS87 M:[0Y*=7;HWWBLIYKCW:W4GOL,KJ@2\[G?D*Q M/:F&)M\NUB0`C46L(0H2JXO2N:G!:5<7LN,6_[20M@S5.1WWI#[/<4_JMPUS M5ACG@/E0S#.CAEQ5YW3=-[\\H#XXTLG&+UB7C2QWC'_X'>[_`U!+ M`P04````"``FCF5'S>L-VC\!``!I`P``$0```&1O8U!R;W!S+V-O&UL MS9--3\,P#(;_"NJ]2[,Q)J*N!T"5K(..BN"(:D$N.G!R`N>N)655*P80'CM9W>"EZO-OY.L&D(%"#!H.! MT!$E6?5LML8VIB2#OBJCXYH'7%BI5@KD33N4_4[%S@A>AZ,<9-\^_?W30\J0 MK*OOBX2F=3:Y,0&X$1%50#%L'\^RK\\OD]FYYGU7C M@DYS2O-BNJ0S=GG-BMG;8;(3?X-AW0WQ;QU_&4S;184UG+G;I)%IN>DS@20$ MX95#9621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[ MMR_>X%#BVR]*+41B1%G\@MNN01.+5) M#3(3/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X M$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7`\:V@S&L%&KQMU MAVC2/'K^!?F<-0HACA* MFNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$ M5FJ?JH,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7O MN?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X> MRPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/Y MZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAG ME<90-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>AP MYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5. MS_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#) M1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86%S+D4.Z2D`83``>LX=SFWJXPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[! M?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9C MC%OT-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0- M:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0````(`":.94?U M>[KT9@(``"@,```-````>&PO?SOG.)^G81PDK MM:/X<8VQ`EM&>17!M5+E9\^KTC5FJ)J($G,]DPO)D-*/LO"J4F*452:(46_J M^PN/(<)A'/*:+9FJ0"IJKB(X[R#@XN]%AB/X=/GQ5RW4W0?@QHM/%Q?^T]7= M&+^T$U<0.(ZO602#Q1QZ+R>=^(=Y]=R(>G&`NG4W7%WL./CZ6/`P>AQ^\[IE M_655(^);0^PU!Q.'N>#]^4RA`^*P>@8;1+5_8-Q3084$2A>`5F`1CAAV'O>( MDD02`^:($;IS\-0`MF8:/T:XD#:WRS#.,_'[3+)((N@WOY>G2WIV.YCE$4J' MR]-`')9(*2SY4C^`QE[M2KTX+CAV(JW?$>]"HETPG>\%V$'G383,L.PR!["% MXI#B7.D`28JU&94HC72AE&#:R`@J!$?44+81C:%I4TSIHWE#?^8#[FT.G(\Y M8Q\"HZ(U]48T9E\&=E.]?3;'O4\[.XD7;/,N@8Y&94EW7R@I.,-.K(.6HGDZ M1A\1WQ*5*[Q5305[V_R0PE.7_#\U MO?VN]6IT";[W]IR8BJ->TT[V>/>C8'0J2FE!%>*L!F3O6@]%- M!\VT[]::,]OVC=K.*I3H:_L@BR;+<(YJJGZ0C5!V,H*]_(_4$L#!!0````(`":.94?!K/D@[P,``'T.```/````>&PO M=V]R:V)O;VLN>&ULE9?1.79A]2L&1(RI3.$*`M,Y1T:J;[+&P1 M-)$MKR23;+]^K^RPN0Z""4^V;.O(DLZ]DC[;T9,VCQNM'\ESH4H[,N-HYUPU MZO5LMA,%MQ]U)4IXM]6FX`Z*YJ&GMUN9B9G.ZD*4KD?[_6'/",6=U*7=R%6M>"'&T;.*B.+6S7/I M1#Z.$BCJ)]%Y8.KJKI;*%P;]0=3SL$-7?QJ2Z5RTL/5.VK]?7D0D%UM>*[>& MGSVT.XYBFE`Z;!G^L]]2/%D,]`\(SYSIG#`S[L0WH^M* ME@_`BLA6&NM2W]WFRT*6LI!__']#R>[TTW=MY!]=.J[2S&BEFEK^15,)6K#_ M/X%_=#+K?.CXYI>?B7$T[`-P+ZW<2"7=O^.HN5?"]Z3WIBO-\+_>D;(9G,,4 M$U[F9%XZH)!%V4X>#(W_!_AXD3<-FY&$&[/(XW:H,&AZOYK-5^E\1N`NO5\N M9I,U%.XFR\EJ.B<(1!&(7@IB",00B+T;E*[A\F.^0J`$@9)+00,$&B#0X%+0 M$(&&"#2\%'2#0#<(=',,F@F;&5GYJ29Z2^XK8=H8;WQ($>@6@6Z/02NX6VIK M"1!(NN-&H+J?4-U/@=Z`V'RC?"DMUJ^/_>L?4R9[+@&CQ#78 M>YUR)4@JLMI()P5T!Z,Z*H=C)8&AU&=3!N0\VS(4)QJ*7:4AI+MN9"A"49A M:6E(VA,A\S):&(7UI0%]NY$3'&XL+@V(>T+``PNCL,OTTF1+;S$*.TW?E6[) MU4PXF,YN[[#>]*+4V_#P8HOU9I?F7Q9C%%:"[4X"=I_,*"T, MH[#=26AW\79I"_\1-CMA+X>#U_,`'(ED*7)_6K)-$W# MJ6Y)QVO:!8R>:'JBZ:GW`&Q$]E@@ M=012BY[/!3HC8!"I.6&P`@`NB"-S9#)+9N6-PT:L'PODCD!NT:$_56:0!;FR MEJT<&YI0QC6PQZBV7$I*-#BW3F%>T:Z2W_!RZ+'%_(3LTO= M\>!`A>SUNLV?*15$.@&>9&NHY!L\+1IR%FJ:RSDSKY)9"-K?']GII2__`E!+ M`P04````"``FCF5'A.J&LU$%``#%&0``&````'AL+W=OE<4S>SG\7"JG^:[ICFGBT7]LBN. M>?VU/!:S8_ZS_[\_=?\O_14;#=WD#CATP*D=:.A`MPZ@ M[G900P=UZ]#I%WTE70Z;O,E7RZJ\S.ISWLX.2)VZ:L=P`\]<\77WMHNW;_U8 MH5HN/MIQ/$G62["72(JUI]"29.-)XIMDX2R*/C'PB5U_ZOL;_Q:GWD7;Y>Z8 M%(Q)W9BJ']-*8V:]Q'028XV*Q3MS51+;*'I/) M%,6)?>Q&!VXTHG976+0HA.N`2#U MV(@)C!AN!$4CAMT$D8Q6HA=/IA$L/G9C`S>6NR'1C66W$3_$-5%8SWE M,PL)#,2P3O+,Z#K='S:$*7":DDQ3\#@YLE`]T01V00A2X"15,DE!/URG$'!T MPCJ%D*/`0:IDD()'24I$RJU]5:*3"6Y"F`*GJ9)I"IR3,24CV7"5T7K*R@AA M"IRF2J8I6`]C6M[P?!5$$S9?")$*G*E*9BIP8%H[0HW$FS93MAD,L8H27[,K<[3CD'AE!%#E7Y")0AIR6Z*1&)#%C?TXT[^G0TY5B5ST$9 M>EBU-C'RX1*T_$(8B]O2^HYLW$\(5>)0U3)4"0)ZCYU5?:'2J*,I M&858)8Y5>;?-B.,2Y).JI_EB)_"4/CTHX#S5(T\*."J_N&_$L9&?*:Q#I:$X MGN(J)"MQLFJ9K*3\V8%)(F^%OM!]=R4U82^DD*_$^1K+YUWBY+SS%9HX)-*"/80[%M5;]S"SGKV4[Z=F\'AK[I^8 MKC'=8/L4+VRG=$-2NTHW2FK7Z49+[7&ZB:5VDVZ,U&[3C97:DW232.T0I1N( MQ"O@KH!XQ14-8M7@R@:Q;G"%@U@YN-)!K!U<\2!6#ZY\$.L'%P"("8"+`,0, MT&6`8@;H,D`Q`VP_>#$#=!F@F`&Z#%#,`%T&*&:`+@,4,T"7`8H9H,L`Q0S0 M98!B!N0R(#$#:G\4$#,@EP')L[^=_F(&Y#(@,0-R&9"4@6.!NR)EX);S]0>+ MQ:_UNEJ>\[?BK[QZVY_JV7/9-.6Q>PK_6I9-X2@0?76(VA7Y]O;F4+PV[4OC M7E?]KPS]FZ8\7W\TN?URL_H?4$L#!!0````(`":.94=7&PO=V]R:W-H965T&ULC95=DYL@%(;_BN,/"/B!FHQQ MIDFGTUYT9FB$O78?YW1R@;MV$4W@9>VW,C]0"H2G#WU6U'>M&R/N#DM`V_ M1)M]!+7$*'ZU9!1./]#P!\;>=/"CWH90,Q!*CE*GP*JYDCVA5&=2E?],2?_7 MU$:W?\O^S4Q7X1^P('M&?[>U;!0M#(.:G/"%RE&14F-_@>!&2 M=3=+&'3XW;9M;]K1OLGRR>8WQ),AOANB]*DAF0S)S``LF9G75RQQ57(V!F+` M>K>CC9)SG41E#M1DA`G-]C4;1(4LQ("I=D[24IW(V'T^/%>:Y<9%K/F-8.4^ZMM%L[E:(H1SE: M8GI49FF*/L44P?FY!%TJ[W;L)LU4#"VNTS.=)0+.H3G@,_F)^;GM17!@4IV_ MYN@],2:)R@97Z@_1J'OQ'E!RDKJ;JSZW-X4-)!MN%]_]]JW^`5!+`P04```` M"``FCF5'5/O7V7X$```5%@``&````'AL+W=OR,-'Y(8.`:J1[%[6*#H87M68B8V*EFN),?=;[]ZT,Z0 M.ZJ$O<06\QMR_IS1#,WMM6Y^M`>M.^]759[:I\VAZ\Z/OM^^''15M`_U69_Z M_[S6355T_6/SYK?G1A?[T:@J?18$H5\5Q]-FMQW'OC:[;7WIRN-)?VV\]E)5 M1?-/HLOZ^K2!S6W@V_'MT`T#_F[KW^WVQTJ?VF-]\AK]^K3Y#(\YDP,R$G\? M];5%W[W!^>>Z_C$\_+E_V@2##[K4+]TP1=%_O.M4E^4P4[_R3S/IQYJ#(?Y^ MF_W+*+=W_[EH=5J7WX_[[M![&VR\O7XM+F7WK;[^H8V&T<.7NFS'O][+I>WJ MZF:R\:KBU_1Y/(V?U^D_<6#,:`-F#-C=X+X.;<"-`?\P$+\U$,9`K%U!&@/I MK.!/VL>=RXJNV&V;^NJUYV+()WCL\6:8I)_9Z[>K'1_'@$RC[[N(;?WW81X+ M22:$30BGD`PC<"?\?GW2"68[D3!D3OJ08B(2I`^+D^0SD\RZR9V]XJ,]G^SE MLKUP[,5H+R;[T';Q-.W$A$331G(N@*)23$5,44R&&1X(05*Y10FVK$DZFB36 M%)&:)D1.@6&T(HN)`E(19L)0D'HP$\.*5`P=/2'6$Y-Z0K0&E(!,AQ0RH@-X3"XH5 M.5..H3!B*^*L'$D*2R)S,E%H$2%I*,50''(R%S(,@5#T&YMCBL5"K5`%@5O. M`ZR+]"8QC(D5,#++4XN"0-*E*+.Q,&9D7,6"N.H;5D7XGAC$K"4F+PQ"3))19 M4%]Z9I1ABO,5/0_D-OC(<*"R"U.#+,8LP@!?`JABT0"\7+$%I%L M&2:\2Y/9_AGJ_HGL_8 M8DXO(]DRDAM$W13%*]H]<]L]P^U>T>W>,&HI7`XV%RX'FPF71<$#CU:(<_L^ MPWU?T7W?,%->]-[09[155.90$4GE\W/-*W/[//L?HA%]+D@= MCD,PDY+.?)S^B94[W'"4-O8>B_UY=1-Q><^>K_1_,R&.S-G M/(''%(CQ#![SZ;[R8_K=]ER\Z;^*YNUX:KWGNNOJ:KRD>ZWK3O>.]S5AXQUT ML;\_E/JU&[Y&0Q2F6\OIH:O/MTO8^TWP[E]02P,$%`````@`)HYE1UC[>@KZ M`0``;04``!@```!X;"]W;W)KV;I1)X++`$^_8,NADRSLD MH%H%S]%REQJ$!?QJ89"S/3+>]YR_F>#'<16$Q@)0."BC0/1RA@U0:H1TX3^C MYK6D(<[W%_5O]K3:_9Y(V'#ZNSVJ1IL-`W2$BIRH>N7#=QB/D!G!`Z?2/M'A M)!5G%TJ`&'EW:]O9=7!O'L.1YB?$(R&>"%,=/R$9"RZ?'@M\-CHWD+6# MQ!:2)S[(=@Z))@36];TFXEL3ZWA&CWT%-G-$GGH]?"FR^T#D0YO)7:\2RT\< M/_N:G][Q4\M/7:^?;BUVKA,.DEM(DF:9#[2Y`<5)X@-MYZ`H3!:Y#[6;H_)% M=/_M\.PR,1"U_8TE.O!3IUPGINPT*9YC+&X07.7+HB_HIS!=IU^*#[V^C9-P44*F6VN6F\&P-0@T0-HDR M^^\W'XB$BNM[7B6G3GM`/5F+,G<^F;MG&+3GOUI['#B5N$'LA'6[% M-R="&\3%DIX]UE&,CHK4U![T_:77H*IULU3%WFB6D@NOJQ:_48==F@;1OUM< MDW[C`O<6>*_.)9L&MRRBK0.Q:>-^PK6NT0B%.!7A7LV>7=D[7M" M/N3BQW'C^K($7.,#EPI(/*XXQW4MA43B/X/F/:4D3M]OZM^46U']'C&2E*-9WG2,^H4O-WTG_'0\6(BEX(#53G\[APCAI;A37:="G?E:M>O;ZF\0? M:'8"'`AP)(QY[(1@(`1W0OA?0C@0PJ]FB`9"-,O@:>^JLV`[Z?>50H9F*W&0(6)`QNDF$+`B/!$`=8JH%G% M%D[HT)8@GR+BT%K#4Y'=`Y&'90:S9@6*'PS-^H+/<"80*H%0":R`66.K6Z$A ML8(LPB@);:C<0$$`8ZM88<("?VF%[0P8B&`4),^]13-OD=$<^%Q@.1-83IH# M_,#:'8V)]!Y;S>13R")8V86**0H$/K3VQ92*5L\]Q3-/L>')NI?;>)+%MUIZ MBBBFB`6`]DP[N\Y#,\G,3&*8B:QF$O/X+JW=SPT4C,#\%SVX,F%P95?;);/C MFZSBF3EOJ#=Y;.T M0V?\$]%SU3)G3[BXRM4M?B*$8U&X_R+Z7(H9/BYJ?.+R-98;H,>:7G#2W8;T M^$\A^P=02P,$%`````@`)HYE1WZ*X>MZ!0``QAP``!@```!X;"]W;W)K,4;2O+O/YO5YRJZ_U2+=\??#N^'MKNP6J[6=W*[8]E<6Z. MU7E1%R_WRP>USDPOZ17_'(MKXUTO.O-/5?6]N_EK?[^,.@_%J7ANNQ"Y^_E9 M/!:G4Q?)U?QC#/J[SJZ@?_T>_8^^N<[^4]X4C]7IW^.^/3BWT7*Q+U[RMU/[ MK;K^68QM,%W`Y^K4]'\7SV]-6Y7O19:+,O\U_![/_>]U^$\2C<7D`C`6@-`" M.!;`6P']J5Z/>GW3J[[`:FA)WP]9WN;;35U=%\TE[]X.M7;RN@OB(B]X>G/K8KL9O6S"T0TNT$#@^:F6+GH8A5`J]B!5QRD"C)?$>OY&I`U`OOR M.#8BG@^@60#=!]!]@%11C^>A%8,D[B5W@)$591F1*0,&DWD[AMDQI#T!`2P+ M8+WVJ"@5&S1HS*C16E1EOBJ)(9KW$C,OL>]%1:*7V*O%`*!HQ1>!C13.>TF8 MEX1XD0:*D7,8HHI#,C[.3?"YJ>75#0@2'=$FS/@R MUS4V(+T##D]`WX^,FU'S/G5E,[X&(`!]P"$,/H2UO,"!)N2S$V:("E(5,E*< MQ$!(#!-#Y2,605Z6,Z)R.8)5(2D:F.H`D20.23^`P!9)^RDGN#GQ0)BG*^7)&9)"" M#<$7)41@;ZH)17/B)QDR+0#@J2I65=^!$9OV/ MG]-^.'HU24%U0`JJ.2TUH>5$GJ_G:4DD+GU`#)E^')::P%++L-3SL"02=#,O M9+0Y+#6!I?QN[D91_)D97^(2D8#I9&ZH'&(\]`\^+\)19M0G7V_\!4$L#!!0````(`":.94=;FZI8GP$``+$# M```8````>&PO=V]R:W-H965T&ULA5/+;MLP$/P5@A\0RK)2 M!X8L($Y0-(<`00[MF996$A&2JY*4E?Y]^;`5VWE=Q-W5S.PL'^6$YL7V`(Z\ M*JGMAO;.#6O&;-V#XO8*!]#^3XM&<>=3TS$[&.!-)"G)\BS[P107FE9EK#V9 MJL312:'AR1`[*L7-ORU(G#9T08^%9]'U+A185;*9UP@%V@K4Q$"[H;>+];8( MB`CX+6"R)S$)WG>(+R%Y:#8T"Q9`0NV"`O?+'NY`RB#D&_\]:+ZU#,33^*C^ M,T[KW>^XA3N4?T3C>F\VHZ2!EH_2/>/T"PXC7`?!&J6-7U*/UJ$Z4BA1_#6M M0L=U2G]6RP/M8T)^(.0SX2:+QE.C:/.>.UZ5!B=B!Q[.;K'VOKQPN(STY3N'GPH4 M%P)%%"B^'/$<"9O\*H<>`>/W'1" M6[)#YT\V'FJ+Z,";R*ZN*>G]^YD3":T+X4!"?$`SVXR22QL3["=!OY^;2<- M;>GNOL0SDW/.G/$E']"\V1;`D0\EM=W0UKENS9@M6U#<7F$'VO^IT2CN?&H: M9CL#O(HD)5F:)#^8XD+3(H^U)U/DV#LI-#P98GNEN/G<@L1A0Q?T4'@63>M" M@14YFWF54*"M0$T,U!MZNUAOLX"(@!&7BO=F8QNG'ZKY89#A$\QVQ*0C9D8PKWZQ17K: M8IL>T=/_TY=G#I>1OOSF\*\"V9E`%@6R?XYX@EDE9TW8T9XJ,$V\.I:4V&LW M;MYY!UOX)&;1FA+=NC\R<9#K1$=>!/)U8J2UK^?.9%0NQ!> M^]B,5VI,'':'!S*_TN(/4$L#!!0````(`":.94&PO=V]R:W-H965T6CFM&^N`'`DU>MC-O1 MP?MQRYAK!M#"W>$()OSIT&KA0VI[YD8+HDTDK1@OB@],"VEH7:7:DZTKG+R2 M!IXL<9/6PO[:@\)Y1TMZ+CS+?O"QP.J*+;Q6:C!.HB$6NAU]*+?[=40DP'<) ML[N(2?1^0'R)R==V1XMH`10T/BJ(L!SA$92*0J'QSY/F6\M(O(S/ZI_3M,'] M03AX1/5#MGX(9@M*6NC$I/PSSE_@-,(F"C:H7/J29G(>]9E"B1:O>94FK7/^ MP^]/M/<)_$3@"^%CD8SG1LGF)^%%75F)OOK#X5\%UC<"ZR2P M_N>(UYA;E^QB3S78/ET=1QJMJ%#U\$[:7QI$#^G"R MZ5`[1`_!1'&WH60([V=)%'0^AO'X@RRNM?P-02P,$%`````@` M)HYE1T@O;JV?`0``L0,``!D```!X;"]W;W)K&UL MA5/+;MLP$/P5@A\0RK+=3TS$[&.!- M)"G)\BS[P107FE9EK#V:JL312:'AT1`[*L7-ORU(G#9T08^%)]'U+A185;*9 MUP@%V@K4Q$"[H;>+];8(B`CX(V"R)S$)WG>(SR'YW6QH%BR`A-H%!>Z7/=R! ME$'(-WXY:+ZU#,33^*C^,T[KW>^XA3N4?T7C>F\VHZ2!EH_2/>'T"PXCK()@ MC=+&+ZE'ZU`=*90H_II6H>,ZI3^KFP/M8T)^(.0SX2:+QE.C:/.>.UZ5!B=B M!Q[.;K'VOX]?7GA(YIKAHPD[V5('IXM6QI,91N[1Y%4.O(,';CJA+=FA\R<;#[5%=.!-9%.UCDZY4 M2AP.QPF9'`[R-)"59D66W3'&A:5W%VHNI*YR<%!I>#+&3 M4MS\VH'$>4MS>BJ\BGYPH<#JBBV\5BC05J`F!KHMOQ21X MWR.^A>2IW=(L6``)C0L*W"\'N`7;SSZGR]KM@A M"%U@=@E3),R"8%[]TQ;%98M=<48O_D]?73E<1?KJ#X=_%2BO!,HH4/YSQ$O, M[543=K:G"DP?KXXE#4[:IB#+*ZU_`U!+`P04````"``FCF5' M.+GSD9X!``"Q`P``&0```'AL+W=O5W$W=7, M["P?Q8CFQ78`CKPJJ>V6=L[U&\9LU8'B]@I[T/Y/@T9QYU/3,ML;X'4D*:ED6L/9FRP,%)H>')$#LHQ]X@O(7FHMS0+%D!"Y8("]\L![D#*(.0; M_SUJOK4,Q--X4O\9I_7N]]S"'.7 M5(-UJ"8*)8J_IE7HN([I3S[1/B;D1T(^$VZR:#PUBC;ON>-E87`DMN?A[!8; M#S=!Q"L3[\W&-$Z?JH=RL;XNV"$(G6%V"9,GS(Q@7OW#%OEYBUU^0L^_IR\O M'"XC??G.X:<"JPN!5118?3GB.>;FH@D[V5,%IHU7QY(*!^W2YLW5^7;>YO%, MWN!ET?,6'KEIA;9DC\Z?;#S4!M&!-Y%=K2GI_/N9$PF-"^&UCTVZ4BEQV$\/ M9'ZEY7]02P,$%`````@`)HYE1TR=0.*@`0``L0,``!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RO*CK2$+B%,$R:%`D$-[IJ65 M1(3D*B1E)7\?/F3%-H+F(NZN9F9G^2A&-"^V`W#D34EM=[1SKM\R9JL.%++[7X5$!'P5\!HSV(2O!\07T+R M6.]H%BR`A,H%!>Z7(]R!E$'(-WZ=-#];!N)Y?%*_C]-Z]P=NX0[E/U&[SIO- M**FAX8-TSS@^P#3".@A6*&W\DFJP#M6)0HGB;VD5.J[C]&8#;70[*S M/55@VGAU+*EPT"YMWER=;^=M'L_D$UX6/6_A#S>MT)8&ULA5/+;MLP$/P5 M@A\0RK23!H8L($X0I(<"00[MF996$A&2JY"4E?Y]^+`5VTW;B[B[FIF=Y:.< MT+ZZ'L"3=ZV,V]#>^V'-F*M[T,)=X0`F_&G1:N%#:COF!@NB222M&"^*&Z:% M-+0J4^W95B6.7DD#SY:X46MA?V]!X;2A"WHLO,BN]['`JI+-O$9J,$ZB(1;: M#;U;K+>KB$B`GQ(F=Q*3Z'V'^!J3[\V&%M$"**A]5!!AV<,]*!6%0N.W@^9G MRT@\C8_JCVG:X'XG'-RC^B4;WP>S!24-M&)4_@6G)SB,\2I/6*?_A_$#[FL`/!#X3;HMD/#=*-A^$%U5I<2)N$/'L%NL`MU$D M*)/@S:4T39^K^VIQPTNVCT)GF&W&\(R9$2RH?]F"G[?8\A,Z_S]]>>%PF>C+ M/QS^56!U(;!*`JM_CGB.65XT82=[JL%VZ>HX4N-H?-Z\N3K?SKMTB.P37I6# MZ."'L)TTCNS0AY--A]HB>@@FBJMK2OKP?N9$0>MC^"W$-E^IG'@5W$W=7,["P?Y83FV?8`CKPJJ>V&]LX-:\9LW8/B]@H'T/Y/ MBT9QYU/3,3L8X$TD*)S2/XT&YH% M"R"A=D&!^V4/MR!E$/*-7PZ:;RT#\30^JO^*TWKW.V[A%N63:%SOS6:4--#R M4;H'G'[#8815$*Q1VO@E]6@=JB.%$L5?TRIT7*?T9YD=:!\3\@,AGPD_(X&E M1M'F'7>\*@U.Q`X\G-UB[>$FB'AEXKW9F,;I4W5?+:Z+DNV#T!EFFS!YPLP( MYM4_;)&?M]CF)_3\>_KRPN$RTI?O''XJ4%P(%%&@^'+$<\SJH@D[V5,%IHM7 MQY(:1^W2YLW5^7;>Y/%,WN!5.?`._G+3"6W)#IT_V7BH+:(#;R*[6E'2^_&PO=V]R:W-H965T!O\=VTM"6UR7>W;0/@R+N2 MVJYIXUR[8LP6#2ANS[`%[?]4:!1W/C4ULZT!7D:2DBQ-DB537&B:9['V:/(, M.R>%AD=#;*<4-Q\;D-BOZ8SN"T^B;EPHL#QC$Z\4"K05J(F!:DVO9JO-(B`B MX%E`;P]B$KQO$5]#O=;;N$:Y8LH7>/-)I244/%.NB?L[V`;H*(5R;>FXUIG'ZH M[O+9OH_?7[B&ULA5/+;MLP$/P5@A\0RK3SJ"$+B%,4[:%`D$-[IJ651(3DJB1EI7]?/BS% M-H+F(NZN9F9G^2@GM*^N!_#D32OC=K3W?M@RYNH>M'`W.(`)?UJT6OB0VHZY MP8)H$DDKQHOBCFDA#:W*5'NV58FC5]+`LR5NU%K8OWM0..WHBLZ%%]GU/A98 M5;*%UT@-QDDTQ$*[HX^K[7X3$0GP2\+DSF(2O1\07V/RH]G1(EH`!;6/"B(L M1W@"I:)0:/SGI/G>,A+/XUG]6YHVN#\(!T^H?LO&]\%L04D#K1B5?\'I.YQ& MN(V"-2J7OJ0>G4<]4RC1XBVOTJ1URG_X3/N8P$\$OA`>BF0\-THVOPHOJM+B M1-P@XMFMM@%NHTA0)L&;2VF:/E>/U>KNH63'*'2!V6<,SY@%P8+ZARWX98L] M/Z/SS^GK*X?K1%^?''[Y7&!S);!)`IO_CGB!N2^NFK"S/=5@NW1U'*EQ-#YO MWE)=;N#]+HJ#U,;P/ MLA_F!+*^T^@=02P,$%`````@`)HYE1]##[2N=`0``L0,``!D```!X M;"]W;W)K&ULA5/;3N,P$/T5RQ^`D[1<5*61**L5 M/"`A'N#932:)A>W)VDX#?X_MI*$MA7V)9R;GG#GC2SZ@>;,M@"/O2FJ[IJUS MW8HQ6[:@N+W`#K3_4Z-1W/G4-,QV!G@524JR+$FNF.)"TR*/M2=3Y-@[*30\ M&6)[I;CYV(#$84U3NB\\BZ9UH<"*G,V\2BC05J`F!NHUO4U7FV5`1,"+@,$> MQ"1XWR*^A>2A6M,D6``)I0L*W"\[N`,I@Y!O_&_2_&H9B(?Q7OUOG-:[WW(+ M=RA?1>5:;S:AI(*:]](]XW`/TPB70;!$:>.7E+UUJ/842A1_'U>AXSI,?VXF MVGE"-A&RF7"31.-CHVCS#W>\R`T.Q'8\G%VZ\G`31+PR\=YL3./T8W57I-=I MSG9!Z`BS&3'9B)D1S*N?;9$=M]AD!_3L__3%B<-%I"^^.?Q18'DBL(P"RU]' M/,:ZK`-/'J6%)BK]VX>7-UOIVW63R3+WB1=[R!1VX:H2W9HO,G&P^U M1G3@3207EY2T_OW,B83:A?#:QV:\4F/BL-L_D/F5%I]02P,$%`````@`)HYE M1QHM.)C)`0``X`0``!D```!X;"]W;W)K&ULC53- M;J,P$'X5BP>H"2$AC0A2T]5J][!2U4-[=F``JS9F;1.Z;U__$`H(*7O!GN'[ MF0&/TU[(#U4#:/3)6:-.0:UU>\18Y35PHAY$"XUY4PK)B3:AK+!J)9#"D3C# M41CN,2>T";+4Y5YDEHI.,]K`BT2JXYS(?V=@HC\%F^"6>*55K6T"9RD>>07E MT"@J&B2A/`5/F^,YL0@'>*/0J\D>V=HO0GS8X'=Q"D);`C#(M54@9KG",S!F MA8SQWT'SV](2I_N;^D_7K:G^0A0\"_9."UV;8L,`%5"2CNE7T?^"H86=%Z[GWVFFV2;8JO5FB&.7M,Y#$C`AOU58MH;G&.)O3H/GV[ MJ'#KZ%OO'B?W!>*%0.P$XJ'%>+7%.69WWV2W,-G-!/:K)G/,?W2R7YCL9P*' M59,YYO&^2;(P2:8"AW#59(Y9G@D\.8(<9.4F3:%<=(WV9VW,CL/\%+DC_`W/ MTI94\(?(BC8*780V@^!FH!1"@RDB?##?LS;7S1@P*+7=)F8O_03Z0(OV=I^, MEUKV!5!+`P04````"``FCF5'H_*C4J,!``"Q`P``&0```'AL+W=OF9'`[R-)"59GF5?F.)"T[J*M1=35S@Y*32\&&(GI;CYMP>) M\XYNZ*GP*OK!A0*K*[;R6J%`6X&:&.AV]&FSW90,@CYQG\7S8^6@7@>G]2_QVF]^P.W\(SRCVC=X,UF ME+30\4FZ5YQ_P#+"?1!L4-KX)%T9G(D=>3B[S=;#31#QRL1[LS&-TZ?JL=X\YA4[!J$+S#YA M\H19$6PB/0B=2^_?BY07@F44:!<1BQNCGB)*:^: ML+,]56#Z>'4L:7#2+FW>6EUOYU,>S^0#7EQ-W5S.PL M'^6$YMWV`(Y\**GMGO;.#3O&;-V#XO8!!]#^3XM&<>=3TS$[&.!-)"G)\BS; M,L6%IE49:Z^F*G%T4FAX-<2.2G'SYP`2ISU=T7/A372]"P56E6SA-4*!M@(U M,=#NZ?-J=]@$1`3\%##9BY@$[T?$]Y!\;_8T"Q9`0NV"`O?+"5Y`RB#D&_^> M-3];!N)E?%;_&J?U[H_;4=)`RT?IWG#Z!O,(11"L4=KX)?5H M':HSA1+%/](J=%RG]*?8SK3[A'PFY`OA*8O&4Z-H\PMWO"H-3L0./)S=:N?A M)HAX9>*]V9C&Z5/U5*V>BI*=@M`5YI`P><(L".;5[[;(KUL<\@MZ_F_Z^L;A M.M+7J7OQ'_TW-P*;*+"91]S>'?$:\WC3A%WLJ0+3Q:MC28VC=FGSENIR.Y_S M>":?\*H<>`<_N.F$MN2(SI]L/-06T8$WD3T4E/3^_2R)A-:%\-'')EVIE#@< MS@]D>:757U!+`P04````"``FCF5'*-'^\+P!``![!```&0```'AL+W=O!?=M=E]@LQ#8>('-V.+C:HLSS&-\ MWV2[,-G.!))5DSGF/S[%;F&RFPEDJR9SS&9A@F^F@X-J_"'0J)2],&$,INQT MSIY2/UU?\"+O2`._B&JHT.@LC9U1/YZUE`9L$?&#;;6U-\$4,*B-VWZS>Q4. M1PB,[*Y'?;IOBG]02P,$%`````@`)HYE1X?$D!JC`0``L0,``!D```!X;"]W M;W)K&ULA5/+;MLP$/P5@A\0RK*5M(8L($X1I(<" M00[MF996$A&2JY*4E?Y]^9`5VS"0B[B[FIF=Y:.N6'+ MF*U[4-S>X0#:_VG1*.Y\:CIF!P.\B20E69YE]TQQH6E5QMJKJ4H!-=[T*!525;>(U0H*U`30RT._JXVNXW`1$!OP5,]BPF MP?L!\3TD/YL=S8(%D%"[H,#]&H4;?[@CE>EP8G8@8>S6VT]W`01KTR\-QO3.'VJ'JO5]Z)D MQR!T@=DG3)XP"X)Y]9LM\LL6^_R,GG]-7U\Y7$?Z.G4OBJ\%-E<"FRBPF4>\ MOSGB)>;AJ@D[VU,%IHM7QY(:1^W2YBW5Y78^YO%,/N%5.?`.?G'3"6W)`9T_ MV7BH+:(#;R*[*RCI_?M9$@FM"^&#CTVZ4BEQ.)P>R/)*J_]02P,$%`````@` M)HYE1Q\`B?BN`0``%@0``!D```!X;"]W;W)K&UL MA53;;J,P$/T5BP^H@22]1`2I:55U'U:J^K#[[,``5FV&VB:T?U]?""4H4EZP M9SCGS!D\)AM0?>@&P)`O*5J]BQICNBVENFA`,GV#';3V385*,F-#55/=*6"E M)TE!TSB^I9+Q-LHSGWM3>8:]$;R%-T5T+R53WWL0..RB)#HEWGG=&)>@>48G M7LDEM)IC2Q14N^@QV>XW#N$!_S@,>K8GSOL!\<,%?\I=%#L+(*`P3H'9Y0A/ M((03LH4_1\W?DHXXWY_47WRWUOV!:7A"\9^7IK%FXXB44+%>F'<<7F%LP3LL M4&C_)$6O#*1=)J0C(5T0:"CD;3XSP_),X4!TQ]S9 M)5L+5T[$*A/K3?O0=Q^RQSQYN,_HT0F=8?8!DP;,A*!6_6*)]+S$/IW1T^OT MU<+ARM-7H?KF[KK`>B&P]@+KL<6'BRW.,79LKQ?9+(ILS@22BT7.,:G)`8\?'3TZ%:,":B&^L MB\9>TBD04!FWO;-[%>8V!`:[TRV#+&C4MS\VX/$:9>MLE/A772]"P5:E73A-4*!M@(U,=#N MLL?5=E\$1`3\%C#9LY@$[P?$CY"\-KLL#Q9`0NV"`O?+$9Y`RB#D&_^=-;]: M!N)Y?%+_&:?U[@_;9Z2!EH_2O>/T`O,(FR!8H[3Q2^K1.E0G M2D84_TRKT'&=TA_V,--N$]A,8`OA1QZ-IT;1YC-WO"H-3L0./)S=:NOA)HAX M9>*]V9C&Z5/U6+%\7=)C$+K`[!.&15P'>GK MU/T^_UZ@N!(HHD`QCUC<'/$2L[EJ0L_V5('IXM6QI,91N[1Y2W6YG8\LGLD7 MO"H'WL$O;CJA+3F@\R<;#[5%=.!-Y'>;C/3^_2R)A-:%\,'')EVIE#@<3@]D M>:75?U!+`P04````"``FCF5'SXELB:(!``"Q`P``&0```'AL+W=OM]MV',E2UHX6ZP M`Q/^U&BU\"&U#7.=!5$EDE:,9]F::2$-+?)4>[%%CKU7TL"+):[76MC_.U`X M;.F"'@NOLFE]++`B9S.ODAJ,DVB(A7I+'Q>;W2HB$N!-PN!.8A*][Q$_8O*G MVM(L6@`%I8\*(BP'>`*EHE!H_&_2_&X9B:?Q4?U7FC:XWPL'3ZC>9>7;8#:C MI():],J_XO`;IA%NHV")RJ4O*7OG41\IE&CQ.:[2I'48_]QG$^TZ@4\$?D%@ M8Z-D\UEX4>06!^(Z$<]NL0EP&T6",@G>7$K3]&/U4/!LG;-#%#K#[$8,3YC% MC&!!_6H+?MYBQT_H_&?Z\L+A,M&78_?UP\\"JPN!51)832/>71WQ''-_T82= M[*D&VZ2KXTB)O?'CYLW5^78^\G0FW_`B[T0#?X5MI'%DCSZ<;#K4&M%#,)'= MW%+2AO&PO=V]R:W-H965T,<=Y) M]:XK`(,^!6_T)JJ,:=<8ZV,%@NF%;*&Q;TJI!#.V5&>L6P7LY$F"8TK("@M6 M-U&1^[575>3R8GC=P*M"^B($4W^VP&6WB>+HMO!6GROC%G"1XX%WJ@4TNI8- M4E!NHF_Q>I\YA`?\JJ'3=W/DLA^D?'?%C],F(BX"<#@:I\#L<(4=<.Z$K/%' MK_G/TA'OYS?U%]^M37]@&G:2_ZY/IK)A281.4+(+-V^R^PY]"TLG>)1<^RR0;ID['?':PI43L>'F>KQP+)1"#Q`FF?D8XS-J&/@,D\)GE. M'IND$Y-T9)+,F6P#)B8>1!;TZ3^:64Y\EB.?]+'`:B*PNM_.-'LLD$T$LE&" MY>PG'V.F;>*[L]JR,_QDZEPW&AVDLG_A22@-6B2QLPY6]OH:"0VG<-+-S M%?[H4!C9WNZGX9(L_@)02P,$%`````@`)HYE1S=]7$OJ`@``RPP``!D```!X M;"]W;W)K&ULE5?;872_YC72O](PQ<]Z;NJ5K M]\S89>5Y='_&#:(/Y();_LV1=`UB?-F=/'KI,#H(4E-[T/=CKT%5ZQ:YV'OJ MBIQ<65VU^*ESZ+5I4/=W@VMR6[O`O6\\5Z\(O>T7/PYKU^]CP#7>LUX"\9/5&^OZM_$^GR\%\0Q26I?U<'=N;1^JYSP$=TK=DSN7W'8PY1+[@G-16? MSOY*&6GN%-=IT/MPK5IQO0W?)/%(,Q/@2(`383K'3`A&0O!!"#\EA",AM#TA M&@F1=H(WY"Z4/\\@16'=[T(5W:X750LQ0\R[+X5$"2Y]]8+ M*9C-@($"DP0FR%:&@`GA\0",44`UB@V4Z-!T0"DCDM`8PYN%.U[%+3^P%(%C]T>AV#=+'!>B6#S,;@3'Z>PM2(*E54DD*SP2HJ2,T& MSVK-_V7K+08J+09:_)U"O3%`L-1@J#<&""T,'D%CNC#S0Z/#&@S,E+^=VNX3 MM2$]3YK4&MR=Q(Q,G3VYMFPP9=J=YO!',89K^QNP*H%A?\OG]F'*_I`O\@LZ MX9^H.U4M=5X(X_.E&"V/A##,X_8?N--G_F8Q+6I\9/UMTO\$PZP]+!BYW%\= MIO>7XA]02P,$%`````@`)HYE1[="@7T+!```BQ0``!D```!X;"]W;W)K&ULE9A-CZ,X$(;_"LI]!\HVAD3I2)./UNYAI=$<=LYT MXB1H`&>!=&;__?+AT%2UF3B7!IRWRE5E^VG;RYLN?U9GI6KO5YX5U7 MA>]7^[/*D^J+OJBB^>6HRSRIF\_RY%>74B6'SBC/?!8$TL^3M)BMEEW;MW*U MU-G;RPQF]X;OZ>E;RKC?K>'X_>[]M4NW"?\MJ=1&9S_20WUNH@UFWD$=DVM6?]>W/Y7)H8MP MK[.J^^OMKU6M\[O)S,N37_TS+;KGK?\E#HR9W8`9`S88#/W8#;@QX!\&XK<& MPA@(UQY"8Q"Z]B"-@20&?E^LKM3;I$Y6RU+?O.J2M!,0%HV\;)TTGKVFOE7W MV8U@W_J^8BQ<^N^M(Z19]QK6:2)NDVS'$A@4?A.`-0J&HUBSD3FS=;`9*R)A MC>&AD]UC)Z_(2?@X$T[JR3M[;NHI'SL0Q('H'`CC(,)!%GVY>DW4:?[@(@QM MJ@U6,.L8I)5C+)R*,N<.)@_ MNZXAH*0-4`S6FFV-J$]5<17.7^004T^#":2,*'X":R*9(C673 MJ,8Z-U8#A36XT!K<<`TNO`8W8,/3Q`:*;)`.B`/IQ#@DFX(<$DU3#G?IA#F@ M]`:,;X<-#%!40OSTRJ>PA#F*PKH*UT9DJB)Y$-C_Z_U.-[W!I/1EF+Z1@PM* M50;/%H91JC+F0`TCNN,@M-=E0V1LHGQ&-FSPA%VWP^XBZ51EBGR&D6^EQBL; M4YHU<3MU10',$(`Y67GW(P$2@1PO(\)`L><*)D8(A.EZ3TG M+'(@(*.48(@2P@$TC%*"/4T)1BG!$"7$Q*$.BUQ.9'3I<[3TA4.HG"Y]_O32 MYW3I<^:0+1$Y4(I_.H"B)2AB!Q=T:7'Q=+9TU7"\?;"?BWB(0&#?/Q,D( MB::.1DCT^6SDCRY.NCNNRMOK:U'WQ1A:AWNTKZR]>"'M:UALP-*^A<6N MOR7[<+]:7I*3^CLI3VE1>6^ZKG7>W?0&PO=V]R:W-H965TF>[#> M;M8WN\.IR,[UJ3Q'5?9\O_HL[_8VZ2`]XN]3=JV]ZZA+_K$LOW4W?Q[N5Z++ M(G[S$[0__ZS?OO_7#;]!_3.GLH\W].A^;8 M9BM6T2%[3E_SYFMY_2,;QV`ZAT]E7O=_HZ?7NBF+-Y-55*0_AM_3N?^]#O^) MQ6@6-E"C@;H9W.*$#?1HH-\-X*<&,!H`,5@/0^DG8I\VZ793E=>HOJ1=>.$&8W8%2/D3?$NO4>#*%PB)WRS%4H MP(./[<6\`R`.H'<`HP.)DSP/(QTP;L`(;:0*P?8( M%AN(]7PZAJ1C4#K!.+L!8X;W9H*I^!#-F%9+TK`H#1U,PWHQ?H-@&@@BE9I/ MQ)%$'$HD',7Y4;0SC#`Q"1.C,,$YW<6D"E1P6O:QEXV*I0683R2J17BC6<*D>2"0(EE'2DC)9NL7# MI2R5,:<(?`)"`JSQ4@+*Q(_$((:B!%1BZ49*C2"!J&ZZQP+JA*")88 MD7`2HB14B(0)PP.EC5J\7BM*&P6<60%4\P[`AJ<%X4#;A/.N*0V53T/-6/45 MY9>RB^>%\DLYSKSX:Z4(3XD/@;:/83!54:8JS%1&!Z(H!56R=$HTY:#&ZUM8 M+T;02"`CPJLZ0FDA)*/Z-26TQH0.=W?:9^I$,CY$,<184R9KQ.2)!F\$_:Q8 M)B#3B7SHW]$Z.M'@C2!^%*H9FJ,9&G`AA!4#H=I"``;=-14,C==M!L,T50R] M6#$T50SM./3PY<`FB0U_<""8!L=1#4U50\<Q).QH=P$J':HQ,./1+_ MNR/\28@QDM$F`A4Q$`R&@%C&$*#2!)Q>`R2N!3?Q'2Q)+7`2H@H%N.%W#!=4 M6V#YYL"'W0'6]H`O"6VO$8B`%+UFJ!R:9+_R]29:]9DLEPXKYJM[;A0V)I:IB):-DK2\7 MS*U?2^7"JOFRW5M?"ZR1C'[$4CFP2`X<9U8HD2TL+4=+66H-0ZZM3S_0,=U` M?IL5'\;<5;(?SAHL0ZZMG57)"F MNW3M=36<&P\W37EY.P:_G<5O_P=02P,$%`````@`)HYE1^#QUVXR!P``\#0` M`!D```!X;"]W;W)K&ULE9O=;MM&$(5?1?`#1#O[ MOX%MH%91M!<%@ERTUXI-VT(DT97H.'W[ZH=V.;-<\>Q-9,F'X]D)/\XA=W3] MUNZ^[Y^;IIO]W*RW^YNKYZY[^3R?[^^?F\UR_ZE]:;:'WSRVN\VR.[S=/:Z7\?+-<;:]NKT^??=G=7K>OW7JU;;[L9OO7S6:Y^_>N6;=O M-U=T]?[!U]73WWXYL_'FZNU#&)9MW<=\<8R\/+CV;1K-?'4(<__4\?]?\_>CQP M^/-[]-].ZSWD_VVY;Q;M^N_50_=\2%==S1Z:Q^7KNOO:OOW>](MPQX#W[7I_ M^G=V_[KOVLW[(5>SS?+G^76U/;V^G7\357_8^`&Z/T!_'$#VX@&F/\"(`^;G MS$[K^G79+6^O=^W;;/^R//YWT^>#?'<,-.FN"4'RW'4&24 MLF8ZER!R":P:?CI`%`%B;362")"`:J3!0GU*08^68Z@R]E"UZ61(2>84*T@` M0F384FU)2#)'&BA*+W*]R,;QDX3)H@H!..5),DP,8A^!$)([LM5ED>210\KB M!NMU-JCQDX7)C+4^`0E)DHFA#(60`%*H+HM$D.)T61:]J&?($7)F2U2)LPKP MI25?6M4N5TN^-`%G02\Z+]>:Z,)H59@L.960-64=DM,*]"0M^=*FNBR2+VV1 MLMCA-:/<:+D.[+1:\JHYKXCYD(1I7UT829@.2&$"TG"9"NRX6N*J.:Y`S]42 M1)VJ39D$T2B@*KUHJO$R&=AYC<3:<*R!ZY.1()IZKYJ958W$ MVG"L@FVKH:R:$!S.O" M,/<*=5XK:;6,U@CP925?MMJ66LF716RI'?K-(+$H"9JM]J96`6<"7WMFA+RTV M7J8"&Z^5M%I&:P1".,FAJ[:O3G+H$/OJAKY4C9:D("DG(FEVC.8(&#PG^7/5 MMM5)_AQB6YV=+L>XI)Q(]EB'41R1!T,2.U=M5IW$SB%FU87I!V# M-P(NU4G>7+5+]9(W#[C4A6/.(^_=!6EALL MDX$-UDLZ/:,S`N[32ZY\_?/2[($I],1T:"O):?+C9'"=32D!5SXO.?6,TPCX M3R\)\]7^TTO"//+PU*?)JT5!4GZ*+#D-C%/D5`N2P%#M3X,D,"#^-`R-9_F> MELG`>]H@>0Z,YP3XTR`)#-7^-$@"`^)/P]!XEN]IF0R\IPV2Y\!X3LB:LGV+ M:GL:)'\!L:=A:#S+][1,!M[3!DES8#0GP)]&R6&L]J=18S2E0C M0Q6Y!$<)5ZPVGU'"%1'S&:?-9T%23D0B&AFB"8`J2JABM?F,$JJ(F,\X;3X+ MDG(BV:8B0S,AVY(2IEAM/I.$*2&/2).:+$=!4DY$(ID8D@DPITGREJK-:9*\ M)<2<)C-=CG%).1%);6+4)L"4)LE;JC:E2?*6$%.:_'0YQB7E1"2UB5&;@,Z3 M)&^I?A<_V\:']O&GK6A!BKQ-(";!CE(S-4;3II9&B& M6"9NO$`T])WDD_&%Z0XN3$$AGHKR01PVB6.@*N?#,U3M5"D?GR'+,AE]Z'/W MKNH?#GGK]/C3(2%TWA)RTX8@H+DPW'57I:R@1O2 M!L%)3]O9DN9",AG;;';'0"1FPS:DJSTM9>,VI#T"D?9@G^)"M$]E(SS$9G@, M06O+F-35+I>RR1O2"<(I@7V*"]$^E4WS$!OG,00\.Z)L`H=,O>?-9G#(:`0L MH\$^Q85HG\KF>H@-]AA"G$XVBT.FWB%GTSAD'(*8`1QR07,AF8QW-MAC"#KY M,CI-O4/.IG'(1`0L$X&RC&LN))-1S@9[#"$7K6QFAVR]+\ZF=L@2@E.O"I?* M4M"Q;VW7MYN;X!9?'MNV:0R3UZ7#:/3?+AX\W MZ^:Q._YXW!S8G;^/+/K[D=/L?4$L#!!0````(`":.94?'JCE[ MI0,``"`1```9````>&PO=V]R:W-H965T30GHDMVTP`N8#C]-]7?)A(JF3(Q8#\]NGM@AY: MYE=6OE4G2FOK(\^*:F&?ZOH\ZHEG6,/&9__2DGW,V@>+YC7W;ILOEOR857;'L=[JO3URM:UM[ M>D@N6?W"KM]IGX/?$.Y85K6_UNY2U2R_A=A6GGQTQ[1HC]?N'Q+T8?H`Z`-@ M"`C=NP&X#\!#`/+N!GA]@#<$P'U)?A_@3YTAZ`."J0&D#R!#0(MWNN*VMV:= MU,ER7K*K59V3YH%%,XXN&PY.;/'[4;67[1WO1M^7&)&Y\]X029BXPT"+(5@' M68L0)".*%K%MIFC&'"Y*JPQD93$(E*";="4BB*?5-4JR&2?92B3^`#%F@I4: MXS8>]S4.QPD\A(-+5-^XPI+L#$0G!T\'6TV!;$09NB"*DJ\R3*`R" M\<1\)3%?B(_T>740O\O=\WT=:.4+%*!DE0@ MWBUPM5D%8E:^JP6MC2"C%*)((9(4[<*,B5@6'!JTF%%&,:$B)I3$@%9,.$F, M&644$REB(DF,]H&)HTEBS"BC&.2J+NQ*1:J1(=E(R@4(U0$2^7MI#L6Z&<[FW_ M(X.B"?.HCH0D2\+Z]P82W09X5V%ZPB/Q!6[$;>_QF7=JJGV!9%]8_YX!T9>^ M`2"B7<3KB;BMC$,H="=4'52C`\GH#'LKD!S,O+F:B-OV..WVRBQ=M42`\97? M8\C=C<9*1H'AF9)0R/7TL(T$(\&D!VJPUJ)/#8]V"ZJ5@F$O*K44(B90:^X( MG5-.RV/;%%?6CEV*NLMG&!T:[T=H.B]E/$:S%=*,K]%LHQO?\@9>.PZ\L=>, M\_+P/[!N9O!NWP*'G9=?`=Q7-OSM6\N,TA.'IP4NQW8G^032; M1&?=NJA8W1:\#AJVF8:_X.T2Q3TBB3\%.[:#^Z`O_HWS]WZP7$]#T-?`2K82 M?8B\NWRP.2O+/E*7^:\.^I6S%P[O3]$?9;M=^6]YR^:\?"W68M=5"\)@S3;Y MH10O_/C$=`^D#[CB92O_!JM#*WAUDH1!E7^J:U'+ZU']D@(M%!`M(+X9$BU(?`54"^A9@"\+4BU(?3-D6I!]">0Z M1&K]Y.K?YR*?31I^#-I]WGL"WG9XTP?I(@?=DK=R*%\J]?1CAC&:1!]]((.Y M4PR2#(+`Q2-!L!6`"P#Q+J"S*RR5C.K&*J2Q$D*`'!Q#T,NIAB-<(LA M1Q#"(]S3D$,)@`8XVF%L=1@/.XR=F>X4`X&$P`U*D^MYB)6'&'G@]0")%2#Y MZ5I2*P`U*G"Z;6$R^'J2U$J2&@&<-EN8#+F>)+.29$:`Q/D6*8:HM^UZ"KFX MQMX$C"1.$R\LR,.A\-L>"(T0F3O/$$+0X_6#]E8`T3`/<5M/0VK6$/'Q$[2W M#&CL&02Z$QGF)5[.A;9UH>%=@IR[DX9T2S3-Z$A%%[CQDFR70\/FQ,-`T/8Y M_+'1H>UT2'TFA@X:[G=C@D9FYA(X7I2],T##]L3'D[;O8?;3J4&VK9'A6$)< M'2\UI#J&*`->[R>RK8T,:Q/G66%I0=0CS[?_\J:U4U=/CQI2CJ,`>/9DNQN9 M[G:>".9HZ&Z<^N:R_8T,?R?.+>L>#7V;C!T6%A&ULE5==DYL@%/TKCC^@"HB:C,G,YJ/3/G1F9Q_:9S#V'N`#@$P&O`-8\[``T!Z!:0?!F0#`&);P8\!&`K0Z1ZE\JM2E[. MBXZ>`W8L^_<)3`6\ZTD$%K:ZPUA6$'K*D M%D'ZJ*Z919`9NCH;72@,5DFR.'9*-@H:+26W2LD-,3S6PL0BF#PJ!HCM-1U[ MR#&`5*L0C.@QCAHOYY/%`$,2Z$$!;0KXL"CVV@7(1Q2DM3L9%644-5Z.[03` MM`(/,P+VL@/X85'LA0=2#T,:0/AK1S)0HY9DH$8]RIQ M"GLM@_QAA>W5#"8^"D^T?IWOW/(^9'4?LC8@`*1PXO&MMNT%FO:"/2AL2X#@ M46&A;0D0>@@[@/"G3Y,NK0$""&=.=0U4FCM!:S,?SGWDM8T*FD:5>E#8Y@*3 MA^6US05B'WFQOE>!B=L9#!1"&7;KJZ,2C%*WP$9&D$WLMR_2MK\-Z?;RX,&" M#3VU7"ERG;T>;IY@OWVVYA=@N@2.^94X#*FCRXU^7AS+/?E5=ONJ9<$KY6+3 M+O?K.THY$77'WT3=!W%NQX*Y_\!4$L#!!0` M```(`":.94<\+DO@N@(``"<+```9````>&PO=V]R:W-H965TVT#YW9V8?V.6I49H%8$F7[[YL$1)*- MA7T1$L\]Y]R0>^>F+6G>Z1EC9GU494U7]IFQR])QZ/Z,*T07Y()K_L^1-!5B M?-F<''II,#K(H*ITH.N&3H6*VLY2N??:9"FYLK*H\6MCT6M5H>;O&I>D7=G` MOF^\%:K>$^1TA[V+Q MX["R7>$!EWC/!`7BCQO.<5D*)J[\IR=]:(K`\?N=_9M,E]O?(8IS4OXN#NS, MW;JV=XAM5>BC>Q:U?+;=/V'8AYD# M8!\`AX!!QQS@]0'>(\#_;X#?!_AS%8(^(-`4G"YW>7(;Q%"6-J2UZ`6)^P26 M'-X($LYL\>.B$V)@13TT$FHE@G$4T@R#4",)Q%A$P?B\5`Z=%(DTD4@B,MVZK8F9\T%@3 MB16"P"BB8L)ID403210"8XGE"B:(ID6`JQ>RJ\C$1AD-E,S0^=0PP)@B=HUG MIH%F=`0`=1VH4)@+6@-Y,W3TF@:>0F%L+;D&,E^4IZ#G9O3^`)0&$8>F\L][ M4-PU6V\!/1-LJ\*"13*C"('>*T"@&)IS,?5N`<*O]AN@]P(039?05@7%,[HS MT-L!4&H]GE,>>K&#Y*O90KV2H3LC6Q7TJ6,XHRF@PLU)SE_4VI-KS3IWP^XP MX[U`,45H^VNPS(%A?\-GPFZ">]!GZ06=\$_4G(J:6CO"^.PBQY8C(0QSU^Z" MIWSF4^NP*/&1B==(G$4WQW4+1B[WL728C;-_4$L#!!0````(`":.94=R(W(* M1@4``$4=```9````>&PO=V]R:W-H965TLZRD0W1"#&2;'K>?K046)E.1#(70.++I:J4 M?RT:';/\=[%)DM+YD^[VQ?U@4Y:'.]LSR-R^HR?W.+ M0Y[$Z\8HW;G2\WPWC;?[P7C4W/N1CT?9>[G;[I,?N5.\IVF<_SM)=MGQ?B`& MIQL_MV^;LK[ACD?NV6Z]39-]LB\]NIDW_. MLM_UQ=/Z?N#5.22[Y*6L7<35UT?RD.QVM:[O[;K<5-EZ`V>=O,;ON_)G=IPGM@VF=OB2[8KFTWEY+\HL/9D,G#3^ MTWYO]\WWL?TG]*P9;2"M@>0:*&N@S@9*]AIH:Z#/!CKJ-3#6P'P:J%X#WQKX MGRGU1PBL07`VD*+7(+0&(3="9`TB;H1ZS-N1\[@QQ'FP!3O*:;C%YWCK?HO3 M>`N%@KCMH]@\R-.XC,>C/#LZQ2&NRUO^ZF<.]7C6S2738&T=S_&*O)& M[D?M"3"3EI&6$13S`!E),5/(*(J90493S"-D#,5\`XPBF3G#SQ/#SX+A9PD9 MGV)6D`G.C%L-)#V:$HVF;#PHZR%D>%#(@VH\:.LA@GGNV_YOF:!AI#'"([$Y M#UOPL.4UK,W_>S=_Z3,Z0*,.T!T'.B#;WR*F1<(P"GRR_3QLP<.6``L\(P.R M_?K6]AO4?M-MO^>1'6`ZN01:>Z$A.X"'+7C8$F#2^(K3.A^USN^T3BAZW/Q. M(++]3W[G6=1*^P&G5@.42@`Z6I"I!)U41*@U61I/`9GPY4Q"E$G8K7G/,#Q$ MR$-TL^X(#T]$'D-Y+'15>IC<@LDM+6-7R9;`<9<4K&F%K(YA8&ABW#6 MQ_7DA*<,(:^7Q-1"IUA"\F+AR44HT'YR!3!%$+D$F%V$>K+!2B^`U'NDZCQ8 M2+0K).T/(R\D9X49))491A%NX>GI!*3QAB84K)K!6BV@6)-C]V"AL!T[,507 M'CN`!<.`K(09#WL$F(B&`=EG@MKO_!!;Y'SYQ1!K&'!RBZ@M+.D M`FNR"&^75*S*(KK^>$PL1#T>/>M.K-ZRJ]Y:D(HUD5T5%49$70GL"89E5`(9 M%>34.;&0#:8C7W,F-OEE12U!+%:^6/:DNGDL)18K"<1*D,(RM5`KT\H/62HM ML:I(H"I"TZ&ZRS%24687D)Y,<,5*4(R"5F@+7=,WB%T2KCG`N%(CL0)(H`"" M%F8+16U&T9#&IK*[O%,AW=77F4<8+ACBF?74`2QLT8/U]!-6.1F"?F+U-58Y M>?OB4V'Y4E"^R`Z<*K`(#(+(-QQI5UB^%)0OE@\L2^I_[/2_;/45I]'JQLV% MPLJE@'))E@\L2%NGWR5[@L M%)C\Z8,,RP373C*8W(+)+2$'#S-Z3FIPU6I0M5)Q?.!BU.+FKM:X:(]#; MNI7N;J%TM5EC3$G\#%(G,`2+""R=<3]<]+0"B(N9X8E724)7(.EWI[H&3,(H7ZJQ, M>QNJOG'%!BN1[D[0DCRVG@#&%R@UM_-"(DWRM^;-7.&\9._[LJV[\]WV[=]2 MW'UO7FB@^U7^=ZNJ#5__J3(XO3!T/T.,1X?X+5G%^=MV7SC/65EF:?,>Y37+ MRJ1*O-IW#YQ-$J_/%[ODM:Q_!M7OO'W+UUZ4V>'TTO+\YG3\'U!+`P04```` M"``FCF5'>B,_P9,"```O"@``&0```'AL+W=O=&9G#]KCK$9E%H@E4;=WWR1$2])8 M4P^$X/.^>?GR&:C/=/A@>T)X\-FU/9N'>\X/LSAFZSWI,(OH@?3BERT=.LS% M<-C%[#`0O%&BKHT3`/*XPTT?+FIU[758U/3(VZ8GKT/`CEV'AU\/I*7G>0C# MRX6W9K?G\D*\J..K;M-TI&<-[8.!;.?A%SA;P50BBOC>D#.;G`F5\?S^$M1:)E; MD&A!@[8`ZAN#0F*I[H>IK#"5$:9P MAJFF+0$C=Q83RB*/+!#8&S`PTI0>%G_MX?!_VP7:^QE,C!25LR8:RO2#`($2 M>DQE[WQPNO4A!-Q3I=/2YI&]/<23I]P![\@W/.R:G@7OE(L'IGI6;BGE1'B! M2/P=]^+M[3IHR9;+TT*<#^/[S#C@]'!Y/;N^(RY^`U!+`P04````"``FCF5' MS!`8*JH!```C!```&0```'AL+W=OZDV2>@O`86\]@;KE!`_` MN0N3V1?6_81AAY8%[ MQ4UXHOW16"7.+0D2]#.N3(:UCR<_TJ'M>@,9&LC80*+Q*!1L/E)+JU*K'IF. M^G>7K5VY]A!'1LZ;"6&8/F9/59YG)3YYT$7--M:0H8:,-=CQKXJ0F0@)@.4` M6'X/6,X`RP#(!T!^Z5)&E[$FBS:SQ0TJ^4PEGZB0XH8Y5S/`ZG_G+&:`XF+. MU=4YB^F7PC5JE++@6.G".6[=%SL&'!KK MMW=NK^,ECH%5W?F3'/\+U3]02P,$%`````@`)HYE1W]FHZW\`0``V`4``!D` M``!X;"]W;W)K&ULC539CILP%/T5BP\8".M,1)`F MB:KVH=)H'MIG!RZ+QL;4-F'Z]_5""%"DS`M>.)LO^*8#XQ^B!I#HDY)6')Q: MRF[ONB*O@6+QQ#IHU9N2<8JE6O+*%1T'7!@2):[O>;%+<=,Z66KVWGB6LEZ2 MIH4WCD1/*>9_CT#8<'!VSFWCO:EJJ3?<+'4G7M%0:$7#6L2A/#BON_TYT0@# M^-7`(&9SI+-?&/O0BQ_%P?%T!""02ZV`U7"%$Q"BA93QGU'S;JF)\_E-_9LY MK4I_P0).C/QN"EFKL)Z#"BAQ3^0[&[[#>(1("^:,"/-$>2\DHS>*@RC^M&/3 MFG&P;YZ]D;9-\$>"/Q$FGVU",!*"KQ+"D1#>";$IC3V**<092YREG`U(=%C_ M';N]@G,MHI21.KTP2U-?NWO-PC!.W:L66F".%N./F&0+&4ZC$`YZUMI;\"T.S6Q5]]6IN#I17O\^ZND%6,7+S+!D"ASX[UQ5EP0^*M3V\"B0/74?%[V=@?%P&47!: M>&OWC3(+N"SPF:O:#GK9\AX)J)?!4[38$*.P@I\MC'(R1Z;V+>?O)OA>+8/0 ME``,=LHX4#T<806,&2.=^,-[_DUIP.G\Y+ZQW>KJMU3"BK-?;:4:76P8H`IJ M>F#JC8_?P+>0&L,=9]+^HMU!*MZ=D`!U]-.-;6_'T;U)'STV#\0>B,]`1/X+ M)!Y([@6(!\B]0.J!]%X@\T!V!6"W67:KUU31LA!\1'*@YOQ%"RT7QD0[([V_ MTH;V"[K58TG2K,!'8W2A>7::V&OR.;)IM_F&#=Z6R[ M\56[L>43RT=9=ML@N3)(K`'Q>_'ULLC>[9?3Y$X3FN=V'G*5AUSD>9S+LR*3 M/.&<8CU5?(GSV7)?;MILYA6N%SPY;P/=PP\J]FTOT98K?73MJ:TY5Z!]P@=] MQAM]R9T#!K4RTUS/A?O?NT#QX72+G:_2\@]02P,$%`````@`)HYE1\B/BV03 M`@``2@8``!D```!X;"]W;W)K&ULE55-;Z,P$/TK M%O5JIZV#T[80*H-J:V$[K_?OU!"$%422_8,[SW_&:`(>L8 M?Q<5@$2?E#1B[512MBO7%8<**!9/K(5&W3DR3K%4(2]=T7+`A2%1X@:>MW`I MKALGSTSNE><9.TE2-_#*D3A1BOF_#1#6K1W?N23>ZK*2.N'FF3OPBII"(VK6 M(`['M?/LKW:I1AC`GQHZ,=HC[7W/V+L.?A5KQ],6@,!!:@6LEC-L@1`MI`[^ MZ#6O1VKB>']1?S'5*O=[+&#+R-^ZD)4RZSFH@",^$?G&NI_0EQ!KP0,CPES1 MX20DHQ>*@RC^M&O=F+6S=U*OI\T3@IX0#(3AG'E"V!/"1PE13XBNA,BTQI9B M&K'#$N<99QT2+=9OA[]2<*Y%E#)2U0L3FO[:[#F/%E[FGK70#69C,8'!).$< M9#N&^`/"509F702W+C;!^(1H]H0Q))A#[+X0^=)$.&E%:/AAWXH'JH@F`I$1 MB'J!B+D1-_D=X72"8"R7>?23H12&]Z$&EFET`' M=FJD?2&'[#`>GP/]R4[R6S4V[92[RN19BTOXC7E9-P+MF50#P&PO=V]R:W-H965T,7N=U[%47.+XK6#7D5GKPPAL7O':&\V_K0OVV\U>=*F0U0Y&#TG6I& M&EGSQA.DW/I?X&8/D9%8Q<^:='(R]TSS!\[?S>+[:>L'I@="R5$9!-;#E>P) MI8:D*W\,T+\UC7$ZO]%?;%S=_@%+LN?T5WU2E>XV\+T3*?&%JC?>?2-#AM@` MCYQ*^^D=+U)Q=K/X'L.?_5@W=NSZ)UDPV.X;PL$0C@88_=>`!@-R#*#OS.;Z MBA4N$5H/N*?93 M190DHP;H#NZV$3IMA!80#8!T&8`<`+(`-`"R94#D`*)9!^MYS*:/V6M2JX%Q ML%PD=HK$TR+I`X#$`23/QDP=0+H<S'L*[.0=19D79ZH&D\)^_#YS500\@W*,/PZ?3NH,"TI*9::IGHO^MNP7BK>W MRW]\`Q5_`%!+`P04````"``FCF5'AWNG<'!#``!X,`$`%````'AL+W-H87)E M9%-T&UL[7WK;AO9E>[OX5,4`C5B`R6:U-7JR0209;E;'5\TEMQ! M<'!^%,FB5&FRBJF+907]HQ]B_@PP`YPGF(>81^DG.>NV;[5WD45)G9.3:20- MVZRJ?5U[[77YUEJ_JZHZ^K)%4U>_\MO#HX/?O/[ MWU79[W]7__YU,6V6:5Y'23Z+SO,ZJ^^CBYS;S(H\VHVJVZ1,J]^]J'__NQ?X M#7]W$KTK\OJV@F]FZ:S]]"I=#:/]41SMC<:'[8K;I+Q)H]/I-(6WX)T9O]\UFF*Y!**\JHOI#W%T1909 M?6CJJ@9R@<%U[H"]$&_@1V^P[3=ERX+O_NN^M]X?WK\^?W]U_CJ"OUU]>'OQ M^O0:_O'J]"T1W=6WY^?75W"6/EV]CI[M/(]VHBR/KF^+IH)Q^V-)IT`/8SH@ M!^V'_VO\O[MV.ZFJM*Z^]AXGU2T=IRG^)?U+DWU.%O"^U^_5+6SQ;IV6RVB9 ME#^D=3)9I%&53ILRJS-_@S^F"]JQ55+"WI3I-(66X9,JFI?%,IH6BT4R*6!7 ML\]IE)1P/&_29:CCRS)=)=DL2K\`2ZO@>QQM4=\"W4R=N7D'NZAAK]:_\Z[/ M5"Y+X*8X"^P9EVB%`XVC/*W]Y5QET&OV5YCY/(7!TM#K(DI@":P%"7[\@2:U M;C+A9VJ+%UDRR18T!6^?X1`A?\-TO3GRSSC4:QA%\CG)IVGT*BM6<(Z6 M20R<;SH,-%HV.*6TK(H\3Q>[:I)JL[J^R'*@I!1NKX[AR%+(V];$_.,P3V'V M,UC>SVG>^-S=(8(U#9T5^6?8Y(Q(H0'*!)9!4\F+.JWB:-:D<.3VO-/]OLAA MUK"X996VWCU9,]B\8_<717[#IVSM6)?+K*;3PF<7;EM@<&D^A9>C9^]Q%-%^ M'!W1TY/GK>]19/BZ6B73]%]^`S)!E9:?T]_\/O)./#+2VV(Q@]W];31+Y]DT MJSW"@N,IDZKP_:^CG=%P-$8JCX"3-"DPJOV1R`E1TM3`1O!TP`$HU*]95>$N MT[GN9M?"WCM[&8WBT2C8TWA\'!\>'U('X_%1?'!PV.ZZBHIY!%=MG2XGL`M* M`*%/@./*K\)U8]B_:I5.D74MO$OK&J2LJBGOU4C'AV906W7CG9W9+$,Q!^@9 MN!4]8L&SZ)PBF+)>ST+9Q)9+=9#O].HV>+HJK:Q.%\+)L>/E15 MB#["KUJT3'/M]2F-$M/)FD M:0ZMES#G&5\[20-KV&YQ#B<=C@Y-"7Z@<^7QNGZW^+/+!,_V;5IG("@\AUM] M)WK1(27W:G'#<8O-$8B>`4',\%HM*^3(W*NWO5X#WH'I^P6?G;YO]SS9VT_( M_7KC;(*OAZ?BGN3H-EWXK87W\.H:_GAW_AXHXL.;Z,,E:!C7%_"")>6IGBU1 M+]X@^NWW5JL\WK'E.#UAKKA/%B3&T24K9RD@TN!A3):H#/R55410SA27VB@4 MX<<[^_'!(3-$^.O>_CZU``<*_BO3-%KR"J2X`EVQ?M'Q_SWX_AH M/-:MY5G>:JSJ;LR7;:UEZ)9DNY)V_A[9Q^=N_OTJJ M;,H4D2T:$F?E3<-1?9UPT_A[](E"WG66?,Y`G9A47'\^_A?&#[8883$H`]PO^4PXW/"W&3P-"$ MH\$R!4T>0:;U-JVJKZ./3CM;-7#FC#1TJ/LMS.G5M]&;MQ_^N,6"XS&9+XJ[ MRF'BP`82U'6"JNCI[,]-):HHD`QJPB!*PRPU[<.O^'>R+ZW*`@\A"/'WT3,Z M/UG^/-B/MS>O4U@5$-*):NGNLL@XJ+KNPH$D47^)G#OX7OLH0!?+K%E&Q!"T MO2O+/Z2EE!OHE2AVTLH+;)8M!I,/#(J$H6 MU%A_56Q1S2'ZUMH_,4[0[/6Q1 MEE'0G_>#S847L%EY#;)_P([7Q\857L2-AJY8&ZNF"Q"IIB)@67*8_:JV8/:P M<+W?_O!L.MA,T.N_N6Q`EDS0WDKG(F0!7?M)+R/QNZ26)[T_N4H66[S=UQX; M(!7F:4RC*+_DWCNS7_8N]MD';`)$2S0:T"2F?5TKW4N9U*"EW&1Y3K+X'/E/5OA&B'7? MI\AKNKZ\:E:K!?%1X%>H>\"-W92IIB2D1)A*IX>5>J8CA7JU,NIOT0M<,GS' MK.E#D9-<8'FJG#DQL-3IHD&34O=B;TF"Y`6HE&2\UB>`\RV<@^*IVDV";N=#8T,,O/BQX]^_FG_S`_ M_OS3?\:T#/`K"K])?D\_`47!+W?XW+HQJVR9@7Z&IS.',8!XG@$?0$\L,^D) MR%XW1!$H]RT6^-<\O8N6Z0S&F:=$$"L8&1$';$B"!Q9'W.1+(*T\Y1._@)N[ M3*BE#%ZLK-GC10Y4P:<)GG"L@MV.LF*72;( M:=J0(E<-(WMM_AWN+)#@YK#,!4X5?@7)E,>(?:,K(H.5+F"71/["&RU/\1VB ML&\6R9G'__[OUZ\^GC^ MX;__*SI_^_;B\OH4_H9S.'W_X:/S:QS=W6;3V^@..HO^7,!Y6-RKQ>`16B ME&FJ82!T?M"`!7QR&IW"AE-OYB5>@ZL_1,^T91HH`,:5XN97BO+P#?U1Q0MC MC1Y6/EUD-YG(CR(6T,>PZ@4J)NC7<^VD)PO8WI28_(R9'ZUM(Q)ME=$V5WA4 MO*O_HT6FT2G<-$Q'NP&R>J?("M;VIDR6,5*!M9*\^+G3.4V4 M&1"_)8<5%H0$`AKJJLAQM6*X*]`,BV<5VKE-%J2%`L=`R2,MBVS&"X9;P6W" M2&;-M$:69_?*DC<^03*%RWR9W(-`P%;"S[0-EI+!]PNNB^QO8PX:3+GS%*FC MYK[`&\+G6_O2G,W]>*97!";Z0")O$?$`K7[$C2_1,0W[B&/!&P15):8;I(\F MMSQY(2]AR*<'\X"-HHFL$%3"9$P-ES.B4MKF3\.K873#5G+:WREZ!F;TGEQZ MHN"C)D*<]/3TDBA*2T'9TAJ!)=P,Z>I$.>)F<4^W'C#,`N4)X<(PS\5"F0NL M#VFQE`("THW<`-@S^UA@;18I"`]!9R9ZL&E<'PLQP$$;9CR#8'^\0C!D<=90W2@]1L[A&EEI(?U8,,'"(#L;@*R?S# MISH]U6W1+&8X*,21BBS[9V'`1IC=;N.9I'&X*4Q8R(`:QQTZS?,&OF%\(=+9 M&]C[:#S:_8.W'FD`00'=+I041'*"MA,P@O3+E#5.PM-4)/7C<;XZI^N(^DLG M98/$M'?,*PPHSG`V8R47J'$O-P MURU_7=G<.,8BBQ#8%@MMH+UB%];O)K5$O(#\AY(AZ!T52CMT<.#;WKW1O8Y? MP(+!KM["G7"_6]PATP<5J,IF&2Q'O$:E:DGWYC&NZ3#Z8^H8"';V3_:'HPAD M^H5V1U2W<4"5A7$'33Y="AY?LP)4<+VH#I(.P,_LU:)*`-R$'4-#>D=59+[:']X:,T# MM\K60=LV'WP'3EW($",#V4@ST3T5>HG;]"UK9`R:^(#&1S6!)I>$A-& M66>6KO`HHAJT:B:@&"Z(%&=BA@?VP]PHS/$TPX9#GFY!LLC$&F*2L+0-DXJK M>YCQX@6^<`XK,6G->!)6GY@U9WC9$NN!G[ME.(]-P+%X'NX5NA(:%\$X:%1)8>SEB*4!O@& M7_]PC,OJ-EO%?`9!=&W$4%U(P]KCSKJ#G*]9BLX*G%8V9Z$%%^VSZEE_IK]! M'O#]Q;D2(E-J'9@B20])X$N27`M0J7432LC/$Q)FR?+\I1:UF=]57\/M^RH1 M_1_G*9/FJQM&?)=:,[A+:?#BIR'K!KOTIYE8.DA\A]%7Q,>M>XR?Z!%J5AF6 MN?[H?DN4K5^T3@`(TD:1YA72HYV)&)#@>&(\;4E3I?H]FD1QQW0T`Z$0=`C\ M#;UP<"Q90;%-%\9Z*3WK92[@N-ZP>(3F\4E5E!,2=.A5LL:0K)+=W-:V!BQP M"+ZF8FR268@O7%%7X9.OQB+B$I`VB"[PJ3I;+,E42HI+0:A!%Q'9&R[8M&:; MI-@T-!4Q`\Y7]*>TCDYG!_[2B[<;W3Z\^T>O8U>[H)(XOXHI8DF.-6+YW!,JZ41:62VRI)8L+=L`'G+&(-PDO[J<&*&><\0Y40SRHI\"B%^V-5:>/C\CA[F@_-I??SS_] M6W2!@!RMZNE',+@!7*PPXBI`L0`[0$TR6Y%G3]*MIE0XC:>9] MF[8MAZRC$.Z_2$@,IU8\L#,(F2D*.X2M1"Y"9K*D+$FQ,^>?]4J%XIZ8T`=4 M0*L:%3@T!O+)0#T"3G]Y@X>I[B9XE&0=`CJ*>>"I2W$N,<'9YSN%R-_:M4![ M0V"?>%-HVIV[VWR7\NB2U6K!6ZC7WSD+"V*.R&B\JX,5]P6:LH`*D$0#6Z,N M9/<@..JI%:RC=FL+;3IN;Z:($B;^`T?E^:?0Q_A6(3.OK=MDQM\+ M-\0CRC2I/S4Z\G#PYB%:BD%`QQK32,J53TT.C)+4:-2$V=+!CH&NB=#+[,A5 M41K,TQ93C$(AJQR[:;)2W3UW9%ROLUTUU^'@%/_Y6DW=6'I(WYP7BT5Q)UY! M[-M8%IQA6';8F3G4SFVR!MNII//U0_T:1H1[8&/YW:4?O,>M6?/\V05I2XSB M>SZ@G7HVIK\B%P2<"MD`K>#H&5R:D@E2\!AGZ=`N_^@"GXT]2KPM$M*O)O?*WJ#F6*'52TQ!RHS6 M#679Z-.?-:62G'J%,`RCJV92P58@<8H?3#46\Q0#R$:-3_=D"E0+>+,Q@*73 M,&)FKV@"1*^B;(\@(IN(Z!R=K0T'2(#6'NZ%]O"@UQZ.+0+X.]C#/FSS'V(+ M?6B,#<$\70/!W!]&W2\/4#IIZ<%KWRVW";8)1WJP(%PI&:NS$8T58!G*Z5G% M47;V3ZLZ7["W9HV]<+VL:.E%CHFD92\TH2`QV0V?",2CH#8/-$7:BV91&%\N MN/(NR(+OQDINY^J7N1C-I&"HQ>"[_:P7.#0Q2 M)5%(E=T(`0D*C##P0L%XG+!R9FR>LWYP6M$0T+:FM+]%TN1B/&<824)^Y?5^ M>@WS:?TN1(NN\1ATMI6(!><-`H/CD!<=7W>WF[4W9,EB:V2&O$KND;\#7T=+ M#*TJ_(J?UK@42)X[>WLC7P)6RA M](E@#][4;*[=Q@:?PW:WUB(JTL2.:-6M$PE+U9>4;4UXDHJ1`0\%S'4J:&Z$-W84>5:8F.;L)CT:J8SV\,Q"G$+&)K>W`?FQ4*+Q'\6^S7LZAD M4S/V<#2$941\VN@KT.)LAJOD(>9K^*D>4C>MV_3Z4(I'!(N)?REM&TT+X4?& M9V5B(A-U$IH!J+=I2N[%)6=AL4:&F]=J%5$L-RQBJ$L`N1S[(@TZ8EL18F#Q MFW,/QH=G"!H^6R,'(\[A';ED]Q70@27G&D5/?4NZXNY=&D8+*$"HBRA,T+,@ M[JG$NCH,1C51&:\J)=BVKQF,[LSF9!"]+>ZT$I_DF3X]:`1FD<^1C,D32@MF MVPSL5X;195.BI;!FRB&5;O<.[[`$P7UFT#%*UA*HANRO6K\,=,G0QT2358I, M)9J"FHRA7\94%6Q#V3!@PTA#$-&F3KZ0"JYQ"1N^YQ,$%R;Y"NB(K^T.;Y7* MTG&TRX@X6FM&VF:`;ZYK5A_R=G.P+1INJ-R?RP@(7T/0,.N=H$2(-$$B89D9 M-:P*C?[)%UXE^`BV%FY.)!ZTI27&M6F/M$HW849HN+B[DZ86KDL-P=DGE%Z3 MIU_PNJO0'/YZ.T62@40X0;QC#O:/XI>CO19BI'MD;&Y,66GLE(Y<',(!ROZG MGY-L@92S"\QI%Z^K-G3J#6+JOJ\H28:&37=K![C29RI341WIL"5L3Q1" M,M890Z'@6*?FHY4;ET74K9BW$*$M37-&B2,;8:1\S#,\I8QIJA.V=NE+A0,R MI;UY8CN[DNEM!F-5\'WRAV'`(4MVBWNUNTJ:7`$)($`F(0>"I8@2^O[?R7Q( M:R11HC)E)Z(`'C8XBD9?GVME3-P`!2B>HNEO1GVR`Q#T/`0QJE'R,OF)O1Y* M`.V&4/I^:%N#M5\2J8@;A_"4(JXYWU"XK`456Z][.\XV4NAMY;2E6_J'=>`= MKD%G9!;I<9M2Z@V"V>D&/__T;ZPE4B.X#$;X)JPK9\_9O!A5-%&HF;\T!7[. MPT"ST335R*8J)8>_Q-U8P="*P92I:4@^+29BFI.;R)+Y\0V"XC&"H$T@[5'B M>:W(@,'6*C@6=U^'5K^U/Z=:2SDKJGKP38FV>BO`_QL87^7__)80+X-SO:*& M.`<,#$>E)Z>S;>T)*^:X,SO>:XDD9AL\'YP5(*"3=,&6;OS%+$P"O(#:P/_> M`1^Z5QLR!^Y2Z4=F\W>@A9T`W3WI6G`X^#7>NM<@Y\'XX>JY`'DJ*VE^^-JC M%FSCLN$+_M+QKQW+A_]]Z'=/ZO>?KUOTT,+C?Z<=.=UB&\B__B"B^&'C\98F M*AIE%8K\%Z"S0FLI7V:D?)FSIM0\,`R3)6,;&H*^T$:1^]RX(\A3KR,1:A06 ME11:$["]=>H9-(E8I,80#/O#-):>@/WH68=W%MD/W"6+)`IBH&,9NCJ3)#VH M+Q'XE1<4*,Q8(=!ASW$'2O>3,!E9QWN:FX>K4S?Z#9%]:Q9II?`KX<7LS.3' M+@=]3%!T3]B#O9Y0.O:,XJN\H1GG,6Z!N^S$MP2/\IA56UOUD5@&($4TKUM;:WC>T7N?;B&QE<(!]K MS[*Q61Z<&`=7K`^N$E:=1#.2,H,W5SNB;=SFM@ZH09=,]:'9-`,\V4O^9(8X M-ENDR,E6HN)N)-8GG]DH&@(C9?RI0!*]<\KVRI#4(M.WY:[0S>+,J?LP?D)! M]^L!IN2N&`E6U67#"_&O+/%\];5_!8%_6@L?^[)G_MRU4B_&^[17K>HNL/:]ZCY_8&" MB,)`V303VEKGRG]K\IT,UF?>U8EW];?J3S_SKLZCTQJA*Q5;N5:\-OL2FQ]J M]"NM/0&M;2NQ_8^BS6L5RZC?[I9/E&(L)GV@.=ETYJ].3ER+;C*BFTC'&JNP MS`EL["WV%-UG<#]7L;%%4W@/6K_*XH>T?#&#>PUHE?1)--LB.`V41RX]$8,X M4NQ6A,KF<>.'NFT[D]4DP]>+^9RBK`@A#']-D0QF&&IE[,&R^SI:B`./E,D[ MO&@;$GNH;94(QL6`T^IE@D!3;'\4VQLHR`!^MO7!8"9LQH[(&52=O\N/YIBV,_ MPYH4\">KT\X`^*?.!Z?*Y6]6+?)739M3UZ4*T.JN^O.:;$*MM?_;^8=%IL]* M*PT[T0IZ[`U@*NQ)1)`"NP,3R[%'*:=ZP8Q`CS/H7CL^'P:04%R_F,Q:R]-2 M6:QX-B#@_)!+"#X:/:&,Y)DFU%Q4YM_Y2]'ZC> M]]S>CX='G9UW:LRL2(1C!2C[L:=?(H(,R&4DX7`4)`3`2 M=9CI#1L"QP.*@>(XF+2Y M4<`4B4>B8^P.E#+TD+`VAPX;M\Q@W M$2+"@&F64RN!'=^3"\G"15+0,OF2+1MR5>H439H,R$6H$T_9:&'!?,G'7B@+ M&VE-0RXYD>7VOCTIY)1[\>%H!*>J]27:H_3;%MJ`8KF1=&Z`_=7*.;^S=TBU M6*2;*?J\9B"44ICE&HOY0T\K+3,=U+WCE_'),1S32^-6W;6`Y M(K:M''&$(&%N^$41*U`VG/!R&'VCLA3%(G4HF#@9N^G\`W.]D300*OTHJRQ: MWFJYM!7DQ'9,WQ3)@N*HD+FDNWA)LW*)9E0*S[DCO`I+5632I^;D7`N*F"D* M'R#JP(3[(M5NPL03&Q*(58B8G)?B,]7W3UI:.1#'GH-?P/O-A%]"8G1XGY(H)@"NH M]2JKTZX)((FIE5`7&P$Y$3TTO567FCD;A!=6!*+,\K6I:+2."M'Q<6R!273& M$J='[`%CN.]MUXE:1)5Z@'P,ZX).6![HX$V:L]0Z''SJX.\,]Y1159&+DS$+ M(CD0.]8W%(QB&J>ZCY+!P5WEE!+0*;=?P7A54NUUH$6M@\<9%,\&"[J[)5M, M)PCONCWM9/I#7MPMTMF-+(J#Z=,!R4Z:`9<[V(=%^ZXX[6'7VAC\PY)1$WZP M3:R.K`5Y$`I35$L08K62&E3$(CVO9DSOL'UDQU99&!5JA_(TE1-P1MX_)=CP M)4^#%KV;.2%G)R*:O'9V]VB?N!TQ*S."\"QP*"@ER'2-`X@R(+10H=*''4F+ MA-"QS,^L^\79%AF)]>[SENL.7V\-?U((Z=F]D6;BS,OJ7WODA%JZXJHXDM4" MK8O1(EJ3'$JEWK3,W.U\493W[M%YHJR7'67"V@)QK`O)270%1=MC+M%)VGJ7 M$_ZU]\U:29>-N%NG+D#)DH$IA9@_K=/HGO#:4.1JWP2Q$F!0NZ0"A2O@]]\^QJJC%)6.8.JN0=6] M'MWQ?1N^Z0C$\Y$]&^]_/?YN$D6PAJ:.4!LZ*;V=V5%R"#";DAO4#@1")ANW MP^40@W%LA=#JVUU'R3J&FG\&M6PX7OL^&FK^F>@17;?+K&?]J]ML?HDL&,'$O-@/#PZ^&IW;S@Z_&IPKMD% MJJ-89NR>?4>'NT>#[PN,SL'L/X/#O:]VCT9?#5XK<80\NMKOI9.C=&&*@\N& M3-$O:@>Z\34.YG4Z\V&_A] MV[O/'OV/R@W,SU4](>W9YUND-7#\>$-'KU5'%R8A$@QP7P)/.;/SC,&6L[2\ M*U&7R<73;>R6 M4N1$\-P5./7/]/%NGMX4-7.Z*31+?^!-P8'SQ-N3J8[2#RGG>GR%*N@%L^09 MFEG#Q958N31%2B4<#-JMA^.]PZ\H;0Q;7%",S71A=F#KRVR7PTDIY12Z'\D3 MI4K*.$M/_(FRWZ'Y6;1G;#>V+?>Y>H4(?W\X:`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`>'JX&AX,GIY_$#A*B0L MA7KKE);&P_V]-M/Q-M<=M&&QL4?=#E?C4%K%RQGAB;9I0TFFN@XNM(R&+%I[ M)T/,5^M"S#ZXDO%!K&7(VT[12G@<^YFTL$1W]C@^')_$!Z.]#=(Q45BH'R$(=2YM&9K\N)S)0+=!:],Z8J$U MW.K88>>'H^'AR_'+)VOS\4=Y?#(\/OZ[.56H7*S2A:R*=^U*="*)1Y3(7@E(.P>'(SNUQ%IKBQ-',,^^H#.:ZD+X M9)L[X:APE7_,L0]CXR=?"22R" M+LG,9,!DV-)2,LB#=)HU2UC&2]625;KH*%8;R;E7M"?8M&7!*0R%ZON(Z%UF MC1*Q%2]]:V^V&`J4U"=?Q&M-#]8*D1&&1&WD+I*&7+=>8?J/.26/XP:X&YB* M`LHR4%%90V(LEN76RC*%=\278RHUSF8V!D$-M45V9JRQT7]W#@TD7[#N+ZU< MO2Q1SQ[A*SD<0I_^V$W#WK`?[)51:]C:L-Q8?-:<88YIT?%=?LI!.],.I_M3 M,HYC,O],U0CQ(T5R,$'U5S)0$%8*`4PY<]"X/1)]UNB\.NK)G$QFCOT)Z9MQ M9L#_NF0K%:O?IH,[JH;5D(NS+1#8(0^(NEY?.*$=#E0'-EUGMC3^)CO'I<50 MO;@*E$E$2O]M])H*.'ENII?#R'[OYY_^7;VI,^+WRX.@'%ZV6^#_>'QX?VLH[\09R+Y'PJ[PG(:G-^'\XUV//21YT M3#(>[QTSZ/47F.;!<'3RP&D>#D_T/+?/:X''UU@G#_8.XM'+\5K9VTK[AX$M MS*.S*8II=;':;5:8_$Q"64S&X],ECX&3G(FQ^!N*F7;K5,<1@W@XOIP`8`L0^:IK]V5%!-CB%L4C`N>J+*@A#.$`P:ZUL"VBB%'4;Z&KU9C(#=TKY1>EGCXKO823]BY07)[QY17()*D$M6RYPM2,VB)NV81"0ITV MBY1.PLMC"L)U,1L8>.N7/T#LOI&_$PZ M^*247!?]/T^F7+.+EH34UZNB`39Z!03Q!H']B&V,H[,$A*:BS+-$A;U;==J# MMG+;*Q%Z0Q)94>F\A.P].5U[-!`[1[KET)E(]J8%U_84?0<4CMF"SAX9"QO^ M@IS;C`!G/WUTHQ:#38K:R1ZMFG7Q)I?B(L!6@2_0)46(T5L6<1&/HL)%\V&1OY#1N M[@SZ1:H:'+'[M3;F-7GD1I+@-4A[Y;`$Y8J4NG!6>&>F]E"O-P=FCRW1OC.A M$BE.=IT+G7W+0+.L%"8;$E4[^3:'@RL)JC)G\:,35&7"FRFMIA0/NY2Z"1>Y M1/3=&6QA_S`MXAZ3(D=T`+=K&0DU(O3_GZ"L8##6X&\2C,4ZZ3816"WZ2>M'`7^ M0BKAHU.GMZ*.;COC6G^-'?L'CQTCNI(`%,OZ309ZAI=H`WUE%9/U>2"+VH>. MZ8\#&P4TI4/'#MNA8YIR_#'QK"7J`>2\MO!TP8D=8*F26 MS02NQ2(^IQ6HU#&2O)!TJ3\4;1Y=1PAV4;52,8N\9!:30#9>E6(^AQ_9R:)+ MD".RKKACJVL985EJIA-L1"?MM"[-(1?S,57HV4B&=F)-ES9>2VMD;0^VC-`0 MFAV\P'3050_-1ANH(@+JZ\HQA5P)"]H_.E:CI7J[%.,E*77.BAE=`N.3ET>V M,<.*HY^ED@)#E2:Q\T>H[=3$1`WBYETK-_+']$;JFPC)JU%3OM*D9O2%`D,2 M!5CEK8E`6ZO6L3)WPO$09E/I`053:7`>#&S.67FZW%$JTIY.I`3.I4D"L?J* M)T))]N;IC.*E#"U+(M;/\;>,.@>CD2TV8M2[+)YTA]_H//F)2^@X$0)P M\W6'@BMFHU5RRH'X>4$.A:/'QY^>,\6#9+=`&KD'QT=:U?$J*M>J$T[J$],U>*RFR1G* MKPG$QV[AE@6DZV,N_.#(-6*\TJ,A=[LZ56NDZ345@H=4MM69(YQQ3-L/_,)) MZM>OG".[J2W?VM"M&KGFT[9VH,Z+02F2"/EQ]Q)Y8G3VW=59;!63ZU,P-&E? MT59](,J%IM,E3KM#-5`8!Q;+$!X^M^FR:*^G?*YI/1. MJ!AC'1YHS9JPFF1H.&<&&9+9M=F4SQ11N<1$%3')X58N3:L;10L$/"L8YK)8 M[*K>)6U\H7S$]C@8C\V>8]Y2+/T7F%YPSW6G*MQ7^S=-QMQ=T`IFD@Y\PD5: M\+:$%;Z!?T]_J&(W6<"<,J.9EM2XRK1N2N'(4@-U5N99GNG.Y%5RZUT=H8S3 ME:1!E<.E-T\DXY=8]7VC_KKB5QYXP8!9SS^'"B>-]YPBTOP22I$?IG5!#M&7 MEH\HR?.BH70NO.K3=)$:#ZL@>3,V,".KX,+N$HVS,SXTH")VJ%GQ8:J2%I>S MSZCJFN;<*N4?VQV574G4`M^S1VFC%PE#_IHRX-T3C*F)GU'X.&]8,`'DVWH] M')^926^3X*YI$\?KIL;SS'P!]PL+G="%(C2AVV]6!#H]/K0MD8%0#9-OT7%' MHCW"@,IV7@YAB3F9=-U*E7;N+5Z2T0A.7+($'\YH&7R(8([)L,M61(R9/@*T+,CDDHDL$ M,?$F+:R;&,D58J-*P?:U0E0X4;W*E4?G8Z4@QC);`8?A]8TI2[\Y/:6DG&)! M0O#ETAJ!?;1IS02H3%SWWM31X>SI5C446_L2>B#KJE3!@9.#/4O>/([[#DZ< M>#V28P&"EV;W3[:&6IY:IJK*!_S?M+VA16'6>O)6"%WLXFAN65GDI`ZG&8VI0L36!4^OP^4MTULLAO=9+DI]GV]:D65#U2#RBA&>T:FY,^II<7Z?8HEV\[[0B^3BT?`SFUO#J4416.V%.QE M8.A3G9[J5OEM,3V_Q+S_&2X2UZNPW<8S2>-P4S;;F#H]B(=BG/)'*A^`=/8& M]CX:CW;_X*T'\FNOS,8\6]C>A%8EP?,O4PY-IGNZ(ALP'N>K\S,ZS86-'SH6 MXZ['L!0@Y(KM,R&>YK_2P\(S4=K3-&VXUD=?:\?6-A]2])0:IZ[;WKU1B`1^ M42-HHR/.(%S.-D;S_)`6/?28$T+\,35)<:'-G?V3?1?7C*BE=,-M@=QLQS[\.C<;AY8 ML1L`5>0VD/Y`F^"5`F\R=EBY^HPS(#BL"32]Y-*DR`O3%1Y>1#1R@I+%/1<) MF2G/G"3O"?)(S>)9$^Q-LLCV&F*K[-G`]SLR%$5XY2^^XXU-N&1Y"N M5>IP`I*@.6!ZFHDT3?X;&'TEBHB^,OF)'J'FL6'Q[H_NM_6M+0=:1^?ZXYEE M!/&*')+$D>!X,!_,-&FJ5+]'DZ"$\(3@*RD($G4Z.U^!;:VW:@QSSWJ9#1Z, MPN`S>4B-GBF*L""\'Z]ELBL`G"5H@4$I( MOXABH@9J(SYNFFQFY9TG/8U`K3`)N@&A7VTD(?V,T.*T;85V">TG4O`5!Z_"@?PI3.Q/<8F:RHK@TTFBZ+9Y2<8*2<.((7IWG.@F M00+TV^=)2G4#XCX<YH/S:7ZL\__1M63&Z,MJH?4<*1*@-=/YO?R\7B*K:!*"OQ MT^L)$J"B,O2K:=7*_-2S:1^T1:#.(C'X-P>WR>*O]C?8>4,$?.J&1^I%Q:X5 M[.6>,M&@#HJX*@.T85<('*:ZF^"+O$5`1[H(B$-Q+C&1`92R^R#Y6[L6:$^2 MV!C:G;O;K.H9(V:%MU"OOW,6&,R&C,:[DMCVP$7[[NURJEVQ=>8@^)5P105< MCU8,47W^;,M7RTN(=[H3T\Z+6'8XL`_@[VL!^\\A]@"_UXH:ZR?KV88VZ`-';O M(GM>_<'$2?Y-^*67X=T-AF_5\M1YTM^F5?6U6Y6/K'O]2H(.GLO_N+=[M2"# M*P%]3_$RS6@C=J-WF&I$O)62B==>1!6TK\;67K53IRCZ%2))6L;EKHK0O>ZZ M=277VQ\^*)4QX:N5`\,RFM)LKS#5!-_@0?OIX%WP5YT9/[1@SO3<(N]T!0:K MNQ,V8YNU"$R^M3RGNN\SZ)O+L4:?\C(5"OL&F%[E__R6K!/!@M^;:F!OK'_] MW*M\_?SA]=6MPJO^MC_I6G"9\6MT2U\#P):VY8A_4^BS8<6H>\E9_45+7N(&;_6AG]`;?B^Q:_["9V> M\7J]5J$+X6$L]0\+)/-LYK]&D?T:1?9K%-FO462_1I']&D7V:Q39KU%D#XDB M>[H0G]?H&UQ4SZ,=RAW,%.0)+=\U^3`:"88Y_%!DOT]7KZ-G.YZD=;8MKMN& MB7=<(IYDI6^YHI\51D%W#+HZ@,)N]X(NN!]9(9XZZ>UIY;5_ZE3YIY).=]UE M6B)!2O$8!;YT<_-C-J.&D*Q:*Z>:<$8U[VY_?#@WZPGBJ/K/=*6N!]?,+?5'0]K>?7)^\V!5K0?/A&VX_SJ\C*8B_HQ((YM MO,?6-LDQXU/;N4475M"9EXEX_1H&9?##H;N21OHFP1]Q@H1,T2/&YPZ7_$7W*0R'QF[^-T;K_S3I6. M8%0JG_&0-.9_R$42[7"@I=N81Q%D&/57G,V>6S2T+WJ,QRU5Q0!M(]D:?M-' MR/Q&LJ]A4]YUB^)D&>C6$&PAL/HD'%'GB36=OLQ-;R8=":I;'LU0LFO;L>F1 M8C_)VB,8S\WY].<\VNM_TL^#&"64PBF4Y;>5A9(6#RRYS(QS,RR%!+RUIH-` MS)!$O9,9:<-CX(_]J6'SMUWTX7^Y@6)"'ZRG(?^+!U*5W]!F.O._L;$-54]P M0QP)%.$7;OZ1F_[4??V11^*17?4_`5MVM#7!;]W^MO2]90=/1LY;]OM8Z@W`SE3S^T_7TA-2[9;= M/(QB-W3R*&K=V/9C*'5#X[\(E6[H4$!?)7C0 M9\$A!%"%JQ;8(]!.%Q"Q5Y=/*MX]?0\/WY=?9"P/VR!_'(^1#Q[=X!.OZ99= M_Q)+N,TE]:C&?L&EV]#M`Y:M/X!X:U.@U_0JW'3(NZ9PNV&CFS$].&X5Y0A7 MOGLN+S'3:)7#![9#.=4PEOV1WQ\_\ON7C_S>V_SMOM\;;?D]GO.4H&\=#N!M MS.7M)A3L,U+V3XTGCVS4=G09-J4>2/F$`P7IV#N(9LE]AWEY/3E:@'.G[Z!' M-HCG5F[.KM7?)_5"#4+?H,:O39;C7U^E4 MMSCN&-@F=/J/D8=3-2[&7P"@<*[PTNQ$OU0I""X7B;>KEV[=5]MK)+"$8(&3 M*N0W?1ET?L%M@HH.>YIS+H*R2%8KS@(ZYQ)'DA7#\Q<==-CZ+1=MJPE8;=Q- M;Q\;DQ39Y&0(GJZCCCX=GX<@ZJK0BBG,T&^K*%UD-W2/VH31U7#>)HK$X(\H M88\>N$39(SADPV14VV;G-C0=(%:!.)@*3]JYP3ER)5.)[^P;[T7G#*8P!?Q" M1-B__)];^0^572?/P8_(,!5";-=XRSMF5+2*Q^HTUH0-:>K;HM1%YKIF>6T* M]"%LL`]>S2$X`F77NAS=S`K2J3I;8N6DT'FJ-E MMU-L;L+TK+M!MG'@;)I'>#6;W)J.\QE%KUL0&9U`HVL#`GS.#[OQS0@=D-`? MHU[?=P<%]6UA\R;LXR8X^"OX]T[T(@I??TXC?#X]GZ$;M;*.1KQX&"M6R%O, M<'C.!NS#>'AR[%U2'4W%T9)!&!O;/#K8HDWAR>O;I/`B[VKOB#9JOV<"CS;A M55Z&[FSS>=\5.-S;V$ZO61\%<2-NT-2&)@Y"+3PNSLJ[5?WRNB6.FKSD9[L,^]X7C/ MYTMG!O!:2IWZKMM"O\@:1PL?RW8?RI#KB&;(ZF:H49>5*;?Q'"62SHO)15>; M]5$KIU-BWJ8J@:D4]0:9;H56VF!,7HED?05JWP]*4U;F)<*,+\B\XNEO#R#:LV3U5!V$IM!_4U@` M7+$;80)RZEVTLW<\/#ZQJMUTHC_1"*H@TVE=+U@A4M9V1,_=X^NDYU/"= M_'[.TZ#2+F4-?@M7)V9>KSLL^UT"5'=X$\A/ M>P=QT-!.PD+7PS?I!!Z.P@^5W!JH*RL/R*T04*DZ>;M80-(OZ"&OME2FU%?F M[DU"S?DL):Q-4S372F"WGJI*"`0W`DH#O=?-\,R^]PU/7C//TQOHX`;ECI5K MSFP9>$(]<3!>Y4?C.93U-J5&U8USTR2D&*3KJ2HDO_JZL:J>3'WT`JJJH&D] MC/#V+)Q!/VSR;)+I;Z"C9(0M*UW+I-.U6F,G*8+W=&_M8\?R[S\LNQ\Z%OZ' M6R8#$_?O]C51KVM.&'\28A3&:[32H4*!V-I`FM0J]0)?[40/G-%]&C1T77`Y M[NOD2_J0&`LG6+3]<%/)<[>RCEWVO&.4=M%PGPEW)`O9WEGL%+/N7;GFR3.+ M6,DS?/5O0R2W3UNM<'85$KTAK-V1[KSSU*YKZ2RV__0Q=_J':3W4M3+;#WM5 MOMPT>N\>$LU2N1$XGK1OZ]=60[ MF$,ZMP$``*X:```:``````````````"``>X"``!X;"]?&UL4$L!`A0#%`````@`)HYE1\WK M#=H_`0``:0,``!$``````````````(`!YP<``&1O8U!R;W!S+V-O&UL M4$L!`A0#%`````@`)HYE1YE&PO&PO=V]R:W-H965T&UL4$L!`A0#%`````@`)HYE M1X3JAK-1!0``Q1D``!@``````````````(`!QQ@``'AL+W=O``!X;"]W;W)K&PO=V]R:W-H M965T&UL4$L!`A0#%`````@`)HYE1UC[>@KZ`0``;04``!@` M`````````````(`!7B4``'AL+W=O&PO=V]R:W-H965T&UL M4$L!`A0#%`````@`)HYE1UN;JEB?`0``L0,``!@``````````````(`!Y2\` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`)HYE1[DY0+>@`0``L0,``!D````` M`````````(`!/#<``'AL+W=O&PO=V]R M:W-H965T@Z``!X;"]W;W)K&UL M4$L!`A0#%`````@`)HYE1U6?.F&?`0``L0,``!D``````````````(`!OSP` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M)HYE1_+H@9^@`0``L0,``!D``````````````(`!/D(``'AL+W=O&PO=V]R:W-H965TE%``!X;"]W M;W)K&UL4$L!`A0#%`````@`)HYE1Z/RHU*C`0`` ML0,``!D``````````````(`!Z4<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`)HYE1X?$D!JC`0``L0,``!D````````` M`````(`!D$T``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`)HYE1\^);(FB`0``L0,``!D``````````````(`!*5,``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`)HYE M1[="@7T+!```BQ0``!D``````````````(`!,EH``'AL+W=OD$%``"7'P``&0`````` M````````@`%T7@``>&PO=V]R:W-H965TQC``!X;"]W;W)K M&UL4$L!`A0#%`````@`)HYE1\>J.7NE`P``(!$` M`!D``````````````(`!56L``'AL+W=O&PO=V]R:W-H965TU&Z8Z M&P,``"`.```9``````````````"``9MR``!X;"]W;W)K&UL4$L!`A0#%`````@`)HYE1SPN2^"Z`@``)PL``!D````````````` M`(`![74``'AL+W=O>```>&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`)HYE1\P0&"JJ`0``(P0``!D``````````````(`!)8$``'AL+W=O M&PO=V]R:W-H965TI&A'DUP$``%8%```9``````````````"``3F% M``!X;"]W;W)K&UL4$L!`A0#%`````@`)HYE1\B/ MBV03`@``2@8``!D``````````````(`!1X<``'AL+W=O3T/X!``"-!@``&0`````````` M````@`&1B0``>&PO=V]R:W-H965T'>Z=P<$,``'@P`0`4``````````````"``<:+``!X;"]S:&%R9613 @=')I;F=S+GAM;%!+!08`````-``T`!X.``!HSP`````` ` end XML 13 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814

Capitalized Fees Paid to a Related Party (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Capitalized Fees paid to a Related Party

Net Carrying Value $ 197,824 $ 197,824 $ 208,191 ^[1]

Amortization of capitalized fees paid to a related party 3,455 $ 3,233 10,367 $ 7,611

Estimated amortization expense for the remainder of 2015 3,500 3,500

Estimated amortization expense for the year 2016 13,800 13,800

Estimated amortization expense for the year 2017 13,800 13,800

Estimated amortization expense for the year 2018 13,800 13,800

Estimated amortization expense for the year 2019 13,800 13,800

Estimated amortization expense for the year 2020 13,800 13,800

Estimated amortization expense thereafter 125,300 125,300

GSK

Capitalized Fees paid to a Related Party

Amortization of capitalized fees paid to a related party 3,455 3,233 $ 10,367 7,611

GSK | Long-acting beta agonist (LABA) collaboration

Capitalized Fees paid to a Related Party

Weighted Average Remaining Amortization Period 14 years 4 months 24 days

Gross Carrying Value 220,000 $ 220,000 220,000

Accumulated Amortization (22,176) (22,176) (11,809)

Net Carrying Value 197,824 197,824 $ 208,191

Amortization of capitalized fees paid to a related party $ 3,500 $ 3,200 $ 10,400 $ 7,600

[1] Condensed consolidated balance sheet as of December 31, 2014 has been derived from audited consolidated financial statements.

X

- Definition
Represents the accumulated amortization of capitalized fees paid to a related party.
+ References
No definition available.
+ Details

Name: thrx_AccumulatedAmortizationOfFeesPaidToRelatedParty

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the amortization of capitalized fees paid to a related party.
+ References
No definition available.
+ Details

Name: thrx_AmortizationOfCapitalizedFeesPaidToRelatedParty

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of amortization expense for assets expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyAmortizationExpenseAfterYearFive

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets expected to be recognized during the remainder fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyAmortizationExpenseRemainderOfFiscalYear

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearFive

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearFour

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets expected to be recognized during the sixth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearSix

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearThree

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyAmortizationExpenseYearTwo

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the gross amount of capitalized fees paid to a related party.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyGross

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyLineItems

Namespace Prefix: thrx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents capitalized fees paid to a related party, net.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyNet

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining amortization period of capitalized fees paid to a related party, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyWeightedAverageUsefulLife

Namespace Prefix: thrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_CounterpartyNameAxis=thrx_GSKMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=thrx_LABACollaborationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-Based Compensation (Tables)
9 Months Ended

Sep. 30, 2015

Stock-Based Compensation

Schedule of allocation of stock-based compensation expense included in the condensed consolidated statements of operations

Three Months Ended September 30,

Nine Months Ended September 30,

(In thousands)

2015

2014

2015

2014

Research and development

$

220

$

1,357

$

687

$

2,589

General and administrative

1,248

3,375

4,536

11,795

Stock-based compensation from continuing operations

1,468

4,732

5,223

14,384

Stock-based compensation from discontinued operations

—

—

—

11,629

Total stock-based compensation expense

$

1,468

$

4,732

$

5,223

$

26,013

Schedule of assumptions used to estimate the fair value of employee stock options granted

Three Months Ended
September 30,

Nine Months Ended
September 30,

2014

2014

Risk-free interest rate

1.97%

1.64%-2.05%

Expected term (in years)

6

5-6

Volatility

58%

52%-60%

Dividend yield

4%

4%

Weighted-average estimated fair value of stock options granted

$

13.23

$

15.92

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 16 R42.htm IDEA: XBRL DOCUMENT v3.3.0.814

Discontinued Operations (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Components of research and drug development operations presented on the condensed consolidated statements of operations

Net revenues $ 0 $ 3,129

Loss from discontinued operations $ 0 (94,934)

Discontinued Operations

Components of research and drug development operations presented on the condensed consolidated statements of operations

Reimbursement of certain research and development costs to the entity $ 0 $ 100

X

- Definition
Represents the amount of research reimbursement recognized under the collaborative arrangement by the entity as a result of reduction in research and development expense.
+ References
No definition available.
+ Details

Name: thrx_CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5B

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51716988&loc=d3e957-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3A

-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721523-107759

+ Details

Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5B

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814

Long-Term Debt (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 18 Months Ended

Jul. 15, 2014

$ / shares

shares

Jun. 30, 2014

$ / shares

$ / item

Jan. 31, 2013

USD ($)

item

$ / shares

$ / item

shares

Jan. 31, 2013

USD ($)

item

$ / shares

$ / item

Sep. 30, 2015

USD ($)

$ / shares

$ / item

Sep. 30, 2014

USD ($)

Sep. 30, 2015

USD ($)

$ / shares

$ / item

Sep. 30, 2014

USD ($)

Sep. 30, 2015

USD ($)

$ / shares

$ / item

Dec. 31, 2014

USD ($)

Apr. 30, 2014

USD ($)

Debt disclosures

Convertible Subordinated Debt, Noncurrent $ 255,109 $ 255,109 $ 255,109 $ 255,109 ^[1]

Non-recourse notes, due 2029 488,976 488,976 488,976 470,527 ^[1]

Long-term Debt, Excluding Current Maturities 744,085 744,085 744,085 725,636

Proceeds from issuances of note payable, net of debt issuance costs 0 $ 434,677

Interest amount added to principal balance 18,449 0

Convertible subordinated notes due 2023

Debt disclosures

Convertible Subordinated Debt, Noncurrent $ 255,109 $ 255,109 $ 255,109 255,109

Loan amount $ 287,500 $ 287,500

Proceeds from issuances of note payable, net of debt issuance costs $ 281,200

Interest rate (as a percent) 2.125% 2.125%

Conversion rate of shares 46.9087 35.9903 50.5818

Conversion price of convertible notes into common stock (in dollars per share) | $ / shares $ 21.32 $ 27.79 $ 27.79 $ 19.77 $ 19.77 $ 19.77

Percentage of principal amount at which the entity may be forced to redeem some or all notes as a result of a fundamental change (as defined) 100.00%

Convertible subordinated notes due 2023 | Common Stock

Debt disclosures

Conversion price of convertible notes into common stock (in dollars per share) | $ / shares $ 21.32

Number of common shares issued upon debt conversion | shares 1,519,402

Number of common stares received | shares 149,645

Convertible subordinated notes due 2023 | Privately-negotiated capped call option

Debt disclosures

Payments for capped call options $ 36,800

Number of derivative instruments purchased | item 2 2

Strike price for the underlying number of shares (in dollars per share) | $ / shares $ 21.32 $ 27.79 $ 19.77

Cap price for the underlying number of shares (in dollars per share) | $ / item 29.16 38.00 38.00 27.04 27.04 27.04

Convertible subordinated notes due 2023 | Stock prices below $27.79 per share | Maximum

Debt disclosures

Net shares settlement payable to the entity | shares 2,779,659

Convertible subordinated notes due 2023 | Stock prices below $27.79 per share | Minimum

Debt disclosures

Net shares settlement payable to the entity | shares 0

Convertible subordinated notes due 2023 | Stock prices above $38.00 per share

Debt disclosures

Incremental Common Shares Attributable to Capped Call Options | shares 0

Non-recourse notes payable due 2029

Debt disclosures

Non-recourse notes, due 2029 $ 488,976 $ 488,976 $ 488,976 $ 470,527

Non-recourse notes payable due 2029 | GSK

Debt disclosures

Loan amount $ 450,000

Interest rate (as a percent) 9.00%

Percentage of royalties from global net sales 40.00%

Interest amount added to principal balance $ 5,600 $ 0 $ 18,400 $ 0 $ 39,000

Debt issuance costs $ 15,300

[1] Condensed consolidated balance sheet as of December 31, 2014 has been derived from audited consolidated financial statements.

X

- Definition
The percentage of principal amount used in the computation of the redemption price at which the entity may be forced to redeem some or all the debt instruments as a result of the occurrence of a fundamental change (as defined).
+ References
No definition available.
+ Details

Name: thrx_DebtInstrumentRedemptionPriceAsPercentageOfPrincipalAmountUponOccurrenceOfFundamentalChange

Namespace Prefix: thrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of capped call options.
+ References
No definition available.
+ Details

Name: thrx_IncrementalCommonSharesAttributableToCappedCallOptions

Namespace Prefix: thrx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of derivative instruments purchased.
+ References
No definition available.
+ Details

Name: thrx_NumberOfDerivativeInstrumentsPurchased

Namespace Prefix: thrx_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the number of shares payable to the entity on settlement of derivative instruments.
+ References
No definition available.
+ Details

Name: thrx_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument

Namespace Prefix: thrx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the percentage of royalties from global net sales, which was secured for the debt.
+ References
No definition available.
+ Details

Name: thrx_PercentageOfRoyaltiesFromGlobalNetSales

Namespace Prefix: thrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleSubordinatedDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Conversion Rate

-URI http://asc.fasb.org/extlink&oid=6509012

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeCapPrice

Namespace Prefix: us-gaap_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: instant

X

- Definition
The premium (cost) of a hedge, expensed during the period.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeCostOfHedge

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest capitalized during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Allowance for Funds Used during Construction

-URI http://asc.fasb.org/extlink&oid=6504829

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

+ Details

Name: us-gaap_InterestCostsCapitalized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(1)

-URI http://asc.fasb.org/extlink&oid=6940734&loc=d3e22047-110879

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 40

-Section 50

-Paragraph 5

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=6445032&loc=d3e90205-114008

+ Details

Name: us-gaap_OptionIndexedToIssuersEquityStrikePrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_SecuredLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_UnamortizedDebtIssuanceExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=thrx_Percent2.125ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OptionIndexedToIssuersEquityTypeAxis=thrx_PrivatelyNegotiatedCappedCallOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_PutOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=thrx_Percent9FixedRateTermNotesDue2029Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=thrx_GSKMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Loss per Share
9 Months Ended

Sep. 30, 2015

Net Loss per Share

Net Loss per Share

2. Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less Restricted Stock Awards (“RSAs”) subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common shares had been issued for other dilutive securities.

For the three and nine months ended September 30, 2015 and 2014, diluted and basic net loss per common share were identical since potential common shares were excluded from the calculation, as their effect was anti-dilutive.

Anti-Dilutive Securities

The following common equivalent shares were not included in the computation of diluted net loss per share because their effect was anti-dilutive:

Three Months Ended September 30,

Nine Months Ended September 30,

(In thousands)

2015 (1)

2014

2015 (2)

2014

Outstanding options and awards granted under equity incentive plan and employee stock purchase plan

5,070

6,771

5,459

6,218

Unvested RSAs

1,489

1,782

1,738

1,782

Shares issuable upon conversion of convertible subordinated notes

12,904

12,100

12,904

12,100

19,463

20,653

20,101

20,100

(1)

Includes 4.0 million options, 0.3 million restricted stock units, and 0.8 million unvested RSAs retained by former employees who were transferred to Theravance Biopharma in connection with the Spin-Off during the three months ended September 30, 2015. Subsequent to the Spin-Off, stock-based compensation expense associated with the awards held by Theravance Biopharma employees granted prior to the Spin-Off is recognized by Theravance Biopharma.

(2)

Includes 4.2 million options, 0.4 million restricted stock units, and 1.0 million unvested RSAs retained by former employees who were transferred to Theravance Biopharma in connection with the Spin-Off during the nine months ended September 30, 2015. Subsequent to the Spin-Off, stock-based compensation expense associated with the awards held by Theravance Biopharma employees granted prior to the Spin-Off is recognized by Theravance Biopharma.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814

Subsequent Events (Details) - Subsequent Events - USD ($)
$ / shares in Units, $ in Millions

Oct. 30, 2015

Oct. 28, 2015

$150 million share repurchase program

Subsequent Event

Amount approved under share repurchase program $ 150

Tender offer

Subsequent Event

Amount approved under share repurchase program $ 75

Tender offer | Minimum

Subsequent Event

Price per share under share repurchase program $ 8.50

Tender offer | Maximum

Subsequent Event

Price per share under share repurchase program $ 9.25

X

- Definition
Authorized cost of per shares to be repurchased under share repurchase program, as defined.
+ References
No definition available.
+ Details

Name: thrx_StockRepurchaseProgramAuthorizedCostPerShare

Namespace Prefix: thrx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of stock repurchase plan authorized.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramAuthorizedAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareRepurchaseProgramAxis=thrx_ShareRepurchaseProgramApprovedOctober2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareRepurchaseProgramAxis=thrx_ModifiedDutchAuctionTenderOfferMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Loss per Share (Details) - shares
shares in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Anti-dilutive securities

Anti-dilutive securities (in shares) 19,463 20,653 20,101 20,100

Stock options

Anti-dilutive securities

Anti-dilutive securities (in shares) 4,000 4,200

RSUs

Anti-dilutive securities

Anti-dilutive securities (in shares) 300 400

Unvested RSAs

Anti-dilutive securities

Anti-dilutive securities (in shares) 800 1,000

Outstanding options and awards granted under equity incentive plan and ESPP

Anti-dilutive securities

Anti-dilutive securities (in shares) 5,070 6,771 5,459 6,218

Unvested RSAs

Anti-dilutive securities

Anti-dilutive securities (in shares) 1,489 1,782 1,738 1,782

Shares issuable upon conversion of convertible subordinated notes

Anti-dilutive securities

Anti-dilutive securities (in shares) 12,904 12,100 12,904 12,100

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=thrx_EquityIncentivePlansAndESPPMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleSubordinatedDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

Description of Operations and Summary of Significant Accounting Policies (Details)
$ in Millions
9 Months Ended

Jun. 02, 2014

Jun. 01, 2014

USD ($)

Sep. 30, 2015

Business Separation

Cash, cash equivalents and marketable securities contributed to Theravance Biopharma $ 393.0

Number of ordinary shares of Theravance Biopharma issued for every share of Theravance 0.286

GSK | LABA collaboration and Strategic Alliance agreements

Description of Operations and Summary of Significant Accounting Policies

Percentage of economic interest in any future payments made under the agreements 15.00%

X

- References
No definition available.
+ Details

Name: thrx_BusinessSeparationAbstract

Namespace Prefix: thrx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of common stock distributed as form of dividend for each common stock held by parent company associated with the separation from parent company on completion of spin-off.
+ References
No definition available.
+ Details

Name: thrx_CommonStockStockDividendRatio

Namespace Prefix: thrx_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of cash, cash equivalents and marketable securities contributed to another entity due to business separation activities.
+ References
No definition available.
+ Details

Name: thrx_ContributionOfCashAndCashEquivalentsAndMarketableSecuritiesInBusinessSeparation

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the percentage of economic interest in any future payments made under the agreements.
+ References
No definition available.
+ Details

Name: thrx_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements

Namespace Prefix: thrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: thrx_SummaryOfSignificantAccountingPoliciesLineItems

Namespace Prefix: thrx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_CounterpartyNameAxis=thrx_GSKMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=thrx_LABACollaborationAndStrategicAllianceAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814

Collaborative Arrangements (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Information related to collaborative arrangements

Less: amortization of capitalized fees paid to a related party $ (3,455) $ (3,233) $ (10,367) $ (7,611)

Royalty revenue 13,341 729 30,449 342

Revenue from Collaborative Arrangements 221 270 664 811

Total revenue 13,562 999 $ 31,113 1,153

Theravance Biopharma | Common Stock

Information related to collaborative arrangements

Number of ordinary shares sold 436,802

GSK

Information related to collaborative arrangements

Royalties from a related party 16,796 3,962 $ 40,816 7,953

Less: amortization of capitalized fees paid to a related party (3,455) (3,233) (10,367) (7,611)

Royalty revenue 13,341 729 30,449 342

Total revenue 13,562 999 31,113 1,153

GSK | MABA

Information related to collaborative arrangements

Potential future contingent payments receivable 363,000 363,000

Long-acting beta agonist (LABA) collaboration | GSK

Information related to collaborative arrangements

Less: amortization of capitalized fees paid to a related party (3,500) (3,200) $ (10,400) (7,600)

Obligation for milestone payments $ 220,000

Royalty rate for first level of annual global net sales (as a percent) 15.00%

Annual global sales level used to determine royalty rate $ 3,000,000

Royalty rate for sales above first level of annual global net sales (as a percent) 5.00%

Long-acting beta agonist (LABA) collaboration | GSK | Minimum

Information related to collaborative arrangements

Royalty rate for combination products (as a percent) 6.50%

Long-acting beta agonist (LABA) collaboration | GSK | Maximum

Information related to collaborative arrangements

Royalty rate for combination products (as a percent) 10.00%

2004 Strategic alliance | GSK | MABA

Information related to collaborative arrangements

Revenue from Collaborative Arrangements $ 221 $ 270 $ 664 $ 811

X

- Definition
Represents the amortization of capitalized fees paid to a related party.
+ References
No definition available.
+ Details

Name: thrx_AmortizationOfCapitalizedFeesPaidToRelatedParty

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the royalty rate for combination products.
+ References
No definition available.
+ Details

Name: thrx_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts

Namespace Prefix: thrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the potential future contingent payments that the entity is eligible to receive.
+ References
No definition available.
+ Details

Name: thrx_CollaborativeArrangementContingentPaymentThatEntityCouldEarn

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the maximum amount of potential milestone payments that could be payable.
+ References
No definition available.
+ Details

Name: thrx_CollaborativeArrangementObligationForMilestonePayments

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.
+ References
No definition available.
+ Details

Name: thrx_CollaborativeArrangementRoyaltyRateDefinedLevelOne

Namespace Prefix: thrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.
+ References
No definition available.
+ Details

Name: thrx_CollaborativeArrangementRoyaltyRateDefinedLevelTwo

Namespace Prefix: thrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.
+ References
No definition available.
+ Details

Name: thrx_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue earned under collaborative arrangements from upfront payments and contingent payments.
+ References
No definition available.
+ Details

Name: thrx_CollaborativeArrangementsRevenue

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares sold during the reporting period.
+ References
No definition available.
+ Details

Name: thrx_InvestmentOwnedSharesSold

Namespace Prefix: thrx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents revenue net of amortization expense for capitalized fees paid to a related party during the period from the leasing or otherwise lending to a related party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. An example of property from which royalties may be derived includes patents.
+ References
No definition available.
+ Details

Name: thrx_RoyaltyRevenueFromRelatedPartyNet

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: invest_InvestmentIssuerAxis=thrx_TheravanceBiopharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=thrx_GSKMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=thrx_BifunctionalMuscarinicAntagonistBeta2AgonistMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=thrx_LABACollaborationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=thrx_StrategicAllianceAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814

Available-for-Sale Securities and Fair Value Measurements (Details) - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Available-for-sale securities

Amortized Cost $ 203,512 $ 285,483

Gross Unrealized Gains 15 35

Gross Unrealized Losses (4) (122)

Other Than Temporary Impairment Loss (3,752)

Estimated Fair Value $ 203,523 281,644

Maturity period for marketable securities

Maximum contractual maturity period 1 year

Average contractual maturity period 3 months

Proceeds from sale of available-for-sale securities $ 57,098 $ 5,000

Theravance Biopharma

Maturity period for marketable securities

Gain on sale 1,200

Issuer of available-for-securities other than Theravance Biopharma

Maturity period for marketable securities

Proceeds from sale of available-for-sale securities 49,400

Cash and cash equivalents

Available-for-sale securities

Estimated Fair Value 76,077 95,090

Short-term marketable securities

Available-for-sale securities

Estimated Fair Value 127,446 143,698

Marketable securities

Available-for-sale securities

Estimated Fair Value 0 42,856

U.S. government securities

Available-for-sale securities

Amortized Cost 7,503 30,019

Gross Unrealized Gains 3 24

Gross Unrealized Losses 0 0

Other Than Temporary Impairment Loss 0

Estimated Fair Value 7,506 30,043

U.S. government agencies

Available-for-sale securities

Amortized Cost 69,965 34,756

Gross Unrealized Gains 9 6

Gross Unrealized Losses (2) (12)

Other Than Temporary Impairment Loss 0

Estimated Fair Value 69,972 34,750

Corporate notes

Available-for-sale securities

Amortized Cost 27,485 80,880

Gross Unrealized Gains 3 5

Gross Unrealized Losses (2) (110)

Other Than Temporary Impairment Loss 0

Estimated Fair Value 27,486 80,775

Commercial paper

Available-for-sale securities

Amortized Cost 54,702 34,469

Gross Unrealized Gains 0 0

Gross Unrealized Losses 0 0

Other Than Temporary Impairment Loss 0

Estimated Fair Value 54,702 34,469

Ordinary shares of Theravance Biopharma

Available-for-sale securities

Amortized Cost 10,269

Gross Unrealized Gains 0

Gross Unrealized Losses 0

Other Than Temporary Impairment Loss (3,752)

Estimated Fair Value 6,517

Money market funds

Available-for-sale securities

Amortized Cost 43,857 95,090

Gross Unrealized Gains 0 0

Gross Unrealized Losses 0 0

Other Than Temporary Impairment Loss 0

Estimated Fair Value $ 43,857 $ 95,090

X

- Definition
Represents the other than temporary impairment loss on available-for-sale securities.
+ References
No definition available.
+ Details

Name: thrx_AvailableForSaleSecuritiesOtherThanTemporaryImpairmentLoss

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the average maturity period for marketable securities.
+ References
No definition available.
+ Details

Name: thrx_MarketableSecuritiesAverageContractualMaturityPeriod

Namespace Prefix: thrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the maximum maturity period for marketable securities.
+ References
No definition available.
+ Details

Name: thrx_MarketableSecuritiesMaximumContractualMaturityPeriod

Namespace Prefix: thrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.13(h))

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_GainLossOnSaleOfEquityInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: invest_InvestmentIssuerAxis=thrx_TheravanceBiopharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: invest_InvestmentIssuerAxis=thrx_IssuerOtherThanTheravanceBiopharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=thrx_MarketableSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasuryAndGovernmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Description of Operations and Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2015

Description of Operations and Summary of Significant Accounting Policies

Description of Operations and Summary of Significant Accounting Policies

1. Description of Operations and Summary of Significant Accounting Policies

Description of Operations

Theravance, Inc. (“Theravance”, the “Company”, or “we” and other similar pronouns) is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Theravance’s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Theravance and GSK. Under the Long-Acting Beta 2 Agonist (“LABA”) Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the “GSK Agreements”), Theravance is eligible to receive the associated royalty revenues from RELVAR ® /BREO ® ELLIPTA ® , ANORO® ELLIPTA ® and if approved and commercialized, VI monotherapy. Theravance is also entitled to 15% of any future payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (“TRC”), relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta 2 Agonist (“MABA”) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement (“LABA Collaboration”), which has been assigned to TRC other than RELVAR ®/BREO ® ELLIPTA ® , ANORO® ELLIPTA ® and VI monotherapy.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In our opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive loss and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2015 or any other period.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (“SEC”) on February 27, 2015.

Business Separation

On June 1, 2014, we separated our biopharmaceutical research and drug development operations from our late-stage partnered respiratory assets by transferring our research and drug development operations into our then wholly-owned subsidiary, Theravance Biopharma, Inc. (“Theravance Biopharma”). We contributed $393.0 million of cash, cash equivalents and marketable securities to Theravance Biopharma and all outstanding shares of Theravance Biopharma were then distributed to Theravance stockholders as a pro-rata dividend distribution on June 2, 2014 by issuing one ordinary share of Theravance Biopharma for every 3.5 shares of our common stock to stockholders of record on May 15, 2014 (the “Spin-Off”). The Spin-Off resulted in Theravance Biopharma becoming an independent, publicly traded company.

The results of operations for the former research and drug development operations conducted by us and by Theravance Biopharma until June 1, 2014 are included as part of this report as discontinued operations for the three and nine months ended September 30, 2014. Refer to Note 11 “Discontinued Operations” for further information.

Variable Interest Entities

We evaluate our ownership, contractual and other interest in entities to determine if they are variable interest entities (“VIE”), whether we have a variable interest in those entities and the nature and extent of those interests. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. We consolidate the financial results of TRC, which we have determined to be a VIE, because we have the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. The financial position and results of operations of TRC are not material for the periods presented.

Recently Issued Accounting Pronouncements Not Yet Adopted

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), requiring an entity to recognize the amount of revenue to which it expects to be entitled to in exchange for the transfer of promised goods or services to customers. The new standard will replace nearly all existing revenue recognition guidance under GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date by one year. Thus, the new standard will be effective for us beginning January 1, 2018, at which time we may adopt the new standard under either the full retrospective method or the modified retrospective method. Early adoption on or after January 1, 2017 would be permitted. We are currently evaluating the effect that the new standard will have on our consolidated financial statements and related disclosures.

In April 2015, the FASB issued ASU 2015-03, Interest — Imputation of Interest, to simplify the presentation of debt issuance costs. This standard amends existing guidance to require the presentation of debt issuance costs associated with term loans in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It will be effective for us on January 1, 2016, with early adoption permitted. We plan to adopt ASU 2015-03 on January 1, 2016. Upon adoption of ASU 2015-03, we will apply the guidance retrospectively to all periods presented and classify our debt issuance costs, which are currently included in other assets in the condensed consolidated financial statements, as a deduction to our long-term debt.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6003-108592

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814

Available-for-Sale Securities and Fair Value Measurements (Details 2) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value $ 203,523 $ 281,644

U.S. government securities

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 7,506 30,043

U.S. government agencies

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 69,972 34,750

Corporate notes

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 27,486 80,775

Commercial paper

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 54,702 34,469

Ordinary shares of Theravance Biopharma

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 6,517

Money market funds

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 43,857 95,090

Recurring basis

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 203,523 281,644

Recurring basis | U.S. government securities

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 7,506 30,043

Recurring basis | U.S. government agencies

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 69,972 34,750

Recurring basis | Corporate notes

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 27,486 80,775

Recurring basis | Commercial paper

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 54,702 34,469

Recurring basis | Ordinary shares of Theravance Biopharma

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 6,517

Recurring basis | Money market funds

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 43,857 95,090

Recurring basis | Quoted Prices in Active Markets for Identical Assets, Level 1

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 51,363 131,650

Recurring basis | Quoted Prices in Active Markets for Identical Assets, Level 1 | U.S. government securities

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 7,506 30,043

Recurring basis | Quoted Prices in Active Markets for Identical Assets, Level 1 | U.S. government agencies

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0 0

Recurring basis | Quoted Prices in Active Markets for Identical Assets, Level 1 | Corporate notes

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0 0

Recurring basis | Quoted Prices in Active Markets for Identical Assets, Level 1 | Commercial paper

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0 0

Recurring basis | Quoted Prices in Active Markets for Identical Assets, Level 1 | Ordinary shares of Theravance Biopharma

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 6,517

Recurring basis | Quoted Prices in Active Markets for Identical Assets, Level 1 | Money market funds

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 43,857 95,090

Recurring basis | Significant Other Observable Inputs, Level 2

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 152,160 149,994

Recurring basis | Significant Other Observable Inputs, Level 2 | U.S. government securities

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0 0

Recurring basis | Significant Other Observable Inputs, Level 2 | U.S. government agencies

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 69,972 34,750

Recurring basis | Significant Other Observable Inputs, Level 2 | Corporate notes

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 27,486 80,775

Recurring basis | Significant Other Observable Inputs, Level 2 | Commercial paper

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 54,702 34,469

Recurring basis | Significant Other Observable Inputs, Level 2 | Ordinary shares of Theravance Biopharma

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0

Recurring basis | Significant Other Observable Inputs, Level 2 | Money market funds

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0 0

Recurring basis | Significant Unobservable Inputs, Level 3

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0 0

Recurring basis | Significant Unobservable Inputs, Level 3 | U.S. government securities

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0 0

Recurring basis | Significant Unobservable Inputs, Level 3 | U.S. government agencies

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0 0

Recurring basis | Significant Unobservable Inputs, Level 3 | Corporate notes

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0 0

Recurring basis | Significant Unobservable Inputs, Level 3 | Commercial paper

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0 0

Recurring basis | Significant Unobservable Inputs, Level 3 | Ordinary shares of Theravance Biopharma

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0

Recurring basis | Significant Unobservable Inputs, Level 3 | Money market funds

Estimated fair values of entity's financial assets and liabilities

Total assets measured at fair value 0 0

Nonrecurring basis

Estimated fair values of entity's financial assets and liabilities

Total fair value of liabilities 633,889 653,506

Nonrecurring basis | Convertible subordinated notes due 2023

Estimated fair values of entity's financial assets and liabilities

Convertible subordinated notes due 2023 169,362 197,095

Nonrecurring basis | Non-recourse notes payable due 2029

Estimated fair values of entity's financial assets and liabilities

Non-recourse notes due 2029 464,527 456,411

Nonrecurring basis | Quoted Prices in Active Markets for Identical Assets, Level 1

Estimated fair values of entity's financial assets and liabilities

Total fair value of liabilities 0 0

Nonrecurring basis | Quoted Prices in Active Markets for Identical Assets, Level 1 | Convertible subordinated notes due 2023

Estimated fair values of entity's financial assets and liabilities

Convertible subordinated notes due 2023 0 0

Nonrecurring basis | Quoted Prices in Active Markets for Identical Assets, Level 1 | Non-recourse notes payable due 2029

Estimated fair values of entity's financial assets and liabilities

Non-recourse notes due 2029 0 0

Nonrecurring basis | Significant Other Observable Inputs, Level 2

Estimated fair values of entity's financial assets and liabilities

Total fair value of liabilities 633,889 653,506

Nonrecurring basis | Significant Other Observable Inputs, Level 2 | Convertible subordinated notes due 2023

Estimated fair values of entity's financial assets and liabilities

Convertible subordinated notes due 2023 169,362 197,095

Nonrecurring basis | Significant Other Observable Inputs, Level 2 | Non-recourse notes payable due 2029

Estimated fair values of entity's financial assets and liabilities

Non-recourse notes due 2029 464,527 456,411

Nonrecurring basis | Significant Unobservable Inputs, Level 3

Estimated fair values of entity's financial assets and liabilities

Total fair value of liabilities 0 0

Nonrecurring basis | Significant Unobservable Inputs, Level 3 | Convertible subordinated notes due 2023

Estimated fair values of entity's financial assets and liabilities

Convertible subordinated notes due 2023 0 0

Nonrecurring basis | Significant Unobservable Inputs, Level 3 | Non-recourse notes payable due 2029

Estimated fair values of entity's financial assets and liabilities

Non-recourse notes due 2029 $ 0 $ 0

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Convertible Security

-URI http://asc.fasb.org/extlink&oid=6509036

+ Details

Name: us-gaap_ConvertibleDebtFairValueDisclosures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13476-108611

+ Details

Name: us-gaap_DebtInstrumentFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of notes payable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasuryAndGovernmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=thrx_Percent2.125ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=thrx_Percent9FixedRateTermNotesDue2029Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies (Details 2) - Special Long-Term Retention and Incentive Cash Awards Program - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended

May. 31, 2014

Mar. 31, 2014

Dec. 31, 2011

Special Long-Term Retention and Incentive Cash Awards Program

Timeframe for achievement of performance conditions 6 years

Cash bonus expense recognized $ 9.1

Total cash bonus paid $ 9.5

Remaining potential cash bonus expense associated with these cash bonus awards after the modification $ 0.5

X

- Definition
Aggregate potential cost of compensation after the modification made to employees under the long-term retention program.
+ References
No definition available.
+ Details

Name: thrx_LongTermRetentionProgramPotentialTotalCompensationCostAfterModification

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The compensation expense recognized during the period pertaining to the deferred compensation arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 710

-SubTopic 10

-Section 30

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363

+ Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of distributions made to the individual during the period.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualDistributionsPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 710

-SubTopic 10

-Section 55

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=us-gaap_DeferredBonusMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014
^[1]

Current assets:

Cash and cash equivalents $ 78,746 $ 96,800

Short-term marketable securities 127,446 143,698

Related party receivables from collaborative arrangements 16,947 10,550

Prepaid expenses and other current assets 615 1,134

Total current assets 223,754 252,182

Marketable securities 0 42,856

Property and equipment, net 248 324

Capitalized fees paid to a related party, net 197,824 208,191

Other assets 15,805 18,101

Total assets 437,631 521,654

Current liabilities:

Accounts payable 154 0

Payable to Theravance Biopharma, Inc. 0 1,056

Accrued personnel-related expenses 1,392 1,959

Accrued interest payable 6,390 7,551

Other accrued liabilities 2,457 2,108

Deferred revenue 885 1,082

Total current liabilities 11,278 13,756

Convertible subordinated notes, due 2023 255,109 255,109

Non-recourse notes, due 2029 488,976 470,527

Deferred rent 100 105

Other long-term liabilities 1,847 1,718

Deferred revenue $ 3,320 $ 3,788

Commitments and contingencies (Notes 3, 6 and 9)

Stockholders' deficit:

Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding

Common stock: $0.01 par value, 200,000 shares authorized, 117,575 and 116,445 shares issued as of September 30, 2015 and December 31, 2014, respectively $ 1,176 $ 1,164

Treasury stock: 150 shares as of September 30, 2015 and December 31, 2014 (3,263) (3,263)

Additional paid-in capital 1,375,805 1,452,504

Accumulated other comprehensive income (loss) 11 (87)

Accumulated deficit (1,696,728) (1,673,667)

Total stockholders' deficit (322,999) (223,349)

Total liabilities and stockholders' deficit $ 437,631 $ 521,654

[1] Condensed consolidated balance sheet as of December 31, 2014 has been derived from audited consolidated financial statements.

X

- Definition
Represents capitalized fees paid to a related party, net.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyNet

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due to certain related party. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: thrx_DueToARelatedPartyTwoCurrent

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the amount receivable from collaboration partners under the collaborative arrangement.
+ References
No definition available.
+ Details

Name: thrx_ReceivablesFromCollaborationPartners

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26626-111562

+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26626-111562

+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleSubordinatedDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.26(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707

+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_SecuredLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 28 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

Net loss $ (4,584) $ (21,271) $ (23,061) $ (152,538)

Other comprehensive income:

Unrealized gain (loss) on marketable securities, net 21 (3,903) 1,302 (359)

Less: Realized gain on marketable securities, net 0 0 (1,204) 0

Comprehensive loss $ (4,563) $ (25,174) $ (22,963) $ (152,897)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-Based Compensation (Details 2) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Stock-based compensation

Stock-based compensation expense $ 1,468 $ 4,732 $ 5,223 $ 26,013

Stock options

Stock-based compensation

Total unrecognized compensation cost related to unvested stock-based compensation 1,700 1,700

RSUs

Stock-based compensation

Total unrecognized compensation cost related to unvested stock-based compensation 2,100 2,100

Unvested RSAs

Stock-based compensation

Total unrecognized compensation cost related to unvested stock-based compensation 9,100 9,100

Continuing operations

Stock-based compensation

Stock-based compensation expense 1,468 4,732 5,223 14,384

Discontinued Operations

Stock-based compensation

Stock-based compensation expense 0 0 0 11,629

Research and development | Continuing operations

Stock-based compensation

Stock-based compensation expense 220 1,357 687 2,589

General and administrative | Continuing operations

Stock-based compensation

Stock-based compensation expense $ 1,248 $ 3,375 $ 4,536 $ 11,795

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Collaborative Arrangements (Tables)
9 Months Ended

Sep. 30, 2015

Collaborative Arrangements

Schedule of net revenue recognized under GSK Agreements

Three Months Ended September 30,

Nine Months Ended September 30,

(In thousands)

2015

2014

2015

2014

Royalties from a related party

$

16,796

$

3,962

$

40,816

$

7,953

Less: amortization of capitalized fees paid to a related party

(3,455
)

(3,233
)

(10,367
)

(7,611
)

Royalty revenue

13,341

729

30,449

342

Strategic alliance - MABA program

221

270

664

811

Total net revenue from GSK

$

13,562

$

999

$

31,113

$

1,153

X

- References
No definition available.
+ Details

Name: thrx_CollaborationArrangementsDisclosureAbstract

Namespace Prefix: thrx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the revenue recognized through amortization of the deferred upfront fees and milestone payments received by the entity under the collaboration and strategic alliance agreements related to long-acting beta-2 agonist (LABA) products during the period.
+ References
No definition available.
+ Details

Name: thrx_ScheduleOfCollaborativeArrangementsUpfrontFeesAndMilestonePaymentsRevenueRecognizedLABATableTextBlock

Namespace Prefix: thrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-Based Compensation (Details 3) - Stock options - $ / shares
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Compensation Awards

Options granted (in shares) 0 0

Weighted-average assumptions

Risk-free interest rate (as a percent) 1.97%

Risk-free interest rate, minimum (as a percent) 1.64%

Risk-free interest rate, maximum (as a percent) 2.05%

Expected term (in years) 6 years

Volatility (as a percent) 58.00%

Volatility, minimum (as a percent) 52.00%

Volatility, maximum (as a percent) 60.00%

Dividend yield (as a percent) 4.00% 4.00%

Weighted-average estimated fair value of stock options granted $ 13.23 $ 15.92

Minimum

Weighted-average assumptions

Expected term (in years) 5 years

Maximum

Weighted-average assumptions

Expected term (in years) 6 years

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Capitalized Fees Paid to a Related Party (Tables)
9 Months Ended

Sep. 30, 2015

Capitalized Fees Paid to a Related Party

Schedule of capitalized fees paid to a related party

September 30, 2015

December 31, 2014

Weighted

Average

Remaining

Amortization

Gross

Net

Gross

Net

Period

Carrying

Accumulated

Carrying

Carrying

Accumulated

Carrying

(In thousands)

(Years)

Value

Amortization

Value

Value

Amortization

Value

Approval and launch related milestone payments under the LABA Collaboration

14.4

$

220,000

$

(22,176
)

$

197,824

$

220,000

$

(11,809
)

$

208,191

X

- References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyAbstract

Namespace Prefix: thrx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of capitalized fees paid to a related party.
+ References
No definition available.
+ Details

Name: thrx_ScheduleOfCapitalizedFeesPaidToRelatedPartyTableTextBlock

Namespace Prefix: thrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 34 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Cash flows from operating activities

Net loss $ (23,061) $ (152,538)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

Depreciation and amortization 10,449 8,720

Stock-based compensation 5,223 26,013

Amortization of premium on short-term investments 526 1,539

Interest added to the principal balance of the non-recourse term notes due 2029 18,449 0

Realized gain on sale of marketable securities, net (1,204) 0

Amortization of debt issuance costs 2,296 1,550

Other non-cash items (2) (2)

Changes in operating assets and liabilities:

Account receivable 0 74

Receivables from collaborative arrangements (6,397) (833)

Prepaid expenses and other current assets 519 (52)

Inventories 0 (1,908)

Other assets 0 561

Accounts payable 154 (7,122)

Payable to Theravance Biopharma, Inc., net (1,056) (16,166)

Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities (851) 71

Accrued interest payable (1,161) 16,667

Deferred rent (5) 224

Deferred revenue (665) (2,911)

Net cash provided by (used in) operating activities 3,214 (126,113)

Cash flows from investing activities

Purchases of property and equipment (6) (556)

Purchases of marketable securities (86,523) (228,899)

Maturities of marketable securities 89,311 292,666

Sales of marketable securities 57,098 5,000

Capitalized fees paid to a related party 0 (125,000)

Payments received on notes receivable 0 140

Net cash provided by (used in) investing activities 59,880 (56,649)

Cash flows from financing activities

Payments of cash dividends to stockholders (87,144) (28,338)

Proceeds from issuances of common stock, net 5,996 35,629

Cash and cash equivalents contributed to Theravance Biopharma, Inc. 0 (277,541)

Change in restricted cash 0 (5,600)

Proceeds from issuances of note payable, net of debt issuance costs 0 434,677

Net cash (used in) provided by financing activities (81,148) 158,827

Net decrease in cash and cash equivalents (18,054) (23,935)

Cash and cash equivalents at beginning of period 96,800 ^[1] 143,510

Cash and cash equivalents at end of period 78,746 119,575

Supplemental disclosure of cash flow information

Cash paid for interest 19,169 6,109

Supplemental disclosure of noncash information

Contribution of net assets, excluding cash and cash equivalents to Theravance Biopharma, Inc. 0 125,337

Conversion of convertible subordinated notes into common stock 0 32,391

Guarantee issued in connection with the Spin-Off (Note 9) $ 0 $ 1,300

[1] Condensed consolidated balance sheet as of December 31, 2014 has been derived from audited consolidated financial statements.

X

- Definition
Represents the cash outflow associated with payments for capitalized fees paid to a related party.
+ References
No definition available.
+ Details

Name: thrx_PaymentsForCapitalizedFeesPaidToRelatedParty

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Transfer of net assets to another entity resulting from noncash or partial noncash business separation.
+ References
No definition available.
+ Details

Name: thrx_TransferOfNetAssetsBusinessSeparation

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net gain (loss) realized from the sale, exchange, redemption, or retirement of securities, not separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.13(h))

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.3)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

+ Details

Name: us-gaap_GainLossOnSaleOfSecuritiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) in current obligations (due within one year or one operating cycle) owed to an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDueToAffiliatesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of interest capitalized during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Allowance for Funds Used during Construction

-URI http://asc.fasb.org/extlink&oid=6504829

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

+ Details

Name: us-gaap_InterestCostsCapitalized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of amortization of purchase premium on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeAmortizationOfPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The fair value of liabilities assumed in noncash investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_LiabilitiesAssumed1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_OtherNoncashIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfDistributionsToAffiliates

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_PaymentsOfDividendsCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

+ Details

Name: us-gaap_PaymentsToAcquireAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow from cash and cash items that are not available for withdrawal or usage.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the proceeds from sale of notes receivable, as well as principal collections from a borrowing supported by a written promise to pay an obligation (note receivable).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleAndCollectionOfNotesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Sep. 30, 2015

Dec. 31, 2014

CONDENSED CONSOLIDATED BALANCE SHEETS

Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01

Preferred stock, shares authorized 230,000 230,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value (in dollars per share) $ 0.01 $ 0.01

Common stock, shares authorized 200,000,000 200,000,000

Common stock, shares issued 117,575,000 116,445,000

Treasury stock held 150,000 150,000

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares held for each class of treasury stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

+ Details

Name: us-gaap_TreasuryStockNumberOfSharesHeld

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 36 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Income Taxes
9 Months Ended

Sep. 30, 2015

Income Taxes

Income Taxes

10. Income Taxes

We did not record a provision for income taxes for the three and nine months ended September 30, 2015. The deferred tax assets remain fully offset by a valuation allowance or uncertain tax position liabilities.

As a part of the overall Spin-Off transaction on June 1, 2014, certain assets that were transferred by us to Theravance Biopharma resulted in taxable transfers pursuant to Section 367 of the Internal Revenue Code of 1986, as amended (the “Code”), or other applicable provisions of the Code and Treasury Regulations. The taxable gain attributable to the transfer of the certain assets to Theravance Biopharma was the excess of the fair market value of each asset transferred over our adjusted tax basis in such asset. The U.S. federal income tax gain on transfer of the assets to Theravance Biopharma was approximately $400 million. This taxable income was substantially offset by our net operating loss from 2014 and carryforwards from prior years resulting in a net impact of zero to income tax expenses during the nine months ended September 30, 2014.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2015

Oct. 30, 2015

Document and Entity Information

Entity Registrant Name THERAVANCE INC

Entity Central Index Key 0001080014

Document Type 10-Q

Document Period End Date Sep. 30, 2015

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Current Reporting Status Yes

Entity Filer Category Large Accelerated Filer

Entity Common Stock, Shares Outstanding 117,425,815

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: thrx_DocumentAndEntityInformationAbstract

Namespace Prefix: thrx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Discontinued Operations
9 Months Ended

Sep. 30, 2015

Discontinued Operations.

Discontinued Operations

11. Discontinued Operations

On June 1, 2014, we separated our research and drug development businesses from our late-stage partnered respiratory assets. For further information on the Spin-Off, refer to Note 1 “Description of Operations and Summary of Significant Accounting Policies”. The significant components of the research and drug development operations, which are presented as discontinued operations on the condensed consolidated statements of operations, were as follows:

Nine Months Ended September 30,

(In thousands)

2015

2014

Net revenues (1)

$

—

$

3,129

Loss from discontinued operations (2)

—

(94,934
)

There was no impact of the discontinued operations after the Spin-Off to our revenues and expenses for the three months ended September 30, 2015 and 2014.

(1)

Net revenues primarily consist of revenue from collaborative arrangements and product sales. Revenue from collaborative arrangements was recognized from our agreement with R-Pharm CJSC, which was transferred to Theravance Biopharma as a part of the Spin-Off. Product sales were generated from sales of VIBATIV® in the U.S. through a limited number of distributors, and title and risk of loss transfer upon receipt by these distributors. VIBATIV® was transferred to Theravance Biopharma as part of the Spin-Off. Healthcare providers ordered VIBATIV® through these distributors. Commencing in the first quarter of 2014, revenue on the sale of VIBATIV® was recorded on a sell-through basis, once the distributors sold the product to healthcare providers. Product sales were recorded net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns and other deductions.

(2)

Included in the loss from discontinued operations for the three and nine months ended September 30, 2014 are reimbursements of research and development costs from our former collaborative arrangements, excluding GSK, which we accounted for as reductions to research and development expense. Reimbursement of research and development costs from discontinued operations from our collaborative arrangements was zero and $0.1 million for the three and nine months ended September 30, 2014. In addition, the loss from discontinued operations includes the additional stock-based compensation and cash bonus expense recognized due to the achievement of performance conditions under a special long-term retention and incentive equity and cash bonus awarded to certain employees in 2011. Refer to Note 6 “Stock-Based Compensation” and Note 9 “Commitment and Contingencies” for further information.

X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5C

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3A

-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 4A

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5B

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3A

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5A

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5D

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

+ Details

Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 39 0001104659-15-076246-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-15-076246-xbrl.zip M4$L#!!0````(`'N!94=,R;]_*=@``'A$$0`1`!P`=&AR>"TR,#$U,#DS,"YX M;6Q55`D``QG&.U89QCM6=7@+``$$)0X```0Y`0``[%UM<^(XMOZ\6[7_P9NY M,W5O59-@WM*AT[U%2#*;FDXG&^C9W4\IQ1:@;;^-;"=A?_V5;+`-&#!@0)9/ M34T:L"Q9YSS/T3E'LG3YMW?34%XQ=8EM?3Y13ZLG"K8T6R?6\/.)[U:0JQ%R M\KUJMI4:NUZJ]VL*H_W8<'W%VHHK&.6^_EDY'E.^^SL[>WME/]\:M,A MNZE:/R.6ZR%+PR=AR;9!K!\KBO/++^RYIL7?%\J_U8/2ZL7%Q5EP-2K**M)) M5#99;^LLO#@MJN.YH^`X6B7'*=M-W@TA,>*(&. MVM[8P9]/7&(Z!A=3\-N(XL'G$RZLRE0BI^^N?J*)T)Y[(T3Q$W9\JHT8HAZI/:3([+P3 M]YFW^7S/Z#<@6+_V/6W4\8,&^MC2,7T8##"]Q^8+IG%M_HN+__`9SVY>V9\^ MZT]0U9+KX=VA1-@#LU^(-YY\8]^)SG]AK5,ED!2>$?-4+]V[WTZ^5)FPJQ_9 MG\;E67Q;7)6+AYS]T0_LIQ#L;?SN&$0CDV=1=,+*A09H\M#MY2(Z^<)EU,XD MH\NSU`:W>Z)T,9]\65(@VQ-KE MV?2W:0V)>R[/)H!<@<[:Q\W0N>2ZXU#[%>L/FF>S#O(:`:<,IQM*2W[$UC[N MAMB+!7/:>4-47X#3#3/H]ACCGF=K/XH!IIF.Q&I*ZE52]V-FL+"KIT4#6 M-V3BV([<_.&S)[ICPS-[M%?,"[`[:L505;([$Z:O[(_H"E-KSW65:TP-E?,[ M<[M8"-"EQ&.UH%AKCY@.;&IRKXJ[0*Q,9#G6$/*)54F)QKSW!)!7X*/G8(T@ MXZMM#?N8FD_8XR*QK:!VES^JV%`)0)$BQPE<5@@RST%@B4U)54:>[:80)*M" M]\@5M:+66!2Q+5>N_3#.?5:?`[(TGOMV9.L:FPQ(#PZO9XX#3XB!8.:>>V(1 MTS?%!OHFPU>RWWG"+1)=W.Z,[/+&%$,/]:Z1A[],@_(J0U7\:U20A22)8J&A MGOXF.OC0.X!O6_`E92<3^,[S!%_90+6KHL^+:F5`T<(Q>CY0`[L/[$6N8B^V1YVKWU&RQ(9K&!ZNRGF^"_[A/;ES71_3V(B'WQ_XXJ+^"%G]:)'1%;&=$6(^ MG-CJ#SO83NO@Q(AG[:&$[%]B[M<.Z;53M=9DCOLKIAYY,3`O.!?2A"F6.TO' M;&CLVZ&0W7!B=:Y.2EY95XSQ-SRT/<+7!':1X_"_AE&DS--Z1V&YW/*,/K*( M?OI<664O$_A;T7#'T-]:&/L`_8#^0Z*?#?"M`-9K_8!6CCEB'9/GKWB(C)O@ M26-`+AW_(G#_ZB/*0@V,'UX,,@PXY5Z-OR'/I[-)KT=JLX?SQE\QP:YT>9!L*HH!ND)'>3(F@YI3GFFU MGO-\OHQ0$2:C)"[!:T!PX0F><8TL$!P(O@@>%0@N/,$S3E,"P64F.+`Q7S8" M[$6!?_G'N3 MI\DNYLDS1G+>]XJL+"^H"K(<$4`-H,X&ZD,N,US]>CV`&D"=!Z@/O)5`(P74 M8*D!U+F#NB',NU``:@!U3J`^PEX@I5BT79;5T[N^S"?AVWLROZZWV2ZY<[M: M?+>(YS[UOHNMX,UVZICMD[@\W4EQ,BE,+D7!GFA'5UAB!`QG@.K!!D[1%WB) M$U[B/,9+G),S3=8Y!%&Q`^^L!&@'M(MBPD,0PWOW`.)C@CAZG7X_^TA.`7F- M!YA2UC/;=)C$@GLZE/)=IOES_Y-X(R8R\DIT'QDW[YKA\^/:@I-F@I/3'M$X M6$S1L?1'F[G6V"/A\HHK;.$!BX:N`N'R-1`I#26=UVF!*]ORW6)`^^C"BUWE M%.E)LU-CXC0BO$2F>CPA?>\ MA(G?BKK#1QD@+LF+3E)"_`"O$94!XI*\Z2,TQ$N(Q](HOK#['!0(3."BBOR6 M(/BHX*,"QL%)!2>UV!@O(2!+H/G]GU0ANK[W.:]?@+7/!SBM`1"P_53*`4XL MF#B+`03X:"UV54)YQ6U*=!J MQ3(#Z7@K]B:Q!(P?1U=D-"SLOA52,_(,89@0`!1%&R86=]+@`\5:KS8L)LPK M'&5&G(#S:*#)PWL&.609B[IF;Z==*HL+19AGW>KYMMHVL[CFN:BK%('499]8 M!E)+MRX32%WVF70@]7%7H@(#`>K'AWIAU]X"?2#4E)'5`J_$A%A39%9#K`FL MAF!3-E9#L%EN5@,%(=J4`>N)A3*U1K2(/OJR=QQM?N)4K9%A57E8;.=S3!(B M:0@KDD8VD33R$$F-B2`22?1%.)'4*K6U*\^C8GFLT6D<702SBR!S3$#51>I: MO3RK.)YV=!2FY;_W^C2H=LQ*_FJSP- MS+%^.D/6-BO`[XN+`Z^!UQ&OLX$%*"X2Q>]M"X_O$?V!O5O?TH'00.CHAE1H M`'U%HF_7IH[-HF7,SR^$81E8O,#BE0@!,HM%9M/$5"/(>$1,2D!B('%$XA1D ME)*\N:\^@<27S"M/1"(Q)+X*1&9(?`&O(?$E,<7+F_@"0D/BJ_#T+7WB"U@, MB2]YR%S2Q!>0&!)?QWI!`Q)?,K^<(1*)(?%5(#)#X@MX#8DOB2E>WL07$!H2 M7X6G;^D37\!B2'S)0^:2)KZ`Q*5+?!T[L)4C2R4!M.5-!QT;XM+E;J1`>PF2 M))#1*#O,)4P='#LTD"/.EP#;\@;4QX9XL:-?*:`M6YBY;8YHWV\%%@C76V=U M9'B/3TIP[WOE7QG`+<-:/2G!O>_L?AG`+4,^7CQPERI)7?8\<%G3M9`1C51Z MA0QD:;@WPMC[:FO!)K8S.N^-;.KU,37OK%?L>H&5*X:6EW4M5NOROA5/D>7( M0$.2MWP>(KAB)4B_ESW#78I$=%ESO6N=K"YR1TP8_!\ND%=DR.1FK>J=1,H, M#IX)70WT8A3.`B_78W"$R_*.B:["@IP4"LL&84I'[BR6P&<)"LQF.5)N0.R# M$/OH:4K@>%E2<<#H`S#ZX.E+X._F_)V_"/P%_DYN2(<&\%B[)]`F2OMV6Q M#)LR0/8:V`S9:R`V9*]+P/'R9J^!T9"]+CY_RYN]!OY"]KKX_"U]]AIH#-EK MB=AMC)Z?D2#5+@&V)<[K'QKAT"5@IX%Z&3">D)"[W3.6,NP6(2>Z MX>0[6$TN+[KAZ#N8;1(4W7`6UJ'/PBI*W"2Z>H&]<,C*<0Y9.;@VX905T71X M[=.@&\_GSVIX5$[?3CDWI_.&J,X3'C.D?&)C#26:A_6>9VL_OEN$V:+>]V(H M\:>7AR7LYYIUX"I=)T:53 M,'MNG1B^1UX3YNKF73-\'>NWU#:[MLF"EJ"NA\$-HA9S,-Q'3'LC1)FODEZ! M!'#9GV``?"NMRXWI&/88XT`D#PZOIR"02;)%'EG4X/(IPM[C(R`R MC)76BD@F.*H06QT_ME*+I7"9%%TZ!4-L5;;82B#P06Q5$D5#;"6(Q3EZ;%4. M4$)L59#8ZI!PG(3ZC20<&^")"6$7#^^)-;(%]@UIP`<#M/@#=&E`"0-T$0;H M`\-1/;J-A`%:J`$ZBW)T$\WQA**,2$B^8K-."3-/UNQ/B M5VPQ\1A,FQW=)!9A7A;BA@0HD9T2F60(I!"#%%M"^)JX6B@]K!<-Q-O"956? M`3#2VCRP+MM/*H(/"CZH`(009Y8=?-##4`)\T`*1`GS00OB@A0=,<6T>6)?M MY\W!!P4?]-B$$&HA"?B@AZ$$^*`%(D7I(`Q@V7ZF'UP*<"D$((0X2U_`I0"7 M`D@!+@6`)1M8FM'.B\'"OM^QRZ75I<1C=:)XQ=\CI@.;FGSOPE!(0SP]X6Z; M30FBJWQ=W#=DXKBEGH/Y(0=?;6O(MZ-]PAZ7)+,_O':7/:HJ-@:#U7\IJL@<5=,WYQU\OJ+["3L^B_"0BQ^I/:3(3&PV M;.L MBC)Q.F)2EKDZ^DO5,=TC.8L^YY7DNM!B1:-Z\U*78$KJ%W MX%I>7$O*$K@F.==6+CCHVCZ[ASKL2<:S3MVOO=^69:ZZ!G+=AT'@C\R]66B: MMI7F-'+!/PPZE'(T1@F"L*'@]&?N776&%`<7B\&L--E-&TP\N4*--RC)UW.2L&KK/L;R:-^S!RF_Q]WTBI MT[B:OX1Y<4O>L?[$6N0A$C\@UKWV<:U:NY@S?4_88(7T1VXF^HP[+@J&/?=J MG+R28GA%QTF:B.*0.8N,\K1.V<6\J8W>Z2B4:B,`YXY'H>0WB*\8B+]VKCI= MVS#0BQTVV['T'I^'P4.B=0R#P!B]TQBYC7PEL+`)$(=S`_4@Z(N^9+:XM5.U MUDQLRQ!OQ1#5$6Z[><<""F9W^O:=Z_J8NN&[\PM#T"A_+D4/A<666_QZ@B`O&. M444S=>'&%(_7>(`I91VS3;X&*_188\?VG\0;,8F15Z+[R`BW.B+6,-S/"+D\ MWAKS74AI+CPK3`E6WY!5DQ='3AQ38X M17K[GK=M'G!I1'IH3()3IY_CPZ=#3L+BLI0 M&NTT:4S,VE)QB)[`A@!X>]?\T??`6]B7MQ`MKYD5L@1.\`'P7&8H%@D!L^L2 MP\][U]W>5I%5\Q!(+2&0FK`"J6432&W/>VYM,G/Q2&W=U[P'VL/TE6B)LE=D MX%O!;`\R[GU70Y181.M8'AK:_%62*^RA6B?\G'TZ!*8^-FLO33^3]C97T*'F M9(X]_R+.CF9`1:!BJ:DHSL8N0$6@8GFI*-2&"$!%H&*IJ7B$8Q_R?>L<-E,L MZV8V`)A"`.8`%B9F7=8>!&%?\(LY\[Z4O(FR[X!H\=^9WFC M5>3R94?V2H_4]XB!'L=>_`GTV-").?JL8G[CXF15;6UA">(]^H]-N;9=OM#M MQ>,''@;++):<;/J]UZ<8N3X=LY+A*ZG%28=D[&S,KY6]W>M+;6IMA^6G.6H[ M[G1GB"V-%>#WQ<6E57RVCI<``_>VA MS1+HMVM3ASMJF+\<+KV:5_:V%-HV34SYUG*/R)EN]R.AEE-Z61SMBA18[-BU M/:Q"A$R!A-&[.(?09H!B&?!4>(4>W8C*L=`4K*V$UK904PEEP%.1%)K?REFP M+;+9%J'.70/;(H="Q?+DA%I@!]:VY-96G".IP-K*H5#AK&U!5J>">97`O!Y@ M10U@JKR8RF>>J"I,BG.&+I/#,O:Q,/OH'3U0ON6OE? M_\:EQ"^JK4@:P>YUB<9YN6^^R5\>L6?H8@:+U/`7XMJ-FGK>_MZ[OCR;_ACC M.OW^H-IK;-DFL995'/")>-A<5NWB_9=GB<YP'[_<8( MK/C\%1V3=H==T/G%6P,-E0FOGO!@O7$9(,-E@EFH)*Z[ZU/*?R2NAHQ_8T1O M0DYOU$QE:OU7U1BW>6UKOAD5>0R,QBW[S=VHT7_4P_:6UK:L0?Y,FS?'_Z8U M&-6VV%SX+-L(-&EDE]:XV"#W"39JAXUL_YAM@5<15WP3C!U=]CM%1K`KW6]X MO%$+R<%I:8T+#<8[-0;;EKH/OL?'7KZ/Z4SK"WZ#PKD67`IIJNA8(R9CP>>3 MNV^WK,/J>:/6_#A5Y?KF%AXM1/<3=FS*WX'D;T5NB*1_F87"#_#5IX&-QB[#XBHO?MY)DK M:6@X>&0R![I:$G65.@?=Q^H%(\+EV39=S%4X!\\$K)--C0V\K5QD,U.\BQSB M(8/\%^L99+,F;[2N#^P-WDTNJ6A5&4NDS4.N4 M7:_5ZV)W(5=LR]7=?6*[7A,(V^G^Q]IQN5IOG8O=AUS!+5E_]XENM=H0"-[I MRT#7VK)&LREV%_(UW5)U=Z^FNYD3ME\188T;^-:F/60DWCKJ6/HM(O1W9/CX M/LR%\4=W^5Y`ALV_]IG(K@P6<6\44/YB>)]T\OK+T/ND3#XKKC."UJS]_FGRE9#@*OI_P>_@M9Y/[M[C]+W_^TY_X;<[L3>VJXWT:L%Y4 M!L@DQKC=)R9VE6_X37FR362%UUPFTK:B\K)194%M_.JT0IVXCH'&;6(9Q,*) M&^/[?D&F\\EZ<9VP-[Q(\MG.G.,]Z1L.Q/5B&WKJHS=.E0@RE8%-*QPT2HP: M!5FZPG&C!,!1DL@1KK-%5@LOVPYHKJ5V9J66A.M?WIK@UJA"+#Z3UJZW#OGH M_1%6-'Y^#1D0+3"$BCU0T(PV7*X--^8,L11O%*3EV`.[6.>?7-L@>I#J>T$& MW]A1<4<8>ZPPXYBK#-B88;^Y;:DTF;#E;T3W1JR>I-GWN``5#1N&@W2>V/U\ M4CT)OKL.TJ;?)Q6P\53'M*+QL=5Q<7OZX5-8LW+1.JW&@T0X9BQTUJ/1U_"[ MKKPRQ@TM7K_GV>;)[/.V/IY>M'[^-&G;LYVVZGB*95M8^>GZ@O^G3"\&+2Z] M&M8>7`^`H/P4#/?5J$`XJBW>/Y',7%^6`X$KKC(*K8M:;9VVSG_."HZ/EI;*:.,'52CL#>T.<'(\^F$C3MO%#F?3\)_HU@J$6H-#!MY;3[0+238 MSEL?JN?G,2H`^`#\4@#_HOFA>E'-!_BA2R$&%@1P+61T('HCFWH5?N*K8@:[ M,`:9*C<]WRI:S"9PA'9,$Z#6SC\T&JT\!S_0UOZTU:A_:%U\S--B%T1;$/)M M8['O#VJF"S_X;YUBVVO'%XS((1$4".^G=YZ'^@3`.1QPCCG*-&H?/C9S<@D@ M+-C/\+.3(+:W"VLFO.4S"D<758&F>T!C`&X`M]P:*\YH?S11'3N%6*N>UD0- M2/NVAPS($V:?7($IE.D4RC$CHMK_LW>MO6T;V_;[!>Y_&!C]D`*,*NIE.3TY M@.,T1:RU MU\S>\VJVO6ZK7>,H*;CJ#%?[OM?K=!`C?JF&U\U>BJU:97F%S*<\E.6'$-O9 M,,EU@-["N>^6@[&86P$P+``#4@&IL!<,2(5%8!R@5VE+,*BXU`/R][OMB[ON MK&.T;T6J4%DX,:M)1WIM]M2LS7YZ7:IB`Z[7HR8Q^RM/].O%]#:6RC`0>A6J MU"M7%7U+,A526;AD83REY,R*;[K),W8KI%A]:/YJ,L@XY9@R)),)XRQ8GHII MGM"[!"HAI_3L_17G]W/)Z>LJGU#.](X';""BY!;K8JU:%]M^\_,4[5/6YTFEAS]UU\W&[]Z?)B3ZM%Z[5$[C$]QUVVVP7:PO19L!]/!])=C.I;4PZ!@ M4!5I.G1'J;>[XVD'`2QP0.O@9O(;$0?8;FSK$-XA[;UWXIWTNH#(8HA.@([% MZ+QJ[0Z/"QVA[2;)N(2DEL+CG="LU^+,6H;8SQ*9ZB/S!'$M0UR]?`6PTRW2 MF[+V2^@F`5:K8$6@M&J(EM$=^W;)T%&S&WTCTPA?(7SU>!=NM>2/IT(B;.6> MK];M>,?-$J2^XA!A:`XD``E``M?%&H&UR@?6SI-8S!;[/(RHT(BMU<1IZ[2] M?O<8L.X!5C3](`Z(`^*@(4'T[Y`]4#>WBG-/"@Y>50ZM7@5B(#?(76W$0&Z0 MN[*(@=P@=V41<\=/.UA5E>7EX5BSBH\5XJBH9]6$#4=%Z6/-_/K-:P%#76&H M7[^U@B"G*^1\U=F=G"Z@]^->NM3@\9+''0NZ`:V=%J?4,"`5%H$!J8!4V`L&I,(B,"`5D`I[P9C'>`"#@ M].E*G#[]HJ<%M_=Q6K"/TX+OM^&]2AVIY'>>F/[5ZS3:.%/I^_CXQ'%'[T5P M_[!@_^YAP1VKFQ07CC]Z3,X?G&7;;!Q#9DLEZTL>%@RR M@JPXRG2?AP7#PF!AL+"]'A8,$X.)[<3-BVR\[M5>C7F\3U.X$A.]\;R<[3.1 MCY.4AU(?ZK,JV*=-2@(+A`4>W`)Q7+L60_^ M`HMR6DU;"FOI,H?F2:-K[4Y>[:;7]'<\]PQT!]T=H7MKQW5KH#JH_AU4Q^:> M,"@8%`P*!@6#LM.@#NU[=$I8>VT'`RP(ZM0A=,-O1!SL,W#C"&>V#8L?U.`[ MWG%WIT,#`=&>(0(Z-J/S:M<=RWJ5WG?G>Z&$-P%[/GR#V+1C.-.A?FZ]!B_/ M$JGGHV2"N)9AQ+)\!;#3.^XWO7Y_)VT`K!;"NN.NGD#4.D1?^?Y>S13]]:?Q M1T\>PN&<<%`+?WR\4WN`^'?EX]]GR60B9!#RB*4\%1)NOI-N?J=7PB2[BD.$ M1APD``E``I``)'"^Q49@OO*!^0M)1>)RQM282THI&;&KL9!\RN-`L'=ADM+? M)QSN?#W<>;_IMO`*J=GFC<[@`J*"J$[@`J*"J$[@`J*"J$[@`J*"J$[@ M8ILS?;`**]3G^G MO?;`=_#=&;ZWL"`\U8()PN,$3!`>"$^U8(+P.`$3A`?"4RV8(#Q.P&33@(0M$T2+ M2TY3;C;QM,>SVC4(NJS5]+L>XU&DG\G&@O$I#R,-P^M1(E\K3K:O1)#+,`LIBV.NIY['F>1! MEO.(37BVN'4;9N,P9EH-9H)+QN.A^>"MX:48TI>%Y#>"#7/)LS")=8K%CC`Z MN?54;KEB/$UE\C6D!$0THP])(=B$4AZK!OL/?231!TRQ,,Z$3B>AUZD,.KTP MG@J5Z>-7%5WSC'&I_TCY87DL!1GFWY29*%&*I8D*=4X\D]F0/J?HF2C\LTB2 MWKVE_(?TX8%@4OR5AU)\.[&!H!K3SP7Z`-C9O$)#JHE)(C.3:I"HC`VX"I7' M;L=A,*8*F.F/S^MQ9LHVIIIB0Y$).2%,AT5.=&JD%DK=+X7>RY/J,I??J$S^ M%/Q42,HVW=4'=U&^J:YBG1W18,^DSC=0)$)LR*PIW4"(V(!R%PA&-<@BH0QR M,\(LOC$8TS,BW"[5'X;PO"W\0&8LYN>&@, M^P?J,3+*>&10E?O2+LUQ+*+AG-/O17`_7[[)5V=A763/ M81Q$N2Z&SAIL2Y4Y%8\:`&_$PB]M&8XS^?C2ISIE0(:M!\Z)XW. MHJJ]I>Q*$9F<+\U/(Z/,[;DA&K/7(JJHJQ*.PH!35H=;,J'ZUKF_G!8MY)L! M03__DG[V3:@!#C86Y@.G9N4/'N6"G0NN2*M-$V1=R:JCD!?Y4P:INQF3`@P2 MJ(R--$93@U&B&SJI'S7&93H`QA)UJST4`]/Q"#C=+5XU_;`-G8:&ED9&'0[3 M+1JN)3&W9M+%41)%R:UZ4RDNK$T56ZQJ;,[/AC8.E^EZ!-0IFWM.;X^:1^9: MI3Q87,\_,'=@R>6*>*K$F\6/GXLO4]&:#?WUHE(*1_EA:1^9>+71Y^OXYJ,O MZ-GUM_;L^D]@5%;TK5M2A:Q-.0Q(&81\B=EXBT(N%^+Z_A,K<;M=4V+'5^)N M7=E;\?%ATWB'H+\LI'"%FVX:5U>FC5Q=WFDLEW_E:[^3T>KWYN[.ZD+W>U97 M7Y2NVOU$BUPVE'MQGBJKYQ-LO9JEXAM4^QBK3.8/.W&0VDU2^^2>!RU#%RAM M>=S]=Y[A8TK[-)*+@1)R:@9PUIJU-(>5P$IL MMY(]FL67.%D9QC[;*)A:J:;F?('A5#[/J71<4P^HH*\^QBO$LG&2*QX/U8_0 M(#3W]C7WG\14K/EO/E@*EEK/TA98"I9:S](V6`J6VL?2?>VE6B_7Z>$V,@N_ MJ?2->>TZP/*I.5A['@&P8W7`(230SO.Q]QZ1`>R`';`#=L!>8=A+[CHYNQ7A M=A.Z+.TIWNT7?FE<-MB-7@(6FP4CJRGB5KO)%IF(7]+)N2^)^AZV927N]ON' M/3[VV.LV>RN`P50P]1&FXK1KF`!,`"8`$ZBS"52DO_+B*TYL\,>J'M-_W%/C M-R(.]NFG.>_W5RS)8=29)[\0[.6Z5Z1<#8"@#B`-EP%A!K<8*SA*I M-UW+S#Y,&"#85@O05(`$ASVD[MCK].L\4`*+A<76UF(1*JQ\J/`LF4R$#$(> ML92G&S92@#^'0``"`781YY#M2[?C'3<1(H0R0!DL)$Y5E`$APLJ'",^36,SF M)RRP$6&,**&#[F:G[?6[QP@0(4`$BP4)0((:RG8MHX2U.,G.5F,]>(74;/<3 M9W`!44%4)W`!44%4)W`!44%4)W"QS4&4/P^BU6RT;(U&FSWU&#=; MG]TY[7#3H81[4U+G!SR>:XUZ9:D=A2V#//M;$\P'\P_`?(P:P:!@4!5I2EK-MM=ME=2)PG2I_;BN;D8`W%-+RZMJKK5E M1?+(0M@PR0>1>'8H#S`]7^X!D]4P07@@/-6""<+C!$P0'@A/M6""\#@!$X0' MPE,MF"`\3L!D55S0^0DQU5B$J6\]=OK?IY`/P@C'NJP5R:G572]TP!<@!(2` M$!`"PAT[9XY`6%8GJFZ[J\53(;-0.S8JUQY-&)NYQ&977#;,!6LU6_L[9MZ. MGC_FPC@P%P:3RV!0,*@2#>J@\Y1[)UZ[AUWZP'PT)6A*8%".&U1EFA*;QB,L M<(:KZ/+^EL2OI0B27"IQU\T]P7B"@V$P9]K3BI/@D&U`I]?QNBWL\@F3A..SRN-G%DR8A%+S#9W?G1#HSS8>#,P/;:;:_?/\$< M+#`?30F:$AB4]0;5JT53@CE8V"O29;6TO*JP@8D+,&$#$R=@@O!`>*H%$X3' M"9@@/!">:L$$X7$")@@/A*=:,"TB:X#):IBLB@O:,K6FN.3$M?LAV<7=327? M+A2^[1C)PT(N&27@O8\VFE"P0430'^NU1\\A*K$F\6/GXLO4]&:ADU%I11V_;"TCX1K-U+TY1=F]+4<;7Z*U_[G8Q6O]^+0$P&8NUS;=];7>CAW=75%Z5K M=F]MF[-V\IUC72Z+YQ-DO9JEXAM,^QBK3.8%+:&T3REM/>:V6R6T_\Z3.RK[ M68;!FJZ&\0/:#B3[:?%[Q\1/@RRK%$^5 M$K!5V*J-MGI)V0A'Q%?BY1*XBVPL]FHD%P,EY-2XFVO-6IK#2F`EMEO)'LWB M2YRL#&.?;11,K513<[[`<"J?YU0ZKJD'5-!7'^,58MDXR16/A^I':!":>_N: M^T]B*M;\-Q\L!4NM9VD++`5+K6?I_HZ``4O!TNV'6_2>&1B/V]%UJNUA6/K6 M8V>-[GD$P(ZY3(>00#N7A;_0H8B`';`#=L`.V"L)NTWSE"WH0U:CIWBW7_BE M<=E@-\E4R%C/YV)*!+G$D?3?82)Z80QV=5DL>GMF,?:R=TN[Z34[[3)W`0-5 M*TQ5[-L%$X`)P`1@`G4V@:IT6&IY<%35H_J/^VK\1L0!]E.O3\#'F183Q+%J M4]-VQSON-LMTC`$PE`'$@3)@M*!6HP5GB4P3R;/Y*8'%PF)K:[$(%58^5'B63"9"!B&/6,K3#5LIP)]#(`"!`+N(<^!` M0*>'$_2@#%`&"XE3%65`B+#R(<(+247BQF+&)V;*8C:C0F%U8 M$S_OI.LU3S!)#!&@P_<&0!P0!\1!DX+0X?Y[I6X>'N>>*!R\JAS:W`^(@=P@ M=[41`[E![LHB!G*#W)5%S!T_[6!559:7M^T(0ZO9:-DZPF`VNF;<[$?,)L4) MMT/&,R86I^.RT9U#<:?F4-Q]R;`C<8/G&A\V=[%E_[7N]1L/&D5,"`5%H$!J8!4V`L&I,(B,"`5D`I[ MP8!46`3&`6)5SD\AJ/KR17WKL8.//X5\$$;[/='.CMDN5BT[J?;!F(`=L`-V MP`[8*PR[33-9W1LRM;2[>'^;W'@J9!9J=TSEV@\+8S,#U1QOP(:Y8*UFJUV) MH`=FB&"2%"9)P03J,DG*/SGVFB=U/N0"7(5<0ZYA`O63ZUK.::UZI/^N%?R6 MQ*^E"))<*G'773M!G+\F(2!G6DT0QZI]R3K=GM?Q_3)=`R`,:0!Q(`T80<"> MA951A8-7%38'<@TQD!ODKBQB(#?(75G$0&Z0N[*(N>.G':RJRO+RJKMGH=Z6 MD)G="/6IEM$++"QP)$"`T=;OJ@E,.(`)P`0./>&@UVU[W68/\\/`5<@UY!HF M4".YKN7\L%IXL;9JE>45@BU'[`$#6XY8!`:D`E)A+QB0"HO`@%1`*NP%`U)A M$1B0"DB%O6!`*BP"H\9['A:7G'AS/QBXN+NIY-N%6K>-IS\LY#+GZ5,Y79_6 MT.Z]9-:OQN+>;(8DEXRR]J*96.>40HSN@ZB?"C80,3!6"?) M9J&(ALIC4J2)U+OO9)(/!?UA(),_A?QI*'@D)/LKUZL\/18JE=.E2J7@^K7L M-J'R#>F]H@#ZQ>6W5P6AOX;Z\60T$E(Q'@\I0?I)CU+F><;G.2,KFW^([BO! M93!F*8E7&/`L3&+5V!)M\');7@;/VZ7)0!I_>UDP$8<-N*+WDIB@#:AXAFD: M\%2&`3U*"69C35F5R7Q"#VBZC1A/4PT_I4_TD>9APY)D**(YL_,LC*@LC-@F M]8?7#&!.IF#,)0\RLA*5A8%B(_J2"JE.N639+"U27TOY,9ZM:^&](90"QZ)A MIG9C?EFTLW1]=`?\Q?L%3)3_MT>^>8)]0[=W3'C]=;9^\8^?LK'\^N9TRJD^ MJ-(^)/*2C/YR:;VG\?`#$>,/S8OSXM!84TOO0Q5$B;Z\(M:^BY+@SW_^]W\Q M]H\GOG=!.,NK,8^OQ(14A\O9QTE*">B/?DJ4TJ33=O"[&+T].E77%Z-KOW7= M]J_U\.D1R^.PN/6%?OBM(U*_()SP2+T]>MT^^F?[N-NB;LZ3I7HJ%_LORG6N M7M]PGEZ?\_]+Y)7FX<7HO1AD5.&__)6'V6P-@Z^A6CY_EDPF0@8ACS[S5,AS M,1D(^63%5+Q*I$XL$[^1[JR>0=6DU_=O/K-.:F!'Y^3WS,Y-$_$ACX=@"SW_ MY?+7A%K\6*=R>D,=-'I`OP>;NEM+5]*TA#-Z7R77)]?MIKDX^N>\>['L*NS0U=BE MB^1T3WY_.;TM0@N#)!K.OZ2??6PC_@5'V(HDUI6J.I[41"#(BPEXM/)[M4Y_$DZ,:X-=?<* M5WCNZ],W(OH:48#?"$:?SF)RJ[5[K=*0'DWDC'&ER#-G@YEVN6)%?K?4+I1^ M]]FIA7&6F#=(F&)V.TZB:/8ZN8TI*7(+53@,2:,\1DZDY%.NW?IWBZ)YJXKX M&`<-]FHU&?+LYTTOK.Z___G'!ON/,-HEPT&NJ^V']DF[T5Q]D_",*(O:@PNX M&GOF7R9(O2UU/$/DLB0J#IM=M+\-)S[49WK4"%HS^94'(FBSK;=_)*SVC'7AKW_9S/ MUJC=G>?HE7;>UY&]3$G8+T:C>VCJ,,/BEJ9?'NEZ"N/-.1Y0JA-=2AXS;%*HYI%-_6KU-O-(OD&^UW',K71:.>3^?X=.WB_ MGNK%,M5ULS`Y&.52=_JH(+H:S4-U#$,]LSN[U@$^XZGI^OPMAA^$4)]Y.+Q* M?A>Z61Q^)B;,3B=$@/!O\[%?OI*$*'$ZRH3\7V+IAW`J-K@(J[[PHWUYZBK[ MK6[;C*O-\[]S;G8LV>]BPK4\R(O1!V(>C_1W=RIAN[MK^3;F:<=RE@->N[]K MV4J"S7QF'G`_>'$H'R44YS+\:D-I*!LE%.;*M`T6%,=DI(P"W296%.M?+_^G"-0LG]61GXO1J23WZ,:,;:P> M_G3Z[O2,O!T^2(KFZ)DQGE:KF&[Q[`HR12NC+I88UJIAV>*$.7//SGNMSH'RY\M,.V[&A!$ MKD,0^6[6NPVVQ@NFB<$T,[2;R]F<').R+U2FXX=W/DV2Y17A3*YC M(U&4W*HWE<)X34H6LV[75:<($P-8_,M4IYL+B>?V`^F3;0LITJ M\6;QX^?BRU2TIIE$>D>S'I3VD37%FZ<)=QM^[T5GIO:WGIG:_W_VKJTW<60) MOZ^T_\%B]V&.Q&1]XS8[$XF09!3M)$'`[-$^H8[=@#7&]K;M3#B__E3;&`PA M8+`=;"C-[@P&NUWUU=?57=6W'3;*:JIN4\U\HP@^3XVR]UAH'BFYV-Y.$G?L M;Z?6C[V_W5'!/HB/FQN]15&;D[RQT1?HU^1`73FS6>;%H&YS!W,5%9F;,7.O MJ;9.7&F5N&JAET<!GC98R7SR9>;C]31L84PV5L M`+!91ZN66TFT*EKU!!1&JZ)52ZHD6A7#90R7,5P^U7`Y7`<(*F'`C$T`-NQH MU7(KB59%JYZ`PFA5M&I)E42K8L",`3,&S*<:,,1'=@FG#P_L$TX1:N6ITW`O`+F%3"O<$)NHDN9 M8>,J;VQ'WB)(AS`VRV>B!G8U3H,B;4WSIWZPDQRR!%F"C@0I@A1!BF!;@RPY M/4>"&9`H`U+R71N/2,\/=];28M[$]EUBZ>Y_,#63)C53RY$3( MLTP+(3FS(^??Q/3SV&CC3#M_2,T,HY-\9^DA0Y&AZ#R1FDA-I"92$]MU9"@R M-&?G>5[I3J#B&[E.HOT8,]NW='Z^E\T^";]U.C\YU.SF1;-95+++LEB% M+D;Z_EXQ*(!\1[YOY?L'6:Y*C7J>?"^#V?,9#,.J4>:J(;4:U:: M11@5GBC01"#AX2G-GDZII?''?,>V M^,WA=TPSB!EEO^U1$/#;-W7/,&PYH4RZCI4\Z`D^#@V;,L5?AK>)+B9Q`8- M!?KB4,OE=VE\9$H7"`@,5[PX_CN4R.@SM7Q0AME3/I86Y["]6+Y>J88^_K<7 M690Z?W96WMZ.O7UYU_6?(,DF%4&B0']OPB@-AA`LL*,P!3M.7(%:7(`^=;SU M8^K%J@#%UH2?`,WORD6-*V#R@GD1OTOBA1I]4XWA;LYR$4.-Q)"7/ZW(T[BH MO_KEE5PN)\X67:N!A"S:##W&T8WD,=:`X2J&Q?PN*1?-UY+R&RA9\G?&I_6& M!(/GZH)GP[_0J9]#+-%P(.,DI%'V<461Q%W;VMM1^@RPJ%<C[T"%")OU2DX`[AC68UY8OCCPOQB\]_`'->/G6(8WC0>($WN85J MU"6&/K![X6!8ES!O-@`O>&7:VH_+7W\1A,_)'HJ.5Y\?&_<]\$C?C!'W/1;W MJSTZ^E*Y]L.QLZ$$?[BAAP-[V!HJ8GCANQ_'A#C##C298!V'%_Q`IK3]8KA# M+L?P:_^O^X!ZBWL',X<^CF(U>GDS'[-;&;(+'ZU<=B7U'_5>5J^30O*F=G&( MXBXF+H]E^<3LV3-B>@9UVVX7/#%\#^4\CAZHUR?@U6YMUK&G3X85R-D-O;*; M-W8]+F-P0_3-/7DQIOXT/<:";QFAW-_A@Z14!)UJX`I,E\^FN!0O)#$"/WO< M3LXJX$QSMXK"K2+6:T@A78#/G7#P?C!A'@W$TW`PA-_88P:P7_MCM\ M'*4$?"[?(^M3]FQHL7NOC!'TEL*NR;WO:H2!);0VU]:V#->[HAZ1V^'GS1#+ M<8@_UBJ72ET)I_3LP#D)$@D`?7R","6P`MCD/NI`=:.9#J^AE.2A$C!9?2]W MO`LQ6183(;9=U018]:"329@V:5OZ-71=3=OAW]Z$?16W1XWID\]<"FU#:(>M MCD"-.X(EEGT/&I5`6H?R!ZQQF_>N#%Z7^G2\0&QQ?_C=M>%J`2%\JL^?A*YY M0@"E).CMJ_R[X=DH%IYU<)-'@#+PM[,>*'M-1]#MU[_QDA^M(O:OMK4R=P^W M0>N_JYEY6^'#T1K\M,N)EG@@6J!P`K3Z$.`9(X/J0=,=/`@.])J"SM,@BHN5 M7GS\5FMK$QI<44S6?NR#0P)8H:*'Z8_DK<1V7:"#UI2DW7I$+\Y'QJ/WL))P MI>^!"G0,!4'$3RQXX9C1X)XDI'EWH#J,SW2EC MO:X>6\;S(,/[`MTXB`RR?`3O=8YD.!SHZ=2V^IZM_0C^NH:(1:>6WN.(;D:Y M/I07_C?ZO#N?(S?K"^FVO')%-,MCQI//7_HXZA"7AS'\GYM_?>,9>D:@$'QS M3]@/&@P%]JGFLR#>NK.N?!M],N?ACD7A0.RO(@H_,VVQKP7RN7B=%XR>"Z*?"')-<#CF3+/ M`$WYCHYGCEK'L?7IP&ZOC#?\M#O!HYY@Z!#S0#S_412Y_;=EIW;6 M34FLU9=DV?;:I-)MR3ONE&9/.6X!?49,GMWP/9O-!N3E9C2BX!M'7XEA?;-= M]]&Z!F>WK`!MUZ6>FU\-K%$IG3O7]2ESN0\"VT9E+EHXWPOO MWUP[7\?^D&B[*<%(6[P>-\V]7TZ>$90R'!95JCL$K7!!/CP MS%O2*\-VX!U3LH;6(E_7,0FP8Q2T12L0Q1JJA""I2KTIR@NDWE`T!@8W^P#, MWH/8WIJ/4(P9F7;MX)J8`SL$FF?L`D`ZMNNU^8CQO:T;(T/;4K-JL9I5>Y5+ MOZ8C"I5=CQ<>ZRO\U_`F0"7>-OO$O'GATQL,:QQH<45<[C+"=#8T;%V0B5'/ M"(EQ12TZ,J!JS<(.S\87Q7&.;KBR+3]I)KD6K_T9H1BSRZ:F>C[D&C3V1/,` ME7OP-O#;+-SI?9\@ZK*KW,^%/^15.R2=CYUF)*GTSQ9)=[TJ)NF#SRW+^<"@ M4\2[ILLVWNWZ3)MP6FUJ:H_G+<,R`WFI.7N@8QOHY''7MNK@-K-6?>4@(M^0 M#(L-X(5>I$&0X\;"RN',W1.I1)9P;L=,ERH]&JUUIKN.\/ M(]IBYWR`Q'V(3*P0M3]\A'_7K)DL,]^`]4K7V.IU6@J_-HW?K@^Q<#W=_YY@6+1$;NLU7V&;&!3LN^*9<-$X>BP;`4H+P! M[6)6RRVSIU]-^XF8T8R6#0VD^BH+OM-GM&X-\`1\`(EWG/B,51<"0EF46^MU M/AX@`K0N"9)?T+N+_[+!+KOQ4\4-^&W1/(;5TF<$]ZW8E@MD@7>+Q_"BDCZ& MK\4J?9+W[RMNFJ!>JK?4QN'BS8<3P^P@?R)N6X`_2_^IJ'),T%UOSDG*?1Q, MX30Z;)"N(;>.+V6FN+^W1H7,U/L4^C4 MUR94]TW>2WHFALG;!^C^\;9U&=`'V;!%2F00Y/.B:?A[Y0WF"P86D_]3+!Y( ML^BA-,O`8@I&^U+%L0CR+H)&37.^8N]+1:P$UZY#M.AZ7L!\B[Y@I9/CTD_1 MAS_#DH56/5@5N`+D*V7W/;NBWKQHX=D5I3B[0KZH-4N\]>#^NV+*%ZI<>FH6 M:E?,S4OO7G'UB0E_K*X[._B-O%G!NH!UH7AUX1K"[;6J(.5=%=1`?OO2!OU8,YJ1UH^3RE8I*SQ#W0Y8RDW7UOZS2@2;[Z2)9E.%1N-)2N0^$C\LR!^JU856V(VQ`^[%,7@0@&Z%J?8@>A/;.9]Y*.- MPG0Q0TAP%QG%0L=L!8[0CKK]JMRHJFH]R\8/K97C(0%*M=YJ9NFQ2V(M#/D. M\=CW[^JF2]_X'YQBRU7Q5T[D/1FTW*M.S6/?4B1.`<,"5:XV:QEU"3`LR*?Y M207$X7YAQX#WZ3F%HT-5HN$>M!B2&\E]VA8K3VM_-*B.G4*4Q0NYJ`%IL#X3 M\X3)!U=P""4:0CEF1"2+2K4F*]F$1,A5Y&J>7&U*U;JJ8H[XO1K>WVG?>H6/RA8MQ,=?BD%(?2Y5VE>S&!;>[S[K"E;8)&?KF?(0B MKK2%HG-8:BO5WCNSAPV5QH<73$WG71>T*EJUO`JC5=&J)542K8I6/0&% M,5[&>!GCY;.)E^?']&"XC`T`-NMHU7(KB59%JYZ`PFA5M&I)E42K8KB,X3*& MRZ<:+O?HE!@6J(0!,S8!V+"C5VLPS_A=3Z!^IAG4=V M8)MP\OS`-N$4K5J>-@'S"IA7P+S"";F)+F6&C:N\L1UYBR`=PM@LGXD:V-4X M#8JT-1/;=XFEN__!U$R:U$S)Z5@H__GA'TI83H0\R[00DC,[YY7N?'W@]GLD_!;IW-STB<#"`^H$$("Z'J],#IE-0417`%0H$[P)7=KE6_NJ+73X M`6A0$?-;M,23FYF9YEB'DN^5Y'Q3V822YG*@O*1>J.F3@N=A2'[HKUP49;-P M%K_G4+.;%\UF4\?9+DJ->IY\KT,9L]G,`RK M1IFKAM1J5)MRJJX/-@7(]]+P';L^R/=SXOL'2:HVQ=;9=WV$G)RRS>$E>3+I.F31KYMD/TS.'3P-C;:Y%B]$==;% M7.-`*&0X)`/FFE^&0RQP75G1+'H^%`I$_E*1@CN$-ZI'RA?''Q?B%Y__\";L MY5-?FU#=-^GCJ$,[A'FS`3?9`&K)E6EK/RY_ M_440/J^7L4QM/],V8\0:TR`9_MT9,5"-%]RV]/LH6=Z=Y\I[])E:/NU1S1Y; M7`*>*%]]GZ#!\W#1HZ,OE6L_S)X/)?@CBU)M.+"'K:$B!A>5RSE0"Z53@);& MV"EH+.Y#XTWN-A&KHZN8@E%>/8Y%4%D%C9KFW.-\J8B5X-IUB!9=SPN8#S%J MG`J.2S]%'_X,2P;5PF'.%21?:;OOY'NUE=F(7)[#E;C]P,&CY[4=H^>R<@K+ M+PHU>CZ8,!H;O;R'.R;N\OK&TJF^O.Q3QZ/3)\J67REB-0=FRR6_4FW5 M9:3_N=#_S-FNBM6FA-X>Z7X>=&]46S4%Y]%E%DF>8KSXC;KN)X'$-J00[)&@ M+>>T"2,*`CC$T`7/?K=XLB3,.G0L[*BST)6J6JNE;P3+X/$/&[[=-Q=Z9&O* M2BHGC]8LD#4EL:K4&VC.$S%GHUJ7,EC)<'K6/%*7+!5*AX-4LGG+I0'DS*8@ ME<8N[S5B7AI`SFQTO31V0:(B44MA%R0J$K44=GFO*4F%!R2K""?[Z4NR>"$7 M-1T=3E^:"2QCWE=KUHGUSMT\QB^+TD M]CE2YZ6O`RT[W5PG%[Y/IY<%V1JI*4P;K88C``Z8YTW]Z3J4JXU4<1(\1R!MKE MB_4*#U40*6:5,(,:(NBVST^72IHQ0S,E=_%HIF*;J4A=LX)#->_8(:.+;29T M/*4P$SH>=#RG929T/*4P$SH>=#RG929T/*4P4Y'R@D69=Q)>\K.]U].PT:]I M3C!?S7[NT'&;5@M1G74QU_+*>YW-'CT?"@4B?ZE(P1W"&Y"F?''\<2%^\?D/ M;\)>/O6U"=5]DSZ..OS`=*CSQ#.>:9LQ8HWIE%J>^]T9,1#KEE*W;>GWADE= M#SQ!E\R"GWOAK)@>U>RQQ;<\_M:^:@^X>0?TQ;LR;>W'Y:^_",+G\'T3PN@5 M<:G>L:<.M=Q@T^38ZZYFRUOFKVC_)`QNMURJ^8%PEO[X3)E)'`?JSN-H1!G\ MVX6_;3X+S^*C`STZ^E*Y]EE0_%""/_P`L^'`'K:&BAA>^.[',2'.,"A_,'-H M^\5P%]_>3!W3GE':]T"#^^`@WLIE5U;O(^1RUB0+T.[)BS'UI^TI^!ZO[<*; M/68\^?SIQ]$-."X#S!0O,U_X!-\RPJ*_PP=)K@@ZU8PI,=TO%;%R*=>@W4F+ M[MXJ9XAS_&5M%\S(C_LB8UH`K)4XUG+E4KR0:AE!O9_6&<+]X'--'T?!36X$ MPCV9=7VF3>`A`)57I_G5>SB(-=3CH-\]W(84SPCV@[3/`OWHQ:LEN^\*K/H* M634MK&^HE05B[\G`RVX]=0OU-F?XB^Y%:L%% M74$+0)C:5@RKQ2\"Z+8[?`G`&X=_1YUHLH1;MO1]KV)S7B_MV.['I0; MV/0-O,4%R(!X["J"HL;O>"W*`K=[6S=&!E?6TR9M7^-O'U!+ MY_X-^ICKI?E/+OW7!]UOGCD`ZVYF[??-%JBM=3!:%W(MCGY"X(Z.MV&5$^_F M14U,AW>PT&%SF\&?>`!X!S^I^4SO`>O)&^U]/70I*@>\/L=;#4'Z&^)&J'H= M9H!7,<@2/9!E9+,IK^:\+PGW++3>T0#VH$AF:%!9-SD6J-+6JN/J.P`9,;_9 MUGA`V;1'/7@3;Q-YZ2Z(*B5T+THS[E[V1"X9Y@/[*A94;W7@`=JUH2*=*-H- M,2':JYC%<8;&Q1WQZOA`(2ITJ>=>^:YA4=?M4VCA=@=D:KR15+>+K%0N);FF M*(V8T$D$R%3@U59]I\`'"#JW_*>VIO&N@@M=2)[VZ?B,@:$%0X>>$/0*/HI@ MZBY`<'ZFF!M;<4PQ_Z@>=B4=O0AFG*J,3 M8*OQ3.\LS9[2;[;K`M"/HP%YB2,F-U,B]K'96)=W'UG2*9(*:"E#N77=X'PE M9I<8^IW5"0]FB_5%5S!OI,1<4FL0X*_Q9*<(>XN<"EVE46N*M70BFJ:M<8-L M=L(W+_SC6UVR@[RI7!EM?0JQB.N%`S+SU[X5=O^?O6MM;MM(MI]WJ_8_3"EQ MRJFB&+SXDM>IDF4YUS=^E:7L_>@:@4,1"0A@!X!DY=??G@'?HD20`(D9H)/L M2A"`04^?TSW=\SP>[\S>H*.YCB&.911R(U#R6W;'_#`2CZJB8:O3KY;$O;U< MM-.S+?7$KA#'>BJDD(-65AEU\,R0;E;KF(NK6&W';-J=G@HMWXZ)?<>RE`B= MGQAE.#Z.]52(KH[Y>674P3$[';NK,-_T=\S=]:ZN:AJ^'?VRZ73[ZHE=:9=& M'16BJU]^7AEU\,NFY:C,-_W]LF49Q?4["7GB_4VS^9OO/#$91`QKAG$B9B-+ MZQ+#,*6.W74Z:X+G%.(`HN_8J%C6H%N&Z(#YT//E'.4KYJ94AY`H?%L4D$V^;8`)(^J99C&&B1E2%AMI1>C[<4^_.9A\@`.18R_WXFI3H$`__+JRY?MD]EDA&69?53_'NJ??0.\Z!T#0[SQ MV54J%E:!(8(C?,MNR;(EN=K7W+LA7EG6W'Z0Q0_=4ZV\'ZE+DZ0;!] MX=;G2)230UD=L:A(ZX:I>KKNV3#9-4A_=V+H[GH"=II&G=F91T]"+?'7JS]R M6K/6ZLHU[/7(E`9.MP;)I;[QCM&K'>!;?\L>?D*%)QR[)[&U6\^;MWU//%FLMW(;^B_A)U"M:^ M;W:=-2F>_%0I(LW-Z@WUQ7KLJS%CJQ,]LMT%*/^+R0WS%N7FG7MH]3M=M:HT M#Z1H+.:MB!\BJKV#;P1)WGH-.L;`J*1>'^F?(1=^,?X\$D&?B+YE4/YDO#B9 M,"[6P7^AT6PKB.V3^1VG.]"D?CP2FP:R3V&R.S_[1F]]U8*B]5R_F7=N:L?L M55*_=]3C-R8Q'W8:5N\V>7GHR_B@^*O7+RSO:JSGWN MBN7',&`/F5=]EP9#]9W.5F=Z-0YY(C;9>`_9:9Q,=G"EIF-W!WTM<%'[O/4T#,>NVOW,?_T?CW$Q M6_7A@YBKNMD#O0\@X(_E`^;:!-:C>S33-KL5T:0$]5F5J\\9#`;5-`@EJ,^N M6GTUB!D:$S0KI#@]HW%E%-CT,+\Y,;4RFJM!5*N0+C%<5@V3_1IS!$&AP`#! MP""CIECH'+?4#HS20B'$!<,J/;K1FMA'4D,LM.]VJ1TF>P99B((*X16BH&9< MI4074PWA*1)>Z0G&H2[3@]P]*C M>D5B1*OG](^P,N9Q-8\_,;\REW*D$,>Q^^LG,RCB9XI,RP>".I40M+*0J#L8 M]+3P/,6"C5['J-KQJ#I`N;UQ,NWU[4.T45[U$_+%4N8C]-X>1'NUGX]_^$BA M*8&D0GK#"+6"+J_*XD%E%*=_2*:0*C'64PL1-0?HFH:!RN-SS<)"XU:R=EAH M,SS4-%@:VH@K.^5)WY2RAE#HGJ76#A)%YWHT"X1:)=$U1$>+"1\Z=8%C1JXU M!HW+R)7%HDG-M[(@-#L55Q@69=KM<]=-)ZDOCF_XC8=Q_$<`DOG>WW!)O>`- M&X6<7=/OQ7:5MO.N[,PIS3$KIV)`4"\U%6FSFTBL0RY%J9.>#AF!U$E/Y>7X M#33&8DVYE7=K6&54EG\5AZF=;ZYJM4'SM%2DR<\[];5&"FM$2Z;0)/R\FP/5 M2G<%=[=22V$?X*JDY-6T\HY;Y!3GF+73JR7344U%FC+3S+L2H4XZJR9_U4]/ MU;3Z^NFIM&;?;**C/T)?M#+JVN$82MV8H&GNJJ&6"DT4:QZM&M&**92[-I!B M&C9ADY`GXNV+,-YT;/!.)_9VG'[N_'OYN^4+>^2V9Y=]G-6M>;%=D_O]W"FD MHAK8,QTT#4M[\(]P[H*J52]U-][<`X_**J-@YZM9J27LMK-;_BS[H+(JO&I' MV8H772.3>T18304<89&IHC4O=!@?165BY1SD(UXP]$>\\LOT_3U>_]<___$/\5JT M^M*9$26O1E"+TQ&=>/[#V;4W83'YQ.[)UW!"@^Q>#$[CC)CBV7EALC1Q=U;@ MT(LCGSZ<>8'O!6SIQ<5[/]%)]"JXB:.L-N*19=E^B9:OEBIX[PV3,92SK`NY M;2YQF>]'=#CT@MO7)\:)O(XCZLZNIP7J;1;7=[+_(BU%_[1'Z,^EL@6H5G"EZ6BUQCDJ">P!CD$M3?/D^1IW>FT'>#6E7Q)&9V:4D`#"/O+#VX'XE\QN M2M(]>3"[J8S9O7@@S5A:%F\]8*(CEU(>=+IS@Y=4#OYX.$ MU,CC.8\=!<(`J]#BE$;.F&I$VJ=J2ZNX0J8;TY35L0-L)\,P%2?@*'AV@N)@ MS';`03`4``-=!;H*=<%`5Z$0&.@JT%6H"P:Z"H7`0%>!KD)=,*9]/`B&"F!4 MT%>ERIA]=BG.T5WO`IS=Q=."-YX6;!_BM&`33PM>;\.[M3I229R__FR-NT[; MQC.5=N/CEN..WC)W_;!@<_6P8$?I)D6'XX^>:<[E"YA[SL.!Z^=FMLVR- M=@_=;*ED/>9AP4A6)"L>97K(PX+1PM#"T,(.>E@PFAB:6"%N?D[&RUGM]9@& MAS2%:S81&\_SAT-^Y/TDHAX7A_HL*O9ADR=!"T0+K-P"\;AN5:QAQ_ZJ#1-X MS09N>7CDX[J[RJP'/\*B',M0I;**+G,P!NV.LCMYV4;+,`N>>X9T1[IK0G>K MX+HUI#I2?0>JX^:>:%!H4&A0:%!H4&H:5-6YAU/"VFLU&*!`ITX3NF[H+0O< M0W;<:,*9?;O%*S5XI]7K%#HT$"$Z,$2(CLKHO"RZ8UFWUOON[`HE9A-HS]4W MB(8:PYD:Q;G-&KR\"+F8CY(PX%J"(Y;E>P`UL^.^T>KW"_D&A%5!6`ONZHF( M*H?H2],\J)EBO+X=?XSDT7%HYSB@A>_U"K4'V/]=^_[OBW`R8=SUJ$\B&C&. M:;Z6:;[3+6&274PY?" M$;D>,T[O:.`R\L8+(_C[A&(ZWXQTWC1:5AE1/L**W7M('"0.$J>A#4=&5`M]4Q>S@P@`,#S]C'QS!@#P2$_HLE9`08XY1X#3L:!IV6,2AA M^D#-(<(X#DF`)$`2(`F0!-JWV(T<&FC$H3.JFFCE"FG8YHW:X()$1:)J@0L2 M%8FJ!2Y(5"2J%K@@49&H6N"B6C)=F4+*2L7+GZ5G&6U+U7&RZS"A_L$\I/9# MK'FM#+?:TWFK/:O?:3G]0GOM(=^1[]KPW<9M%I#JS:#Z2]/"N8('22S0+K2V M"YQ%BY:!EK$Q&3!;7:?022@XO_@P/2IZ=DSI%U4KKJJIARVK@QDLA`S#],9G MN7N8$:;\3AYA4ALF=#SH>.H%$SH>+6!"QX..IUXPH>/1`B9T/.AXZ@43.AXM M8$+'@XZG7C"AX]$")I4&)%29()I=4N#:^@C0[.ZFFN\W[+*ECL_5:BYJM"[F MVI!6)F1F9^`ZIY>9V1A+Y]K)FLW>SX0"D5^?F/()\H1*"WYX^76R?/'O7]+X M]);2Z.S\CGJ^@.-=R*^HSZZ8FW(O\5A\S;XG;_S0_>O7?_V3D'_/7GA#8R_^ M/#IW7:!T`O3]$OJ>^Y#]__P=XD)=X.(K&[T^>9MRFGAA\,V$?RW#['R[#K\- MOMF&O#CY=5JSN90%:ED$G0*\,W;AW:;AWEPTK$;2^\SAW(3^<%J2>/;,2\#W MN1LK(RDB=A[]PEG,@D2"KUR]RD9@>5*YW3VFZ-=C1BC8XR2BP0-8)$D#F@Z] MA(GU(T*@./M-KN>@XL\C+Z"!/+\A!G28.,0X)F-ZQ\@-8P&).(LHA^>\0!;, MAW+WV'LO&9/L[&,6,$Y]_T'<9I$HDLX=`KSN0>&1#S5^N=A9XN+5;^?G7Q;7 M;U_]3$8AAV\DC'N3)9F\`/X^D:QIDW/Y?2C6?VB19,P>(%01A\[!4ZZ?#J'F MOB^X!K>67R0T&&9GTQ'._IMZHC8W#T2((+\JM.6SA&U419N\#TB82_U$ M6GL8LE@'HDMC.AP'3@ MF:'G0KE0SA3FC=\D20AJ)NQ[Q%RINFEM'ACEA`6"0>0M%#NY87QAZ[;9(J(1 M(O`T&`\)X16H/`@5#MOHLE1W6?$X3/VAP)TS*MT5O/-G&KB2MM)?"0[L9EN9 MUQ!$8,"IJ:7)PH41G`=!"N]\95'($V'*$#A-%DB8QNGOC[@';S])/0<$\>&! MN;"+"$Q*<_G='=/@EA%QZ(X7QZ)B*U[UZO)BU:D*F=@-3\&F%U^S>AG1GR-U MC'KD_=@CZ?P.?/D.?UNEWO0[1N5J[>S5O^=T#R/F%]F4 MO0]<<)`Q`R\D?SZ;GCG+Z=EV'9]:]L#.PXW-HARH$FLYYM9*F'VCXY15B="' ME%H`@E6H^%=.4ST3C"@9UU`1Z MM4YVFZPPABQ1)JY]#*H$(-MZ-#ZQ!"*^.Q:`HQ_Q<-)DP*I+&@0*?!D%=P4% MNH3"[+Z(]5*9#"\212_7?W>)H^^G.6)SWS?$]\9^5DN M"ND]5&\JC>@`6`CC97T!3R0]2YG)2K+;!C:.0`"HPB>1K2SE'S)I,"&W6,X1 MWK+8Y5XT2^8_+[XOGKY*)Q/1`0!WKKS;P!M!O@W57P3+1,;)WO0[TT1#OKKR MD>4J+CZQ\H[(C$8IE]I;[N9!JSF*U7#FA@#PWP!0"K)P:0#`<')^R]F4:/=4 M]D>-@-OA?7Q6*V260I[9MCG+T9$XX[BL_NO]UP9\M.3Y;=-KO:[_2TMZ[WHN/F$'Q>U/48 MO-\"LH_PQ'BI3;T4/7B+RRLQX+'6EV>T#L!LJ]TIR=0U8796861V>5D+SFN1*>C4T,249X\'"R;46-1RA'V$>TIL_1O+[9LFSMPB&WB M^NW^LTK+6>.#;!-G=EN]0;=X^Z\&)8[`?_/9'?^0_YKQWVX-N@7W#T7ZZT/_ MAK/=,5I]$[T]TKT9=.^U!IU"QV&8Y290VNZ`N]\D&2WRQ0\LCL$G80\\?Z> MK\YS:21GKXJ)72,&`D34&XK9@'<-8$SEZK:YK%([#ZH5E12*;GED>J M!DZ5*Z1A4Y"TP>58(^;:**1AH^O:X()$1:)J@0L2%8FJ!2['FI*DO$+*RG": M=9!]-GWI8;;`^&!IDO9C&GNG0$J.5)EVRW8*=934;&!VY^9-25A[U@`QK1FF MMM%R'(2U=K`ZA::!X4R!VL\4N$HX3=BMYXI-@CVY@?,I^7C^YIQ$/+SE=%*+ M/NV&30:PK!*BKAKC4_4(HM4S$!^%\>EV"QTQC_@<&)]^&< MJO%'Y0K!,74U<5&M(:E<(3@"I"8N2%0DJA:X(%&1J%K@HEJ.@F/J6HVI7X<) M]4FPON7\;U>_'RQCTGX@(&]E-=\.I.$+9$V[U<'M#W:@.ZX'UYGN@P&.VR/7 MF\%UVVR99@GK8M5@`-(=Z?Y$-,R<:L/%3-$/1-M_7(]Y54E,\6R.LS`0L@P M3,7I4GE[S!"F_"X>85(;)I5",\55-0WLD-%JPX2.1PN8T/&@XZD73.AXM(`) M'0\ZGGK!A(Y'"YA4ZA=49=Y)=BG.]E[OAIW=U><$\R-+*FZ=R:V%W8VR?Q#K M"2_$R>=@O'([8O7J4+*VE^<'V=UCBGX>R_V?_K\%?7TO$A>(*G_1_NJW2+_2R,:2-5=ICR,6$O_BE<3,2D/&D[RHV49;6/A1>!Q']Q>2ZRR%J9W/_;`(._I=`]V^`E_?,O< M]8.US181Y\BUR;DO3B^^'0N)QO2.0=1#1BD'F?F2+""9$'PF+GQQ)IJLB@N* M\L140?B;+"0,;D,A[I#=,3^,Y+M"2VXXF3#N>F*S^&S[>.HFWITGCR"#>`$^ M^EA;\"<*KX.VV/>(N5-ES;\9WDW?\KT1FWDF.G^[3:[A>DVMLPWJQ88`K>PW=/4GX.YCR""#.]CX%#G!9D:XLCC<4)^M)>=[4WF;`74 M4T+<^N'-=+9TQ@+AY*"04$'F1Q=W[L/4'X([FMX6+BS,'&24\BB,L[*3L1=/^?P`_LYW M4U\6U";OX.E0^O^ISXD7)4@_?Q&)PTUAC4(@T3*M;GW8)N\#$@%CPB%X@#$+5@_I MF=6`?7<9&PHQ)F$J0JLER8276"NU!2Y+A'MW;+X81(26G$50-KP"P6Z8H%Q%7G#Z>312K\:U\2F?`_*1\E(9E69C,&D4^PR:1/S]5 M:QD5D66U1"+#Z9U,+-]X832F_\_>DRVWC23YOA'[#Q6:GHWN"(I-@+<]=H0L MVS.:;5M:2^Z)?5)`8%'$-`BPJP#)VJ_?S"I55>E2G& MEMH?D*X\2VV+2=`%>J>W,FZGX]EN.-"."O<&D7OE+W11;=<2SO`%+Q[YS[%W M`OZNDQ@9#L"K+I\"5H&DQ9U'MA4^)'M)G=V$0H86WHG0!B-X[_DS^K^6A'6D M0-?8PXL.,(U]=)3D:C0H=U3=K#2JY&B$,9N+P`(<>R&ZP8B4A<^0\!]<&\C$ MB,/RHIG8@?4#H[=L`(XJL,U@W?U:_X-K/<25*$MHY>O0_Y16:#*\H^ MA$%DG*H'P<[E(%N''O^!CC'L,G7V,10Q1WD@;0Q8(QA)$`'PZYZCP0]@V[`J;04"CWVV',%^MUS81U^Q/T5&?U2A9Z45W:C`V.:9M\6M*$NQ*(JLX5B*&\" MX@3X!W]Z&`8@%U$D4)%C$I-#!VZ4VHYMZDB[9GM0H@C_U.PT%T14E=WN^0$; MX#X$QFSX`/:LIVSAQ.B7;*"#GBIB8-F!UA$J`&F/'&`''375FSER1Z"CG.Y+ MK+_BR.H$E)P_!CWD!>Y+!'.\E:1"WW\KT4BGZ!M_ M?1M]U1GW[.`RQ7C3[C3PP;LS0_OP2[*Q>[XX>SO+?OG;KZ$\?[2LR9M,D..) M7PCEEB/&/SK2=GU4TG<@&A]:%-TCTAXW8_R&= M-Y[COCL+1,C/F#-X=W8%&]AYHV$VS[19^".`S>3=V86\OQ[>&^9]T[C'/>8, MF,G1/WV'#X9YQG[=^;WS+^K?-QOXGO9>[UF`FZEWP5ZN&/+>N%>K:M_?^9E7 MOX\HF5!E#ZKNPXVE5MB3T`-EH-!\CL?%WH#M![\]'G`)S[IHXP&,K85KZM=9 MAFF4CIIBF\IOHJ^)^K5U%!SM]+^'%FBT@),!)OM2SQP@:;-:.ZP0O MS$5*2'2Z;OTP&+%;<-(^`U7`\;']&KL$$L)N[3F6=ALM*9U'3QLWBWR6.ON' M_PR6@0`_;HE7HYX#MP_XT%*E'1YS0"`5(-E\K\Y9Q[D%Y0.YCC*PP$'7Q2#> MP`5?2LER,`KU'$0;1PVIHPX`-%2@W%K_']I$V^BRPGAP` MST-@XR#NV'K!MX+3-XX2&]K&"S"[,[T"\/N5:[C2#55^N6JT`WX=O`XAG'Y, M_&81(K\(E:+_8KVD#S,;9J.FJ?>3V:\;;!SGC]!(MBTAE(WYI%S(..&CWY%0 M0$5S?S+J3998O>M@5]A"[YP/79V+QP"!:&/&#Y2JF MD"/.3R"Y722E?SOAJL[@-R3;'9+M&U>>E:\K6JZ`+MK?N<3LPP5FI22[6="] MOPCKK\X6<>6AH!E*>SXJ.07O,Z)5*F)BBE9.0BN5*7KPO1!L*DTQK)6)XI\8 M7_9?.(^*8J(+E(H>H"8+P/A]Y$+I@">L6@$%\F"AT"8%*C-^;?SDK%.*HN[H M&B%5!&.!]_;C_(5;H-D!<4-@GRB9B>M,M-O26%HGTM"ZWF<0K0(AJ+[".&JY M)]!W-F%AQ!F+9PPY(">JNH!580_!_PP=Z01\&9/$Y0FZY`+#U?8H+N22"9>J MFC;A/RB3`QBBAGM57)!:8S_!%C@?Q$$.304BSH+J'.94XE-MR)B$F(XE+UV^ MROU:__8%&FU)W9T36QQZ6QR@T19S;9K_C$L(MTV;8HIWQ@2(0=&V1&:I&-CJ MU]OS&%F,[+A@D`3JH'K=7I%XU80$GQAY5(?HM(.,=IJNKHXLYK$_<(:./94H M3,W(B*1R)NZ9"E)DO"X11O`H?-AJ@KC89_KAF/?7BGU6.M$.#6'Q?W#W!5^I MZH_`0)>X3:6/\@"W,AH-I%,M'%1&E%A\69HMO)M=MF7_X?G/+A\\1DB92CY. M4"\%N(9(S&-4+=F](B2"-`.;@"`MP4V4`(*5CCE&;!U?Q,'?#!7U'HIKD%P\ M.38_UUMHO*&JVK`8D_&KE>AJ7$9[LRK04/%E\*_"3'6LC%&!BF-NMT?!;RP2 M?!3Q8>@"=52Y":SZGZ''IY1)6[]Z`2_-0ZGQ`&L9F.![`&11WCX+B&TMJF"&^<:N\UB((&\9"")>]+P\`MZ)Y7O"I M7^5%&(S`.OF_&4JO0UP6KO/FV7NS$?W?0MAF7[4/3$MQ=5"0KJ0,]T21871: MK?9J>/1K=H5E8]081K?=W0\4Q6/788"A=Q4&SV:7VUMGE^=1M0RZV1=O#N%V M>>@YC'5VAF@B^`@K'9[XE0?^"/_*@^OAG?5C#QML#L!SHVWV^MU9&)>]>D\8 M-S*[YF$TVT9WCK`'`G$C0VL!B&:_TWQ=+&X+8JN].X1Q-`A>_[LE5);M2I7W MRN`3GDY[N8'?[1>JHSCA]$W,&"SF#*98XQ1*)XYZ1)1C1A4KVS&KZ3][7,B1 M,ZDI61111E@5P$=EN1%Q,/L2T4=GVZ/8.>;EX&]\MZ^R# M"F/Y.I\;H4%7!L`:LOD`5;$N>%0P"$I18/;HRA;/9"A2LM MA*<&GVPKE#RY3BW"?]:EW`-'<%MG.CB\V!\[MH4A-:S"4,%)/.>>%E;J-R=H M3JLIU*F'!^F+!^;Z4A_)K+$H-)]4T,>GCS7N`EW37\-'ZD!=NM2)+YTD&9A9 M=R;I$,,2E;7B>72ABFCCPZ'1X3'8H_`PP@F']#;>$-/OT9PHK2PP?J^<%(_+@'UQ23RF;=,-LSJ]./ M76^.@Z7;GW5@UJ+I\'A-/O[#`?$0]NCE-ZR>7HS:*V\"3H.ZP)A!9X5(5142 MF=4E4=6DJ5E=4KT^B1)'KXKH-#K]9L<\!N>O1"MM(T5G?-I%JBY+M(FLH]!M M^*`/.(-+AS?#`G%YZ.1GD@%&;\]D@-EN&XW^,KY:#L0N<&]DH6!9,WKX>"\2 M+4_2''>QFP>A"P)GB6B"O^G;)+C_T0/XX,J3@0A10633;L;2A$$[R;ND7W)` M0O*,VS@&=NE:$M21RG!-*;=,YFLQ`N=RUD;;Z+<:9HJ^[7"Q"H_746&=TIJJ ML&T)ZG;,JC7-9M^8(OW:]^<)[I:IH?W`3-&?89'T&3?"L;FQ2$5&&K)Y"&F< MKX`PN_5N?WJA&T&>WX([,?^\TH*->M,\ZH(+JVJ*B*R#;DY3"S8Q=%/O=E]C MN=]0+ZU65DU45@=5!LWLZEMG[YOM>K_?:&ZU?KV07->?Z@-`P$&5PRP"6IUZ MO]';C@$.@("%N]5KK+_=J+=[1B_G]7^V;*YWR=?>[:9W]#:HLYZJTYHU0!;! MNO.*6MMS;/^S\X,/`),1FP^S/Z/AO^JC(#7:=O,-V898ZI"(_ MO&1_29__]]O_WA`SK?9<>=]NF(D\WJ/ET-9:=9UVL]WHK%QI]*+#++3`T+"X^P5XH.5Y;=7B-@=D=]>)0^SGC>:S5ZO?TC>*&MBI*BL46I-5$YN*[\B MBJN2T,+39THBP\]Z7*C/7\WI:ZL3,*:1/4:T.>@Y+KD41G-S)EH`J%L:.=L& M;T,N!!]D3Y1G6A;^RPE&5YYJ:1Q:;O:B3U&7A+4!VN:<>;#5.S_]B'HSJ3"R M*BZ-NZE>>(,;'Y;,`T?+UH>H`O+#"](,TV\+7I05T/B"#W@V>D-?1860I[78 M?BC<@R`?'5B^\Q`JCKK!`]OSS-VN&O[G?>A],+8']K_%+4MN]0G^&U4;NSJL M8JBX6FPR&R6AR?N;SO_NB/`E2%J,]F\8YX'_.DORSV9CW\-HC?9"WEGTXBU` MW"?[NDR=;`.2:BA]N2!?W]D;7SUS"739=VX$USY(ZO66T6UC,)9PE+DGAIK= M7F\5:!L2+R=F:C;-9=RT!IJ)P-YA*,KPV>5*IKW!U(";''.QO>X*ONS"7PFKWZ-,)FE[\#>G+-R1P7/=B0 MLY,S>G)-V1P9/=UZH[43>L`"NA[^`]L^+=,`S0-E.5\38W.F<;/3FS,F%N!D M!FU)=>#U,&O11>XIWB?G[4SJTGX*IXNG0>_4F2K?.-='/+/,4KBUE!GKZ\YT M:R62Z;Q[XUK5I\!QQ\F`_C+90L2SG_%<;/;'B.VMF]I M'HW12ML(6O&T*X4@1^+@-YMGYGTG>-5=!9LU\"%J;=.H?CO20FF?F!'47H`3 M^O3\-E)"AQT)D1HNMHL*\1OIT>W,STPI"=6>(15Q-+D@F\453#K1VB/MN M3ZP7X;LN6)S1>%F0_P`[E"H_A/^I&H/[K(>SL74;4%>U0XB^#'%0G1X6F!TV M$*N[J"_T`P=$>Y%*5+T0AD/=)%7W'<#>!]&ET81%U1<6-!APJU(=R2+T#;H# M`BY_6OVBVN)V&.BI[0/5@=R%Q^A73[U3Z32SE6F5ZJO6S]BY.8P'6:O.M0J6 M68BQ9ZVO.F(,X&9J:5MH3?GK(&'>=1S5< MP\[8@E$?WN@IZ3#->.XEML?-/'&:]QQL3O$RNW!LF6W6VHT&[#$S=V*7BN3J MS&A.U=L$^>Q1<&QBH2=9_F2V:^`@Q:^Q+1>KOXT,BIO,*_=%R76F$?JY/KRRASW0X7=+ M9PCUI&;M5OR(]T+8.,&2$'7V=^YQ@?V2:M/-X_,>0/+H6ZY4O3*>:F:_H:R- MS>?R;"U)CAX#5,))/9%(+9G8DS)-\NEU1\W$Z(K]EZVFSF3#'.N4`(YBZ"X: M+;Q\!HL>T)"93;-D])O16HC(M2-&<,^@$2.G.6*$ZQBGQF9-7:,[(O[4K/<6 MSPO),*(>0C+0$Z65$,`>^L1C)U<[8@N0P8 MWF*#J$$_CIY*(@&PJPS4%)G,_$]_CC1:VRK#TL/E8[,$#$RK9OC^DN&AN&(< M+_K"FO5V[.)-7SP5<\K0`N!V1,*-46].!PD0C?B36P?]H@E$\M2*9H2[NI;CD7RDY=E M3EE4!5RX)5;'C+]=9X+-#.3;8>H>"J2;2E$R4V+Q[`R"$3PG6XT1*/5D MPXXXP9W.>WQWAB6Z\%U.+#O^'CT`>^MP`7Z-ZUH3R=_$'][J)\/2&O5&6KRA M:SGF5AN(Y*O^/L!`K_/HX0N"P!^?30/<,M1#(_AF'KB<'(B^\Y$6Z M?]V41+V95VQ.I-X:&DW3)Z)7,-@.(0VSWLX)(4JFU;O>H`?+Q<9<;,[A:'K% M&RP2V`>8S,-S1*L7;';4@B/V"_S)&V,28/2)L[]\[.,_+/Y1\=S27_73U>]* M);"_Z%/KR06ZWFC^_J/B>B=V7%P+E#SJ#H>@IB3[HE)BZ?=/.!8U_;K8;B+. M)LXN'F=_=;P",G9^>]A1&%M_%WGLXR7G]2-R]L]77DJQ8.2'$MQ*^0NIX;5J MV%RCA@VS"JQ9*#6,,17B3.+,0G)FBSB3.+.0G$DZDSBSF)QY")UY6EX1<.(2 ME\BR_W@4?N@-,+;JBS?L+Y>7GSY]_KPM:EC\_T:C;JS"5!3&9^?1A;O%KC?D MK9GP]3`%LT^1.,R!],\^6&WGT,CAKI\TB#L>,YJB3<>>+YBTV.<;0"1\V.:^F9K5Z>>Q[1ZF"T M:M::W3;1JA2T:M7:S0[1JA2T,HQ:MY^38+UZX6P)S9R]EKN[!5.R.N'2(.3$ MDH2EH0LQ*C%J*>A"C$J,6@JZ$*,2HY:"+D7S48Z&D+P\G/S+A0^F3TN?2]A95Q8R5V346IU.F6O-9TF(=21CL)S1TZ(*Z]$10GF/ M8M*%&)48M11T(48E1BT%78A1B5%+09>B^2A4\E"JDH>[C0;/'$R%EC[)LJD8 MTDGA,I\4INH/XOM3Y'NJBB&^/T6^IVHAXOL#\GVGJ'QO=FH-(R?&IRJJP[B5 MY?3.RZ:I&)%$\I MR$2*AQ1/M M*?"+(,V6N30[KPGZA63^D"V>O[8DL_`:U_6?Y1OVDU'O,EBUBX\7 MW+6BJT,/KX?/JA*'^1-UX/0M^\FL&RNO_W;['2[#GM0_]==>"LCXV?%L-T0! M8Q,N`';`N,W/]7'71Z"/O@P7]3QR[!$+1CQ[);X!'@=J3[)G+C@;$"+,:!? MO>P!+A;^`W(R(LRR1PY_XCARZ9?ZCKQ#7+X!EP>*3@&\`]&.GV\GCG=^/1S6 MF.6ZS`\#&0"7(-VG6*RF.$@QD"+\B+L#]O""###F@O'QQ/5?.-=7#!R0E,`7 M<-?SR&>!L#PYY$)HVM^-N+">%)-\ M2!F.)_.']HNPKNIHG:]^(AA*RA]!'T2[HU9'(\&YDAD/'L'&\(@1;)(`ZF#5 MCEQ]H3D>R4!),:#2H]Z=4REAH=1*'/7Q&-0?&UJ.0$L^5)?&^\#TYI%0?!`* M5,F[$[TU:RE5B@QKPHN4%)]H0Q_9G/7C7R?=V>-,_5=3BP[_AX](')! MP6ERK8GD;^(/;_636:^C_"N-$^WI*A:;7NV*"H:%7EN[5V]U7O4@P4ZC9=6M MO34TRBM^AF'.TLZ3C1>Y^;&>;KU9_F,]A9IT?(>J,B79%Z4JT^^?4&?.<>Z# M8+_&G_=\_V)U3+)"LE(\6?D*%YZ"J!AU(Z=]M@QCRLG6(/U)^O,U]"?Z6,29 MQ)DGPYFGM9'.'SN(=M'\3[,7N:WK-T?^<3[$`)2#A.(R8,(*#G-\??7IM9*< M;ME9`1;R^))1[W?_FM>Q/:+OP19^U!:>1KW3^NNY66^T_WJP;:?T?)/7]E/% M3>934N7!Q1@+*M@+MX3\I=#F=8%US3%WC-Q&%9\`G4JO^=OGG4([&B72ZZ?E M5OSNNU;@N$[P0I[$:7@2[1[Y$>1'K-Y-S+^>=QKD0Y`/L0/S?'2>''C[@+TX MW)W/7)+G4'C/H97K!D&$*CRAR,ZOO)W_+P4/'YQ;3UQ8CSRIAAW,E,,NK((E MWV!?L^?P%N-KG_YZJ-/- MTW"NX=?-SVYDP9SAA>S9BO2HA2[8B<]U)"N+[]=``D[RQU"%+ M>0=B\\$%N^?]?_X'8W_+/LR/9N5>QZ-RKSS;'_/??"D_"W^\$*/ZLC0S0A> M<1T&-UPX_N`#'_J"ZYOOK!_JM">\]1L?OCN#Z]5]]P;\@S5#]W?^??^^V5!? MSECH.?K"[_#!`+]DP&VPW5SY[NR\>?;^O-_J-UN-1F,:#0>"O!@H:F=1U%Z+ MHB.A9N)+R_T[J+O)57PT?>&SO_$G#G_(DRF:AMF?98DMP3GHP9^IIC#K+\@6[7CPPO0AKJX#$3!Y[JBQ<\.??<&&H0A& M7##'4SU"U/E[^-]T#PK!AW!)X+.O?I`%FOU7,E#Y\NU'+FWA3/03AAD^4I#? MAF/`_(MJYP(FM#-T;`O@O[!ML)15$XD;WW5LA\OTF1_?UK$O`]A=Z0W8]L'W MT**)6V6L1I"?@%&+6J*`9<0F>),Z^VQ)-LBR?WI]C`;X;8#-)3!NZJEJ;TNW M>H'_C&-`IEZ#I^GI,/3^AZ&[S;G#T-UY?V'K`TK]NO&Z4]6*?D"I66_E7R!T MQ&,@[35IC6:G;K3H&,A6[)C#`<_DZRL>QVR>T"F25=JNY+Q^1,[^^&UV>6.$L^2LV:AU#!ZY,29Q)F%Y,S#G!,]I1U^0:%'M+V? M5*''5QZ`UZ_BGI+];!QN+RY]*F]3(6K3W+\U.T*KWFM5NB`Z#;NU#A=C*`:/ MD4"50*".61/2K!EF?W^SI!@,4`#SI(I&"&;2=UZTFQ(3 M''4'^+G?JO6;K?WW@#)L[]NIJ9E-07^EX2<'Z?8MN.JL[?G,&4\L.XASWLNV M'&L8<#&5O,>LO2XCB/QES))'XQ+D3*_W35N\JV>@:JM6K_>%J>V9S/:"U/>Z M;'?R`)%\&LRHB@3<++[2W]*535V9*3C5XKG('(L^*R4W_61FFO4&/I#%B&39 M,ML$Y0E`VU`M0^RS:562I>#6+*&>K9\X%_A)E=-D6C<-EN'=:*U`O/HQ\W%+ M(DSA/4N1`^%V.^'0[D@4C%X05)L(!]X"P*B:%T5:OQX*/B>>+, M$FHL@2Z'0>TP$?X@!'TE+9?+.ONVX:VH[#)S69*2)NL1]).JYU%C7;Z=W^"` M%G;YS]O+N*P';]U@I`T6YEBJ+FIVU$Z=W62!CH9B<(_K6BP%B_X%;OS]ZL/% MW=7O>4T^PEZQN&^HMIMT_N.4&(UL7=_EX/%L`H3#'`D\K.[5B"BW"Y:4_!L'` MS28FZM`1(+!_AH`G341=61B+;U36AJQ;QY93@CS,R0WTB+1(\H'M1@L8::%J2%X:CY=+3IL^^D]<>*BNSD%_ZW)! MP1_@OUHYVL#+CQRC0P!9`A#630XYAS^E3XKA$CP(151)Z:MZ37@Q_(!&7WT. MH0OWI%]3^V-K#KT\KHV,1ET%3;H3#+HUPS M>\Q!O57=VY^Z%VT[)U!+Q2LN_6C,Z^PQ"<4T"TYRY&4:S'ZNUFG:O8[*S1Z\ MTXVA)%+.]Q3M+Y&;\CHGV#Y[W^L:2CZS:UC\UGU@Z^X$F]G?#;9/E@`M]RAO MN(B/+COVA3?XZ+AAH$_>['AJM)T%T3Q[?V[4F]T4O#4OS@'*[DY0PH[0?TTH M-V+%!5":C2/@]&8$Q!:0YX!+6'9TU MZPR#IJH0`+8(ICBD4AF18N7#E*2J:(L;HUPBRG&8-]J32F\\O(!="EL..@G) MI3H,R9YG&X2E<4[U(.6NV&J?8E&/L'3P>HVY'![UC6.X1C605WL9N]`#Q7_. MVFTXBSUKG_W"9/CP;ZX#3&"=#;D3@!&!)Z^UMCOVHG!V_$(0:VSBHAGLNEE+ M/GZ];(&NC[';@E M\N>B@%=\J^1V*``2+JN5?BR6L'W>;PIXDB*N:<+A26OXR\.\"&?IKP.K:"\& MCHT>([IG2WE%7:Q#`G%^1IW7MEP[="WML5K*"W4$X\,A,K>:4PT/.X_9J?H\ M])H;Y(J<@'KT!:+^8RS)MXDD%VYIU1%D;*"@.Q&@`HXD"(,=3Y:+@86L,'E^ M$$=ODK"AWH2LN*W#8/F.]>UA M93@&O&H?+SFO'Y&S7Z_11T74\.HS'&85V+%0JEY! MW$CKDL@XWK&*#L\"86-$P#4!0=3G*5OC;&5`BUDDY-VK=%MI`LF MFE:`IIU:MVL032M%TW:MU>X332M%TT[--'KYT#1GRZ>TK:9VRV.7PM#[[CUQ MB::3G,?B3Z'H4\SIRV2Z%-L^7GU M"K0B&"JG%:NZU56F6-6O2B)5EQC;!\-&R*BR5'\+'-65(<3`L..I)AB>'_## MF3VEMYS+[PT99JW?:)&+6S6B&@V*+U:.J"2I%21J;I)*T:C#&'E[(6)W^^T5 MSUL0JLI0D$%4(H8FACXQ*A%#$T-7BDK$T,30E:)2H?RNHZ$J+Z^MB@'XDIR8 M+UC`YJAAF7ZMU6E2!K2P!#(;M4Z;"%1H`AF-7,MAB4#Y$RC7R'-)"'0D2Z6< M9EU1!;38",G;<0-N9P,_Q.J,`C:$*#@QB#N).XM+#.).XL[B$H.XD[BSN,0X M@M]1E/BJ_EJ-R<]'&Q5GI#U-LPC+_)BNK9&]=-]A<4:OW,/B]I[^VUB!>/QM MYW%]99T4)UFKWDCFD$4=)6JL46\F?Q3I]`/=+0)'KT2#81OU7G)=F#VQB".W M+(!$S3&(IKRE0[2>1[YN/KW)^%=''1KPN)KMIF]HSY)>R_0WN8B[=W:2'L;&=5?`.V] MU;`14M[!*8QJ7#J,;69F6T26;]Q%FO[F6`^.JZ:,7(;`GK`<9_#N[`J8Z;S1 M,)IG4Z/<+N3]]?#>,.^;QL)!?=,3#YMG[XU^NS\U\'#MZ[>%=AZ\#>A36G1]8;O;W2U\&7_W@?SE`FHC!BE7= M1V^_5\^[>YGPBQ^.3/Z:P(1R?:WTW!>E&-9.IS2Z,\,I#[:\XF,QG6.F\+@A M!N?&>Q(&8PPBPN2WV^\;8M(\$B8_6X[XW7)#?B$E#^2%E]4!7[B%PVT'U]XW M',V$NS%<`"\5\5>SK@V-%^(Y@L=<0J+8:P9P])NTQB6 M;?EQ31_A3S*`S23(#EM!S9Y^4SH^_1II=APEGQG78F4^^\/T\Y*Y+EV>Y_XT\\X[\9Q*7$ MI87G4I.XE+BT\%S:)"XE+BT>EZJR$,K'[>DZG>SD!OSIC0,LY-@+"U@.G`$H M1A.S8ZC`@RY\KG=+82(R1'8B.Y&=R$YDKS#9B]2@M``V9#4LQ6F[\'O]MLX> M_2:'=Y`*)B&&^[I+RH/I/^1,7>+?7.VYGPFZMW>A0YTCB MU(TX]:A;=QZH40SREQ]XXK'8)QY(!$@$2`1(!(HH`A6Q5TZRD7+58_JK/37K MD7OV(?VTTOO]%0OWE&;#),8IU*C83K_6[YIY^L5$8-(,Q#BD&2A7<%*Y@DM? M3'QA!1RX+J`$P:ZZ@+8*8H+C3G#JUEJ]4TZ4D,22Q)ZLQ%*HL/*APDM_/.;" M=BR73:S)@D8*Y,]1((`"`<5BG&/N+^U6K=N@$"%I!M(,!62A"C$J,6@JZ%,U'.1I"\O)P\J^#,!MU MLZC1:-53#T<%\T"R<30GD5D!X_$D+C:T'(%H"^?;W5-&:TMIQ).EQ5AL'LQS MN#.G!$I!)E(\I'BJ1292/*4@4Z'B@J4OB*G&(4S\ M:=7TO]\^) MB\!!QT:&Z-$XGJHE5EUQV2#DS&R8AQLS7PS+GVIA2E`+0\5E)%`D4#D*U%'K ME#O]6K-#7?J(\VDKH:V$!*KD`E69K:1(^8@".,-5='F_^MZYX+8?"LFGW=P^ MY1-*&`8KS7Y:<28XYA[0ZK1J;9.Z?)+(DLB>HLB>9*;B)&ICBBJM1T<(M7DJ M)EV(48E12T$78E1BU%+0A1B5&+44="F:CW(TA.3EX9QBA\>TB2/SA\Q]A6+W MTF<[*,]'B?,B10V+P6,D4"40J&-&8#O-9JW7ZU,-%G$^;26TE9!`%5Z@.B>Q ME5`-%O6*++.V+#BJJ(%)&:I$ICJP1F0I-ID+%!8M26J._6L!KLR'9^-=%*]\M%+YKCF1^D0GD MD^RW3*@Y%DR@=Q)K5JMD-G?=B-#OSAIGZKN<6';\/7I`)&_`(:XUD?Q-_.&M M?C(LK:&X22-%R_7\:E>$:Q>RZ.L?S.CMS(B]5S06",?.Z%7'FV/;!\%^ MC3_O^?(+.W">LEK<$G_PK`(?^N*0[[_"PF_'MMSTC1=2Q$=B)[)I#KE`MB0U;`4I^W"[_7;.GOTG[CP ML)Z+26Z'@D;2;R$B>#"&NKK$A]XV7,9!>K3K&1#,0XI!DH6W!2V8)+7TQ\8071N'GRN'?3!;15$!,<5>WW&K5NMWW" MF1*26)+8DY58"A56/E1XZ8_'7-B.Y;*)-5G02H'\.0H$4""@6(QSY$!`JT,3 M]$@SD&8H(.-413-0B+#R(<)K`4NRQ`N3(TO`F_PANQMQ83U9GLW9!\>?P-_' M%OF@Y?-!.[6VT:6@$06-2&")"8@)3D]K4^"P\H'#+[['7]A8M2QF0U@T51>> MB)_7;]<:?2H2HPC0\:T!8AQB'&(I;YQ9%J0"!1;79L],"U:.:GKDRSJ.@DOM*BZJN`(T9HN MMS@3<#L;^.&#RXLX:;7@Q(B4+1&C",0@54&JHKC$(%51(&*0JB!545QBD*HH M$#%(59"J*"XQ2%44B!A'B%65OH2@ZL<7\:=5@X]_K@%1 MF%0#,0ZI!LH@4,_"RFB%HZ.*F@.5C6+$W,3J:1."$U/5)UH>=A!=;5%U5<(10RY'B$(-:CA2(&*0J2%44 MEQBD*@I$#%(5I"J*2PQ2%04B!JD*4A7%)0:IB@(1XX1['NJO%O#-;#`P_G71 MRG>+R*U9XZI5):!.9L&&"K[XGXJ\?+.G(.R3G'?\1?'!]^X_W__D?C/TM?O[?+X%D-JP:[OW&A^_./H;""AS?NS?@'[-AM._O_/O^?;.A MOSCJMOOT[BLI0RXN?CCR/AB)'_=W(RZL)\NS^0?'GXPL,;:^\/$#%V\-42BQ%S%K`5Z_S%C&DD/B5!RO7V,JNL;4: MT.;9^Q4@3KTS+_"F2;`6/,!C:R4>5P')/2"?"RQV,1@[GB,#!.6)?_HQX9[D M>6+1[+7ZQC2`Z3=G2#M=9KF*P.Z(^5;?;-_')1N"6FKW=N']J$E+("% MRT1W?G2D[?JH*J?`O)#WU\.,^HJ><)\\X?H!C`2U$OGAY:L5P`.4+HLOO!'^ MA(O@Y3?0PSRY:U.-UIS5:*L`GU[CE6?[8XYB^UGXXTM8D^.%H.ZO`1P-;Y[" M>-[N=F:TQGH`\@%X-YD\-PVS:QP%X-UD\]QL-CK'`7@W$3T'&3TT1WS@0U]P M?=V=]8/+3S]`[G6_0/%R%?"Q!%,'%R5\%RS&QRM8GH#M_^B\OS/D1T;1SM+6 M;O5/!$6O*-]E1='K:917P]`-%^A)V6"!?'3<,."#6W!>]K%XV]GUF[#\1KUM M;K/V)2`==&4;Z8<%*S/Z15_91F*]8&7F5OQZ1)IMO;)&Z\`K0]M6/XD/T@>! MTWD]!%G.=0_OM_K-5;IE-2AY+V*W7;8@P.^V_Q4$^-UVIE<'_E5VFUY[MV7E M+NF'WX%`F>U(P^,N=J=-J:R+W6F?>I7%PM5I'"8)HV]#LO=1;B")\^^1)]@G MO[%'YJ:Q3>9FZ4F(=8F1F%6T#>J,Z>_6UV M7A/T?W$V<-0H"(:-1L6`66PB_"='@G0Q\/:8HPD1("'4'X(1?!L)SIGEP9WP M9#:&)X\DX[""`;OEDT!%9%.T-!LUAH)99W=SB;TM`8:7#_B0"P%O`IB8I=)T M`/S8<@#@T'5?F#\N.QCH%Q+9S!(!GC%'?O*?,-_@LML)*-/K(?Q16)ZT;$44^-\_0X^G MZS44-[5J+*9AQ`3!R`K8,X<=3]T><0FP00B_^2Q-AK(D&PJ,(T,7IZ%H5L#, M;7*W9)-0R-""M<'MMUR!D^'J3C>&7\4Y/,MEW_@3APV07?H#=8#>Z/DIM&7Z_>/;7VK(GSY<)I@UF;B.K6!*A%+&[U2O0!&\$RHM M_0(O?PQ=O>W6<;7)@AX5DH)`.`]AH)?H:SF.5AH_5,3.12U(2B2\,^"._CC7@ M!]QZ[@]0;0(&(N,G,%<58'P;D-=,[:SXT\,$((OP*2#`8?SPT0^`0RP]*WEP M;0Y\=+DFY#PIH,^```5%B9B7*&?HGO<*,O5%]TSQV\RS@/RO3/=\P9OX+I*$ MAK.F,]@5N,S_,L_%!::PP?CU'!:)QE@$PL0F\KFS3.:=<,S',K5S@8(J;D(_ M,(>-K:KB&1;,M@-(VUXX]`<%WIPR`2O)S5$!KJH'"<4WNV3\WVMG9!ANZ`3^ MK?Y*PJ9,QUQ?U;0\)9=/7R:TFP90=.=\B.7`>L<,9CV7C]QUP4WF+QGBG7BU M#&`]L/U3\7)EHG<^OF#E]"4#O.D%VZ!;/LB7PO:Y`$7FJ5P$GVO:*@;.S5XF ML!LBMUL-I)'Z7BI:A^HJ/LA-7R:TFS)MK[%E``S[(/`]4H^[]1A:T[I7CQS64"6J4%L`-X-NCMN(E.9A]Z7&U6VDO!% M()0.=IGHW1K@1*,K%<>#=GL=%*=F+Q7:#5';:P]7B:]-P;WUV$RWS.A\%%;? MR#%IH/*9NKO*E%L'H,H7M:F,[JISH8TE+(L+]0O7#_P+?68%NFW]EYF5^6V* MIRL=J#@P_K/K/,%HTTOV&#R\SEB2`73+/`.D\/"C]0-4-E`?'N"QK]A*#K0* M;"3'H^?CD>Z8C'U(G/#^A]?T+\GXG^[_M6;\?<4(ZA0@J'M4"&H/ M6[D,A2KP5.@"/"H\[6>G;>JL&G3F8K+W!-M1$4^EH.,],?D1XXF,PNW15$6* M8*>MY2W5S&1;0++=?82JM;MY+\6ND&RWZ]N#_ISU7A).-I4_[58OKW^O`YO#0-9^Y-^QS/=GF,UPWJ(US^8/V7R',S!D5\:H734KT> MW7:>=FM`4#;0FSJCY^3BSC"7[*WK=)9#6.#F6A.>[23X,"^JR@)G.P)JP_P6 M+1D]&$SMU-7@).Z0`(S^#YPC3\GKFTRS^=5&M("K:WN*-"ZFMK+W_WFPJRP#GR@(),4+L5G$XH]4WH*38B&QT:L'T?:$@?=B\S;9_N7]1MYMIN]SM&SYM:XKH)9BV/M MYWCUT5-^73\U;(U9_=O--2 MI,&4U4DX;HXK>M[6LCGNA>L\,R^P4,.\#Q]YR2-,6Z/+0<4,F:*UM'9EDK<> M?9OWT(Q.*Y.U3K)-G=9L]Y;A:,T%5M+`3NMV&VIK6%:_4 MS%`#5>,4%8JOKG-^QPPW]'PFE(@HA5(H$\-:FW$U-MH.*08Z@T%CV"^MX;:D M5K74ZK<:7:U?IM`^$FH=2#0?9\N6NN[6@R/DC;G3CH8NDE$EHQX%7>IVHM:E M*UB-O+):JZG5U8AZ<`/=7A9K(EVPTA'UQAQ1_4ZGT1ITI0M65X;/OJ-*)L4U8YF516&8= M5GHZ^6?7CO)/W0EU[S59A-92VPWE!>N;3&\W!/(8"%QN5&!/=9TKPXB*>GFFX]9!F M$K65+7NS\J,\;X6O$V+Y2LS$>_DLZEUKCM`"&RA@:TN/(_Z7R!(NC]90"?J MH/'/T,[^,6HY@C,U`"[8(0XQF#/W+/6\:,L^/]6!GN,2:LV3VJ:-B%,$/PH6 MX\49&LA/KN)CESAJ,8,=54"@3.%!'VLXX,L@5BS'PN8K8EQJ6Q4Q7KO;'`Y; M[6@,9,"?U`8J?T62),@`VT`9\A_8#;B[>).:*=4[<.(F.8;E&>$4N[\8B7SQ MV`SF@B?]!<#!U'PWY3=^O]D?$HP$;E/YZ&+#JJB/2]P9"=XLZFG3P`8Q(>;7 MT-@QP'[4ZF<1GB;Z,X-]`C)YJF-#(1\DE6]XUB.V3F(`05/Y!Z^6,8\D+DT? MX2W14\AC?X46$)DW7`)<1&+)QQXUKJ>0]*%A+(_+$B6-.'DEUPS(.GHXJI_*+S.J0>"#0N24P&4IF9?U?&&4RZ MH/%;V*LI+]I2Z](Q>+3U<_3+(G9QA/`CN1\O%H2_#0C0>7%_$E.A@Q5+8PG9 M5/[-`-VOHN^:R=@T#P'O`\1I!Z@"+D,A3@<7ED@QX:N47)6J-46G85I?RZO<1XJC8+>V5G[O+W\>3E21/P)X\G7I<=J8FY^,`\>\"V#!+UP$X]"%PMN/UH^HB&F:T#!& M+RFNKD/RWE<8O.5.+8.$"@HXL(D9[PF7Q:`/E<9FO&\9LLZ$F4]9ALT<2L5'.?\C;]W'AR6I3X-BCS/0`SAH@B,) M.]AYC0ZG.:9J<+),=3A9PRFIGXU^?]CH=8=BKL(!<=,\NK"8>:3_PWUASZ2/ M\-=$A[N83/E-0^W^IM22CYF<`7BO/3BW_"*RI#=_@WKJ@=U0P.58W9H@=:CK MFT?TP#/)":QS$YOJ6G24\YY6A,#<5&_KQ-"Z>SXQX,0'JY-4BGB#Z6"\\@T9 MB83TF9%LN40AH^:$45=$_"SZ`"9;E(SJE,*\2C<4GD^QA.&[SK2>01#!$X!9WI826T"Z(!WC)148!)U><]@:]+'5V-.;F3."]Y.,CHER=+2;=]-<1(Q)^H4KXAH`0V^]I,V;*J]!D(R M0X7G&:!M*C<+#.94V]7)0KM`'"/,S&CZI!:IC:XZ;'1:V@K3CEAG&7;G\;E` M:<.3**>3%*MOXD`S%;4#!T:GNPS"^-`KT,:R)Z#8!LE8F7'B.8ED?$/Q?1]$ M;5WI02FZ]Z[LS_17KC6B[A(^^J#ZD0Z-+JE(?J'FXKGATV19V^O&0F;F@A@G M%)LODH%I&QMX81QZO"%P-`:Q7TZ<%;'I1B(.)^^VFMV!.BAMS-W%ICIL]ONU M$9L<&BXV^\W6TI:YI[$OZW3?4Y`U>UF4+5N'U9V4,V0$&\3.W/!TYCT>D5Z` MIWUR(Q%KP*BJV;P7MM`?A7M$`0",V&K]J0,RJ+7I/9`#G.%%G#'&]@U<$E!9 M1"==I&58>+4S++C:(0\A]WV@$'P!?<=^/7=?'/@;'@@6*,7>Z^E+@(-?(`PC MMRQZ=L1UWR,Z%^@+%;B.[IZH4[K/!*N@8>/\24(<^00>T!]MRY]P8R-R8'2X MI]=S7W6;NL`BI\#OH9\RWS^//HR4"ZP2^>CRXK7\X/YT_R\Z'AF__G/G]HK: M2!J^@\:`#\4N;Z9[ML6](^,0SB;L;/4:;82$S<&T^J+/7U(.N6''-P%=EW$? M4/'B#1U]?'",/:)_GF-@JO_)4O=VCIF:-%%_G.A,'T9^LA%I!BM5GD?=3CO8 M%T&&&@YZPO'$]T!3ESMJ;SN*+FY1(:/KUX05(HMY^'.#L_E")K%,Y:\0+!UT M;&H;<'W9"PF6M1, MR-/*4&4WN< MY-YQB4RGLS7V`B8<3H8FGG'(2V"7F2$8J;YN<^8G9T4FM.89-"+^4K0;`.71 M1[K,P>MAYT\'U"A^QC;RD,3R@(1+QN$XIHO;S"TH;KW,EJ:#49X@^_:6($\4 M28$7I!!=[)MSEGVWV9[7\X&>A;%2R>4>OW#7>5<=OJGGMCPCK,C^\?@/I<.U\C$+=1N@KIM88Y7:`&@RT;&O>]0&I9`&;=K`= MJ&IG4.4">#^@RBAPWNWUDD@5LVH]K.!BTJH0_Z;I=#0%4K:>J[756 M4`!))2O8M"^BIG;*`I_WO/KL^O[H6;=L##5[<"_((9WNY?1!]RVC7"ITM6Y[ M;B-O`DX%:]FNW]JYIFI]M69+V5*\:NU6KVY+V:[-VWFG.YC;)KNLY&7$/2JP MH6"G.?"1NU7]6]>VC%?^_[(CTX%T]GQ=TA++YU1SVW+'L"P]:.K7W`^><)>2 M92_4I)7_98$R,ETP3TUI?55I?>6L7;R)09-&:)-@'Z?H=!^`S:U[IJ]\<.$? MY9?TMA'X#4]'9VU\PM+UI19ID-$>A.9JB#EV#HC>`W"NZ3`T/R&__8 MC><)V.$1;L9:W%(U>'S^(^-CV)$QBU&`//H]\A12D."87Q6`$3VE)*,GUP7" MP!,^\YXQ)`K?-B)<<$>K`WSH"R)R%XW'Z+X-?M'19XO^0O9#1`5'@(J%D(G_ M%%H\J(U?AGP:C6YA%IM%HIR+L.YYJ]W8Q1>]2CI'W<13]^J=WY3KZ2P,XE2=Z)E= MA33%>/O6=&9;XU?A[J;8HGBF`@>BB!:-^5^?4OA6+/EB*9=*8UIS:$7W?=?@ MR1W<'XI!![:K._&E;'1-XD\8J$D4U0LR,.0^U%2HMN>]"M]FZ@(HWG,XM2TZ MTKY2\#_339[)0:*4TF`GP+5,; M-6?AHL->M$GXJ%O>'W#*?Q.@*! M,/]LZDG_J^MX&'>"ZM\7NHN+G_^B_\?U'EYGS+\9HV=]Y)B\Q_@]#U3!SMHX M?C#Q?GR_91[:5\./&*UT!^R#_GA:XF7(\(*"#[ZZY7FWUU%S'I'EB*H6J_'' M?UC,TSUC\OH9M$J[&+'7#IP0/CV@YI!Y9G5ZGF[]Q/2!2Y?%1;Z:7I\=I[R-Y>"R@3WQ9?<5CC$J]\V]W-57+\,[< M=%M!L]U]L=KJ=M0*H-GNRE?M#;1>=;C9-+I$U09;`9/<[)8:IM#NM+K#8H"2 M&;<$:3X98=$R:SOG]F3[I]15=6B6Q-R@;$50-RHOI3J'LZC,QN'FWKB9;N M?WC]2I7T,F?`K><"I,$K@1F_M8YL[I[]K@W55JL8+\N7G<<5PG?MF`R.B@>7 M[J\]7QPME/]YBPF?ZB(>XS99&TF:?(D6B*&3010Z"6?7W`E%!>]2I2GQP1PV MEP&8&S,J(?0UKB!T0=FL%[IM\V&*<=M-X_;ZZT=`+I9*26-V/225B=I>)$00 MM/Q8Y82KG?&K/>D.]9_"5$7L0,?OH#">9NZX+D9QU$4 M][%#/]$'X>E[Z\FQQI8!0BWER$:G->BJ,K2J=C>T^XRGRJY);2J75$DQON\2 M1QG6>,.;JOMP.L5L&TL]=N-.9[KQF'W*]S#,OF3%X@2FZ^/4M6*].R6YX.^G_ M?8M8MNSJ+*P':(0BM^X1_2"XN[&0%[-MJ@T(:,4:6P8,04%<,V`Y)I*Z=$(6RU3T\X\2) M2(M/KK*!NOI37([AT7+/N4%@L##`*H@\L&R.$,/??$J2'8/0(A+NKSW^,[L3/HZO??OUP=W63?%6N/G^^OGT8I?Z"RQY]O;E;^E2062EMC.XHR?7 ML?P@2RRLF)"-#LV63QC%I?&B&EF@P('2]609R@CV!6$T>2BNMO"+%\6ZP$;! MFHBX1_PY(8"/QF_[.;9)T0PK?()%:\4EC'E1"`K@3.)Z>$;L:Q0@*1)C.<]5 M0)*$_W:F#>V#>H,H-EV]@6PLDA7U!IOROT51K>VWF=@<5Q$K')ZM=JI>"11K&Y(Y)\LJIACC(1-Q\/&X6SZ94":"H^C9&JZ9K M!]'NQCA?A,^G/':,XWIR^)0IB.Y2QX@XZ%-*P^?/%SF=X>YB+G8[6X4(L/$8 M%13_^/'7;U^N+GX%C$1"Z8,U1N,"?H6S\4OH&SHF-G,3'C"H,N%YF5A[TCK^(4L&B1@!&(6.FM^#KY%@6>H]@ MSZ55?)(39N[TRCZ98R.N%B3U,=+<>G<1XPB6?@2GA#PDWOPAD3L$3M[:K9// M`;,YR<1+.R-KMZZ3\C=0]3'2'J@BFZ.#%2DJDJX;Z9WJG3+#:C6>*`25*P/^ MK7G?5)X8V+GBF#2PAH\9E3_#Z46Y'JRJD[5W1Z/;[%$]=D6C)6N:@LERX.]3 MXIHF.1!%R5)RC8"YZE)]-1'DGFK"DGZ15SZB"CPB_X&L6TKW&O/SF)IY%:*" MTKXPRMV=@7*$#:MX]X.2L"K*%?GZE(H4H5(*_R5CKY&XE%Y\JB5$(]<3@RKD M.8@33/$242O9%QRP$'V?ZAR)?*^Q;GESB2*(C02:F>M3-EU#5*[EI75CWR)Y M96"$"2`)E2@;KYMY<5I_HHQM]T6D\T6TCT;!-`:D;0241X0 M[_KV'V'@I-H6;+2WN-2@_A24OIK*I8%-,.*U!>\8>@=Q*W^$[97*#VJ=_VN. M]^#MA:S7`4#L.-4*W49QL!A!])1 MBHLOWE](=,:,!5O6!Q8#P-TGJ,^%`:6V(KJ2VOV%K]!-!B$GUWPE]72V^0KF M,\X\]QQ0K!>T;A%)[%E.TH2L!EIB`B:OC8Q%6[$M*W:UH!9@BV#$\P#OMUZ5 M=G-I'P[,!$[#2L46J"N-ZQ26>NW,E_^.6M;DJ/F0[F:3[C)3"#%50A`%(7`O MSQAMZ(9H=6L32YMTI-(1?OK'RF%UI6*5-];8005A&P@55+%"TI)Y?S=\/GOU MEW`"VG1VL5PE=3W6CW1^`F^ND)/T!=AX=$''5!8KG?0N1 M0H<3*O]F47T5QCT=H%)X_L2:-=)]9U.!).F>!$S0AU>]":B%+1,=!5])*CQ' M-$U*V4;O9-20/ZZOYBXB&,WW(IKYZ@5CT7V(Z[-DT.AZR^&]T*D[P8\@[ASI M^LG;?E/Y$%6&QI5'96;(;P%K>&&I-;WPHC2B"#4%N/&6A(8E@MWH4@B6X8L> M\;&%R7^)(8P5N6*'T[^S[T;EH?F#*>G_<'>1Q'!P#,70FL('HB,\V"[/1=[Y&\//1H(ZH< M1+&9Z3`$T8I.O0@6X2N*^BS$Q\E<)8V3%^>R%M^I M4%+6XI.U^&0M/EF+3];BD[7X9"T^68M/UN*3M?AD+;YU:O'M.RDREY*)E!T1 M8;^ZCJ"^8IGOSZYABO-6JS4\6UHP:W72_T!MY8I8%,VY#EA++5O6X-!:G?EM<'+(V:X<2'W0\LWQ&,\+^8=KXW7R M)]UR<.X;)U64R;-\^.F2FB?>TME?A8`Y;^11LYV#%BWEE#T'?2=F#A0WFES8_Z7J0[:+O:9UN M?W=(BG5B3=U5)^ZKR]&T5"$MAF\GY7C068ZLI?#@C[H_X3PKJJ^5>?X42)&B M*Z6KNB%41E)V]M]$+R.L(\C+-$&G2[O>7@+X2B$N@W1'])L$?E M5VAKW.K>C4=N89.*)X,=<$^1W9NHJ?-5_UK-EIH"=:TI2P)S(3ZKAY(>\$=A M,'$]ZFR_"1+GY$4[6TAU^50[@K40:55#)<*AMD44)^-RMHJQ5;Z-"==J=7K]_2(!W,+UV`#1Z M[&96.$A\H>Z5$2JF= MQ71:#4EEJRB'(B4LX`MF`5G!Z\UX3\Z,H=;K+18`&T!5_=(V=7(,V[D>@I6L M;%^4ZK:6B+A5@%2TA$W/FGYK.*CW&KY;H/SYP?=K^@>E*^]LD*B*_#MIL`\3 MW4DRCW,-6U9JC)UAIQJ*XB'-VS/X5S^PO*B?LX:7U)$R=@'$@K]85XH9,#:'.3JMVE[F,?OCB!7OV\ZK8': MJP+-5?)QKS]<'^9[8\+,D*Q/)[!,RPXQQ3"Q/*]^\+1`M&,P9#F,LM.B@SNZ M89==^/:1FYU:X(ME!A,8)XT+7L#08+8]TTV\C'U_UCJC[_Y,-Z+O8H!'US.9 M=VY@MX69S]Y%'W[C(\/26LU6@CJ.R;G5!E[\E7\WE6?=MIXL]?_>5T2#7)3K$^DP0H:9>DCZ!68FR&DI36[ M)2&$DO%IKG<&]7E9FXNU.1QE5[S&(H%]@,E@E>VSY0O6>K1@P7Z!.WNGS@+% MP7(7?[L&C%W>&780QN;?O3+.\2/G M]0-R]B_73D*Q8.*&ONZ8_M^E&-YJD:IV"NQ8*]&+%EI"I5]4R9J2->O#FAW) MC9(;:\.-:4&I24$I6;,^K%F%H'Q;]@]PX@+C1S?^?/+AVH\Q"SYCH/G^@,L%9&J5VL2+W)D`7+G9-2-6X MPC??F20N?SL#88FU7]^?\7_C6X?4I<38=O7@'4KGN?N9;J/53[5EDC0]`9KV M&OV^*FEZ4C3M-CK=H:3I2=&TU]#403DT+5GS.11-RU(!3U'1^T;I$*#*W=V/ MYOM)U,F6K=GF/^065QN=0:EB6]*G9/KT!YJD3YWITR[IB)3TJ??^V7L$6AT4 ME;?EJ^)5:7CC"PR)#+'SAD&U/ORH&712^0-;5/,6R:CU.)C%+3U1IVL-J5IC MV.I($_?4B*JVI'_QY(@J=^H)$K6TG2J]4=4H>3LA8GO];8_Y%A)5QQ"0(:DD M&5HR]!NCDF1HR=`G127)T)*A3XI*M;*[#H:JLJRV4W3`'TG&?,T<-@=URPP; MG5Y;WH#6ED!:J]'K2@+5FD!JJ]1P6$F@\@E4JN?Y2`AT($WE.-6ZNF[0>B.D M;,,-N%TQW1"C,VI8$*+FQ)#<*;FSOL20W"FYL[[$D-PIN;.^Q#B`W5$7_RK_ MBN&\>;LN^O7(Z[C&]BHOXSKW^V]GJTJ[Q@-X\2/PM^;0A!3)(3Y.C(L1NMC?XQ9`0]'R4:X=J2OM* MI]E2``Z;(O)Y18F&TFJVXS]Z<:<[A5>+P-K7\`S6D6@U!_%S83IC$=[BO264 MQU=E['I3+$Y7IY"!0+D6BX3PXUGEXP6G.!,,]QZ*^),)+26TKOPTAO34KO M"J2W5B2].VM);S4E^FL@O1V840KO+81W_O.V'1BB]SEK`N3OSU2^=Y5])>D;4;YK3$6M=[`KM;7#FR6D#K\RE8:!SO$?\N=XK5NI='K-H?'7R]Q M3>XX]A+<@\X1%TR,%AEW0M!6=$)0V\U>Y^A9LU:E/-=L;O#H*;]F#].M9Z2Z MMG(OR+U0N[UPR8S\5E"KW@K5U-%5CWDKY!STFX<511K,FZI-1\R?EOD?.YBE$/9JB!JG&*"L57USF_8X8;>CX32L2M_DK^*Z%,#&MM MQM78:#ND&.@,!HUAOU?F`2BI51VU^JU&5^N7*;2/A%H'$LW'&=-6U]UZ<(2\ M,7?:T=!%,JIDU*.@2]U.U+J$3=?(*ZNUFEI=C:@'-]!MY;/K/)T_,&^J8$R& M=,%*1]1;=D3U.YU&:]`MTP*M!S-(SI>IGAV? MM*PYJH2L/6!ZJB33^N)>DJG69)*"1PJ>TR*3%#Q'0:9::_R@/>YKR5JEHWR% M!Q.*?7$QC3SY?H7YY,G7-?.XRE"H4.\]6L;>T-VX3-H=.:\?D+/WER%[:F)X M971(KURS5(KAJO)5WR)GENG7DIQ97?KH6SKAYR\4H^/]3:6/?F6!XK%GYH0P M3;XL89D2KQZNN#V$:G2UNBRVKJ$:G3U<"LV%<.P3:<14?_N!$QN MJ'ILJ-K&/K4;JC;<72VI!P/40#TY127DL^O[RMASIU@0-+[!4-SX"F.NY&;= M;+&Z6E[E*_0G>IJ>,A,,#IO+^LNPTQBV.[N?`<=PO&\FIG*'`O]Z&E6MBR!- M'S3MWCY!QZ*U3'G1?6!EQ9K.="-0W#%5NEUTY.CC@'G96KB!J[BAE]C+6'I8 MU.'UL;KP%J7;:0P4;BN:8==T7SG?M1J)TE MB*\2M7>BE6X]%%P?/,%-WS=.>) M0G6XA)EYKAF"O/)UF_E-Y6[-5U'8I2IWT^,HO?0GD$_X"*\7?G=^BR6\E8M_ MWE\TE)>)94SHU75*HL-CNC+3O5B61I*RJ=RF@>9%UI^8@\(U@H7_`B_^L@^+J'.2W27_SV*,>"/7+`%Y^8N@=`LAB@+!!PI@Q^%,R4@27QX+0<_C; M+@#L*3!Q2%T=_#TTH8D=,J0`9UTO^]6)I4)WP@K=SBUJI$(WWZ7&C(X%>Z7# M,FL-HJS9I"E,1]%)*EK31RS#QQ4Z4AM]IGN@H>&`)AQ"MCLC52Z-_U.KJ<:M@'8D0G,^-6!'+E)T$6W?6).-K*@]$K7UB4/U ME85M@>A,U'TXK%TG].,N02E#`(LXBB8_NC&Q@!X1H6!:9!Q2$P$:/IFOA(`G M#W6!&3,LF-O&JB8!5C6!HQ1>C:8%6/$;D(?]%5K!:QX6ZDK$]5&#>=B6*=6$ M"+X`RE5D']1\X1DL/:GTE,3[>_';/:WZ`ZWZ(K7JY)G+WVA6>G>8>1=U.RN@ MI>(3%X3M)]3VF)]Y'YEF''JD&5@.(03GD"V.-LEGV5=^RJ($F2O!6/?,>[9P M,)"GQ#=IMAG9,(3HLG07;Y!;YEDN/.?+UDD'5"V/*@VFL_-'SNL' MY.Q]MD`\+3&\,HY'.P76K)48KJPAH>1,R9EU3/"2G"DY4\I,R9FGRIG5),6^ M):MH/NLD,HG>5%+LW8(;R\HDW]%G-ZV[F=3CSN4KED'5)O>UFH.EQ=\/F=JA M::V$1^0VD-O@;6X#M='NEM2K3VZ$8]H(;YSO>P/)]9+KWQK7:XWNH+1VVJ4: M5T=;VV"[`)JCL"4_4=:33::D;DXM!W,4*(JUUGZT&GO-#JOI:9U!F6>>I%6% ME6?:_=*ZS4E:54JK3J-;5G\T2:NJ9:#:Z`]+VEA[#YP]0C7G.'N/U'6S'APA M;^R2\&CH(AE5,NI1T$4RJF34HZ"+9%3)J$=!E[K9*`=#2%D63OGA0EJKJ=75 MQ7N_*!E?E.BBC&>LM)`D]EF5ZB^6]*T5?3N-?EN3 M]#U9^G8;FM:6]#U9^JJ=1GO0D9?YA_=R'\5E_G)-;T$1IY.PG0\@,63C`LD$ MD@DD$T@FD$QP^)"'GE9JS.>1$.M`RN!Q>D_KNED/CA!Y[U%/NDA&E8QZ%'21 MC"H9]2CH(AE5,NI1T*5N-HH,>3BJD(<'-UC6A4"T':A,A![])IW5^ M?,*RYJ@2HK8L+QOL$,5T0^S0M:Z;39)I?2U'DJG69)*"1PJ>TR*3%#Q'028I M>*3@.2TR2<%S%&22@D<*GM,B4^18DV2J-9EJY1>L2[`*_XK]T?,>V>C77;K` M9[V?*]:X;%4QJ+,\F#D7\T;][:/W.5``\OLSE9Y0%J!TQXG3KROI+__S:^B? M/^GZ[-V],6%F:+.;\=5T9KNOC-TS[]DRV/U$]]@'C).Y2(7)C&S;->C3S?B. M&>Z3`ZLP;YEGN?"<'_@/[$?P`9[Y\_?___\4Y7_FITG&O=5?L4/1Z$7W3,I2 MO9E1\ND?NAWRR7P_G/*_/2#'Q&-3@1+XM,_KNSW0C^BX&$*<(R#U;G_GL7?3A-SXR+*U%,C*#R;G5;MH3N3MH=CI[ MC07\FOV MT-MZ_KTUE==(N7Y3>T63>Z74O?(5'GP+6T5MJL=\K.1,$ZEK2%U#ZAIUD)^5 M-9.7)[ODS#IRYMLZ2.:P_W-9D??+`ZU/F+Y:Y0L_:!4NM=GK_'RN-5O=GRL[=HZ> M;\HZ?D[QD+GZ,6-&P$P%3IBI\HOE**],]_R_U]KPJZFLP;/DD"=&:=T&RS*# M:DHGK7PK;_^2OWO>J[6A<41R_6V9%7^XMAY8MA6\2DOB;5@2W8&T(Z0=L?PT MT7X^[[6D#2%MB"V8Y])ZMF!V4WFUF#U_O[) MZ_G_)GB8>:X_,T]_8@KS`VNJHZ]GK%L>HBMDBCM6J.2=XO)`6N7)TYV@(/Y$ MV@8;;K"VK/^R0ISV5JB&![U]:3?+JWMT4E;3*K[7EM:RDGS_3NTVA[6M]X7` ME53G[C0M/_Y5)BC5+T&IC,RA7%82,T*/F9]=Y^F!>=-+]A@HEOG^[#I@T_-6 M2QV>93*-1O[WF_%W5?O>ID2CSID2.A;_Z1M\4,&^,)D!.ICMOS\[;Y_]WNFW MNEJ_U6JEEC,_Y6J8E@'Q7;SX'=\(Q!L/KS,V^F'YWX.)]^/[+?,P%FCXT?K! MS#O0$''@KV[`_,N0:2UM^(6BA0^XG"1=:R4,@\&PWZL4AGUB=)O5%";F+4V) MZZ13XE:SK=9KJ>TL4(5S[@Q7+E5O%5Q=32L+K)$'9M`30RGRX;58L-#_W;&_ M0LNW@B@KDF*JX@VJW]#+"IVQ%GW;$`9D)< MX.@^@BJX]O?;WO^N0O*.""R)1E
/!Z[0`B0ORC?Q-,F//9[[UU=DL%6"Z)N!]UR\,3G:5.\RB<)7)) MH^S=0/2MH%2<`IWH%,6H;J=QK9W]WFJV.B4@>MT5UP+!_;>%X,?5TSUN,AUN M[>7G2#F83<000IMYYXO^PYJ&T\52OY(UOQ'<6DX&M]TW@-MR)<(!^;%LT9*$ MY-1&G'8'%8O3[)KWCF0AVVJA&_3*4,(V7OK^4,XIK(D8XIK56=X^8KEZ,%,Y:#R$B6+M7 ME=&Q9.DE(9R;XL)K[H_"8.)Z6*MKF3/Y"'U5JWP@JC9LE>,%6830:NCUK%LV MWEQ\=+U/&+&QEL-Z'H^1ZP:]U=8SPP?@#6U-Y+6U5JNKJ>4C+[^Z&N%P#2FR M)O:T_F#8/Q[D"5\>#>E?.]Q1^\ES?7\#'WY9PG@.F67LX,4K/!`*^Q*%:TT0 MA;J->*0;_7@))V9\LAY`7>CF;`X*K*@*PRL14$/L5VJ'S&$?P[GJA/UM7%6W MH6=,X(^WH"FQFS&\/74=0H6X;ZY($*]K5`_RYDAW@F<;.7(?`"O@K!>V[OMP2N-:,LA.K7%-;NXT6\,-N+E4'-06_PL8O`K\ MMYO]34SM*O&/4$]SY7Y=(12N[5CA-*YIK7;G6'60IJ;34MJ]?8(.QJ@23)CBP`,*2-M@XBL,"YTJQ=5( M%=QRC3@K)7"5F5`,%%55&VJWI_AD[F(&BQMBY`X*<9',\L(\IC`A-4U%#Q1= M>9G+AQ&__U][U_K<)@[$_Q5=F@]W,WX@X5?ZN!FW:7O7Q^2F23YW,)9MYC"X M".+DO[]="3!@%.<%U;7]DC$(I-V?I-W?KB1"-M*U0#W'TK"3#8]4Y1VR0+'# MV/&)ZX@5/!FZG,]EH\X&KJ[EB1K_!E[M#0G`Z(.X/?(0;0<:;3N4C3OX,;TF M]$4B\4!](9[)%?XU<1H3'9R2%RP?,G?>GW_,A]&<#-B@8TWH;:,('A8)YL%@ M_'FQP'$!7,1SR\$Q%E"^1+7S_))F,^8RB08%2<] M2%!T*O?&#[<2>X'$8^O%*]GE_'KC*5*"K>.=.CT(Z%\S%'`8_)J:S8E^%I!W M?!8E3G13!#WW73`37H?`\K'K3KV(NW$8"62W/DQ!&/3D&[P*O0XC:9X=H4>K M;/58P0GAK=(TA=DI"OP6RZ'N,,JF$8X2Y+GRS5DB0'P!!0'Y[,!PWDE*F9*T M1RY6GMB)L(5J-HXWKWG%IMDKH/L49H5?4'Q@K.)EPW(7O`8\/=%]X5&.<>N4PW'9,OYU-1\A7)KN12%&!,<46?1+`K M(`8-":Z,Q3Z7V!3:VJX\=P6&VOJDC@0=D2MBIO8>41 M]SEZ9L46%TF$FZ9!(;F"JBR^JLA;;QPWSKL:>5G><1N53!#9L\QB-I$'31"- M!4)2DZ)=N7P&GUT-:]56D4BN;R>C504(@LGQB)+WR3Y[3#9>2L M=WL#INLP"6):EZ,#;2<5A;'5_R+JRY&Q7O'Y&;@C@`!KK.RN.$]F@G]+ M`,FW5_!G;RV@4GZ7HVLC7.]2WX"OCJO#:#PAA'MCY@"$GX&N+SSL[-A=31,7 M^_8"W5=TM@!CV@IPX^'3X%9N7/Q*>?Y\*4_*>F0W#H@:",9I\4,%A*F9+00( MDP+'=8(`IJK+YP4E\U_(WQS7!5JXB_AECL;9>)B1BWB<1`$!(0*5('`P"V?E M7%B%#Q$O9"VDH2`<;)=DQ#E\3C/VM3EP3HJ?ZIR/J6X+`ACXF-T%:^@#XXG M/4!?!CMP'X(6X"-16G0",5TI1IBIM4NU)1+DP,:@E\7"<;.^=A-H'L:Q7"Z; M>Y)7_*P<7.>\RC[N`C`'2GXC'61Y%]Q?W+]U*^O>TF=UV5'QEYU(!]IZK&#: M]=#FY$JW"[H0XT0Z"C[^"I0@"T=V%QG#.?@%!-:C;/@&C_]&L3?S.3Y895%- M\/C!R6@PU(!4UOL6@-3FI<)R.AL]'U3+-G5 M__[\XUTX]Q`GE5WAW+MFTTB^FZ76G+Y7LZS6T)]1HO6JW'M]!K_%D M_&1Z_=;MO@O#&-@5)^=BL'`O#H";63.^2B] M&X7(359QO'G>[V^WV][U+/)[8;3L,\NR^UC/9.59]<`W2K7*_VP?1EFE MJPAQ>):Z!FN2W?>=&?=SEV%-OOHS_XCT2U5GDD^C$R)M*GQUE.':M:`3Y?_H0])7D?)>`*!1K0,`O./W!R`3HDD` M+%LS`FP#`,B$:'0$4,T(H`8`D`G1)`!,8P.8"3:`M6`#V%@#P-@$`,8M3`%+ M,P4L`P#(A&C4"`XU1G!H``"9$(T"H'&#E@ENT&K##8XT`(Q,``@`:-VB9 MX`:M-MR@A@@Q$X@0:X$(,8T19"880=:"$:0:(D1-($*T#2*DX0',!![`6N`! M5.,%J`E>@+;@!9B&!S`3>`!K@0=0C1>@)G@!VD8X/-``,#`!@$'S`-@:(F2; M0(3L%H@0U83#U(1PF+80#ELG&BI\8@``F1"-C@`-$Z0F,$':`A-D&AO`3+`! MK(U@2.,%F`E>@+7@!2P-`)8)`%AM`*#Q`I8)7L!JP0LPC1=@)G@!UH87T`!` M30"`M@"`K0F';1/"8;N%<)AIPF%F0CC,'A8.9W661(RX")/(S1NZR\I[5;@4 MHI(0UVL?[@?+5T<\Z%Z>'_WY)L0-ONG1$1'ZGCI(/'-\>316K#B/TY-=I]Q5 MY\Z>74^M[`CC@*R@=,9Y0$`]#_>^(BC$2>9>7*UUX>&!6\_QB<@VJXG>RWX) M!K4OH7SO$US`_9=]U!I^_`=02P,$%`````@`>X%E1\F2KBJ^#@``C=0``!4` M'`!T:')X+3(P,34P.3,P7V-A;"YX;6Q55`D``QG&.U89QCM6=7@+``$$)0X` M``0Y`0``[5U;<^HX$G[?JOT/WLS+[@/AFFN=LU,$R!RJDI`*S.R\33E&!.T8 MBY7M),ROWY:PP08+2\8<@&UI*_[4ZMU__+SY\PVWA%U,7&^GM7/:V<& M7/D.,95B#U@;WI2NZ.XO$;,HS+\]IYO=8\KZVE[TP7 M4D-^/)O&>7WU35@^<6Z->KUZ46W4ZA=&X[9Y==NH&\^/JX2/`&&"4U/:V/GS MEOUXA2*-3Q??NM84S_K58_/C[./U^I?4[H&V15:U974L(4 M[+]*F*S"/JK4&Y5F_?S3'9\9H'C'Y65+%!(FAQK&4G\TP[3UZN^/#T->^0IV M7,]TK+745BF!7/WFYJ;*OUTEA>+QC@JML@;M&<872FST@B8&S^/66\S1US,7 MS^8V*YM_-J5H\O7,F]+/"K-`[:998_A_&GI@2,:.#G'&R`&#PQ\NL?&8&?C. MM%DIPRE"GGMFL&)^?>G'ZN5-$37?6:ISB\RJ+$E5*5,.6$KWU<."77WK#B:# M.5JVI=Q0BW+7$GZ'S.8432$-?D53[&'DMIWQO8GI;Z;MHT=DLL3[ZF"/PLJEG,9WU4ZCJ&9BSK%GVO@O-+Y' MR'TV\7A$7I#-FO.S2;W%/LU%.N]"H#\0YVV$Z*R+7KT]4"9FHPS(,FW+MWG? M^0#?!2!843D')1&%H4\/@<1X]2GV6'$0Z]4@6#96^<+?G<%3M_&GW!S5VKU(!#^*?CXC[;K1C0`C139?`02^[):6,4Z/J6@ MZYWU"]+\<=F\N&XTFS"JN;X!:K>NKR(UCS"I3>,@3&J%^<.?6^2*VRI(477] MV8SG5L%`AU!^0LEL6WU!842EXH2.$86AX9GANU`?,F=EF?:9\8'PV]3CWQ1A M%A;`@--FOWK_\_$[>'-PUVVO8U*Z@.$K]^0"__B^EQ:KE2R_NB).%8NWGR=D:Z$V,=MIZ#+WW/GU?#)',%P\QE&0AZ0FL4I M4+B%B\6*9-EE7'D[[P%O6_JY,"V<:3ERF"A_<#(.-PYQ03:[8*WR"+: M7:3S2'6PB6G+8$=U`('M+G1SDP_8?,5V.%DY](CUYY384%>7>0UO(;!T@W+*([WC@$A3;I]ILK%M7`%6K@IJYFS8=4U[.X['J+(]:2:<'+B([*M`L#O M%H-W?30B[6B\.?H@R79*37\$ILJ&L3RAN+3/%:0^`A-G0:AKO-Y%$P2U'K^@ M=^3X*?XU.?$1650!8]T,RB?:H-N/;"@06#,AI=:FE!ZUR`+3->;I$.<= M40]##S_T7Z&6V&']",.1.@4B)7L<9LX.5=?%I;7[<;P._,;I]MXEOMA,=A M1DE<@?VN=+-?A\QFQ.$@^.:Q@>^Q,T'LR)@PLD!4UJ*&5F@@N? MF!A1OA=^L88EL/%VPB,RK22XU%%/10>3ML<0Z/&*L?7LOA,LV*D8!XU[)G6@LW(C6"'BQ!86A=OI@D?$@(Q@Y8=67ZH;AXP. M?/)(>#`X8@;A$:2&[!&DX0A^/?:>1D-C<&\,GGLO[5$?$IQI?1@I-/(SHL.I M2=&=Z6(+`OPNMGUOK8[-M?`TJ6*6>4/GM-PF[GC8\:&6:Y-#=3=JRFLO7`G. MF)]^OD#2RO%EXCS1Z[H9)(Z2G:5<`H7.;X4S[.KV84^FG(^01_GI0=>%%\"R MAKS:SSXBD7@ZZ)0Y5`%[E',IOO$DN8C,GC5F1154.,EB M:3+E-E@F=+J.9U8>)3B+G=HSANGTLV%VYR@'3FI5K)CNS$6@*'8]2A7WC=(U_^M9SP,AIIOHTG8)9?2BG9*G,S"=;QY-*!YM`KV#Q*6 MC/J"//#J.J,@VO_YJT/1\JZP;P`-^M5?3.PP_`,G_]=?#LY8!]T>=/K!?9*# M2>0.R6QLW+N\HZ7C8323.H`6A-6%!DN1)V=D@J16QB"I/?QFW#\,_J-[<)1X M,_O2%P%UV)$CU$7+WZ)H22F+@L(G5KMG2MXQV/AN\2L0I.^LIJO;EH??.=W% MD9-D!AIZD`P6WHBB]L&N:P#U(Z3.P[JG%71W$?2K%N8ZA;]MQ$WEC-LS0CW\ M%_]<0!09T1-@1V8UZ!KZAEOM6<`Q8_.0NTB0G/@$S*X`7-=%F7HSW7 M8/),T0S[,R$1)&3CJFF":BZ.CQ59]:#K=4)Q!/?8,1T+-,-IST_,N))\D%)".+-4*P$=@G?VPOL6 M$]_;DZ:(3&8G29O,B@FI))ZEU(=*+.!VH#3Q"L=.F9,D1AK^T/[Z'2D2^,:U M2$WG.;":XP&%AUIB9]4_`8&W(G20T9'82\ M*,.DY\;3$A'C@-MP)3% MKNO.*>CO^)9L")0M4`M%`!#:B[=XMDW'`X4Q9?$;/P2:*H#6WO40(560B-^;%? MA@,H_VAZ#,IB,%$G3;;<3H%`.6I&U[V>FQAS(-`/UNRGCOR?+1%X)G1*+W.V[87EG^B`V?CRY2=X1JL1TXP26R:R:1M=S#]D0\E+[/ M1RV3N+8N05O7Q\*<'!4BLUMTS1Z]QL:KG8]9Q\8)&>C'F@.-C66Q:QN`!(YS M,.EB!LP9N^DOX^T6TL_V>]I./+914(#4N'?M(IK%T\'U*'[U^3U&T25&"4X( M)$^,&"I:4+PV3(/12M]U?78S`K\4*LU?I,F=`C,RZ4#;;B."Y@7-5ZQ_08SU M%H3:_/8+Z<@B9_JPX[;&43UZ=(^&Q"ESU(:LM=IM.J-6MUHV*LLV6WZ41S-J)9 M&_\,,O_7V8&NT/FN#YT4]+Q`K%J"QAI/I$_#5+-&[.F`=$3?[1&6^(G&3).* MBEF4V8*YXGH]=BG2Y9Q"X=$;Y4*"U=R*ER<>76[W[_0HGK MKJ^;9'=N+.]5%]^?N'>^\09W7;NHU0J.W119$#MQ?A!M*,XL%;1TD04[N]'E M$`R+Y7OR#$O71L:;RO>-9H18^/&HT=1T1F@VAX">+OJS.?0MK#=)>+9SS]R. M@B"'T(',Y)3&?D?9H1P%$3+"E)DV*DN(VY".<1OYQ[A&0_,HETT?]1W7HSZ_ ML#G4HZ"U"%,7T=8[Q'E'0'NP#ZO7JC9K$XH:O82D?JT_Q5+1UIX5GZ[WH_(] M&<$YI@0PHOT+NZ5*;>$LV.0W[!]TQC=MTD5M9N(B8>9W78+!BC!8&89'#-,( MRC%X087-`Z>J0#`5+"/'+5]O7;9:%Q>7C6;KIE7+*4!/+9T/-#+5FTO&.7O# M+%ODY&)F96]$X7N`EW''!QB(K8>.&W?FR4\KJV5QI);/0PLZ3C8_$.=MA"A? M>51SUE?;SIIE5F&Y&2R[LLP-1U7`;A'<>:.%*''!,?/0?UV^B`D$E,(A):M/ M6Y:SE2!L5@1X8$^=TY7R;.C*)@#7^A!8.B%EF>TJ"R?')QJ_5)=Z#7P4?/)_ M4$L#!!0````(`'N!94=U!N&Z[R0``&]X`@`5`!P`=&AR>"TR,#$U,#DS,%]D M968N>&UL550)``,9QCM6&<8[5G5X"P`!!"4.```$.0$``.U=W7/C-I)_OZK[ M'W2S#[?WX+$LCY/,5');LCV>=:UMN21/=OY">@BH"AB`W3.SM8- M_W4]?.BX@1//L1]UG'6O;R2:9?VN*7&GN-/YX7WW_47W\GUWV_L:A:PU&R\9 MIO?^(OO+9O[`_]2YN#B_.N]U+ZXZO4^7/W[J772>'[.&CXR%"=&V](C_^R?^ MGS&;LO,:DD^A,\-S]!`X"4>_O)M%T>+3^?FW;]_>OXZI]SZ@4S94]_(\ZR5M MP?]UMFEVQG]U=M$[N[QX_QJZ[SI,\'Z8S&TPR:8YH[#0^MOEINW%^;\>'T8) M\6?$#R/D.]M>>[.L^UU\_/CQ//EKUI1-3Q0$[0W-_NI&68=\XZOS](_OF*`[ MG9]IX.$AGG22Z3Y%JP7^Y5U(Y@N/CY7\;D;QY)=WT8R^GG&PNA\ONUQ4?[DE MH>,%84SQ+0X=2A8A\:)]5GB/J7(GV)N<:H`K1^S%5;[2S8Y M&GOX+J`CY.$1=F)*(J993`7O$*&_(B_&CQCQQE5E4&&RXQ).KU'I]-KZ3-"" M1,@C?V+W#N/P&1'W)1ABCR^ESXA&JRJ?B_'8K;`^B@+G]\2?N`GF"^R'B=FN MP*]F0'A,'J3BNA'AL7E9.YN7+;'Y$/C3%TSGMW@<55!4X3#MX,8=A5G@N6R; M<8N9@T2J\*4:K24G9#XG46+GF?V_"1*WCVVBJOF;)J,"9?<@BV,T;"L,\Y\2 M[GI0C.:^T$A>-$`'%X-D5HD<11S[$7A9O?)*R= M=2_6D;T28TF!\BZ#5Q@8ZW.&24!HGV(J\=?(9X$5-GQM2Y/Z4X"53L MTGI;6*1V0"O1WQ*2^TN>&$83C`X> M!H06]>MF"N[%%[*%_W<^=G#(QLHU@Q'[$4^+T/8_P?62V M9LC7N\/&@;`T'JC4V0)Y&.T&(738?C4MOY"4`/S,/@TV! MILSF?&;S!W/BW',G#H?1P+^+HYCB9[1*5/FKSX27J9T0[$K#-?KI'NY`R56@ M$O<+2@)*HE6BG3:^Y>LX9)2'X0@S!STU*^.0614G$B&I:MTH4)<6@%(Q9QT' M?J!%R3A.XZ4W*)SQ4R[VO\]_Q&2)O/6J\8CH[SCBYF*;5'+O[U,N`J_V*=I< M50V5-P.W=N8;T(CY//"3#(3D/[=D25SLNT-.@!A?98?6#6DIM)2LZ&7_\WGQ M#*.^71I/)G9CC^]+F(5UB1?S MC,CM=_/YU?%B)H4[I@(\?2:.4/KU?4;49Q8YDZ'H",/6)*UL9ZM1?KT2#Z`( M25F=L?UC%[L:6-A.VQ0DA$B+D#SMD8"^&Y`P60.?GEY=@)T'6<*\&$KJ=:^Z M'^#$SX#I@5!6-IQ([MU&JWN?[T`9+<\>2E(P/H^>G^4Q-H-.(`)JAGJ<>94& M?`'X/(>8.<7$B;";N+[*$+>D;9NN_B'H:-@!``K;/BXQC0C?&,9CQCGQ^04& MGCNM!,B@7YMQDRI@&;`&`+C^-T1=?GJB\I:+;=H_N&W0ORVR#@"P=+W=O7*1 M/SRY7FW;K`.G"1M;7GR7VW:M1V-G*BB>KTCQ\]#;X?ZD056G@NU'MZ%5]7O+ M]2C:Y_G""U8XO24V2$A1.@.*]A#\:9O?35Y%%&(``.J.#_J5@1$.1U_+N.&[ M?2"XXTV!JQ&%#.`6?=^6)`-(Y2LZEWLGJO4&HQ_:3`*Q):+"DEFSE]]\&@D( M->S/^4F_'1W9U'Y"/ M#RSW7N8S583!8 M+HFC,FOBIBV8-5FHL1&S)I8"'"23&C`I::'2C"G:`S%;*MT40"+BY"WA4CRH M^]"]ZOX`Y^BR,E9"[JS,`F'=TFKC]L+6`1P"^-R&W)HK5K'1>I!X9,*;QW,E%CMM(*P6`@7*"WZ'8@AR1J]Z M.1?;0(B@Z>13\-EHSV)0XC+N7+]<]T^^1]?<.[# M,,94L,XJ6[:PXEZUL>(JA0`'/N$^1-.VY7780!$5`-2^+6P!@N(2=\66N!_; M7Z?K@$7(F(T=X$N6XG!-@L4,T3F2;_04C=M%@DF3P*;9PBO8M+#`_M+FE4X@"`+!YHI0Q+U%#(!L^K7(6SKP$?!PW#B!7 MFYJPJ7_!J>NH.:O/HKG^N-<.PJ91KFW%X^$]XD&(OK*M?M`D;-<[17M)VS9$ M)4[:$=1>@@(]WAL`7F81*S#7-0KGIJ?)^`)"^LW&G1J%$K)89-5*`UDT$!M M/PF#8OMIV*=1Z"112ZO0Z450'W)U9?(EA$F/>K,_-XJ=)"!@?2G,N&WM`QN, M/3)-K/A=0!^)A\,H\+/RNV4^.]U(C0+Z(Z"/42>8UK#?&'YFZ_F[H#YV'YA" M>@._E+E5C=(HYC\!PEPEE-;P'BVP0R8$N_P-[C`AB&GD+8XPG1-^;S%'=1D- M*#=NHSKQ$9!.E!,3-*OP\DU28[G\*,U&O+J`5$`EE=8`[_M^C+R4-%[",HFB#V77Y0OHSQFXS6K)0W'SVJ0CW5UV)YM#[XQXY;40`A'@>>*L%8T M;A;(-N)G"N;;+!;17R+B\<`[LRC)N;S=I*)._F9CZ_(A%RZAA7_=?W;B.A<(X]KTVB& M^4,03EHL2IX)(F\.L3"$(6+YH(Z<00#A-Q%QRO0"50<@Z1XZ!=2!`RCKHT9X MBID2/W6O^$8(2A9(/9`)602`HO@Q)75>B+(+A!01O6H64D64_`#`:#0+:/2" MZ7SKB*D14G6`<&Q?#A\5-S8V!J)GQ.0)O*K6$$[6S62M907`9_"(_B^@O!)2 M.)CP0O7\]8?D40BC5Y6,>T,LI'*`:V?,[W$@J_0L2O0'X@>6U.62P`+R$AN# M%K0/V03<4#W,KZ,7FD1"5HST+\$24U]:EN[G$V-2U2^.P1_M"*6IJP"@/4FH`L>!L9/0:1S;PW[0'!R*P&HX0\$:O,Y M5`_(R)I#"']LQ(^,L8``/08^'B5 M;F[O8M]5`R1K#"''LQ)`,L;@7%8_@G(/VMJ`)7;JIRH.MG;9`*HXG&H#6*X- M(,OJ2&@9\,R!EQGR2\G;O&^;FY9RXC?G"=KM"Q.;^J"Y#%MRC/9NNQ[$K.0= M(MT*=*RW5!7Y/ND%/_X(6"A]1,BT-X2`1&5U,.86VE>O(-QQXGF<7/;[0H,P M_.I3G%[C_,($>XTG`7]$Z[4\_*;C0@ATV%0,4SF\!95Y8/^RH3([XT*(NK2B M,CMRL']O7DKCUO7!&Q#Z8\> M1@C(XM=\3.CQZ-4.12-R5&VJ`?A!OZE:VR`9_0('VF@8.Q&_)R.RG1 MI=VJAR+!_E1;K,$FIOTO7JOTG7Z0&_2Y=)KA^&.+F)^4#0F'CK MX_&$)7?@#SG;E/C3]*HFW?SS&H5$>=>NQO';L"H9^=>K'+YW%/\18]]9*5*Y MC7K"N:%7NQ[DK8R1+`"L(2(SDE&IS``VZ@DDK;N$3@M!5+'XUD$LY"]_N.A> M\;ON4!*X[0$K9!LHUF%FHY0I5&9=(>S&2RBT#M9]!J&"F%](:%YOYU M>Q^UD.B[0LC?K`R,GDT`QJR.D,&#YFYUS7.T=_?:BK"$$;7J`9RW=W=;HEU@ MTH,M'DXKE>:8[FGMK%.9;+89O_+7R@UZ0M@\6L?;2!+0@$^6OV>T2O1TGV() MZ-I>$/:AU@'72@$:V%PM[_V0+2));M6&9`G(TM80-K'6P95RW^8]#^W+Y^7> M1[K:?Q\I-T.'3]'AD4<07`8@[Q(J;.C"EO?TKQ^O&[(JW*`\L2 M_8$<6*ITL?B:N#%G-J(=7T;_D,CF^[;_UK2,NJ5=W$)SKGFT& M):U#M^;1?MF^;0'!=5W2Q)`/)F*R1'B5'J+-X&)5X$HSV_Z']H1WR[*5Z-=F MK-#Z1Y9P:/\3*^B)EBCA)U9VB#;38"I_8F69;?\3NXLC7L4G1[BD(&+UX=K, MK;'^0:H8;Q_E/%V?7Q=L@XN'F(N-R8HM`"1TD/=OC(3[P!H';W/G6-?G8*X2 MYG(!J2"R``O^71#7 MM@YLQX._4:KY+#W&Z*NJM!NC>.W@`9]GB^\8(73M4)]RUC4$D)BB,V/H'`;620``!`.,7-?B,-\$CV(DK80 MKD@U!:-$!`"`W-"N6'B+3=I/<&QDW2TR#0@HY8()=*D3*9E(V(#6J`/$7:S4 M^4/WZN(G.-5*RT$@9,5&2&'SM!"_ML[VKIP*UDA8%9QX"?\HK`@QQQ.=FHN$F,&3MQ85;2_9M_=C52)DR',P9LP')K\PC(/[T MAI((4X($RZ^\&9RZCU:68#GC#0`AM/>JABTOL3IED@G4YM6E:B(%N8Q6$W-C MR^DSII.`SGEPEK_'R`B15:C4-V_=G"O5*%_S1LX#M/OI6BLI,Y(/FDHW=0S< M7GF;^L12B)_5MS@=:TV;A*FQ7K#C7;Z?U_][[N#):8>6BR8`1],)IC7L)`_P6Q_ M3@@%?>I5MH8$!U??GF(N],$D^V@2BH7;KOKG@%`O")(^204%5W^*I-:J-KM# M0RA`!$E;=N4#5TD>T2N9QW.^%:%D'">]PO5BC*;\,76/3'D%M?RXM>K2@11` MJ`L,2>4.%"-XS=P8WJ11N#E??D2KS3=V&R?+N3UC5XT0"*63`>KI@=($KZ[] M.2\DU`_SWV%S1K3,[!!*1P-4S#(B?#/ANN+7F*^3^X7U509/K$S7J&Y^;#QT M8D5F;U49XVC&^/H3[R[J%N=I]BBA>XSZEY/6FU&\Y#]#_$=,0L)?)*)+XJP] MCXNZE4\]5[,*V.PIAQV)05/"OI<,CETQO^N+,+*K`X:=FU631H\83$5@?4/P M$D3($Q/Q$ESC(7:"J2]8GLIV;A;+YB+X)430)I8W01@]X=?HY1OVEOB1.?\S M8:2]]!#-XMI<)+VT(*!9Z(-ELDG;VY2B#P?\BN'+#/F#A*'PB;\[$3+;E?I, M=;L.Y>=O5@<;B<^W($7[]Y6WQ^')?V[)DKC8YR]C$7'!&76'9F%O+D:N81OL M=>+,@=+>)^Z5OD_)[GVD34Q_F\G)R'OA,G&KY-2=EC^_DMK%2 M!@!\#`E]RDLZFCY`KD@9Z*L!4(`N4-4.53&)^F/WJFE6=\`D9!8#H M$(>8"6C6]]U;O,1>L."TKR,'NAO`^IX0KFX9*>W.Q5X]9P"P^X)]YF9YC,R^ M.V?2Y<5G>"Z?"7J&?2&DYY;&SY`W``AF3`V8RX#X/8>^PRA-GH,;I8GG"N?& MN/=W'TH)Q6XYZ-0](?A%%FL[SYLL%UG?Z?"I@<2I@\3VF M?;[QK,^:O;PT*UE,?990E%9L2Q+H]M+F@NC?.)(FE38PWU&L6P1V^N%N7-I:9^>T>!C0BOC>MK4,2_GY',;YG*P3%831$D330:']>"#YQ M@\;`FBJ+I?O=*?)Z_]*6/F?3'[5[`%RM,R%_?]J=[AI;T^[-]$?M7D#7[HV0 M06KW6,_YV(1SGA'$\P[YBXC*&HV6)CSJ[(,:--B26$'J;%TBWO#Z:^"Q83S& M9E.NLVSFHWZ^`Y`=ELGW.U3G!AUH#0%'_5`(>.7^/IQH">_-N=$:`H[ZD1'X M.@[:E:Z;]UPUQ4:=DN*\1_TZ"4"-+DKWS2BR\*SHGYA,9SR%?XDIFN+DC[>, M[TP^C1SP&5!QU,^>T;F\DJ++2A2W;,$I]JQM^I8M&_(TZ3HTPS=&T$X2S=+6*9:7@#;BQ*/F/=^05)RXU7X^?@@B' MMS'N=7L?M?+7=X5P]%L.!3U/`&S7$'O\@ODSHM'JA?F)(7-0N4-YO3Y+*=277K_?9P2CT:KA@*7@`@DR=* M:8=$#8$L$%KMRL,AX@,"#MLGFY0WL`3M(%@DN1H59+]//`#1IP'3>]_%S#E_ M">[#,,8T3&N$:,):9EU;,%F23"A#DV7&UA%`I[1HIIV!6+DR:EH&3$!&L`$X M"_[D#[WNU>4'.,ZS78B%K%L)_E"R9"NRMWK"TR`BW%6]08L%_Z_G*2I3E.T, M8>$KI[+;@)`YEP"^2PUN\F800G3E$9+S`P"+YS@R@&*O%82;!(D5Q\:,^D+XH$K`:\@5 MN(Q5S$C#;CZS3Q;L%[6$X*^6`$G(`S1(\M1I/R998P@7.DL`(V,#&C9%ENZ0 M@_OS():B(V\.X:KBP8M7GA%H"#W3P,'8#>\8JXDVX6@PX7M8GM3,J][+O`N3 MCA#NX)5`S80E:/C=XB3F1I8)@8/)W[$[E:=8"]M"N$56ZML2;N[SFE$BH_( M?``(%WT.7K74K,'&-;>[2'_D$:XAOVLDJQ92HG^S(:)NS;`J63M"5)\I<7`% M5#?]FT6U[OB(DC7K2V.1EB%V<7HQ,"&@'V[MQF#"?N4[9(&\U"'^N@C\@9/N M7QSVY[O8=Q$?!'DW,QZ>$ZVG5J=K5@\.#Z38EP0T8Z`Z:!M%E/R.E;;`O'NS M*E`]3&/.&31(<[X\6B1$ZKM!'QT-BN);E5'0ZQ@QD-;)48^",< M16G$7.S%JW8RAXS6+%R'QW`J,VH=TWO?H7AMJ]/14^BBLLD>S\!T>4S)BQKIAS?O+PV"%O(C@)!K\ MQ0O&R'O"T0AY6&A)C;LVB\CA0:%R7$'[C#;!JR1JSVP[8<9?\;"RO'FSQ^K5 M@SUR3J!!]-5'\X!&G+B$O_4YB_JM=%VG9N&J'L71\=/J"[W<_,X"C_$:WK+Q M'%*RBM%/^U6,\F/^=V<]ZK$4,QK%XY"X!-'5@*:[Z[3JU7WZK#+FMG!]6^QZ MM=]XTTSY-F^M4[3BP+`)!I-<12]%,K&D+9P"2C80+[@[8@$`L,[Y)\3ZOOO$ M*-G^)G\%7IGT67H4(%G.2B4N/+E;2L$R-D#\%7=\-`[I@M>XH`_X*NPC>*F<"K+V#:-8OX!8#C$BW5Z0Z9A MN[1J2I\8]P=B#55:6ZQS8LS9J=9)224ZE4"Q8-ID;P-9-FVGVBFV+=:I=DKK M%NZ8:Z=LO^G/>2DFXT@7Y!,Y%-4&@["?2USQ:C.K_7#&PEU21WXVK`U&@W" M+:]ZH#5B%]K!0L++.L:T@W#0[W8*HQ]+LLY#$(8%PE5I M-[+&AW]A(7;>3X,EPY]PFC_P'SBI'W*DLE_]]H"GR/O,9A8^/B)L`2<]1BUC M_A$)&:C-C)D*.9U<>)BQ_^>6CS`42K$1:)%>R-(L%.?]\:)[]>&R_;K$)24L MY,%&`/,E,_C7)%@P-V".Y.?9BL9M>D`R_<@"C0JZ`7@W7V+$WQ#%>##VR#39 M[K(][A.*V,*H.-76=X.3MZ.WV>9<`44L)5%Y=JWO!N0DVU0C=<`5F7N[P(%< M<6R"6?_R5%OPC-FF:/6`V08@8T)=WEO9!<+&WE1I=P)G"JX`(+6W(NS%F'2[ MI0<(60YZ-HH5%,7+X+%6F!TP'4.L]]&:72KH[@/A%.'$S M(K($YZJ#0KBK=D2*)I"@]4NJFX?;ACAB]!!>J3^84C1_#I)_(^\EB(J?`"_D MV)]$F#X&+ID0)_FE*".LMJ$AW'UH1XWJE6.;AU/\I^3(*,;N^@24*7FIS/"+ MB_W,\/RPG>VXQY(3?N\S4>&L.,@U\KC\1C.,(Z8H?=$P*>IB@JP M4S,'`#[[5DH7SVR4@O8"FBT(NECVO:'5Z&C#DB*F4JGQC+3DR5]1DYS`M+?( M:YP!0I"R996N59[@XD=Y,:FE-,1+[$LS=P\9",*B:^%[W%&>TF(!J".'B2@M M"\2+RP[B*(W77^-)0'':^06]UFW"3&:$8-+L:YT]^5F/3=X$'M.'@"8/VN6" M;4,<8B;M&3/ZM^Q;\8(%_^TZ-!\.,9F/8QKRER?3FY^BX&1]8X,X3;&C1C5+ MJM6W8^)QB/^(.87+Y(9%JRC!,[6::8"!%"6K"YIB?N-E]^K# M%9Q'%MR.V&8^3Q^A>^#:6#B833.5@ M&79L$Z(J>IE!9L@GM&CKD`=:%!Y&[N^P7JHR<2ARQ$,1M=+#+K0`XAWL* M@`$YT.L")THA[[2!L#8(-",OY1V*(<@9O>KE7&P#X1Q$)^YM^(]'6P``)F2!@`5`!P`=&AR>"TR,#$U,#DS,%]L86(N>&UL M550)``,9QCM6&<8[5G5X"P`!!"4.```$.0$``.V]>7/DN+4G^O^+F.^`Y_%$ M=T>DJFOQ2%1C$+@__ZS;LW;W]#:."&'@N>_^LW M:7SFQ"YCO_E?__.__3__^?^>G9&+B#H)]___[]VW>_)^__].&/?WK_CMQ]*AI^XBIL6&=+ MGP7__!/\SQ-G2;[&[$^QNZ4[YR9TA4;_]9MMDNS_]/WW7[Y\>?/U*?+?A-$S M)_7VP_=%K\86\*^SO-D9_.KLW?NS#^_>?(V]WQ!N^"`6O#68Y,VYA)767S[D M;=]]_W\^W3P(X<]8$"=.X):]3KAD_=[]\,,/WXN_%DTY>]8B4$&:6X^0_XQ" MG][3#1$T_I0<]O2_?A.SW=X'WN)WVXANZNGY4?0]]/\^H,_P4<%"/X"%WOT! M+/3?LU_?.$_4_PV!EC_=7S>*]D.%5M9)Z*1EWN^E/G(\0.<;_E-%+?HUH8%' MO5PQ8-="6D@C+"LH`^W0K1#T88R%4=50R3;Z>@9#]>T/']X*,\!O_G&9N=(Z M\*Z"A"6'ZV`31CLQ1M=/<1(Y;I(3$N)+2KK]>IH)E`$FZZBJD1.YN1#\QPX# M92V^=T,^G/;)F9]],M%]$X6[?BI(,<(>G?[A/PT8(KGN%<4C&H=IY-)>8T/5 MM^\W*V3G/0&I:7#VTT,/9?YGSH0X@4I1)',/HV-D`[@=J5@ MM-:W0#@T.P0=.@X+%21N")]L:3>6">+J?OF.7SYWJ,,_.MW\`.XU>\4M^*_ M^H><6.[I,X-I*T@^.[MC2&]IAM2ENA0#AVIJ@]"=.D4=.MJR545)E0#9>8?> M!1_LD>-?\X7[U[_00Z/JI^W0#[X&U:JC[Z@1ZN'7).O(\9>1)8(NX83G&H'Y M$ON1DZU1^NC/B,=;G2+Y,%/_AG1TU8HX>M\$U.8>27W!ZW0C\R:]6J#LA* M$]3CL%[2D<-/$"4YU9D!,MSMPN`A"=U_/FP=;K#;-(%+88@9:/;&]D[HAZ2. MTD>0V=(#]8#5$GPL?`H>1#!9$K2\)_>KB]N;Y(PV"#KXB%20(S_G!"T%A$RBE6TGRLY1M'SIM.TB7*I!Q5//.FJ( MWL&:Y!TW(E?%V1H.AS.M9:Z=(ZC_R9X#7CCQ=AUX\)^K7U+VXOAY^Z#,+`A@7TUJD M$_XMV\+BRNS%83X$XW\,HP_:F@GRR&&B6 MRCJO'PG$$\A030:O#7-^9YLP.HLY1U(R61%@6OE%QG<2Y'BAT5/8L72(IX3UW*,8K3CS]R_[@(?4XZ>P!\QZ>7 M@./JD57Z]$,*`KU5+YXBZG2R[.CY0VTAT]!O-WH,W],]%UXL`Y(M)CV1(N@`]=6EDT8WQ,NE/M(/=86,!\F8B$V%8$..#M;L;*?F-`&53&)A M@U#8P*T,3OT9V^NQ0O-3L89_&Z,'%\[3/LT2H]`CL\KJ2YR?K, MA["1HXH*(>Q..=@X0PXL2BJ8W7NX,G,=6Y2L+5UYS6^B3Z;.*TRMSL,]Y7N) M.ZZ.2,'S2\KVL&/X3)N7Y:U=D`.%CL+5A7AS>\3.KR7V\'6G)+XB@KQ,JI0S MX%Y-K:VY9U!::$M+;8-3;4<<-UXX>\87'>Q?U/M(:7S'E_>/8;;KAU.$PZE? M]NF'U#E[JUX<-^ITPG[-;LF/;#A#(C:124@<$JGG2V)LSWR,.(LM M%"8$N!!@0QY#LB;Y`9O@-3^2V;%!YR"8=S,WGQ$XC8ZXC/E68LKY4.<.KJDM M4GC74E%==-4V1+S::I=WZ.BLGF;:WBM-J:/UHQ7!O_5,";]W594X/9!$[#]' M`IJ-\9[SY-'0D:-M?[AASA/SQ=$$WT:)9ZO;T/"I;7# MXRU+<^ME^+7I]QX*:3Q/6R;4-U?1+UE8?.2R=ET((^/;Y0-<,73OST^"6L M]RZ=]D@=3%O5LO!(2V/LQ^Y:L@\_7LU.%;.X7B>&]ST0L/OD^%!1B,1;2A/B M<>;PE_#)9\]"U)AX*86#6)=&B<."ZG'L&_(QC(CK\QVB+/A4(<>GW*@:5IP' MKXBT;6$`K.+4W:K3%?D6&$*Q*LXL#"@Y0"88SB7[%9`)H%**3^`&S!'IW]R# MZU/"-L0/@V<:?3?S-<&DW^Y2VO_X,H!SL`.;TVN<`3%H_;CEG_A%#*ES%NZW M#O_P*W(=N"=?>+Y5S=5N[X<'2C/M3U=S#?.,3C^D4-Q;=779T]D)\0I(7_;! M.=DR#FPLC*97GJ^1HA0F$RY*&`34+ZR0!Q';<_/K@!N(QHG6YJ6Q M,7*';E=2]>+ZEHA=MT/@H4,V)XMD\S*1EKECLES;$9L8@Q?2VG-M^>OM`@[9@E&QLC=\IV M)56?K&^)V"4[!!Z\:<6LM(TL5T):9]]X#?_?2FPT7-A!-,#O-- M?UW!)Q,H5WW[AF+FNPB#%QHEC*^*']*G,/)8`#M7>*K3&3&IVQ>Y8_8R026# MFTY'Q.[;3_[!I_8E%Z*R$2_7[(=@SF^$6#5"$":`='!;\/[M^P\6DW'#PSGJ MW83!\R.-=J!_@\7J6R)W\A;U*IFU3YLA=N`V:0>G@9(T"1"5V:!P^.D4NG*= MSB+JN2)/V#8C`;)!?\OZYZ).[H@]TT=A>NWIZ?M$7NKEM@&MJI\:2G) MVW?:>52NT\_>D:[>0Z.F#LA=M5O9MK/=1;BIAM`&3WAM>^CDVOK%.@+%?O?H M#*W'S'K:'KFO=JK:?JA2T)8E`E3JTP1/:APGS:>OJU(G MWWZSYL")_$'_]X3N;E=UZOFY<\GO&?B\8%_EF<<)7>M57>=D;Q7621.PI M3?(`VCL'Q9.GV))X^>C*BID7M^2D6A4"^>5YAW4;;\$2JWU2NJ;XD< MFUK4.\J,?-P,,1JU23LB[6^V#,X*2@NR*W(=QRF=IGJ,AA].JVD,1/]$?OOV MS=MW\!*&O$B=WW]X2V)93]M)DVT80<*@%0G"_+=,&$5F1C97<'OQR M2=WLM^_$;W\'3^GB/76AE()_L`<8CQ%UXC0Z=$[ZM0V1PT.S)VJ".SYD*KP. MLO2%"E0VF%.K(W(OUE>^DIRALQ=B+^\A_.`7004+F9^4!23CLB+9-"D86*%Y/BSI#KNX_HE@8Q7R9WF MT?G:9+S>5+`CP#"S'.5JZ4,",S8,U&3$T\&<7U8!J<*12);D6V#ZG4C/#G,J MYVPM^XLU\V3%D2KF89EY?#"//62YIY#M@WI73@3E@&-%[.SDL<&>6AV1XX>^ M\BID=/="C!(]A!^>\UVR(#D/\JWJ#!F;DS$_#PS,H+^JK&?[]/[TGD+[0@._ M_S8KUWZ?B-@_6X2=X?[0SCNR"726[\CBNBM#%(\W:_.Z-IA'HQMR/]55O$\> M8\0^K"VZV;S%UA^!3J.L=&7_2&5DKEV]AN1@>AL])+`"$$>5=S02E_I:=Y@M MG9&[>3\C--^N-_5$[/(]%3!V!W\G+>.@>MBJZ+!`3ZXJV^7%LO7"//A(:-/>.V'8 MW"#/-:YNU6M9K;IV/;8["*Z[UP)]MR,8KJ/+PKS89)18T]C&%N'9<_NIUQ/Y M0.^A?D/DYP)WG7VD'QD:B7>_.:,1T.\T%5MH;C/;>RS'Z74VF"W-E^'DQO=8 M5>=&LJ^<06%\.\H3I5NWD\VME^:QS1O)AJ9+\E1#>ZHZ+YWTW55_%S6K*:ZM M8R7T_',*H=^W&ZGVGZG?Y*+=O9"[JJ;:C2\F3KL@=EU=R4V]I9`LQ",#.(.I2;!%VW?5DFULC]]T.-:OU7FJ;(O;5+HD'3SZW MGR^O/C]<71+^T\/MS?7E^I'_X^&1_^?3U>?'!W+[D=S>7=VO'Z]Y`X-U'N_# M@^,GARQST4?^*=6*:Y]I;;%'G4Y(AVD_I8NRCYT]L-=^U%=@>.QM48&D$-1BA,..> M1BSDS;D&XM\^AWCX&RH);3NJ9!E!?$JI:2LF2+8MR2=,XU[F0MQ1J#99T=GM?%-/,?R\%^K)E[I9$ M0FP(6MHY!_)$"Z%9X/JI)ZR=P.>:N9+E#",Q^V`9"VF4:FE+SL9"2G#_6/^< M%5ZP2@KOWJX^_.&/\N<_KO[P[EU!+6#!$;&XF=B\<8AVOJG!R?\"SH^?0JAP M^T+74<3E$^N:.-.F3E^-/IBG?EV5BYF_JP/VB5];_N'SOH0:ZD3P\B;E/@H/ MSA2NQ%'82DA*]_P_@:CY5Y,RK_S]S'/3Y,:J,"`JAU4^75F8EV8;(^+;-]M@ M[DQ.%I3OE.&5^7/2#&_29'JHTKY-\3G#BR>;GXD[RO#NLK!KB_/J;=3 MX8!HO:R[/,'OLXVJM:Z+$?MELZSFUL%V=J+F-9-;TO!DZ8O`T\IT:5W6J+1< MBK>=JE?K;V6S)7A/A#,_#`.;_@>A%9_#(*RJ MW+YP[>R$W2NUE#ZIJ=G8`[.OZ@D^V&U%%DJ5?N&_&0M+.?EFT3O/MYE-H]]9 MOM2Y#EYH+"J5265/@_S:6R+WVA;UJL&G)\T0^V>;M,.GFIQFYHRK^<.BIM6/ ML^54,_^SZ7!2D/;9\K05>D>K5:OJ9)4FJ!VL7M+1@V^20QG]XA63Z47K]9K[ M/04LNB'H3A;S3/D,?ELLE\_I)HRR!-N/SE<:7WU-(B>,/!8XT>$ZH3M149OW MY-;TQ>0OE6NTY900IF)TW1`U&SQ"-!A!/.%T;DVXRVI1.`B37EOMAX?&Y$ M08U"I?.I2+Y]:OB8F-:%@R>`I8"2CO+]%EOHH4I+^,F7/IA*&\Q@EXYE2?'0 M+#FMO&0+#RY9G,E*O=(2'=7+>I)8%$;H&:09+=K[+P8W--4PB"`J1P5#U')E M*]A$^:EXRGP';S7#X`1BYMQ#::\U9K)JB3^>:DQE8_3MYS"A,7F7%4FVN"SA M2I>V6;\XS(>[4CM='+VKHB]_X^!F@H`]'8#S$. M]!+?3(&(@L]*!8><++3G=,F3[F)&%L,9!%(-B8?72N;IV\U%F7;Z(Z7QG<.\ MQU#-HGQDSH$DD(+,&(,468I[]L>>M'BH.@9J%T#.\4IB=`XINGG19\Y6/+>5 M5'[D=D,4C@18$N!)'L-JKOVY7[Y9,,_#1XW%E(^6QT[(TPSW\JXJ/)S MNY$GC'Q&YGL)#A1;&L3L)7L(U!&DT)\*TFEJI%G417!/$HA7OT,U&;S-U*D3 M=7'[Z>[^ZL^\W?5?K\C-[<.@>E%FG$@DP*BQ")S6%V?R,K)5#6Q]#&7D?%?^ M86/4D3N=83.>I*P93QJQDYK6<%PRF(H@U>C+HWNVAH!O*97]E,NHK.I6K"K? MP5H,E&HRSD]!1.6BY\^A#UO]'QT6@,5N@P?JIA&#>EWKB$'EKTM1\^Q.E#OK M>)\R(;N%`J,I0^L@Y5A>"X1.8RI/B*6EC"03DH"4>6`$7%H4HI),5B*%)5): M%8]Q@:QU^RO&?19&]7.C[ISHGU1.5G$ABN6,9VUSU3UGMYO2M`/QV`2_A0*R,5/KKEU',5L@))O3>4),/A:0 ME!+*2#60491^!"G%;8Z"(5.AL7XV+;S&EP>0]Q501HK&-?;KP-/V'L@144/= MHZ"3IN:(44E'ZA$A)GH[9DS9%^8SB-TW>\H)*,3`?/3#+UU5PSJZ('=G'84; M#KM/VB-V:"VQISW&7C_\F7R\N?V;Q>-K[K*@_5T40F27=W[X*:;>=5`D?E^[ M"7N1FZWV,3^($')/&&Z+4S"SAS/E7B&&>W=P/N;32@:`Q]`,$DW$"CE6 M36E@%JM=/%D1V(F=T$LJACB]XSGF=DSP:IB..B0=SFZ(V- MD;MVNY*5TXO:EHC=MT/@44\HSN!GCZB$[3CH5$K"&[E,2;=%27NEJJI1RW<1 MW;%TUV`DW;[(?;67"=H*7-5V1.S)_>0W6`3K.%0]8X6C,-8T5CA6>2_I$O%L ME?_IC,NYXZOT7!:KU25D@MN+,$YBY=U"H_T:FZ-W_'9%Z^IL';=%[=X=(H^N M4.5XGGSP"$^Z]A'C.]*]XY,GAQ-V17`!_"$(@S/8KZ;<$8D8YH%(&>REE+Q_ M^_X'>XF4)[?/+DP#Q4PG)K+GY$HXVVG`1(/!NOH@=W$1WRSPNUC8C/7$M]9[AL1/J"VMUH3"#6HM64\M&E,MU2>5_ ME<0G?BP!R+^YOC*-\L)J]$?OY`"5&9'<5+,BW.;/O"%_BE5?5&4/K M]]0SVN1BR_OQ+3LL=+8X41'A\W;@*%5EYYU.=2A##KOU#B M1!&L!:S?41W;X2ZBD.#JDFYH%%$OVQ:M`T\8:"W6*MI&U22V.(CH8Z1VV-"A MM"@HZ:6087C)>!<%VV%)+2%'\L6#-K-8*3='7M5=V".466C22.3F<6KM8A-_ M((P@X-Q8CU5'M<_BT*1&Y7;04#HL"AOJY#8,`0H+/-YN5N]&!:WO&,K`_7[+ MA(;.BW/D-B-H[!Z.>B[*M5L5F&07H;QY03:Y3V(+J32^^3H_&[ES#H/.!3YMN?9G2QW"]V3"?<0", M+^1^0=M4C=T7Y^3MAFCW]?J^BW+Y#A4,>S[G!O&=);\5R3ABP8")[)%!"BC_ MR.=YYT4$^)RS<+]UHIVS@L")-Y:CWVH!,4KYZJB\M>R#I:==%P<.S0;H7`0< M]5L4*+2(;WXI`)R(P@H+$DQ@A%Q;OG6(PR"@_EE>82(_PEL1)VOC\F[,=7Q9 M%HF^4#_;T>Z9GPSTSU"P.7)>L^OB<*39`%T'@(;/Q;,GI)DK$0Z/BQ(,H$9O^0L2$9'SQG@J8-4&A:MSG"X-7W?$D2I/KG@:?]%NO51ZKK M>776:9%>?2S[5%Z=\<$R;YM67_'I6CTQ9A-M,%8O`L@=O;\QAF4-1>SZ`Y28 M,4NHG;S9,]ND9SXZ=-@ATX,8R$3<3FB96*)A'`U,::&R/&S1468BC"E88\JF M:<%,QYF(66$7##ASYQRRW*)K]Y>4192;A@-A/(`"5&W-85&60S9B3GMB*"GSQ]+UC:.HB8TRA<_*T#8<8B M+9=D(ZQ`FZQ@$2S6+P[SX40T*W549C71M60KA:7!1;]^)%^Y:A?U"6$:SGF#M\V(/;H;'%O6RIBP M1<"0`>QY78`S%F5>";3,C2?+@)!)K0+D]"'#B`$TDK%:'!AYYD;G=&",@])D M&WT5`/GVAP]O!3S";XJE*M=+R3K[D=+XSF$>E)P1L7-W#M^''EEK2'^DP#C8 M%("*O3M;AD0O=%.0M:[4Q7!=AF=XV',EY+9N2^4-39@F<&(*#[5"J!E"/?*% M)5N(OY(;0"@9[9:BD0V7C8AGVGQKZ)`\X',/$KZ9!$7JYI7YC5?LB#DWHK`C MP(\`0_+(]\HD8TH$U[EWQ?.;Y4)S:.!9DO)U^D7H^]25V5`_0T[RSCQAO8D@ M1=]Q1NG8_K906-#25%,1PYO=DB4L2033R5*+C=CA3FJ9'&%ECC&.'-P8LF0` MAJQC^A>:HV]$\>-'?V,,BP=`C!L#E)CQ_A]5C-%4-FF),<)U]]]@ER(3^]@8 MHW9"R\02#>-H8$H+E>5ABXXR$V%,P7H!,493FNDXQFA3V`4#SN1+J-O-)0.3 M!%Y\$>YV82`*$'9DK7Q0/4]T","YJ"CUZ!\RV(F%N]G`OLZ&/@ ML0U]C[NE[>M^=`:PKJMZTT%%;2?,_JXMNYGCB)P' MC'_)A0@V]L\?YM`^+U0DW5^J+WS>TAO8K:K<*GF-,(PUT]E`K&
0L:9J6E'T(H89;T;K9&8. M_K9DSF'I.U+R%Z<3J]J#"/O+DWE-)LLRP5/SJ#0/(!@.++JD3\EGFMQN\D6; M*#2I8<7&C@M"EW;EFV"DOM="\*)#>#/``$Q$%B18K13[E(NZDJ+SN_\L%JAL M3^!>-$^2)+8GZ,JMZA_.CC[=Q8\0_8TQ[&X#,6(,4&+&NPQ4]Z53V41L>U:3!M3Q+(\6.(050$Z=,?,88,4F/T MV8#X0>&W(I(CJH<7VS"_/#+ M=;`)HYV(Q.X(LM#OC1PU>II!!0S-KHBQHJ\&@]_5*'PD5``GHK"R'B=AQ10> MBUT_C-.(%K>IXJ4!*QG;S`.9I[!E7H/1CIH@=_4ZA:J)',N_(W;:6C&'IV*MGB#I\/2RY2&=T9>,7.Y3JAN\Y@QA[]D;M? M;U-4MO>ZG1$[;G\=!B\_)27G"S/N7.9X^623?(3#5RRFUXS_H8 M.4&\H='MAN$9-6X\S1F`8WC![IWHL9'C[H=D?I\?^6+IZM:O;"_6>VGQ-!A MG7,1XYCFE7_%R$`%@GA,D)V$*YCZ@L<$*?D^9CG,R0\/&3<*?)?/652DK@0 M<^87J_.;#C;KDA').9&2U;S8.*,)+O+HC>Q!73F"5H1^=?W4@P'3>'*!->(# M[IFX:B_]_K6R+W]!;U5-^N:8;8F]ND'3I^%9HD(VIGLS.%3&YCY_/(V>G8" M]B^Q@N'8$H<^\^0!:^#=RC++C97'ZPELK*I8:Y@H^TJ_)N=_\6,N"&*\9&49\&&,@,D"&UXHW M8TPQ%)I4@5>D(K(`)U5H0*A";%+*34K!):"UHQCY&<0G0GY+Q]"+^TS+GT&N MG"C@DD#TSU1X[)G:JJX-G8&#'*=^N!G1'ZI)##5%<3?7HB]!A M!ZLP_.RPX/5"B'/&=(@Z<5CT5\=/Z2?J@&YMAXWCJ2&%!$-F*B;+X:2P!W<8 MT&QX8!?QZ(8%3.[)7&^1,A`%$EL(HEW:L+HX1? M%\)TK$7,47U]N#/%=/VXI2*LC*]3E$A*B+9N+1(B?',#OODB?'.GB(D>OJ:P M8R&%J)9PC&3K9B0C/RM+16LK18R6M#@G=%:1:#U=Z=$9,[;W-D)YLJ+;$SM& M]U=DV4O!^?2MKRB_:K9O79?I=%^_8*)-%#BN@L4\O*,EAVQ?J.) M(@5AV>`8J,HC7E6"8MH3,JQD),69\'U29'.V?\-FVX`(88L^)(N!)-@0>_X`F#Y[-'&LGTIA8?EH(@(`>(T359-K5% M/CI;5:P\+*MKB'ALMLL[:F@F^="X+54Y?4,D+U%,&U<$XHP&P84*4+N+)?*,"HJ)BS<[-(`'.]J[ MH[XTD*/#()-4XY1[$$",$L/T&!Z86W"3.9Y5?L@=I#N*OR>1U^`B';'\?2@L MW4E,AJ^W>`FN.16396SF-7;#'7UTOFI/I^T]D".#AKK5),B-S1'[O([4PU,D M`VW"B2,;M5US7$>7Y8W;UOFKK?VR1JXY!"Z'+JZ):":E;?HK:";FNY1Z988& M/NWR/^S#V/%_C,)TKQ/FTH\*:);C2_4>)!#[_E!-QER:Y_R4M"$VD[56 M%.6>*[/.UAM&?^8S0!:_'QDQW)%CC:*)V]/,J#;"]80`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`'YHXK%HU/-''.WO.&8<#XSO1;,.!W9!^% M7NKR7AY'.]X*&.YIQ$)OYB/-90P1=;YH+K1`,DEE!CGX8H6P9_D'7A(9-,Z,VYFR]\)XY%W3APX#YS]6":RYB& MQYFL9H8=1G`YD^=(_(MI:?YB.:: M="R9MK+=*S+8;VHRV%?%('*2L!=/A,]\K2//WIE8LV6Z#KGT>B*%^@'JJ\=0 M&MT0GROUD=Y,E8;X""UL+R+GM$0%!.1NC$\K;L@W.;#TYLM2MA,S35DN)>XN ML&(/,8I"'^LXIN)I^0USGI@OQ,KJ;7BWP3V("GLVWN!S&$3Y/T4D5NLJ"V*TFU#9H9#04*!F10HA!#2H8J"!3(3F5!&V%DZG.2+OS/K? MY]B[-S&D0&;&2'7'T_TH+6?7/%0QL]MEI+5&[)FI`)7;#=$O0W*$T7:/1FU9 MK,=PPA`,KA\38IX? MTKE@-E/71X@89H9XB3N]SB8P(9>-9,)5:C6H\JU(*2%T5*Z@I)"RV`.:)?$R MS.]4;!J+@A#2]JY:3X-^A9\I84$6Q5,>BGOP!Z]Z/![S)4YVJ\BIAA@>ZA=? MXZ2@QOJ+$WDBU>SM7D@)&QGY3>(XWR&`@W:=1ZW#;!81%@;511 M$Q!14SR'")E61$A%,K%6I!",*)(A!&1T)G84>)NM:.7[YO M[H,D,TJR'&B:^_,T8-U<8BP#/&>WQGP9[#`B\V+,K4*]I]JWW%&3O4Q=`K^< M;4O>=`N6[G9.=.#K:_853Q?FOL&:T309+[&5+[E5 MGN;F)I%@?8+0+%3*NX MPY-WE$0)4"4_`UV+P_.>[KG5MERZXF'&L>:7X,CWUV%X4H6<4_D>B-0XAV1G:7T]GSGT-1^QEOWQX2^?Z.Z)1G6SM_I'I&Y: MKT2QRBS^@GT->2KH""^26Z487M:MR!>6;,F7;;A3'[#R\:N^2H5X2T=Y/K@B M<>IN"6^4;,-8OGGQZ`OUPWT>GLFWBSL:N0S"7.!W'MML:`0>F[]:G7FI:_F)O%?'(&=QNE&>I+:OR,I.A,$TWN)A?4D,NA0LU+0C7 M^B%/"K+.5)FMLPEC=V([?.G"$H(B4!);;L9A,P[&D$Z8^<9'G%P.`EWS,VSI-\& M'],DC8K483]!SJXR75>=1<>1PPRE!@Q5P.H(6M@AUH1JAA:U^T(4$5">"4-8 M7@.`P>+D0#9"IC+OX\[QJ)+ET=HZUZ8E[RJFR[F7Y1,X?DD!RK2)0H269'XS MP#D>BXT?;).6Z&HHX=K=&C-`=ZO94GL+.HW;4E+H:=+2+ M,$@B]I3*%ZX73KSE>V[XS]4O*7MQ_.P8]),3_9,FL!$HLVY=!Z=:U]G&/`O, M+CV100L<,$P?^]IL*G6'EV7*'ONY7(:5^%]"2U%D8NY"?J9MK(D-@G2#D MLV>41SAXG"K_;4TY0`)G_R^"QLRK.6RV5^412;/!^&!P\S\R+.2<]9N-\ZTOMV]X!]QRBH:PR([2TQH_O.L(;VET'*=P8"/06;+.'VAZ+BY'LB'2>._FT M1XHBPLFHXVZKO;;4%W46N`?"M0GDY8#=DA/'H=BN,60V4`\;:F# M2<)D538QSEYH=)#MJ\TGL0YG]A0BL$\8>2QPMJWN)-Q@3I1#BM M4:%MH2_?59,\+ MX>PM.5P'<"W*>=YQN>$0[NKA[JXY\%FG$U*G[:=T<>+4V0/[J9.^`@9.GIB2 M`V-/HX2/65$=,\PS!*Z(E(<4`A$AD3A\+1/QBB.3N_S)L6@Q\P'1]&9K,`0$ M+5^1!W+'_\]B?/+T^M^F29SPSPX#),\?*5Z[0B;,(I5D%GU!I;%88:P]YRH' M#9?(9K:0X(6/_^C+/N+6 M+^=`5!8RVZ3=QV+3:_\@#T3AX%-M]R'ECZP4"2I.>%3;%4'%Q MI&G6.W@X,8W9"]JO&^^J)C0(=I+PZT6Z(_TLP]R*2'D6B7`&35D';^1;%F1W MY=]AN.]6'NV^T-,,"F[#G]74!GIWW@89(0?!Z8Q;?_=MB@MB>)Q061-WX!6A M2&U>$+>IR5&6D.&WX+I)0GKD`<%^=J.C8',V#Q0G-/T3=DR3DZ.:1D'$/_[X M\!5-G^`T0YR=YW^XO[JY_>OZ^MYV M$H])\W1@2L-A2E$HBP(8%3R3)YHXQ'D.`Q8GY%O@^%UU])A,L3$@F]'",Q?U MSE*T](Q$'J:`.PA/%0DT'#'4N7R4DH!^(9O4]V7%"!&\R@'M M.7)V$NF>V0LTAO[RX@=0TV>NJ.](8=\1PYR?X6B1BE#%TBS-/GO>RFH2EC*; M3OXIL*8OFEQQ_L_?*8F)\I%G;P=X)T?8;9354&T)4VQHBA1$=114]U%U[1#O MA%K%'9Q.0%VX983M!^+E4D$JL4RFU@B\MO;+&*S-JM:,V-/&^(=MB\RCQ^ZZ M,G:MAM?-H*VCH^V8-!YLDP:N+,7U*8U=)^+K(G<-.4?$RO^<[P+>K^7/S6OQ M0520^NI(LY3I0'J3P+Z"'Z&1@36]RIV4[$G)_TP(L"(.V5&/N2R@*_)ER]PM M83'?SHJB`G)Q#L](CX\YQ%-1"IEUH"$+(`-`VR9BYC6[!>-W6YP(KB1C:W-E M;\$\G];G:XL5E>!@N64UK_X=*=(VJE*I>)3_$?&JYU3&P7@'E*ROR(44K8&@ MU19+&%_-P9W*G[&/,5.SJAQE5@,S)]!GQ.K8C-]\XG/.+MVU>LYQ&^2^4ZN2 MZCV5!HC]IU[.P7._I&;9AR;1R:+[.%^[W>>H#7;WJ5.IXCYJ`\SN4ROGX*$F MJ=EVGRETLOFH9W3(S$U'1+]A%LB==PJ#5E\5F:./&#HF47/X6R5#(5RVGC,A MLF5#Z?BJ_=0JH!9WM.'!\9/#/7VA0=H4Q'K2"#D^U2M5V=I66B#&B`9!!V\( M)3F2T9L[,]ND6D%PN8C/=PJG$Q6=C:;RK(>1VR>?/0M__QA&GYA/XR0,BN3W M=<>R@RDA=3T#YE&R@@XA@_V2:*16AH*_=MD&PQ&O/$2H59C`&WS')[N<>5DP M(=DZD.PSA7RAXM<6"BI9,ESC@FA%2LXB8*[@793GL)(/U(J5CDQQ.H1F0-]\ M-N&0?PGUOZAW`[>9M\'Q>F8XE26B;K=9.A&WF<12T59#(T-(&V5++;@GSV[; MR]J?Y`OS?;Y,<2F`2UF1YJB88Q$:"C&U_,\;%L6)+'+'5S<^2`X0[@1!RO'[ MV0^?^'\"FI#8\2WDW)_=Y"T87:QTP?P9WQ41G`EGC0BAIQR2ZA@$?)8#J&O@ MD&\=ONO/*WH->J;9$\(?]M1E&T:]!^`O].?3U27E%MV)G%.*D?K8MB?=)<+\ M$--U`G\?HDN="@;I:&AR:'*\;%DNIPLO$X763"C.?N^S(IU6S=11ZHED&IC5 MW"T30R$'$8)D4P*`HR)+9?I`-%?,:L1U99#*`2JGCC26)YK%"*T,3GM+_L8II"/R]+A4%DFG!IMD:YPV2K7S+>T5'9/=22DYS MT;+]`QA8D8[DXB&:6ZR.39W!./_T`C4L^7:)_Y1=A3QNG>1*+-0NX+H+LJ+U M,;$FO25.&'U,U3DSZ!!;ZA302S=#6%_>WF:U[MU"B*-;7&4GPF)"??8LTB[S M77RV)T$R(\QBQ6;H+]GGM[G2?%*"["X<9$"$[[.8[$YGI,FA!$$"!C'\.GBA M<2(NL[_P?9',*_X0^EZ=C=H:8T;?3B4+:&ULB1TWNP4?.C8?*Q5RLTJ<,:=, MO#22B8SXLICNPTBD->+K#!9Z,^/==-J7E(D@O2)9ZGV@;@&FIM.TN>QJ7*.J ME?*I+P[S`?_X_#B8RL!:\SO@> MZPS.["HE!6W7%OWD_-\P>N1/T(VUJ`Q';!N'^38 MH*6RB@>M'1!C@)[<0T?Y3^2!Y/2%PY<<++\WGUCO-P]OR'.I*X922S\]E&JN MGVG@`IAQV"FAIL.AM;NC]^U^AJBZN5Y?U![?4X4QSJ_X>\Y+SG7J!&<9".8R MQQ$F.!DSFTDJHCV<[-//84(U8:"K#W+?UU*YFA>BI0-B+]>3>_A=5D:=`'D\ MSCR7UI9KQ5X4N5+OG#V-.ARVOBUZ1VU1L>J@-0U1.V:;O,.'9DZ5"++6_7!B M)?=`UIX#'A\*M'I@8V/D+MBNI.J#]2T1.V&'P$,':,WAC54WG$C-VZ.+T'!# M'K.Q4/N,*"'3T[T3YI\3`.OW3T;&R-WSW8E*V?5M2T1 MNV>'P(//7($LD72)(&P[Z>&4>NZDGAL@;,\5SQT?4.%A2VER`VQ8&+1#!?V#E^^+X$"#UQ!Y\J,"IBJM)\8-"W_81RN1*BZI+\`,MZ5N,9]V&4?)(HUT9RMONNJT= MD#MNM[*5$-7&UHB=5D/HP4&H0)H`;:(0M^RO4^M[!FE/LDT=1-:.C"EH>/?R MJ:#?<;C9W1JI"VJJ63Q]:6Z*_>V+AN0&7@36CDC"?XCXG_T#V5)?5/,KWP+. M_`AF0C.4I.V?^T66"34_=1L,0X2*()%+JND21 M@@@Q2"D'`4&(E(1P4>RL6^Q;L-8N.!*0["*&/ M#M>[O<,B.+\$,>K.LD910PI!ALQ4'$X/)X7]\-J`9H;2W87`#Q*R!23).1)6 ML"0^N!6DT6X[[9CYS-NB]=JA6K`GP)\4`I!2`H%) MOM736"3J=:@RT<&_R(%0LB4_YXPM70S.;I^,Y"%+C"HKN=H(;I+%B2&=,>B5 M.GXNV9T03#O*HIL.4L08;9KV4*D.(MCWH:-T,K0#S0MH[W1]!D.$U=0VJH^] MRM@2A2\IH$9RQA*6-;V!I"E%F&LX,;P-8R=]N M9!8(Y5E"PQY`IQ]2G.VMNKK-[>R$>%^K+_O@:T.(__@6>'P'MQSB0#_&P39RUK<5YXSKP;ICSQ/PLQ%\>/MX&]X"!4'Z$-_@< M!E'^3Q%9V%8.PB1]Y"!AW)0JF!@CCAATS.LXU#?+(VB2\14^OR(%;_'*5>5N MOS!%8;[S@R+TQXC^DM+`/;1D1]'KN13WZU:_UK&:NRW!932D'[QJ+PF3@K+U M1"J%YG5ZMV94T>NYE-'>K7[M:&_NMH31KB&]6>A7![[5_"OSFF#5TP9VW3\N M9N?6!`^:71<(`$T&Z$*`XWX+@X!&\0TO_Y35G]V<$+,8H53VJ>[YF&575Y?> M_;V]MO<2';[9#)T^?]IU:6[?HH%ISZ_N]/`Y_P2FJ*B,!0+.#\6/?V8TXNZS M/=S0%^Z%6KO;]LY+`0`M(S3L<5MZ+L']]10PL?`MR*/JOEVAY+ M085F=6LQX+3Y$CR^16H#PUA2)Y(\EA7O!"K_[S2$-P=W$7-I3%A`UF["7FB6 MS3\6\3K7'B288?+L]_W]NSW2_;L]_T\^_TB/?M8:L.>_1ZA M9YM2^8$]!VS#W39(LN>AMT\QC5Y$^)GDESOR>UR._*&W(W]8LB-_Z.?('Q;I MR,=2&W;D#P@=V93*JB/_%(1-3OP!@1./"%RYZ4@J:IK'4H#"I$E-!U3=+"!I MZ31ZFCAADP*)0"I%I/QDP8/8R)9P*R$8@M2GN.Q;OJ(N'XN+0GHR1?8W?$/# M`B<0M2Z=TOY^*;+-ZK/!"XT2QJ$='H<6AKUDL>N'8,JA?K5/; MV0TQ.O61?G!1DI*'>!^]4L\K%4:VDBK,;8,X?0I%I4V`"5%QFGC<$N_?OK>X MA(+"VO&=+F=1<+T MF@=G?$G!!8]IU:5_L.?2`&;709Q$XK5FH7:#B9I;(W?A#C55UVUHBMAENR0> M.F!%GI*2\*S.VI6R?"J=95ZG43 MSYZS)4E('!))UOPWT>S5F68RA:(\9T.`#WD,2<:)"%9C7H9I.7A\JE[3:6+_ MWLMQ=1TS-/A[6]=E.;V6)D.'NSAL8T"*^W:6[D(Y4,H^%URCNW[J\?'/`@X# M(HG"&_*XY>W+-DY$21I3`16>G/$I4`TCF2""!9LPVLD2P$X-07EFR) M)P)KR$[<+_"E+N4R2&X MT[LU&^HY.>4B@U%$`6S%'8RLL20Q.*V=F&0;..5N-5(MHPWI0'QG,/<^94L?D'-R:#XT'G2(2D"`1DP3@XS#/G< M$O?%D%^K0[X^%]644X:HK3'(6GG/14\%%?7U85]T6SS$5[4PE);N611KX4"> M!LEB=N^3&:<1*=='6"G8801%,W:0)7PNG"@Z`.@-SKW>5+^GK$2DXNGMIEZG M.D/T)X$9^`8:I"S/TZ\_=B@980F)5^ZNO>QK$5!XF>#3B M4Q"+7`3OK>C@Y4]QE%!9.E/)4YSJ9G'F M\"LWD1=^3W"0ZX;/@?!H+Q41_?)X-Q.2;(2,XFB74_']\$O>!K2,$[7!&W+U M5=PXPM4C1S&V$^>_3A!``G5Y4AV3+UL:%'_/?PG7D,69,LQ(A'\!7YQV[_=1 MZ+C;%8&QFW-]U MV0Q:/MYH]*6JCW"O@SG*\@0'NC]^"4W9MB3WVB:Q(T.-FK8R6J]QHCI6#D@ M^"KG&=58XV<:H/9JYYJ*(V7I..7]$ M,.5\Y!_`I"$S>J]QPE%--7J^`6*O=;JIZ(9DMMEPF9+MOZ<;P[AIY%./GFU` MB@5--D:,UG.N^0\,B]RKE&,=7XN883>[5SC:H;EKF&;?X]U9B? M:DQ\Z?%3#9=B25.-":/UG&H&)>0P/-4\L*\FS2C)O<:)1C'4Z'F&TWJMTXRJ M&I)9)F9?_SW+&)]E3'SHT9,,%V)!)KG'KJ%;0Y`3D@T;]W.9/,/V:_]IA92$BRN`V/6?MU3$E0;X$* M;["7?_#!W5(O]>GMYF'+/>2769TJ:@CW0VF\R4:E9$8\01YU$TK^/@:@J9)##1"3YG\'N/J-(051SR=*@T MS$0B0J8QN/D=M\-G9T=;"H`>-4'N:W4*J>ZB_AWQB*\5<^B@!6($J%DO MQIFKU5IM\Z310H9<<[W,:HL%##M#A1V5@6>UG.7L:HTX,KCZ)67)X9J/N@!* MZ0$OWJB^.IU6!Z3>HZ]LL8UO;8U]BZXGO*&D#$"92(ZD8$G$N'5BN:U]X8L1 MOC:)86T2?@FX"\V\BYW6(+7*"[/8*?4U@\K-']T@/#WL*60KO0F#YT<:[>YI M`GSX$AS6LS%O7U\AMV]?S*#5UP0%?NEVQ`YEO?4PA&H97P*,SX`S*5B+P[YR MT&=>(`4B=U'X'#D[DHIG?U^VS-T2*EIDFS)'MH.#0-XP2*@W,Q;.9E'5A.3( MA"4SFQAIQ13MHZDZC.SMGN0Y!N?2LEL_;H,42%M54K=.E0:(=T[U<@Z^31&G M0T#.^I9]^(E;:9+`T]KX3\0*N0M,:>#*0?$$?!`[Y*3J#IYS@"$Y[S@R/L^. MC+.&U2-C!1JX?`3+$0M*G2@19RW7(IU'RI^"%T^4JWC^L+1;(O=KM_?!`:;?O MU;=$[GDMZJE^5],,L=>U23MX4LAHHO"X&12\XT)O^1],GP3^E3LU"YXO(@;A M5$[-GK2E&5)GZE*L.,JK:8/]U*Y-Y*%#[5HM,_44IHG,O@"+TW!#7B1'$?P7 M*S$0KKKRE6=O,Y^W36&+C";)B8[8N>MY7.U>NK7A@KSN=!_;W&IAGF=H<_.8 M>5JLNEH,AYH;!OG6L3N=(3. MK[TY9I#14+2`FI:VV`%'1_219RH"00K8D1`CZYKEG`E7+>7[LIE19DK=%=JD M)&[SMFPF;<_<@CCBFXBF$\:;AG*^1@DCA3WSQNMUI]!)%?'A@T'E1MT7=(28 M=T28W]@J6HO)C'`04K,.GL0@+S1Z"M&;I#J:Q';`,K(_==OCZ=@>^=G67<1< M>KOAO7=A(+XVG[P@?*/M`TS%<`DSP:3&/IDA)N&&?>:85FEK,\I*.5`&*>'T M0[@MO-AD+J$%GAMVZ;,@-/I*@[ MJ\G+2..)&6(_`)E-?T.1S6[)5L2>AB5C#@&2,$)!ZWV&UE;. M>-$;7B<"JYC_:@.P+HZ^E2(KR85M*'8^1_@T]@]P;+Z6H3YH1V)ZUONKG-4Z3#I^%FM@\&IGK2Y]#>SX7YRQU8/4YBGF>FLF]I'8RS M2%5;HP8](?TJYXQZ`XZ?*JIT7^T,T:"FH8E!A7W`^N/Y@7QAR98%\F]M>YWC M?K#7>5W[',,?8ORLL5W MQ?GA[>;*9\_LR:%; MW56^5"Y\AO;!%AR@C/=LGTT7^/ZJNDY9OSC, MA[(''\/H1\BVV1;).PT[I!/H7(8V\H*K@Q?VZ/PI5;88FW^Z"\JE%'>I0LZ% M/0.;Q>HQB2@\JA?[E(K)6!RG\`1V^;B;)MLP@J)7$W\AE<^O!&E/3#L%Q!9, M?@78>JHK*E`MQ%LVEAJVLLA$X\JW8.+54EEI0M1B+-@M'5C%_]Q#"OF8)?2! M1B_,S8[7WIG^9!V\7BO`ZIC8",BV,7J-0*NEKT6PE8<-A8`DD]#**3UN8S^R M'=U$D/I95-=UMXR^2`M#`)N2JH;[JEMF558;[*_=&3D: M]C-"I0R"5D_$>-53@<&%$W(VS=4Y,U9VD&0F,S0E/,DK#!N\=WL,$\>OU^8Q M/*?W17GONG/:/IV1^O8P(Q275MH]L=\Y]5?$4,Q&`HR5TME.0KXPWS^J+9_= M04,'44_>B?B4#+EIH;![I1A4-5&F6I?A6YAGZ5=GM_?I*C^GSS,TK$@:L&25 M;7S"O8QE@_<+4,T[8T%8$">1,&3\G7@541SRQROB,2XP][M8;)=<&B4."\1[ MB=1/')#@E]3QV>:0)]5-(NHD,IXT+@G-?`DVWX<7G"JA(!5@?PSAFY?\+-P[ MS6V+N`GGF]R`!84+S#,'7(1Q\IE^31Z_4/^%?A+O07M:KH'$0N>#-H/HS`IU M_1<\-[2J8VN&"+A`)!$2Y4^87_%\01@7*=ULF,O@3_4[1U$<<4<3/)/+)".G M8XH!G@28$LF52+:X9II)#-.UHXC%#Z*231)6/6N!![QYH=["^6[!*1^W3G`K M'?5SF!6UD2?JIL^-!O!'.AU:^Q1&#H?[,D=\`#._#2P>(A=5L`NAB9`:)O^` M9'*O2"%Y?L>WL./EV3\-5/`B89K$?'GAP:KB6[[@D`N;[Q:73'=VZY7WR$$8 MG.5+OC1C8F^:O`[XC$X?^/I=V.L&.($)FZL,M_=`/A5IJ*M.'BW-$<.]CM3# MJSX!;5(0)SEUZ\6*&[1NK3K9H[FY#G!KA^6-:$-%=EK&M-6ZNMBTGK5: M+N5^L%T'WB5]H7ZX!PFS&[*NVKD:/9'[=0_UC^KJ=G5#[.-]I!]^."AYB/+9 M"I?\8MA^#=[Y3`#GAE[)Q9ZS_T@#&CD^5WKM[5C`^)K<@0QA.NZNVQ>YP_KR6AT1.WT_^8>.^8R+\/HJ'R2./Z\91$!NA8_%8]I\^7&[IR!+\+QVN40L M831^H,]BP]Z\%]7OC1P`>IJAS=WPN_?&K*/=?"2!2EY6%[`3J^]HG58T+;NVI2?JR3JTS0N?FD%FC0W)ZKY\G51!B4O!YN M=?"V]LC=NE-5U9D;&R-VX6Z9AP[;(M^@()W%F5AVU^FT?5`C5ZW>$R41@\A# M(=!/`4OB^X>?NFZ(6OL@=U$ME8]NA9H[('95/;E'7(-DU#.'%?3)/7D@/]F_ M!9I2\8>?,,RE\CET??Q6$7LE:Y.+<.>3(.\FLL!9D9@MO@YDIHL?HS!NO+R;A!-R5)[0O$9> M/32S08S$4VIK\25#\59!R@*6$\!LNX\)>+$QH[(PT>0;:W)`M3Q,6@*0? M'1;]%5("K^,XW4G5UH'WB2;;T`O]\/FP?H+(#==X^MQ>G%\KTO8WOQ'DU6?[ M&I%X@/86D1FD)4)I(O`43/-F`NEILKXG3)MVKAQM>RYJZSX"<60,D.6Q^P M9/]K1_&C#S$KF&>\?\V8?FR"Y4#[BF2ROU*,-_5E&J!^17:2P:\(\V69)FL? MM&#_J\?\ZH>8%_,E[U\UYA^98%&8+V5_K9AOZ,LT8WY6J0X5YC]U6_1)QZ)7 M6?:Z1QKM6FMX3,5P";@^J;%/D'P2;MBQ>UJE$:)U+B@!22U",T[#%];A2NS$ ME2:D;GXU-YJY>G\-?4[&9\EAKG/Q1LY+P.%YS#_9TKJ>+79DGDE[S!!=BOQ: M#L@G^AB*H5"MEJ[!3A-:+\2$O@?/69RT\R M!603`BHH4\7"I@%+7^KDW1&-$[83#_0W8,H7,>OF%3N+(IW9"U-[L\8E?4K* MNE6/SI/?A.SU+9&C;XMZ*D+6-$.,8FW2#D8:=TN]U!=#]"8,GL]$E`!PJI2^ M^UEPLY@#%V0#T4"R1\ZL)9M[0U/D([9-077(UK5#/&9;Q1TZ:*L#=46`L/4, M[,>:MN9=;VR\L%':G&.]ON6"1JJAG.(Y68FI?V4!@_4ZV'9 M$[W0%4L+L;P?],E&C]CS,(K"+Z($K9,4Y=M&/]W4%1F=8)0%`J.J9M&<#/"J?-?9&M_:`'_8G&< M0OM(_&L;^AZ-5H(J_>KL]CY=D:7[M^\_ MF$?5'SZRKU2 MRR^VE#_D9^=D`TPE[HH%1&64_V`'V":W1,Z'"$;BXD6\7R""%\F8(<"YR2WQ M.0S.(.-ERH7)OOW>.!1;H3'\%K,VK&L^]YQ#J'9%2DJ M#C&`NO_3Z8=X-]A+_''Y!DG&!3*Z2CY\:2%.T+S48A> MSP4[@['R:Q5W>,S=(?<&#*?>/LQFM8(3*5D1R8L`,[NU@VP9 MXRPHC7$ZD.PMH3K`LZ494ICL4DQ=`"&#OK:ECO&1:=\5)U--5CS:1\SE6W;. M*OQ"?OO^CV_^*$YV9.)T>PYWER8:_G;:"KF[-:BE>MM1$\3.UB3IX%D@37"X MFFG%*I[F/(4OE/SVPW^\>?L6@Z?=RX(T=T[$MT"1$\2.6)[%YP?U+RT'9;T( M(/?/_L:H%MG3[8W8JP?77]U(,#VPO)@7QR$HB58Z>#UXQK0F'-KJ!89(K;FD4_ M.BY=[\*TT6];FB/WW"Y%FR?2LBUB[^T4V=!4"@_*74HD<0Q3J4%5;T(G($ZM M9G,ZI+C.8"\4R@S?;OY,O>?FYWGU;=&[8HN*53^L:8C:"=OD'>Z!.=65+*8= M;HB@;,O]IE`R>\X;BRCXT\N[03-D0Y##9Q&M?[LI%5%>.]YQ>VWA?7'=G:9V M3Z0..$#](K9!KQOVP(:>6AB*:BC?AW@%7\*4)[;[G//,$0LSF>-SH7_)J/+$ MN&!E(5!A=AMTC0$LFP&U.LA#(HX3952XT[(@Z4$`*4@.-T;S%J*M-^KU3&\E MC&TSCHKO2(:DY(AA[S&I1:Y15L>L&D!YK"9_C/F\>P^S;U,1G#[]%P40&J9H MQH>6SHN!!QT=QCV*!(+%$UT1^(#FX*Q6^3N(V1CA"$7_Y3M"U10]'4%V7K8C M'.E@P!%$1-!QU+-\0L>")*P\$!>E?[S0]YTH+L.&!DTC#9OJJ@GNJ4=E.D:A M]SHNY\7;#?]5X+*]X\MCNY_V87#KRE-WE__Y8QIXCMC$^1?BO7W=HGU:=DC] M;2Y#%WO^"7EA/RB80_6A(/"XI?E*$++.<0C8YR)DQ]6+"?&F(MSM4ZEI MGH`B*O3)8,1)LEP798X)LG,.D/9B$W).XAD2]*([$H<["KDKX'0.FL-+B\I. M5BQ5^5=)_21G&!8&$5DRR*8T"I%9-<0*UZ,;%E#ONYF/03!_[.-0AE(Z_ M#TG$_DE;%[D]NB.=BV89&G.-)S=<)7QX]\ M9YX"IX>1P8[1([4:ZBAKSV-`B6]A,W_A>V8_]92#*,=W4[\XB/*8G\*=[M7= M0]V1T9YOE;E;<0D/LBF@$-ULJ"N:U,2(S0SBENRLL"62;X[D*F=`IM.$(--$ MV+_0Z"EL0>_78*AY+Q;+:Y[L,HEZY90FE1!;<*_M=K$7$:1H/\XHQ_>,^A10 M;U@'*3+J_+GDMR(%QTJX3N99DJN]V)P9#5,NI/.;UFS6$_3EH;NX&G$+F>R! MRF-$G3B-#B*91`:_[B\IBTX"G?5Z((<+#755;&AICA@(=*0>?,68T2:">.[> M*Y(SL./A4VI\ZLZ)<.=(;#:'1>6V)UP7%UOWX<'QX0G@1SZ`?_3#)\?G.\X' MQZ>UNSG]KD@]=(@!CA.N=_7#OD'KJX:A$[-JR$"4,R;P8B*8@"^]'`X]4`(XB)LNWCH[(87.?DJKZYOV'HB7.)J"#QWE"OFL M[&'&@&0<["QS)M9::,IR3=TP3BQZ\$/Z%#./.='A-I+A!)]HL@WYKNV%Q@FE M`&>W&['@.S^<-LZ;M14Q-A#'%F6$%_* M0W).*[$F$?=Z(N(;*D37=;TO4.5]=C$2[4 M*OAXIS@>^O:S?4VM.AQ]R+*!\3=\Y;)A+AN4LJ3A@$*(*\])+U-(KB\KJLL3 MERS=^IWON.)VY3%4DPW6;5K&D4/JT*8,51QNC*"%_<##A&KCS_6JY_.>$"0_ M&.'2'-]![Z5<9)\+!C>%T$"FP=R#=#.?@MBTHX16R9Q([D2R+T^',Q'(G6JR M2MY0"T./G`@^!QV;0-PP7]9^#V'R=;/SQ%]%@,K MPV[UU74)[1;WT&V3F_AC%L]T]95&+CO-:S:*$%*8'V^_+ARHS: MK)X]B84/7P_!&;8,`5U'$;QT%#@#IU5*NRP;(%E_<2(.3YE,D$-72@6QI1EX M6=K@SV]'88N8T)S@V%6D(0`"`<[AHZG?5OFT\?FA;)-]5Z'*D8'BZT#:\&^4 M/6\YA*]?:.0\T_SO;4_I9A<"._!9^2@5T)Q5`LR`:\<04X)U/`*M5R07GV3R M%ZUD.@-+<+ZLKY03/W,R&^:30KD\=>IF"TSOI.^BT*74$\$K?1:J.OV0P[.V MZI7*?EV=$(.@ONR#XY4R#C)`26YU,R8%P%A:*DZO_&,H\H8X\9;[OV1F\?D* M>V$>#;QX_10GD>,V5I*H:8?<;QM5J[PS.6Z$V"^;91T<6Y13)#_G-&T57)I. M-P3.E;VC`SBYX'[?98/3YDMQM09%:SWNJ.T2'*])Y.&I1_@DX!5.Z%&7+_@H M7W;_]NV;W\N*L>IK)4_\+B2J^01`KR,4W2B'YB`=NEN[Q6TF7:-*?H M]T;NL3W-4,VZJ-45L2_WU<#4J%\1R8IDO$A1G(MSL^/S<\X6K\K=+?52>`YP23,7=8-/+J#B=>#=A7$2T83)3$?G-*`;!K=5CRP!3B49WI;_ MENM8S[[U`=T2!$>.:XNPX0FXXI<:,<(OR'B#PP4R%66N4,FE.3E!*J M)=%KP@EBX@3\'Q5]2:[P"F(0A,[`NJ0I^L"?N.+-0ED_=9E\0'2=XLPJ`')H MGO]C5//2S<4=,51:,,+P[`DSPAR"IZP+^C0/>^HR/@?BARR M_`.!D:\#R&D#:63%-5D64'L7A<^1LUO(9'!/?TE9S!+Z0*,7YE(9;=:WHAH.8K#CBN%M&7XHD M_GL:\=_NLB=O@1%6PAZ7;)89IH'Q+US6%-0^VBBKPFY M&HTV&+=.*+X6U&I6;$;,J@A![FHB[Q`BEGG+*5'X$K6&QB`VI/>`72UL:HL] M;;9QO%V^Q1Z;,/W]\$!I+*LSBH8^G!PE<'(4 M%2='>ZGFS(E"L%@;Y"!'9VF9**20A4CLJTP9(`X1\A!5(`L)1+"8\I[N'!;` M,;`R<$\7N4X!NH\>KM9QS%-XO,T9@&-XP>Z=Z)&/#%+'O/$,X$AB\G' M(&WL$]`4J@[UY4P6*'$'U=T3YVM>FDXFI0(O%T]11>P1EPYJ:WJ*;.*-MI!. MI*H*0MXPRHN6>JF8H9XRN4E<"#[S+(31Y(4PA$M#KHJ"@"`0^19$^@Z,?7ED M;"D7R04CI606IB1,=OWIS<,;LCD=STVC%D:T'+GV#F&NA9A@/GF5Z/APNOVP MI319!UY9B;(,+HS/#_P?^S!V_!^C,-W'UT%V50EMQ&N"E'I9F#'?$K;%P\W' M'>FL9NDSJ.<_,[%&?%`TMP6&/\J4+(GDN2(%5Z*R)25?^_%9T]OV)"9H]J][ MLYP(+0N?8UZL.8V!^37BC;E(("DK*81=D4Q<(N05T4!*O6I%9`@>'8)8-[;C MM);T>1JL:#.O1HW"TJ*P%H?4/;5-%&-VIKLQR0$Y7D]@SFK"#V/D$>/M%%J: M=5@!C("SV:Y;''C4-ZU`K/W40'@L"\?.82#B@*'0(HTI][.MF*"\*'TF'GVA M?KB7L5SE?),5]N0FYK:%'3D$=L'QL0<_Q:'//'&"'.?S@2`?XH#:Y!XQOW083P`^=`XQSA8T\JN&%PJ#)F=JS=RS\(216155XW.]QP-[G6%E>! M6=D1$/,L3),B*_23$#6GQ(5=V,IP!NN+]$O"N)YJW'%KNH:K_PM(%/T4`N$7 MJL30W6?KTW7@798+TRSB-[ZG;/>43[;9B>?>Y"U/YL*;8K44Y4[%-*Z/4E<@R5]6&.-72)]`@N_H_ M*FP542]U!72RX&AWJ&P,L]"AF8,#$'T@U?P0!DBCQ&DSF"AZ#B$6I>7MUD&F MOZ1@([ZB3KI*F=5SH^;H=XJ=8J[IBJQI(H$53MWX4>J\GYK;^R MMOK<]:T7-DB/U&P;IUG3!0W58XF-C5:1=^5GH(UKQ%Z&$'NK;YVB_?)&;575 MCG$K&R]KY![);'CL2NH6Z\9CT-::KWZB4*U;SSI%VV7Y:%7%%O^4#9?CFT?R MFEL!2<(X7'(B)2V>HA\I>-,1F-;2?%E^>*)HBRO>+"`^JU-DGLS=HZ3;9A!&=+:W$,U93X2;\W=J?M9X:3PLW=73&[=$\-!H]Z M42^O9)2_\%R1DA>1S"R66Y[!$)(. MT.49*[C'\.B&S\O>S+<2LUI-"SC%2WC.4F;_M/#:<%:3B`K'Y=B9`$+5]55, MW3?/X M@&1+,X3K(!UIAS\1R8D22=70L?7H$5E[5-W5=EFC\O2(NK7ASX+[9S:,^;.QD@]3$_)8GWI2?<1[UEP%FXVQ'$3]L(2J/.9Y4W@ M"Z`P$JUE]YG7QM,9L]]SX3MQ?+L12_VV$R6]D@13EO5 MZME?0V.$:PE]F0<_,@."@$%ROVH[/D/5KS4PH[8A\F':K)PZ/D];(1Z8+<*. M&Y&WQ8BT&G4QF7YAEWXS^ERXVX6!D*8UQJ*N'7:/:U*MXG#'C3#[6Z.L(UX9 M@MY^1ZW3M!K(]FC+U+G&F2"8INIVQ'[KK.W'@8V MH4R>AB+PWQX!G"V":.S MF+IIE!TKM`\2@VCX8_A"HP#(KY\C*K8IS?#7UA@SWG4J60!<8TOLB-8MN*%G MY89*,X/GYTDC=K>AVIT0^I7?1573Y^Z^B#TP]ZB#UY/2`8AW_25 M'%9$9"H]L"AWF=XEW#7.VSL&%>*_K(84ZI.LR+46[U_F,N MW9MZ"R)$T&= ME/YM]WYE4IVEJGOG(%/*/N?D%U*.]^IKEAQ3A+J?PT.&NTR7=>#=A7$2T81% M,H$Z#>B&)7RM`R_E;S>UC)K7N1CD0@Y"&$QT@G36A4(,IWAL,SB#95[=^%Q6 M4@P\>+'#68NW.2(U):>\DLDQP@VIKX9L>T^22R64`&,*%3(-E`^BUFCI\^>61Q)M M'9![:[>RE6<2C:T1^ZZ&T(-'N'BF?OJ>W_J2OU[G]JR6[5T6.8Y;^J!*$L>=.LF(9]UH5MSI&1_$DC]=HQ!RNP]_?IC MC[4QY?F8V;B.PY"R)PM-FY"?*46<0 M=3^%'MLPZEVFB;M=R^H8C_`H/[K=\#U/,];J=L2,L+V4+W!5JQ=V-.VGA($H M]M_L,HY$L"2.Y/D;D@BN'#(YVY6LV.+F93SS3`]:7C$S9,YCP4]5JV5\B&1$ M!">;\#B/$1Z5(:(J^9_?EP+=$_X+_-?97WY;_Y_4$L#!!0````(`'N!94=+ M]R'J;#T``%6'!``5`!P`=&AR>"TR,#$U,#DS,%]P&UL550)``,9QCM6 M&<8[5G5X"P`!!"4.```$.0$``.U]6W/C.)+N^XDX_T&G]F%G'ZI*DF_ECNFS M(=^J'6-;#LO5L_LT05.0A&V*5//BLOK7+T!2$BGA2H("""DF8LIM`R`R\T,B MDYQV$$0S\7S_UOG0_=8#O!F/H3W_]E$2?GY#L)%$#HQ&J#S^7/>\+^N7AXZX\!-YL"/ M.V[>ZR>,9^M^5R$<3T&G<_ZE^Z77/?G2W?2^T"<['Q'\)7)G M8.X\!&Y*T:^?9G&\^.7KUY\_?W[Y>`N]+T$X14-U3[ZN>U%;X/_ZO&KV&?_J M?DW_NFZ*/@\9$UH/C;C7Z?P]##SP`B:==(Q?XN4"_/HI@O.% MA[^=_FX6@LFOG^)9^/$92Z![>=+%]/_;30Z.U;\#?WSKQS!>WON3()RGW/_4 MP>/_>+DO32B>@=!YQY/XX@;SK[C)5['14A*%N/VU+GFC&.$4S^0Z\,?`1WA& M/T2!!\<8OU>.A^<_F@$01^)42@UJ)K'/3HC:S4`,7<=KA/*M+QC#AO5?H^%D MN`"9QE0F?-KHAI/?"!R$/F4D8ZZ#^2($,]0&OH.'(&H$'H2/F,D,)YK=><'/ M9IBP&7R/Q-_`R/6"*`G!#8C<$"XP,HL@1?O6*)G/G7`YG(S@U$&`$W"2$,8(-PM>=`\/?'2\!C\#! MC2M37>4K>F3M+&#L>/`O,+X#`&T^"-T0G_!B#%#BM1 M0AQ&DPZ=SV&?P1]*SDI*W"/R9(*3SQ6KE# MWX`8:1\M&_3ZTR;LSS7X0!O)K!VZ!H'\,5NR1]?@08V/M8LY_;URIV^J$5-G MN0B/;9`94X->SH#F$5D)XKP1S2/S1#F9)P:8I36`2AS&%&=KG07(&,TTUVLM M,X0_JJ'D5M(X0L/J]CS7D"=I%(..B75.1NP!C?!*U]$WM*&D"5N$($(CI/QY M0'_,J<'?4Q7(5V`9^(B!/P;C]6]AC+_3[78ONYW/G=5`Q1\=?]S)1NU4BP], MZ424>H%;FHN'PT:#D"<__)M_L2@I*>84I]1& MP/TR#=Z_C@'$,;.G^`<\_=//W5X>O/IOZ%?_RC[^`J80?]./GYPYV)HOK=F_ MSD_.OO5/3GK=DV^7%Y?=L[->8<9%^`S"\NR=T%U]`_VX@ZBRN/(67Q=IY-=G M=P:]-4HF83"78F@^BT"2JB!$^_>OG]!/283F&J2.%1Q_MB\!72/*0L>[1TOD MXQ]@29705CM;1"1"5BZCO@89K0A[1<,21%/\<_LEPJ4F%\2)1D$\@Q`&B*3Q M#3K8,R12:F>/:/ADY3(ZU2"C`9KA&,_RSG.F!-F4_MY^F?#)R65QID$6UTF( M";Y#YJ/C_3=P0OJ2H35MOX2D*,N%=:[/$LAF^P(608@/G3@<.HGH!@&Q>?N% M)DU=+K@+;8*[@QX(KQ&NID%(-^!*K6P1$Y^H7#K?]"VK8#X/_-3#FKKLHF$2 MXQPYG$))7UR,3K;(3IK&7)27&LV_C2J_0[\A*4=*R_8+38:PU:FVJUU4F<$J M)JQ"6]O$Q2-M)3":'^+O7[>==O5=>7+9JB(>O5X7>_36XZ*?KX=/-[=/H]L; M_--H^'!_,WA%_W$U>!@\7=]V1K_=WKZ.FG+L%=$[<:*W=+PD^CQUG$6:;OX5 M>'&T^DWJ`BQ@.?_UO];D#"=WT$<\@4B<0009?D"YKM679'6B!E&$Q,J9?KF1 M,4NRBF#PJI0@B^H51&1.`+),QP\9JZADI#3$((Q`VE*GE'-36DC86VV-D[F` M[&@"%R'-$KGCY%E\>8G^N?TS@>^.EUYGQM=.&"Z1=9?&!5%P(-2WQ+QO7<2\ MO@FX$!'Q+CRJ4VP)7.AQ9#AF8_-?.7MI"D1N%*L@I()VZBV'')C>0?@6K.&T M0&8G^O0R'5<.6Y1KT1?@`K1&)?(4HU\'&EG!2;J44N] M8JF#`AU*Y3D$"P>.;S]P.!M`^G6(SR`EAE(4B4!/*X!2EU[J34_+=A\!2-@K M?&$Q[UXB28HYB!VO!4;&4^"[2NR,S4"&`J8A&X-#MR(S0[?6>`Z#!0CCY;/G M9'XY9+DOL#/@"=#W%7H7.R`B3:$B:Z,Z&"A&)C>98U?*POW:+>IZ9#9@,FQ. M&*=Z-$'!6N+N'<2V[0:$/&FJ#`HC[$:FP6B'9!FT4&-6VF4;/D#G#7JKS,7T M1CI/K,$[6+SDN*Y%NQL'AZHW&+4(ML0`+/!`[(*#WL$X7-22+Q,N(I3;XM7. M2A\@ZVB)3TTWM$7`U M4BW9"V[G"R]8`I!3OLM$RJKG]K,''_5(UNXG4(.3>Q_-`$2QT)9`;FP?(B3H MM.3&(3TJ"RL)2FO[@"!#J"4^A)M\LB_@'?@)1R&0&]N'`PDZ5?D?C#M+"I\A M[1._G`;8S;IIE^OI.O#?01A#M/.-DC=$%/2Q782OU+C>9*&^)@-$A7.A.A,L M.7RD-Z]HKN5B\B2\$%J6&=-#C#FQ"AVB)%MRP-ALG7Y\C?Z%?"7"ZF([.J1I MM_0`(G9O2>Q@.T0D*;?S7"*A1+;:VPX/.<(M.:ZP'T4A6ZK4'K8C1)9T5><: MW5:I["6Z**/M0X@DY=2"!NT"R/-JMBGYK(PP0DOC("$IPUT0B!*IZ%:4EJ73 MT[>CY*4@4M+I)3($>M@'#EEB&_!L:`^S?`W3.O)+KKK8;6@?(`1IK.O5N,QP MX(-I>E>[C81S38$UXS',",&!Q_=^'HU<6"2T(!MN1_N04I%F2QP=`]=-YDD: M:9`>Y$M/6V>5J/$C+D\@'DY>G0]Z<);,*!:"2`$#+/&,O."JUSX8WSJAC[;? MJ,":S<.G)!#Q.Y;9UD=L.VTY;BK2;(F;9)=]PD=?^Z`@2*,EM[H\#T'%1`+C M8-%PX/=VM7AD4\I#1.ANG/:JF']4@5WM201-HR:JG#I)XA@[F?VW4 M`A,EVYTL18<0F99$`I$HOX^B1`H160>KT<`@T9(X(!+5?)\ZIY?5F.#1V<"S M%DJN2R0M!8&>UHBY*JV6>*IVRJMS#01&#QM!(6,:M-T7M4,VTRZ@M+87!'R+ MH.WQ.*4;PZ=D_@;"X20C_C?@T8#`Z64-(*K0V5@6I/'<3!16ZNI?1LL'0\_ M*YD&F^+"K@(UR;B=C%O%')9OBMQ6HDR["XA6UHJU$6",5K/5<,J=$TJ*I5W]NHW2%:%#EA=%\"YAOI?XT+ZW,>^^$VK[, MI!/$I+/6"%J.*$OBCEZ01!`W\;,.-PCH7I!608_XF1:50#T125ZJ`3/^,5W, MC7RQW:C;+UL:"SO6@5_$CGRU7J&#UX2:Q$)IW7[9W;H.[BJ-;#<" MU;'$DON];>YNT2^X\6WUL@U#5P'R'`34SG5!C,.7Q*6N$**5X:3^BPR M4](#JM2GZ(O6IZ#E"K2K4H5)N0.#>1#&\*]4=L,)]P5O4K2YY!#E=7&*UL6Y M\9I`&9V-'9ST+O]2Y;=BC!)GX9]42Q*Z'CX^O]S^AMK=_W[;>1B.#$\6*N2? M96!+2W[O%,L3KU(C-LJ!>GT-4"D5!:[,&]RTMM$0&\L%NUNB"$[0 MT2R5U_A_DBS0$SN"!\/K^[L@'#D>0$?J-5,KKH/:WSLNA#WRM>X>8&8A>@+[ M.&AF]#`.CPK,"EER&_/@:SXT.]'LS@M^BAZ63RL>E@>CWSIW#\-_MN>0O.:, M^(F8T$73\1?/Y#D,\)W#^&KY`P'@WE\G,PW<&+YG5@.;-/F!3-845(%NG7A5 MD&S)H??H2%&(B:-[A8&TC1T780^V&_@N]$")08@O2K1:$Y\Z',SNC7N6^&9N M`)JO"U/9HY\]D(+`'QEJ'/#VAH]=:%;FER4Z=!6-!-*S$#+[6>`B M-S["J1*'+-%5V]G/YSNEK5"7(1TV0J)NVT+]-]CNC^ M=K!8D6-2W7H\)M5LP?7><7I`^F^!E?E^SH_4%1S@B#9E7&NLWKYN\`W<3",C M:0#XCKW3PK#;[6H62)T/$3_"?&C$'V4&D%;FXK.SK&1LY_T. M$3XB++"F//,V\3<)>`T&DPGT(,)T=)V$6"+"\"%W/T0427#"FAK0A)44)FCV MT'E#;(AE3*#=KH<((D$N6.LU6EU#YJJ853V>W_40`23(!55UGDU*XB*HY)R6 MZYD33B5TT5:_0\21"`MJ%XXVV)Q>T4]^IE*XWR%#A\4"9;6E]:XX?#_SQ+?IM^E(E!4'B`Y39>('8>&FDDI)%PB[$:O+$FFO;'3ZL ML]'R=/I-E*`HNN@C'#"\))EBSZ8Z)V@Z)P\%:39ZHNE$VT^>U MSO>IZ_-B#&0IW[RZCZ($U\I+R\7S@,3K=T!8JL2*!CSOV@MK%E=5E)4ZQ2^.%(/& M!/02I6>9B]^Z9^==6P%5D1F-I!QHSR`N+J\7L%CSY@5@WKAHIJGQL,MU`-APDR"%W7]7"9&]HGS MN/9Q\'#P59,GJCQ;!8^#=KV%^8&=?.@??'O_[GA8LV=O(FS'N5&0)C.$<5B3 M=3G4)E;5YJ?[<5,B'P9H?87A$BVEWQV/&D(JU-=2I(A0J6@_6Z2@1-,.XP,# M2N\PD-)3MB5E4+GU=4:]C)+%PDO9YG@KMMW[DR"<9[+C/"P@UKOU6J4.G=;D MX*WR?2"O_"5N8I[(:XAP%Q!<4BVIU[RN;K:Z'?3':[O]'BTA[O68:/\R$R\1 M$UNVG=2C5'N>)27`Z#5T_&B"7_%&I[BLWL%5$D$?1-$((":2RG>+=S1.Z/6$ MN!5)5)T%EB@/[$RZ#A`OPPC'L81PBGCIX=\.YK@.0H^B-+C]K,5-/0XT_$S< M-STH*J2HHT64S,&8AAM"2^N1(DIS`]$6!"]:$P_%X9*[7A`E(;@!D1O"1184 MER?I!3XNRSM*YG,G7`XG(SCUTX<7_3@OMH+?&@T\Z!9\MLSWXWI=]+_.Y\[F ML_@_-E_N!)/.YML=QQ]W\J_COQ2^W]E,H%.8@<$ORPW#J>/GM8\WC_%E#Y0\ M%R2XKHOL>)MW^GBO1ZL96TOMY#I3W\`(PY2%SE<$R"N/'NJQ[VD8ISJ5PK-4 MQ]D$SC9F\S6KDY%IBXL>/X,P?8M&4,7V=U4L&JB#1^H@W=I9C66PLKQU0A\) M=TTY1__1F^M0:=NSX>D>:GOCE`1/+,5U+T=52QYZ7L@FRVXS/]["E1C! MF*5<5;3EI[/KT=W2Q4Y/:\3G3`>&Z:76(W!P8QDM<+JK!=;?^CP)PL_X:YW- MY])S$?Y@)_UB9^N3^U02\CQAZ8PZHRGQR,I/@*\MU`U<6DR77;28^AJ52'W1 MKYVYS7&GI:I&.-^8HUG."/;%9N@.'KN#!^_$03'4YW@Y*_=\=^6FXWU.!^QLC6CP M47Y#0IHOM)YU+OXT!#H](.()CE=I(9P#?]U!M5S8B<[YJCAGWAFDYJC&:!BU M<"E=]S7`H99JI(?`G[Z",$U$$-1#%[MZ"(_R&0_3R<S&&`"G M9_VS?N^R>W'2[5[TSC3=U1:DQU,+Q+;F+79QAA,N9X5)5+1:WT'X%NS7@L!J M:19X:/K1#9A`%XHNVV\$\Z$PV+]W-L,9O'I3BR>?,@XCCI>X6@LO;);324L@ M,'%.XIY&X?[&+7$Q$9;"@6O1VM*=&6?2P^SIT[0^47JW"7R)P(I+TE7">M#4 M9;@]K,$KG\$/X>U<<@P]=Q`"4^1?0\@,8IR&J"3J\G5$;?I;JC6R=Y%?G0]1 M+='K[FJ);)#.:A2#E<*:7&$5P.RAZ8F*[0GQEC>KBW&+64!$6\].R-'6TH6* M?TKU4@+&F_A&P35+"IDLC-]S!(%B*N/ZE1-/GZ M"G-!*/>2,=J4R',75P5UARTOJ1Y:4B?ZO7T5(+'EWE//DY:JF5'R%H$_$S30 M[;MX_$&/$#"X&:FS'LI@U;)-.#>SEMP<8^&L>]'M7_1Z%]WS_L6IIHIUVQ/D M^@=H[8U;\5*L)S@'I`AMZ3*NFXHAE9*!$-CM-Y62T?G;ZJ?_,%N!'+,SB&RY MX)/T^O\[=L3,/MYU8G[(W<&1@G MZ>FO;R86.42IUD1-B*I+OB5^PS6_LBJ0B(.%LFTY#\=#_P5S)^-N5[%XX10G(3/<+)#6:6 MMJB>#:Z6`2T]:)&3PZ56_?GNJJ>EB+?$BWS,%=_QC-[.%UZP!&@S#M^A"S:) MRD52!EXZE]0WNO%49"_XI/2).Z85?\\8G=56?)86_#M)W4^\%/)QRG MBFR8$A=A*S)C':[!G/U.R&!7^Y&#@G)C#&OLT+F_R@E2F_3%[B9=KI_0EJVY M?B$%W9H&S^K>1W-)A"JK\#N:IQ&80B*O="GB6FILDY-!9-9QK[>[CBE)6&U9 MT(>3C54`NTRR4):G:!V? MZS=;:N9\F<+&MJK#FODE-R!VH">F.4^;?/&C\[=\*H;K6NNR2VA^4B'XI-LC MT3,JWMTXK=9,6D!=CE`5E)X`_P2'GB^P8_?)F8/!!Z2]]$YJ:HS(E4AF=U,3 MIMDHH;Z`11*Z,Z18!],0I'#>)N0FF#MP^QU#Z?[&B%]:7KNBKD>T=A<@1?M_ M'_WC$L_&B?'>L+84MAL,K5+3LV:?T4?&$X*090,34YL:PP&&E+E MXD13W:%:(K`*8;%9.(:S^4WZX"JR4;"93ESF%44\:+1AVO[BG#S#$(7RVF*K]C=P`_FT%TE,0_]NR1. MPG6ZQ@\?$;1>)$0,U1BNC7AB`V`+4ZIY8ZHJVBVWP`HWI+>V'A"2I&L/*:!,^G_WQ>7W_KG9Q??SG6'%M0M84"X%&OF(^6E M=8:6UH69)2.(0F8%`S3&':-N7&I2>;4D#\#PX3;X1>/`N`V9P"_#, MO3CD=3,.6?L6LBC,."PSU;#.G@:Z][&_`M'S[#EI!-/MZ/F9[GOF=FH):C@R MV[*TJU&M7?"J`A20-0'=&&39"\RK*V);VR`A3ZQVKXZR`J/HZ!=#[&!(WA!1 MT,=Y,C@`GHD*;C];$5*-<$O*AJ8)3_@NF&48%]L8AP(]IBR7)0QM4OGF2-%A MGIRP6;CJO5J2$^,V5/MCO+URK=$0 M+69X/=.5%DVF>GCS=%T+_=AL;AX!G5Z.S7$X3S-HSL8V#LJ-HDHYB!E,;&FZ M,+5TMEP=<`"5:Q9/+M+^7,QN%TL:$'5AXQ13'7* MTN^9/4;=]"K.&S-@:]J3%'?A(\X>HQ!@0(:9`:@1%Q[!.E%`NW:'E6B&F402 MF:&B5B&NK=M\&=)-E725O$&Y7#@[95^)!Y9X$I66#SE'K/EVH+:#,'>,2D[7 M5&C$`*`(RXOD+ZY#M*F[1Y5"(P;(L9XPMG8"-IG:):=FS3^'P3AQXV&85]1F MJ'Q24^,0H$WE"W.'ZF37*/ZT,&$V[XBIXJGMC0."L#RHHA0D4KLBH"5@PTGB MN]ED'I/(=4+H(ZL6IYX'/HSB*Q`[_4'V,UW7RX]B*A($Q;FU"2BB7SM(%%F( M6$LRMHCUWXT#@;9]@<^RA*0$C8;ADMC1/PWC=>6>;D:#EK*EFB-@"(!S)F6V-` M("L+KA1;>`Y[74?^7,%@,7/"N4,_;E$;FRY2\1.5'(G:I:HH)FA5B#Y]>GPX M26.+&0M77B`R>_0N4GC$.9QAO\AKF:`_RBY0!_"9:. M%R]?P#OP$UJ@A''^$)/`"_.D`15XY"JC,``P56E"J)RC[P1"?4Y>(A48A#U!E/%^P::2L[F]%)ON?,_'S)@ MA'C!<*W7QX:J_8;&M.&;!Z>I].Z"\!%Z((H#?_TT@XR"88]TR"A2S3:JET][ MB7HRB:M-&>W#-V""F#9^0.O)&_I2&QA]E".VU+"L@@=@4$W-H?FLE-"G+\/4GY=T.V5&. ML%/#LAQDEZT$V<#W$\?+*,;5O*/B$USHX)NN/+3HKH/Y&RZ_BDA;A0S+H+#& M9XXPW1-/5S[5;BN!C!]Y0CL"^BDW@E]G3GR+?AN0XLX*&RLA5`C2:K64U M>'>@AV]:D5[&^KGPCH8_OG-@^+OC)>`1.+AQA2)7I[M%KM:?_#P)PL_XHYW- M5SN./^[@[W;2#W>*7]96`TN>2:R26'5&T_RD%W7F@J]UL?N75]FW[ME%5V,] MJ_I"ISS*58$)1M4L>G3^)PAQR9YH.,%/'^"74]('583>SA+L;0P6U`AP%Q!U M^-`V.#"C)H7[&P>).B*L!`@&'RR)P/LQ>@U3C;I$Y'\/WD'H4XL@"?5I(V@8 M8MZ%C3SUUD!E0^T`G>SP4]Z8H1L^,%LZ6HY$4Z6:43W$45"O,\>7$K)H7WMD7HMB M[3;8_N*='CAE7J3&,`8^33ESZG/#DIL"1DQ95C("/Z$=45^S%>O=2CBQQ;\+ MJ3J\4+55%\3T,HNB''X*L&LEWM"E<@4F`W[3^D,>< MV+B'CL8:7+)D/ZW"G`?T7TU`LS3N$9J5N537(4.L3J2FW!65WHU5"^8X=B5< MWL\7#@RQG8PIEHO5YXUF-;B:X$U=$X]3\.K$-.4GK=6L1E1%\A7%BI3+[AEL MS.&@BTC")SVY2]P($S8#$]B>/E1"Z?`0(Z,46T MRCC&H4>)I$7NK:HPQE1W*8G``5*/SA341A!OG`*C+KO='F+4R6$@J!)C+#D= MXF,PM@F'/N;P<)+%$Q8N_2F;&[>?<6AJ8C>KQH5&"V2=:7L;U05@'.%:J1DO MI$UOF2$.`EVU&:*HW!7-/%\7E32T1D+_4TGRC"()??5%$CK]8YF$?2J@]90& M4032$B4/T'F#7A[;E$YS//1?,!DA]*=9#9-P]9]73@299124C6^,ZFJ@S$*S M3#(J[WY-ZM6RP)V[$/R9`-]=,I(*!'H:@Y']")8!)$D>F0D1$@G,G`2!GN9" M1%)D#.%+4J_]4-\<;*+URF)&J(MT-1>V-:UV\->DNL8Y7%5VV%ABC5EJ14JRV^:B,RXK8&[#YQZ0$J_81PBM<4O-,9- M2XSC9K+/[0$=&P2[P)-DCR7.OBTK86N`[QNKKWHSA,TO#<%?$4,%%: M'T$DR1M5=A2[U%ZSZ9_7S@+&66&L.X"7#QR_!B\@+9SU[(3Q4NY%[+/=%[$+ M7^C@3W3P-SIQT'$Z^7T/8#-90$KD5.X*B=UE^?U[= M_'=G0,J[%.]HC%90P.XM]T!U^AFVK^:27-=!XJ/=:('G_^3,`2.>BM349&G+ M"(ADA0I2*R#;GA[9OH!%$KHSI/<&TQ"D@8C;5#'CH83[&X,":>'MRKT>T=H/ MN12=_WWT#[KO=_U'X^183QA;ZIM-IG;)J5GSV!4^G`S"T/&G*;\8"IW8UA@, M*-?HXN0R/`FZ*VAN9A]EQQ=G\YM7]%.$;!DT6?8=K^0HQD!"7I($KZ4"VK7K M"HJ6?QA<#:X##TD;!T2A.=%U/J6I<:)6(:ZM?4"&=%,ES3W7T.[@)'L;@P=E MNX$*!C3@!234\6H:(O\$<#I#_Y$77/P1@4GB/<")P-E?9C23(20M>5D=!XH7.@@?AV]=@HO**0OSR3"FHX(5-+`HGD$&5> M72)>:2JTW`!:5+"BD;A>E3)V44,^EE:A.Y(8H M\:I_V3WOVH,5%:QH(")>@S*Y2V)0ZWG\#A^B3439XRV`G"119'-;B6J-',FDGLD)48HI? M?P:J<)@/=T1>#3XU>L3;FUN)1C0:M9IGB37@$6^U.&6'(Y-"]EV0*-MF5^,= M\5:'40TDDA@$-_BN5+_A\8YPJ\.H1@^KNN$V@MM/`=<=[@BV&GQJ]/0J'3^H M$&N#"9J3:OU6&O2(N]K<:O0-LST]+#6*`_>/*R<"X^M@CNE.QY-+)SC?32=( MA_VE%(V?FF%GG01*/MZ8ZC40*@81-`G^*"^^\@!B3A%B/=5"$ MVI.?G9#J:XS`*\IN2_BUR-:.`T4Y$>D6A;["V*)+;8S!@*X]FL\-HUXVJLZ4 M#:'^6&BK;^)3QL&-+WZ"Q;\OQEBBE&[G"R]8@LRKP2[#NMO2.,3L3?J[P!-E MCR6X>0'HU`U=="SG(X?8]HB=*@S27CV>8A+_CBB`_O0ZA&AHZ!`L'%HS\W"P M)R-'BB&,``C5ER];4R*:(?2&QHA3BKULJ>S7"E`OT6<03H)PCB\TK@,?4P8H M#\3PFALM77%7A"R%9DEY3X<5FFY[X%3-K3^P,2C3=>YMB(66U,?=7`&QN?.V MS9WGO$;+,[*ULBNF>>"G%E=>4)N%Z$8^:![2FT$>!>+[XZE9&ISF5Z[*?+2) M1,Q4_8TRMWN(VYK?[C4(*N=> MHUD`VI'YZ'S`>3+'Y]\0OB5IKR@WH9PILJQN/3C%M>V+XRH%<*49''&NB\F- M9BF8LAQ6.U?:*%K=Z3PZRY6^N$E2(ZPYM5YG(L?%H9G7K+3-5U[6+,6'J+ZCODQ_8P.?.[P%H86C#;RPJ/UU M)U4,3.(9(N0OL&TS-?:=(^:;964.]LNCNE\%`KV`/Q,8P1B,0/@.W=Q<[*D& M/.M;1]`WS\[5C5+7)N0/O'1P,";S,<_SI<6N"W4^7&S6X,\*;&;?7[[B(IMD MXEZ#*_`"W&#J$S9_NT=ET1KSZ MDQSB"*;*7%I!RI";.\VFWRI#;O7"9C3$521>9XX_3/D2/>'7@B.D_3/S6K4Y M*/O]PP.^&2Q>K9IF;A7/517@V415I?]W`]_A&/CC%\PKDMIE=B@SHH\8<6HY MUBKR9`6.ALM6:ZR/L^$2KT!.7[I`3J=_+)%S+)'38+PVAN6Y7LW5FA(Y.:^, M*J)R[R-UA?03XA2>^@/^$J:0GH[/Z&$<-)H5Y"YP9'G3!B@P<^Z9?8R#@ZQX MA`7,H->>W&:`&#T;^.,;\`Z\8('IS_USO$QG7L^V`(4AYEVH5*7;$L!\!SZR MB#U$_6`\AS[$NRV.X!>!C%!?*T%3G7+M6?"*S.`5^X8+@$GWIP,7,0#&$$0C M,$UW9;IM(MC;..CLVTZIPR>SR@MEDR60P2X5Q.EF'D!J"(P@_BKD6[(OY;1G M.>X)3B++N,![=YW;SSS,5)$R%2R2A-N%%NQBR.@'8SF\L'I:CAAITBTQ86K6 M-#0!!WLV1_C6JAACR496*L67WOL1D66E*X;>_9!28@L!E$$,Z5U?EC5G$TQ6>`+).'S)1U MP&;V#$4:%;T3"QW$_PUB:NY"X]\[7$3OEZ5F%4\[1K/7"+4^0Q*].)!%HI?% MBDSJ=Q"^!8:^Z'DB'+%\(A^Q?'*,6#Y&+#=X4#%`$[8F8KFLTLP(4ZUYO6:` M^)L5EM3UFHD"MNIZS0"X\<6OXWJ-A[QVN7$:NEXS`#U[0T+EZS6[D/2"^][6V)PP*DPUG2K[3FO3PCC!LAE-$8S]*_41^K@V)%.LI39F"I8Q MMUW1\NFQ1;A9X4^V<(MM;!`NEQY+@@U:>AN!FT*82W)S$;OK4]:!OD[!X:_.UX"!E&4S#-& MHL/H(XAGP3CP@NF2XY;?PY>/2V+?S#UT(X;$OA<8_7$7`G#O([)`%+\X,?5: MINGOVK,B:@*UX24CS/M&]Q3I\FPM63WY25G7(LH_?UQ+^M822P3'/4B0AYE+ M0MLJRCY_7$4:5Q%#!#9E+[SQ>?@FPD,LA?/BZ=_6PR$MQO]'G/,VO7T!Z//LP)'%>4 MSA4E,R MVN\RXO*^T5=*V[9ZB!?/_P1P.L.9I>\@=*8@_>,-8N>:[7N))>#.XKBR]A2( M4$T2^WD@M=D$R8?`GV+ORPUXB_/41<&LR(MN;SLK$@_V&8_6P<.MEQJAT,+PVXGRA<=+^2$V- M%)>($';%)TR>T?)C)N21&QLG0V%)\(7(H%![*#WE)3RT];N(0?TOO?[9-:Z( M$,80H1A31(R7%^MDO)`9DMJ(N0:MAHO[\@Y^@/3LA`V5IR`&T4T"^MW^)5?H MO*[VB;X2Q98$A60'A7MD^R(6O`;WZ.""9I355N%LX")=C0-+]0V],KE&)3?R MJ&!N^&*=C9-Y9Y=:"0 MV$5J\4`[+-3H%0Y8:,WLA(44M988$L])+"#_K59VBU^$6%NB(E=/7EU[3A0- M)VD5$)&WW[;;&X>(Z@:C'(T,(*R5&$+@0:9;(.R]I^.R$:+<+'3]RW/0:\6I9_`NKWI'P M`,8AI+J>KTDT-?9;-P*8NGZW89FX"T3::*O7DPA8T@V;MRH!RT/\^^@?] M(+_^H]%B9'!]ZU#.ID>[B+26GS-`J#6T+9,F:A)`RPK)&2`B-J,I@K%_S=6L M-6:*8!ESVQ4MGQY;A%NO2F`[A>!4AZ.T-D[@U7=2&0H;R`'2 MX]!8QW>,DC=$%/2Q;8DY\13X;A)B;E.='`)]#8<'6\@D[T=5FAD;@F9WY@B@ M>2.\%D*":4[JW9:6R5>40AO?EBH2S5W\Y,:6H4&"2%775OBU,_JK23KM@SO' M!8-YD%`A06MN&2BDR+3DG<_G,'`!&$=WB(_I8@#Q<(+O@G%^2?K@#^UZF]O1 M,G14)+C16@V:"I_>@#0."+ZG=`\GOX'QE)ZI0FAK&33$:6RTP(#T9D+QGF>/ M"`XG&[(*3P\^)Z$[PSEX)->Z6,\R9[YUSWO=-DJ_+L6-YL0;85@4ZZ6EX0CC M/`S=8:@+T0$L09$BPFU,$2^SI'!`SWZ,$(4O6,"T'!P;=*_=65R4@*)9'>:8O8`RRT@+I]`;11@<.)^A7O@L7 MCI>=T7XL`G_H9N=X%_WY+O''#A[$\:YG^**`9*XT^#E+(*2%32O$6578FQ5N M/8I#^`=@ZB[1[I;@3@G9*QR1?+G:M[+UB=%9I"3PC\]Y0\LD+$C@2I:LH'%5 MN]#J3)?6FXE>@`O0#-%V.?1'((Z]-*B:?.)CG8GE1[-$TDUP806'9LH(2Y=` MI0#IWG=#D&]W67!U2OT@1IKK+8DQ_:_!=@+=ML.UQD@V`4@A!U;@J>N3+3^Z MIKV"+F;NQJ+/S7PPWO`[XUBZAXY99R3Q02P!F$+B5]AJQL.K"5FO(7"B)%RF MN2'YNG.1#1;N>($%>I39=HG8UFLS9F0I70'$$+J9["9:.%T.0WGQ] M]X(WQWL"\A:!^&:*.&?U$5!*VY M);"H1.8*"G7K3]+L$DUW0C]\9QZ$,28[969^98ZKW_H1[=S+[F092BH0NPI3 M(WEEZV\CZWC%9FN5IMOE+/`0*=$-F$`72I8L_;9;LK0XYK]W\E';4KDT-2+R MR6=.+ERBB_<8+*>3ELC3Y"V"8^B$RV&8S2FK#'R/3.HH!@#OAWF.\M5RM_&J M&:L$JLI/&*=/Q(!0BF]MFAWFACGC:B7#2:%4-"-/D-C6//$W+4S".4:8,>8" MH3![7(S\"4UK\YMB7C0SZTER%./`(R[)712HH%U[@APM*3Q`AK&/;9'!-`0I M18PD<5ICX\2M0F1;YUDYXK7+6U7"5((/:PN0%+/*@S37TMZGB%`L1[%_BRVD7\:6O%R_"PMN5>SVBM>L/=45$3)!C M/6%L[P1,,K5+SN2*?B9@0<,>(,<<^TL!&@$#*9D0]G4Q$BU1!VI*`9H@=T&Y MD0PY$=(LD?=&[Q74X0.G9@:[4YE=?<2NT\/;".0YU.C;\-+[",4L3.G(0D!N MDA#ZT^S%N>SJ/R^0_NPY;G;^#HHUW4B&9(WA#$:9L,BW[$W5W&A`1:D/MJ`0 MG;Y3J`Q0`J,=#IZJ,J/1XB":KN=WKYJD[QN)3WVV'D`5Z554+X06Q*$I?86I MF-,_#E>/&H/0A;OYX=4',@]5#*M1/->$IDJ[DUX)`B<#\V2+,AVIA.&*^"BZX#/T;'%>"[$$1RH=J7 MNZ':A;$[CC_NE$9O2\@VBT%K8CE[K^08>DK(1E%I8JS0;')CXY1`)=&5J\@* MT]ETT&P$W"_3X/WK&$`LU%/\`Y;E:4&6Z%?_>@!3Q[M%4R8^;D5H89S4))B^ MD9@H850Q-2^9;&;$4(/M/QLC$U&VE@7!)47[Q3+EHN9UO55>P6"!#,*Y0X\0 MHS8NDWR"2#[3)SVN++8N5.2HTBY(-9O?]\0)'3\&8/CFP6DJFNAJ^>3$>'^@ MQXGQNAD#A%JJM1:UY@8"D\C)B&%&@_&Z&2?S2F(3DSZ7;DO4PW,8+$`8+Q\` M.H.L&<%^')S1I140X.QHU0=.;!F]@W'0J+5C2-+9J'=>TRXS M1"O"P0Q(%T5TE^!5E3]3EM^+13<)[9PMV-M\U+`%OXN<.H2;%1*FV%B)[AP8 MIM%-&P\&SU(A];$/,O+D-NJ^/3?%?;N)_^;Y;_O5_+>=_M&#:X('=^3.P#C! M%Z`5\,($X MNN,5PV8XV0R#VJ+?IIGII,\S"WT8/W'CM&5MSW9+>=Z`^[9./<[F.4?E$<,M MI7U>QBV7EJ*=<#UMI&B-7)57@9^D=(8!(@RS`'&BP*L-G[#ZQ'J23CG3(]C< M!XU;1V;"C[Y,]B022_Q8):XQO9N$EL9B=4\8X(#0?B]HX[J!YU7=WP2,P_K1 MOE$CPP8\0L8OQ1?P9P(C&(,1"-^A"[)\#/KS`?6'-F[Y:$9=S64@P^5&?>/: M7I&48%:Q$;M`==UACRA7BG)1#MN8%R;%J!L892_FX%O\9P?2)OG4[F0`W'DZ^.]#'P05#OZAD MAY-!%`%TG$TBM#:B:`30,J4J'H7#&Z=\!,2Y5@U-\\$25]B:I;FAFJMAWNHH MMRXSZ!0QZ+P50*E"5J-&^[?];`OXI_0>/@'C/'P-V7)R.T1O=XO&*2H5:*'I,SW<5+0O M>H8$1:^9N`[S';@Q.M[@5Q5'8,IYX4>PMW&PU`D@0@!8#2X:%>^13Y9`!C-J M@]?-./C4$1A!_%7(M\0\SVDGKR%FW(-`3_-P4T725,!(DVX)9II7WKSPACW. MP#@,F[5UZI:$+5$*)-(SWF)'$J[L1VQ28&N58V.U+QS@DF"#D'#AU3"W+=E) M2C)@B^`%O`.?FAPJ/Y!Q(&X:,D20JF":/5BLQO^LJ#5^@VR8Q%G`T168!(7+ M,=4JF?_%([KWSEWME@CE.O`Z\!#N`DS<.RC!JL8^8+@VST>99^>:O1;"18W!GPDFX1W':,A= M"/5W+X0V`W:R$=MR%;3-"=XK))3FJ;L>^^HO+[[U+T_/+TXO]3TK5I@@,\.9 MT-2X]2_%<(*#2)1&L[S'6[-&WV-=/9!;FRY*J7L!"1)-ER3[`H#6WGAILD0B M)-`#RLZ#6%G*G=K!>##(Z';$8A$&[^@"7]F)W-DA$ MFHWD!7N>&';!^N]E)IPA)ERTU@Q@$R7C/M,@+*8Y7VAAG,#87*=(B4&+)2LP M+^S*%&NIC9F"9FP1KO/!%VZQC0W"Y=*C_>:L$3_+`R>&C=;<.)&K MTFC*"O4T'"5O2!*#4(-NLE\%I MYW8.@3AM?/7P)O'0+M'?%G"H(;S1?,H>\^+\[U\S.>87S>@W_PM02P,$%``` M``@`>X%E1TXW/\'N$```4[@``!$`'`!T:')X+3(P,34P.3,P+GAS9%54"0`# M&<8[5AG&.U9U>`L``00E#@``!#D!``#M7=USXC@2?[^J^Q]\>;F]!T(@D]E+ M:F:O""&SJ4L"%9C=O:K M9?0Y1@);QG1M/&'.B6T;?<:7C",!`HQ6*R#\[?;ET;"8Z3F8"L,,N%Z)6$1\ MMYQ8=Z$M8/J,W1J?3OFIW+SI71O?F M\L>;;L<8/46$3Z#"C!12OKG6C6LNL(,,;&-9V7O&G3L\0YXM/I[]X2%;B3DS MD!"<3#V!$P0>C9$(Q.=8/",'NTMDXH]G"R&6-^WVZ^OKN5A@CE:(FOC<9(ZJ MS,7U)5@;[$_=&ZA'@OSU\ISQ.9!==-J_/3V.515#8HYG">*W*;=#\O=M^!I) MA0\DE_2R3:@K9)7B]):(&.+$5VW_8TA*&:6>DRW;$KPMUDOMBT[KLA,RE<`U MK+G&DK\]QBK^YI)B,%O;QA<+_E:ER:0,F:R1_#R%?A226YAD6P8^2-GODF:! MKC]':!FQS)`[5<*##ZHZ*1:)BIO)H[YD,W%FYS"I+QE,%,^E%\C5_KHM.=L! MV1ET=,-071U1RH1R5>I=^':Y)'3&@E?P4MKN1HJ80*T-^?#YY4&'C2IN#)*5 M"^DS:F$*+@P>7&832];B%MF2?+S`6+AG!H':5V&(*A=6S\(S0HE2!=K5!7A/ M(Y('S_WA\]W@>3RXDT_CX>/#76\"?]SV'GO/_8$Q_GDPF(P_M+=%;9?B0:6& M]"?UO.38!>'*?+*Y!]P!B8[31+;IV3LP;FJ6SQ>\#>$Z+(K15W>I,'(&@0KH-PGSE@D@70D!5^9&YE MH-,"]'A?[H9W?_@T>AG\#'0/OPR,Q^&XP;T>[LA=W-OLM3K>$:,>YW<[XMP; M_VS.N*;-7(_C/K-M-%63DA7N<8[HW$?H#@M$[`#6"O0Z--]! MK^T`@AMQ$LZX1",NTO@A$/JO!D,=AKT5&`E-;1F7CY&-Q]CT.%0&NSUJW2/" M?T&VAY\PDL0Z<'<7I$?]71KUJ*C6C/&6+,S8E&8@:AFR/$,5:,1+;!K%@1M% M=V^MHEO8++K[;Q9&MVD8>H^/ED3`A/U/;-UC[(X0L2;L!=MR@!XA+M9YGK\L MGQ[TJXP18"/9D*(-*=L0S$!&(-]0!31=OQS"CXS.)UBF:*8B!\PL$CUN/Z9Q MDT):4HHAQ33H:-$)$KSA_^`Z!U00L7Z@X.D@66!!0L'*^*LE=E+RZVB5Y9?R0**3IH'M*9E4&OHR8 MHC17R1:0E^9JVD*5H?0.NR8G2UEZ'#'PR6//<1!?#V=C,J=D!K8$5VV:S`/O M2N1#ZQN>T M151ZS-ZG,5-R@MU/<4D-1F4S0[J44`$>A;F@!@5M3Y'QVX+9%N;N'53$)"DP MLDCTF/P[HX_$A/S3",0TT.CC1LA52 MZ7')2FC$Y,32&0U$VB''F[KX#P]4'JRR9E"I[WI8,C(4&PF&+Z(!Y)")Q4,E M&$LE&@'^]-+]OA*-Q@_A4Y.;KI)SG,CD1*H]9!/IP+V\Z%Y<%N[K@'P(-G);&1WEJ.'_%T:\AI[J)H6L8^494[7+LFF MQ_LJHXN7WC[5P+MS'C,;4RVM'LCW:2#SUUWFJ+F-(<< M*CVZI3;)-#C5B7ERX-(3ZU&KL)+;8+<'[%*'>0JHB]!+9?T*T6O.X]3![[(2 M?I>%^%68KC*;`7YKH"2_\C;Y%[PS%"7]-W("]T^GKG$6=KRCCGU;J%N M)I07V;7"V^I^ATJ?OSEV2"+E:VZM4R!OZ1F4&TI`W$P)2=TAV%YR!EU*+@ZV MP[J?&>V]:046K:I5$H1C5,I&TZI*`0NVCU4?Z&E5]=GNG/M7ZT-[^\K!X$WR M:D)U,2%HR+@P:.:-HIH+#PW_2M-'9BJ!V6PVYPFNEI33ZG1;G??G4'A88WU% MM#=)YM0BDT<^M#;,Y6M0XN;1,M:( M6QL1.YIDZ][9,O90+/*OZ,I4:9%+:9$JUMC2B_+NI:U#(7"`>5#NXZ5K&2])F_3SBB[@SSX>P9BY[K8N'> M>BZAV'7'>(EX<.Q):OGQK"PQL=6.'2B">X"U[[;5G<0W#J,0//'U@\".##?` M(A!?"2(\R?N),V\9DA(@`0W5,[A5PJR)$F1Y84'^MZE__P1\P%,BJMM$-I[0 M+H&>40!Z2]AR@;B#GK`SQ?PL9KA\&E]?_Z+D&XLYB-#2ZB+XRI$I0MMMVU)G MCEQ][K$%E;7E/0N>8'P-4\7!;(9-,9Q]@LK)5:8AA:#7OQ!9K6/FHQM98*]2 M:[61C=%FR'9SK99J*+O8?*5BH-^-:^F+V;:B*)E'9VU06/[8[\W:](0FTZKTB M;CVA-^)XCLPNA6VDYR9,8Y,Y@>JESV`J*W[M@H_-\'G[:WO@>9#]PM;(5ELR M$ZJ!ZY:[*-U[QD&[*:&JE!%GEFM>[P"MML*=\.WF1OPNX+ M)L[4X]`K)\RW2)$Q=Y#WC:(0DV-K/V'($^)?H)K3^/;JN.>"S@`=\0F&7_BV M'JG*Q?KO;NQQ,X4ZEC;37KS:+9EYU)1$4#O/-1$GE)@]Z6`8A7#B%I3J]OSG M5%BV"_/1Q6NQ3I`8SMS8!OR@W&Q_7%1HA:009/<7TE*A%0];1"8`N_1"K?5KCT>Z"WPS@I%RY-\V"LG( M9$CG@.SP9,T+>`6J:BR3!F[WHM-)!9SE68XNS!S\X2E@9"L#_S""K@GU[:94 M+*#[QGJE/$)&=>76J,%X-`JKG*M_BC"[=^Y%U\/VUT_C_Z:`C+T[NL;XB:TP MIW)PB%*=Z?KGTQR=/H^]VUYB:I+2)I?BZ'3)S"1LJZ,C.@F->M"X8!#?-;52 MS/ZU4RLISRB=AN796/X^64Y@^'DYXZ"!/'D-KC`U/0SB1IB"LSF59[1E(U:' M#R?X3=S:S/P2>M>O59C.0XN0[DB"J)T7+.2UZ]#2E`&I-82F9JN=)//A;(9E MW)1JHH8G8JVD*OLP MTK;$;^\9Y<&A!]?UL'7G;1JYNE4$YG0K)&1X:"JN[1M]`^O6D7#JD_`LJED#KAUL88F;Q5HFF[RILO"!0NX@3=8][W2O(,98R8VR M(%,FUU)MOP3ML37^<-SW'=9FC6I(QU@(GWHXN\/*DT%LM4DHAOV@EH3C=(`I M*SU0T[^>"]GRC!FCOK(]X>_#4;$]ZT.\"2$%LNVARK-&GF)G[N.T3D8?\<_V,YTP0.<)MJY/N*^5YCK7/9+5I-XP1K>W^44BM0;MJX*U;^*V-=GH?9$8B M74=T;(OXP&.X=/4M:I@3Y`==0]^CO)PP"E^R< MR83=QO*<\6,&Y7EJNL%[B4M57UE>;"1)+[5JRK]HJZNWOHK&3(GWDRKV^\C^Y3+N"CN[?<)&U M]/)`M0=5]B[Y2&Q:9I^0FB7)U)KZYXZLB(6I'#0(VVP2TA-INM%27F%Q'%.G M-$XJ,[+V_\V*JDIS'$'PE$+V%^S*[$\?FBGPH=X;B1QE]J?Z.3-+W%@$:N$& MR?G#9L^*-+Y3X4R.SM''/6[?.*AR$.JH[5'0XS?'1I*[5?0D)[)/):5X]8OD M-]-?WRZU))Q&)GD/5MN<`4@MU.]+V/$NQ*?LE]JM-^)LSI$S8NIO9*M@ZHSJ,"_(G"D//PI^' M#;ID9;83;SCAEA]Y;+2LD2KRG%A"L7K?2CGV2APGY+UC.\M*_0J);FM:90$G M9*="Y:!"KENZM834I^V1"]7" MXV8(SJ;_#R.NCM>5;4TZ$7_UKI>C^X)C7-N`@9#OTX3WS.-U+1C(^$X-2%:U MFV`@X_LSH)KI[L.*VX+^XJ;\%9/Y0HZN_M&2SRZ>>?8CF96WH4Z"QGB5]V!_ MVSC6OR\KWEXJ!W%:$2<^N2Y4/K4EMQ+'B0:]=2\/\T]X]]SDZF+VQ6'[N2>M M4HDGWF;KVBJYF7;@+&VVQO@)K<.-@L$A@ZV#*/L!:M?"CW.;:H75AZ&\NGVR M0'2"Y>VHLHTY2T2XY'^,Y1IJ2?B+#_H98<\+E@MXEFQ2]\0UD2U#H#IQ5)[` MTS;M@[JJ6&V3?Z4X.#HT9G;4KW4$)]+W5)U?\#)T'?Y"4V^YY&R%K:$I&'@> M>4MP-$M9XE,UAMK/DX;=$PO& MI<.0RY"CX(ZTWQ=QXJY5'LSDF\$Y__+K MP-.6IS_5OI5L#CDK1]EM)Y]X+[NT"D[S[`Q0` M```(`'N!94=,R;]_*=@``'A$$0`1`!@```````$```"D@0````!T:')X+3(P M,34P.3,P+GAM;%54!0`#&<8[5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`'N!94?)DJXJO@X``(W4```5`!@```````$```"D@738``!T:')X+3(P,34P M.3,P7V-A;"YX;6Q55`4``QG&.U9U>`L``00E#@``!#D!``!02P$"'@,4```` M"`![@65'=0;ANN\D``!O>`(`%0`8```````!````I(&!YP``=&AR>"TR,#$U M,#DS,%]D968N>&UL550%``,9QCM6=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`>X%E1[FWXCT=;```F9(&`!4`&````````0```*2!OPP!`'1H`Q0` M```(`'N!94=+]R'J;#T``%6'!``5`!@```````$```"D@2MY`0!T:')X+3(P M,34P.3,P7W!R92YX;6Q55`4``QG&.U9U>`L``00E#@``!#D!``!02P$"'@,4 M````"`![@65'3C<_P>X0``!3N```$0`8```````!````I('FM@$`=&AR>"TR M,#$U,#DS,"YX`L``00E#@``!#D!``!02P4&``````8` ,!@`:`@``'\@!```` ` end XML 40 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of $3,455 and $3,233 for the three months ended September 30, 2015 and 2014 and $10,367 and $7,611 for the nine months ended september 30, 2015 and 2014 $ 13,341 $ 729 $ 30,449 $ 342

Revenue from collaborative arrangements from a related party, net 221 270 664 811

Total net revenue 13,562 999 31,113 1,153

Operating expenses:

Research and development 547 1,909 1,897 6,721

General and administrative 4,581 8,632 14,929 28,491

Total operating expenses 5,128 10,541 16,826 35,212

Income (loss) from operations 8,434 (9,542) 14,287 (34,059)

Other income (expense), net (45) 255 1,117 335

Interest income 90 93 291 446

Interest expense (13,063) (12,355) (38,756) (24,326)

Loss from continuing operations before income taxes (4,584) (21,549) (23,061) (57,604)

Income tax expense (benefit) 0 (278) 0 0

Loss from continuing operations, net of tax (4,584) (21,271) (23,061) (57,604)

Loss from discontinued operations (Notes 1 and 11) 0 0 0 (94,934)

Net loss $ (4,584) $ (21,271) $ (23,061) $ (152,538)

Basic and diluted net loss per share:

Continuing operations, net of tax (in dollars per share) $ (0.04) $ (0.19) $ (0.20) $ (0.52)

Discontinued operations (in dollars per share) 0.00 0.00 0.00 (0.85)

Basic and diluted net loss per share (in dollars per share) (0.04) (0.19) (0.20) (1.37)

Cash dividends declared per common share (in dollars per share) $ 0.25 $ 0.25 $ 0.75 $ 0.25

Shares used to compute basic and diluted net loss per share (in shares) 115,787 113,100 115,381 111,306

X

- Definition
Revenue earned under collaborative arrangements from upfront payments and contingent payments.
+ References
No definition available.
+ Details

Name: thrx_CollaborativeArrangementsRevenue

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents revenue net of amortization expense for capitalized fees paid to a related party during the period from the leasing or otherwise lending to a related party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. An example of property from which royalties may be derived includes patents.
+ References
No definition available.
+ Details

Name: thrx_RoyaltyRevenueFromRelatedPartyNet

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate dividends declared during the period for each share of common stock outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_CommonStockDividendsPerShareDeclared

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.13)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4613673-111683

+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51673353&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.12)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5C

-Subparagraph (b)(2)

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.14)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51716988&loc=d3e1012-107759

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3B

-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721525-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3A

-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721523-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51716988&loc=d3e957-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 13

-Article 7

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 5

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(a),(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 41 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Capitalized Fees Paid to a Related Party
9 Months Ended

Sep. 30, 2015

Capitalized Fees Paid to a Related Party

Capitalized Fees Paid to a Related Party

5. Capitalized Fees Paid to a Related Party

Capitalized fees paid to a related party, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:

September 30, 2015

December 31, 2014

Weighted

Average

Remaining

Amortization

Gross

Net

Gross

Net

Period

Carrying

Accumulated

Carrying

Carrying

Accumulated

Carrying

(In thousands)

(Years)

Value

Amortization

Value

Value

Amortization

Value

Approval and launch related milestone payments under the LABA Collaboration

14.4

$

220,000

$

(22,176
)

$

197,824

$

220,000

$

(11,809
)

$

208,191

These milestone fees are being amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization expense recorded as a reduction in revenue from collaborative arrangements. Additional information regarding these milestone fees is included in Note 3, “Collaborative Arrangements”. Amortization expense for the three and nine months ended September 30, 2015 was $3.5 million and $10.4 million, respectively. Amortization expense for the three and nine months ended September 30, 2014 was $3.2 million and $7.6 million, respectively. As of September 30, 2015, the remaining estimated amortization expense is $3.5 million for 2015, $13.8 million for each of the years from 2016 to 2020, and $125.3 million thereafter.

X

- References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyAbstract

Namespace Prefix: thrx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for capitalized fees paid to a related party.
+ References
No definition available.
+ Details

Name: thrx_CapitalizedFeesPaidToRelatedPartyTextBlock

Namespace Prefix: thrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Available-for-Sale Securities and Fair Value Measurements
9 Months Ended

Sep. 30, 2015

Available-for-Sale Securities and Fair Value Measurements

Available-for-Sale Securities and Fair Value Measurements

4. Available-for-Sale Securities and Fair Value Measurements

Available-for-Sale Securities

The classification of available-for-sale securities in the condensed consolidated balance sheets is as follows:

(In thousands)

September 30,
2015

December 31,
2014

Cash and cash equivalents

$

76,077

$

95,090

Short-term marketable securities

127,446

143,698

Marketable securities

—

42,856

Total

$

203,523

$

281,644

The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:

September 30, 2015

(In thousands)

Amortized Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Estimated
Fair Value

U.S. government securities

$

7,503

$

3

$

—

$

7,506

U.S. government agencies

69,965

9

(2
)

69,972

Corporate notes

27,485

3

(2
)

27,486

Commercial paper

54,702

—

—

54,702

Money market funds

43,857

—

—

43,857

Total

$

203,512

$

15

$

(4
)

$

203,523

December 31, 2014

(In thousands)

Amortized Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Other Than
Temporary
Impairment Loss

Estimated
Fair Value

U.S. government securities

$

30,019

$

24

$

—

$

—

$

30,043

U.S. government agencies

34,756

6

(12
)

—

34,750

Corporate notes

80,880

5

(110
)

—

80,775

Commercial paper

34,469

—

—

—

34,469

Ordinary shares of Theravance Biopharma

10,269

—

—

(3,752
)

6,517

Money market funds

95,090

—

—

—

95,090

Total

$

285,483

$

35

$

(122
)

$

(3,752
)

$

281,644

As of September 30, 2015, all of the available-for-sale securities had contractual maturities within one year and the weighted average duration of marketable securities was approximately three months. We do not intend to sell the investments that are in an unrealized loss position, and it is unlikely that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. We have determined that the gross unrealized losses on our marketable securities as of September 30, 2015 were temporary in nature. As of September 30, 2015, all marketable securities with unrealized losses have been in a loss position for less than twelve months.

During the nine months ended September 30, 2015, we recognized a gain of $1.2 million from the sale of all of the ordinary shares of Theravance Biopharma that we held as of December 31, 2014, which is included in other income (expense), net in the condensed consolidated statement of operations. In addition, we sold other available-for-sale securities totaling $49.4 million, and the related realized gains and losses were not significant during the nine months ended September 30, 2015.

Fair Value Measurements

Our available-for-sale securities are measured at fair value on a recurring basis and our debt is carried at the amortized cost basis. The estimated fair values were as follows:

Estimated Fair Value Measurements as of September 30, 2015 Using:

Types of Instruments

Quoted Price in
Active Markets for
Identical Assets

Significant Other
Observable Inputs

Significant
Unobservable
Inputs

(In thousands)

Level 1

Level 2

Level 3

Total

Assets

U.S. government securities

$

7,506

$

—

$

—

$

7,506

U.S. government agencies

—

69,972

—

69,972

Corporate notes

—

27,486

—

27,486

Commercial paper

—

54,702

—

54,702

Money market funds

43,857

—

—

43,857

Total assets measured at estimated fair value

$

51,363

$

152,160

$

—

$

203,523

Liabilities

Convertible subordinated notes due 2023

$

—

$

169,362

$

—

$

169,362

Non-recourse notes due 2029

—

464,527

—

464,527

Total fair value of liabilities

$

—

$

633,889

$

—

$

633,889

Estimated Fair Value Measurements as of December 31, 2014 Using:

Types of Instruments

Quoted Price in
Active Markets for
Identical Assets

Significant Other
Observable Inputs

Significant
Unobservable
Inputs

(In thousands)

Level 1

Level 2

Level 3

Total

Assets

U.S. government securities

$

30,043

$

—

$

—

$

30,043

U.S. government agencies

—

34,750

—

34,750

Corporate notes

—

80,775

—

80,775

Commercial paper

—

34,469

—

34,469

Ordinary shares of Theravance Biopharma

6,517

—

—

6,517

Money market funds

95,090

—

—

95,090

Total assets measured at estimated fair value

$

131,650

$

149,994

$

—

$

281,644

Liabilities

Convertible subordinated notes due 2023

$

—

$

197,095

$

—

$

197,095

Non-recourse notes due 2029

—

456,411

—

456,411

Total fair value of liabilities

$

—

$

653,506

$

—

$

653,506

The fair value of our marketable securities classified within Level 2 were derived from observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications.

The fair value of our convertible subordinated notes due 2023 and non-recourse notes due 2029 is based on recent trading prices of the instruments, if applicable, or pricing models that utilize current observable market characteristics for similar types of instruments.

X

- References
No definition available.
+ Details

Name: thrx_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract

Namespace Prefix: thrx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for available-for-sale securities and fair value measurements.
+ References
No definition available.
+ Details

Name: thrx_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock

Namespace Prefix: thrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Available-for-Sale Securities and Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2015

Available-for-Sale Securities and Fair Value Measurements

Schedule of available-for-sale securities

(In thousands)

September 30,
2015

December 31,
2014

Cash and cash equivalents

$

76,077

$

95,090

Short-term marketable securities

127,446

143,698

Marketable securities

—

42,856

Total

$

203,523

$

281,644

Schedule of amortized cost and estimated fair values for available-for-sale securities

September 30, 2015

(In thousands)

Amortized Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Estimated
Fair Value

U.S. government securities

$

7,503

$

3

$

—

$

7,506

U.S. government agencies

69,965

9

(2
)

69,972

Corporate notes

27,485

3

(2
)

27,486

Commercial paper

54,702

—

—

54,702

Money market funds

43,857

—

—

43,857

Total

$

203,512

$

15

$

(4
)

$

203,523

December 31, 2014

(In thousands)

Amortized Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Other Than
Temporary
Impairment Loss

Estimated
Fair Value

U.S. government securities

$

30,019

$

24

$

—

$

—

$

30,043

U.S. government agencies

34,756

6

(12
)

—

34,750

Corporate notes

80,880

5

(110
)

—

80,775

Commercial paper

34,469

—

—

—

34,469

Ordinary shares of Theravance Biopharma

10,269

—

—

(3,752
)

6,517

Money market funds

95,090

—

—

—

95,090

Total

$

285,483

$

35

$

(122
)

$

(3,752
)

$

281,644

Schedule of estimated fair values

Estimated Fair Value Measurements as of September 30, 2015 Using:

Types of Instruments

Quoted Price in
Active Markets for
Identical Assets

Significant Other
Observable Inputs

Significant
Unobservable
Inputs

(In thousands)

Level 1

Level 2

Level 3

Total

Assets

U.S. government securities

$

7,506

$

—

$

—

$

7,506

U.S. government agencies

—

69,972

—

69,972

Corporate notes

—

27,486

—

27,486

Commercial paper

—

54,702

—

54,702

Money market funds

43,857

—

—

43,857

Total assets measured at estimated fair value

$

51,363

$

152,160

$

—

$

203,523

Liabilities

Convertible subordinated notes due 2023

$

—

$

169,362

$

—

$

169,362

Non-recourse notes due 2029

—

464,527

—

464,527

Total fair value of liabilities

$

—

$

633,889

$

—

$

633,889

Estimated Fair Value Measurements as of December 31, 2014 Using:

Types of Instruments

Quoted Price in
Active Markets for
Identical Assets

Significant Other
Observable Inputs

Significant
Unobservable
Inputs

(In thousands)

Level 1

Level 2

Level 3

Total

Assets

U.S. government securities

$

30,043

$

—

$

—

$

30,043

U.S. government agencies

—

34,750

—

34,750

Corporate notes

—

80,775

—

80,775

Commercial paper

—

34,469

—

34,469

Ordinary shares of Theravance Biopharma

6,517

—

—

6,517

Money market funds

95,090

—

—

95,090

Total assets measured at estimated fair value

$

131,650

$

149,994

$

—

$

281,644

Liabilities

Convertible subordinated notes due 2023

$

—

$

197,095

$

—

$

197,095

Non-recourse notes due 2029

—

456,411

—

456,411

Total fair value of liabilities

$

—

$

653,506

$

—

$

653,506

X

- References
No definition available.
+ Details

Name: thrx_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract

Namespace Prefix: thrx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the classification of available-for-sale securities in the consolidated balance sheet.
+ References
No definition available.
+ Details

Name: thrx_ScheduleOfAvailableForSaleSecuritiesClassificationTableTextBlock

Namespace Prefix: thrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a,b,bb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2C

-URI http://asc.fasb.org/extlink&oid=36462937&loc=SL7498348-110258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Subsequent Events
9 Months Ended

Sep. 30, 2015

Subsequent Events

Subsequent Events

12. Subsequent Events

On October 28, 2015, we announced the acceleration of our capital return plan with a $150 million share repurchase program effective through the end of 2016 approved by our Board of Directors, replacing our quarterly dividend. As a component of the share repurchase plan, on October 30, 2015, we commenced a “modified Dutch auction” tender offer to purchase up to $75 million of our common stock, at a price per share of not less than $8.50 and not greater than $9.25, which will be contingent upon satisfaction of customary conditions.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Shareholders' Deficit
9 Months Ended

Sep. 30, 2015

Shareholders' Deficit

Shareholders' Deficit

8. Shareholders’ Deficit

For the nine months ended September 30, 2015, options to purchase 111,156 shares of our common stock were exercised at a weighted-average exercise price of $13.75 per share, for total cash proceeds of approximately $1.5 million. For the nine months ended September 30, 2014, options to purchase 1,127,000 shares of our common stock were exercised at a weighted-average exercise price of $14.09 per share, for total cash proceeds of approximately $15.9 million.

During the nine months ended September 30, 2015, GSK purchased 424,081 shares of our common stock pursuant to its periodic “top-up” rights under our Amended and Restated Governance Agreement, dated as of June 4, 2004, as amended, among us, GSK and certain GSK affiliates (the “Governance Agreement”), for an aggregate purchase price of approximately $6.5 million. GSK’s periodic “top-up” rights terminated with the expiration of the Governance Agreement in September 2015.

On February 20, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on March 12, 2015. This dividend was paid on March 31, 2015. On April 24, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on June 12, 2015. This dividend was paid on June 30, 2015. On July 24, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on September 10, 2015. This dividend was paid to our stockholders on September 30, 2015. During the three and nine months ended September 30, 2015, we paid an aggregate of $29.1 million and $87.1 million in dividends, respectively. Unvested RSAs and certain unvested RSUs as of the record date are also entitled to dividends, which will only be paid when the RSAs and such RSUs vest and are released. For further information on the impact of the cash dividend payments on the 2023 Notes, refer to Note 7, “Long-Term Debt”.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-Based Compensation
9 Months Ended

Sep. 30, 2015

Stock-Based Compensation

Stock-Based Compensation

6. Stock-Based Compensation

Equity Incentive Plan

The 2012 Equity Incentive Plan (the “2012 Plan”) provides for the granting of incentive stock options, nonstatutory stock options, RSAs, restricted stock units (“RSUs”) and stock appreciation rights to employees, non-employee directors and consultants. As of September 30, 2015, the total shares remaining available for issuance under the 2012 Plan were 3,200,521.

Employee Stock Purchase Plan

Under the 2004 Employee Stock Purchase Plan (the “ESPP”), our employees may purchase common stock through payroll deductions at a price equal to 85% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The ESPP provides for consecutive and overlapping offering periods of 24 months in duration, with each offering period composed of four consecutive six-month purchase periods. The purchase periods end on either May 15 or November 15. ESPP contributions are limited to a maximum of 15% of an employee’s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period is 2,500. An employee may not purchase shares with a value greater than $25,000 in any calendar year.

As of September 30, 2015, total shares remaining available for issuance under the ESPP were 278,971.

Performance-Contingent RSAs

Since 2011, the Compensation Committee of our Board of Directors (the “Compensation Committee”) have approved grants of performance-contingent RSAs to senior management and a non-executive officer. Generally, these awards have dual triggers of vesting based upon the achievement of certain performance goals by a pre-specified date, as well as a requirement for continued employment. Recognition of stock-based compensation expense begins when the performance goals are deemed probable of achievement.

Included in these performance-contingent RSAs is the grant of 1,290,000 special long-term retention and incentive performance-contingent RSAs to senior management in 2011. The awards have dual triggers of vesting based upon the achievement of certain performance conditions over a six-year timeframe from 2011 through December 31, 2016 and require continued employment. As of March 31, 2014, we determined that the achievement of the requisite performance conditions for vesting of the first tranche of these awards was probable and the total stock-based compensation expense of $7.0 million for the first tranche was fully recognized through May 2014. In connection with the Spin-Off, our Compensation Committee approved the modification of the remaining tranches related to these awards as the performance conditions associated with the remaining portions of these awards were unlikely to be consistent with the new strategies of each company following the Spin-Off. The modification acknowledged the Spin-Off and permitted recognition of achievement of certain of the original performance conditions that were met prior to the Spin-Off, triggering service-based vesting for a portion of the equity awards, for which $3.8 million was recognized by us during the twelve-month period that commenced in June 2014. The remaining 63,000 RSAs for which service-based vesting was not triggered at the time of the Spin-Off remain subject to new performance conditions (as well as the original service conditions). In addition, the RSAs for which both the performance and service-based conditions were not achieved prior to the Spin-Off were entitled to the pro rata dividend distribution made by Theravance on June 2, 2014 of one ordinary share of Theravance Biopharma for every 3.5 shares of Theravance common stock subject to their awards, which will also be subject to the same new performance and service conditions as the original RSAs to which they relate. As of September 30, 2015, we determined that the achievement of the requisite performance conditions was not probable and, as a result, no compensation cost was recognized for the remaining equity awards.

Stock-Based Compensation Expense

Stock-based compensation expense is included in the condensed consolidated statements of operations as follows:

Three Months Ended September 30,

Nine Months Ended September 30,

(In thousands)

2015

2014

2015

2014

Research and development

$

220

$

1,357

$

687

$

2,589

General and administrative

1,248

3,375

4,536

11,795

Stock-based compensation from continuing operations

1,468

4,732

5,223

14,384

Stock-based compensation from discontinued operations

—

—

—

11,629

Total stock-based compensation expense

$

1,468

$

4,732

$

5,223

$

26,013

As of September 30, 2015, unrecognized compensation expense, net of expected forfeitures for awards expected to vest, was as follows: $1.7 million related to unvested stock options; $2.1 million related to unvested RSUs; and $9.1 million related to unvested RSAs (including performance-contingent RSAs for which the performance milestones were determined to be probable of achievement).

At the time of the Spin-Off, all outstanding stock options, RSUs and RSAs held by former employees and directors, who transferred to Theravance Biopharma, were retained by them. As the vesting of these options and awards is based on continuing employment or service with Theravance Biopharma, all stock-based compensation expense associated with these options and awards is recognized by Theravance Biopharma.

Valuation Assumptions

No options were granted for the three and nine months ended September 30, 2015.

The range of assumptions used to estimate fair value of employee stock options granted during the three and nine months ended September 30, 2014 was as follows:

Three Months Ended
September 30,

Nine Months Ended
September 30,

2014

2014

Risk-free interest rate

1.97%

1.64%-2.05%

Expected term (in years)

6

5-6

Volatility

58%

52%-60%

Dividend yield

4%

4%

Weighted-average estimated fair value of stock options granted

$

13.23

$

15.92

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Long-Term Debt
9 Months Ended

Sep. 30, 2015

Long-Term Debt.

Long-Term Debt

7. Long-Term Debt

Our long-term debt consists of:

(In thousands)

September 30,
2015

December 31,
2014

Convertible Subordinated Notes due 2023

$

255,109

$

255,109

Non-Recourse Notes Payable due 2029

488,976

470,527

Total Long-Term Debt

$

744,085

$

725,636

Convertible Subordinated Notes Due 2023

In January 2013, we completed an underwritten public offering of $287.5 million aggregate principal amount of unsecured convertible subordinated notes, which will mature on January 15, 2023 (the “2023 Notes”). The financing raised proceeds, net of debt issuance costs, of approximately $281.2 million, less $36.8 million to purchase two privately-negotiated capped call option transactions in connection with the issuance of the notes. The 2023 Notes bear interest at the rate of 2.125% per year that is payable semi-annually in arrears in cash on January 15 and July 15 of each year, beginning on July 15, 2013.

The 2023 Notes were convertible, at the option of the holder, into shares of our common stock at an initial conversion rate of 35.9903 shares per $1,000 principal amount of the 2023 Notes, subject to adjustment in certain circumstances, which represents an initial conversion price of approximately $27.79 per share. Following the Spin-Off of Theravance Biopharma, a number of adjustments to the initial conversion rate have been made as described below. Holders of the 2023 Notes will be able to require us to repurchase some or all of their notes upon the occurrence of a Change of Control or a Termination of Trading (as contractually defined) following the original issuance of the 2023 Notes at 100% of the principal amount of the notes being repurchased plus accrued and unpaid interest. We may not redeem the 2023 Notes prior to their stated maturity date.

In connection with the offering of the 2023 Notes, we entered into two privately-negotiated capped call option transactions with a single counterparty. The capped call option transaction is an integrated instrument consisting of a call option on our common stock purchased by us with a strike price equal to the initial conversion price of $27.79 per share for the underlying number of shares and a cap price of $38.00 per share, both of which are subject to adjustments consistent with the 2023 Notes. The cap component is economically equivalent to a call option sold by us for the underlying number of shares with an initial strike price of $38.00 per share. As an integrated instrument, the settlement of the capped call coincides with the due date of the convertible debt. Upon settlement, we would receive from our hedge counterparty a number of shares of our common shares that would range from zero, if the stock price was below $27.79 per share, to a maximum of 2,779,659 shares, if the stock price is above $38.00 per share. However, if the market price of our common stock, as measured under the terms of the capped call transactions, exceeds $38.00 per share, there is no incremental anti-dilutive benefit from the capped call.

In accordance with the agreement for the 2023 Notes, the conversion rate was adjusted as a result of the completion of the Spin-Off of Theravance Biopharma. The conversion rate was adjusted based on the conversion rate immediately prior to the record date for the Spin-Off and the average of the stock dividend distributed to our common stockholders and our stock prices. This resulted in an adjusted conversion rate of 46.9087 shares per $1,000 principal amount of the 2023 Notes, which represents an adjusted conversion price of approximately $21.32 per share. As a result of the conversion rate adjustment, the capped call strike price and cap price were also adjusted accordingly to $21.32 and $29.16, respectively. On July 15, 2014, certain holders of the 2023 Notes converted their notes into 1,519,402 shares of our common stock at the adjusted conversion price of $21.32 per share. In connection with the partial conversion of the 2023 Notes, we received 149,645 shares of our common stock from our capped call option counterparty and the shares of common stock received were recorded as treasury stock.

In connection with the payments of subsequent cash dividends through September 30, 2015, the adjusted conversion rate with respect to our 2023 Notes was further adjusted from 46.9087 shares of our common stock per $1,000 principal amount of the 2023 Notes to 50.5818 shares of our common stock per $1,000 principal amount of the 2023 Notes, which represents an adjusted conversion price of approximately $19.77 per share. As a result of the conversion rate adjustment, the capped call strike price and cap price were also adjusted accordingly to $19.77 and $27.04.

Non-Recourse Notes Due 2029

In April 2014, we entered into certain note purchase agreements relating to the private placement of $450.0 million aggregate principal amount of non-recourse fixed rate term notes due 2029 (the “2029 Notes”) issued by our wholly-owned subsidiary.

The 2029 Notes are secured by a security interest in a segregated bank account established to receive 40% of royalties due to us under the LABA Collaboration with GSK commencing on April 1, 2014 and ending upon the earlier of full repayment of principal or May 15, 2029. The amounts in the segregated bank account can only be used to make interest and principal payments on the 2029 Notes. As of September 30, 2015, the balance of the segregated bank account was not material.

The 2029 Notes bear an annual interest rate of 9%, with interest and principal paid quarterly beginning November 15, 2014. The 2029 Notes may be redeemed at any time prior to maturity, in whole or in part, at specified redemption premiums. Prior to May 15, 2016, in the event that the specified portion of royalties received in a quarter is less than the interest accrued for the quarter, the principal amount of the 2029 Notes will increase by the interest shortfall amount for that period. Since issuance, $39.0 million of interest expense has been added to the principal balance of the 2029 Notes, of which $5.6 million and $18.4 million was added during the three and nine months ended September 30, 2015. No interest expense was added to the principal during the three and nine months ended September 30, 2014. Since the principal and interest payments on the 2029 Notes are based on royalties from GSK for product sales recorded, which will vary from quarter to quarter and are unknown to us, the 2029 Notes may be repaid prior to the final maturity date in May 2029.

In connection with the sale of the 2029 Notes, we incurred approximately $15.3 million in debt issuance costs, which are being amortized to interest expense over the estimated life of the 2029 Notes.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies
9 Months Ended

Sep. 30, 2015

Commitments and Contingencies

Commitments and Contingencies

9. Commitments and Contingencies

Lease Guarantee

Upon the Spin-Off, our facility leases in South San Francisco, California were assigned to Theravance Biopharma. However, if Theravance Biopharma were to default on its lease obligations, we would be held liable by the landlord and thus, we have in substance guaranteed the lease payments for these facilities. We would also be responsible for lease-related payments including utilities, property taxes, and common area maintenance, which may be as much as the actual lease payments. As of September 30, 2015, the total remaining lease payments, which run through May 2020, were $29.1 million. The carrying value of this lease guarantee was $1.3 million as of September 30, 2015 and is reflected in other long-term liabilities in our condensed consolidated balance sheet.

Special Long-Term Retention and Incentive Cash Awards Program

In 2011, we granted special long-term retention and incentive cash bonus awards to certain employees. The awards have dual triggers of vesting based upon the achievement of certain performance conditions over a six-year timeframe from 2011 through December 31, 2016 and continued employment.

As of March 31, 2014, we determined that the achievement of the requisite performance conditions for the first tranche of these awards was probable and, as a result, $9.1 million of cash bonus expense was recognized for the three months ended March 31, 2014, the majority of which is included in discontinued operations in the condensed consolidated statements of operations. In May 2014, the total cash bonus of $9.5 million for the first tranche was paid.

In connection with the Spin-Off, the Compensation Committee approved the modification of the remaining tranches related to these awards as the performance conditions associated with the remaining portions of these awards were unlikely to be consistent with the new strategies of each company following the Spin-Off. The modification acknowledged the Spin-Off and permitted recognition of achievement of certain of the original performance conditions that were met prior to the Spin-Off, triggering service-based vesting for a portion of the cash awards. The amount due by us under these modified cash bonus awards of $0.5 million was fully paid in June 2015. The remaining tranches of the cash awards were forfeited.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-Based Compensation (Details)
1 Months Ended 3 Months Ended 5 Months Ended 9 Months Ended 12 Months Ended

Jun. 02, 2014

Jun. 30, 2014

USD ($)

Sep. 30, 2015

USD ($)

shares

Sep. 30, 2014

USD ($)

May. 31, 2014

USD ($)

Sep. 30, 2015

USD ($)

item

shares

Sep. 30, 2014

USD ($)

Dec. 31, 2011

shares

Stock-based compensation

Stock-based compensation expense | $ $ 1,468,000 $ 4,732,000 $ 5,223,000 $ 26,013,000

Number of shares of Theravance Biopharma issued for every share of Theravance 0.286

Employee Stock Purchase Plan

Stock-based compensation

Purchase price as a percentage of fair market value of stock 85.00%

Consecutive and overlapping offering periods 24 months

Number of offering periods | item 4

Duration of purchase period 6 months

Maximum contributions as a percentage of employee's eligible compensation 15.00%

Maximum number of shares an employee may purchase during any purchase period 2,500

Maximum value of shares an employee may purchase | $ $ 25,000

Shares remaining available for issuance 278,971 278,971

2012 Equity Incentive Plan

Stock-based compensation

Shares remaining available for issuance 3,200,521 3,200,521

Special Long-Term Retention and Incentive Awards Program | Unvested RSAs | Performance-contingent

Stock-based compensation

Shares of common stock approved and authorized for issuance 1,290,000

Timeframe for achievement of performance conditions 6 years

Total stock-based compensation that will be recognized in the year | $ $ 7,000,000

Stock-based compensation expenses expected to be recognized | $ $ 3,800,000

RSAs outstanding (in shares) 63,000 63,000

X

- Definition
Represents the number of common stock distributed as form of dividend for each common stock held by parent company associated with the separation from parent company on completion of spin-off.
+ References
No definition available.
+ Details

Name: thrx_CommonStockStockDividendRatio

Namespace Prefix: thrx_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the consecutive and overlapping offering period for the offering of share-based payment awards.
+ References
No definition available.
+ Details

Name: thrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod

Namespace Prefix: thrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum amount the employee may contribute of employee's eligible compensation.
+ References
No definition available.
+ Details

Name: thrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the maximum contribution to share-based payment awards, expressed as a percentage of the employee's eligible compensation.
+ References
No definition available.
+ Details

Name: thrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContributionAsPercentageOfEligibleCompensation

Namespace Prefix: thrx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the maximum number of shares an employee may purchase during any purchase period.
+ References
No definition available.
+ Details

Name: thrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesEmployeeMayPurchaseDuringPurchasePeriod

Namespace Prefix: thrx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of purchase periods having duration of six months each.
+ References
No definition available.
+ Details

Name: thrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods

Namespace Prefix: thrx_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the duration of each purchase period within each consecutive and overlapping purchase period for offering of share-based payment awards.
+ References
No definition available.
+ Details

Name: thrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod

Namespace Prefix: thrx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the total expense that will be recognized during the next twelve months arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees if sufficient performance conditions are met.
+ References
No definition available.
+ Details

Name: thrx_TotalShareBasedCompensationCostNextTwelveMonths

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the total expense that will be recognized during the year arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
No definition available.
+ Details

Name: thrx_TotalShareBasedCompensationToBeRecognized

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Purchase price of common stock expressed as a percentage of its fair value.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=thrx_EquityIncentivePlan2012Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=thrx_SpecialLongTermRetentionAwards2011Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: thrx_VestingCriteriaAxis=thrx_PerformanceContingentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Loss per Share (Tables)
9 Months Ended

Sep. 30, 2015

Net Loss per Share

Schedule of anti-dilutive securities

Three Months Ended September 30,

Nine Months Ended September 30,

(In thousands)

2015 (1)

2014

2015 (2)

2014

Outstanding options and awards granted under equity incentive plan and employee stock purchase plan

5,070

6,771

5,459

6,218

Unvested RSAs

1,489

1,782

1,738

1,782

Shares issuable upon conversion of convertible subordinated notes

12,904

12,100

12,904

12,100

19,463

20,653

20,101

20,100

(1)

Includes 4.0 million options, 0.3 million restricted stock units, and 0.8 million unvested RSAs retained by former employees who were transferred to Theravance Biopharma in connection with the Spin-Off during the three months ended September 30, 2015. Subsequent to the Spin-Off, stock-based compensation expense associated with the awards held by Theravance Biopharma employees granted prior to the Spin-Off is recognized by Theravance Biopharma.

(2)

Includes 4.2 million options, 0.4 million restricted stock units, and 1.0 million unvested RSAs retained by former employees who were transferred to Theravance Biopharma in connection with the Spin-Off during the nine months ended September 30, 2015. Subsequent to the Spin-Off, stock-based compensation expense associated with the awards held by Theravance Biopharma employees granted prior to the Spin-Off is recognized by Theravance Biopharma.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

Long-Term Debt (Tables)
9 Months Ended

Sep. 30, 2015

Long-Term Debt.

Schedule of long-term debt

(In thousands)

September 30,
2015

December 31,
2014

Convertible Subordinated Notes due 2023

$

255,109

$

255,109

Non-Recourse Notes Payable due 2029

488,976

470,527

Total Long-Term Debt

$

744,085

$

725,636

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(e),(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814

Income Taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Jun. 01, 2014

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Income Taxes

U.S. federal income tax gain on distribution of the assets $ 400,000

Income tax expenses $ 0 $ (278) $ 0 $ 0

X

- Definition
Federal income tax effect resulting from the gain on distribution of assets to another entity due to business separation.
+ References
No definition available.
+ Details

Name: thrx_FederalStatutoryTaxEffectOfGainLossOnDistributionOfAssetsBusinessSeparation

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 53 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Amortization of capitalized fees paid to a related party $ 3,455 $ 3,233 $ 10,367 $ 7,611

X

- Definition
Represents the amortization of capitalized fees paid to a related party.
+ References
No definition available.
+ Details

Name: thrx_AmortizationOfCapitalizedFeesPaidToRelatedParty

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Collaborative Arrangements
9 Months Ended

Sep. 30, 2015

Collaborative Arrangements

Collaborative Arrangements

3. Collaborative Arrangements

Net Revenue from Collaborative Arrangements

Net revenue from collaborative arrangements from continuing operations relates to our collaborative arrangement with GSK. Net revenue from other collaborative arrangements is reflected as discontinued operations in the condensed consolidated statements of operations. Refer to Notes 1 and 11, “Description of Operations and Summary of Significant Accounting Policies” and “Discontinued Operations” for further information.

Net revenue recognized under our GSK Agreements was as follows:

Three Months Ended September 30,

Nine Months Ended September 30,

(In thousands)

2015

2014

2015

2014

Royalties from a related party

$

16,796

$

3,962

$

40,816

$

7,953

Less: amortization of capitalized fees paid to a related party

(3,455
)

(3,233
)

(10,367
)

(7,611
)

Royalty revenue

13,341

729

30,449

342

Strategic alliance - MABA program

221

270

664

811

Total net revenue from GSK

$

13,562

$

999

$

31,113

$

1,153

LABA Collaboration

As a result of the launch and approval of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® in the U.S., Japan and Europe, in accordance with the GSK Agreements, we were obligated to pay milestone fees to GSK totaling $220.0 million, all of which was paid as of December 31, 2014. Although we have no further milestone payment obligations to GSK, we continue to have ongoing development and commercialization activities under the GSK Agreements that are expected to continue over the life of the agreements. The milestone fees paid to GSK were recognized as capitalized fees paid to a related party, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product.

We are entitled to receive annual royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion. Sales of single-agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO® ELLIPTA®, royalties are upward tiering and range from 6.5% to 10%.

Amortization expense resulting from the milestone fees paid to GSK, which are recognized as capitalized fees paid to a related party, is a non-cash reduction to royalty revenue. In periods when amortization expense exceeded amounts recognized for royalty revenue, negative revenue was reported in our condensed consolidated statements of operations.

Agreements Entered into with GSK in Connection with the Spin-Off

On March 3, 2014, in contemplation of the Spin-Off, we, Theravance Biopharma and GSK entered into a series of agreements, including amendments to the GSK Agreements, clarifying how the companies would implement the Spin-Off and operate following the Spin-Off. Pursuant to a three-way master agreement, by and among us, Theravance Biopharma and GSK, we agreed to sell a certain number of Theravance Biopharma shares withheld from a taxable dividend of Theravance Biopharma shares to GSK. After such Theravance Biopharma shares were sent to the transfer agent, we agreed to purchase the Theravance Biopharma shares from the transfer agent, rather than have them sold on the open market, in order to satisfy tax withholdings. GSK had a right to purchase these shares of Theravance Biopharma from us, but this right expired unexercised. During the nine months ended September 30, 2015, we sold all 436,802 ordinary shares of Theravance Biopharma that we held as of December 31, 2014. Refer to Note 4 “Available-for-Sale Securities and Fair Value Measurements” for further information.

GSK Contingent Payments and Revenue

The potential future contingent payments receivable related to the MABA program of $363.0 million are not deemed substantive milestones due to the fact that the achievement of the event underlying the payment predominantly relates to GSK’s performance of future development, manufacturing and commercialization activities for product candidates after licensing the program.

X

- References
No definition available.
+ Details

Name: thrx_CollaborationArrangementsDisclosureAbstract

Namespace Prefix: thrx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 808

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

Discontinued Operations (Tables)
9 Months Ended

Sep. 30, 2015

Discontinued Operations.

Schedule of discontinued operations presented on the condensed consolidated statements of operations

Nine Months Ended September 30,

(In thousands)

2015

2014

Net revenues (1)

$

—

$

3,129

Loss from discontinued operations (2)

—

(94,934
)

There was no impact of the discontinued operations after the Spin-Off to our revenues and expenses for the three months ended September 30, 2015 and 2014.

(1)

Net revenues primarily consist of revenue from collaborative arrangements and product sales. Revenue from collaborative arrangements was recognized from our agreement with R-Pharm CJSC, which was transferred to Theravance Biopharma as a part of the Spin-Off. Product sales were generated from sales of VIBATIV® in the U.S. through a limited number of distributors, and title and risk of loss transfer upon receipt by these distributors. VIBATIV® was transferred to Theravance Biopharma as part of the Spin-Off. Healthcare providers ordered VIBATIV® through these distributors. Commencing in the first quarter of 2014, revenue on the sale of VIBATIV® was recorded on a sell-through basis, once the distributors sold the product to healthcare providers. Product sales were recorded net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns and other deductions.

(2)

Included in the loss from discontinued operations for the three and nine months ended September 30, 2014 are reimbursements of research and development costs from our former collaborative arrangements, excluding GSK, which we accounted for as reductions to research and development expense. Reimbursement of research and development costs from discontinued operations from our collaborative arrangements was zero and $0.1 million for the three and nine months ended September 30, 2014. In addition, the loss from discontinued operations includes the additional stock-based compensation and cash bonus expense recognized due to the achievement of performance conditions under a special long-term retention and incentive equity and cash bonus awarded to certain employees in 2011. Refer to Note 6 “Stock-Based Compensation” and Note 9 “Commitment and Contingencies” for further information.

X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3A

-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5C

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 4A

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5B

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3A

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5A

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5D

-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

+ Details

Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 217 229 1 true 53 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.theravance.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.theravance.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.theravance.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.theravance.com/role/StatementCondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://www.theravance.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.theravance.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 6 false false R7.htm 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.theravance.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 10101 - Disclosure - Description of Operations and Summary of Significant Accounting Policies Sheet http://www.theravance.com/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies Description of Operations and Summary of Significant Accounting Policies Notes 8 false false R9.htm 10201 - Disclosure - Net Loss per Share Sheet http://www.theravance.com/role/DisclosureNetLossPerShare Net Loss per Share Notes 9 false false R10.htm 10301 - Disclosure - Collaborative Arrangements Sheet http://www.theravance.com/role/DisclosureCollaborativeArrangements Collaborative Arrangements Notes 10 false false R11.htm 10401 - Disclosure - Available-for-Sale Securities and Fair Value Measurements Sheet http://www.theravance.com/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurements Available-for-Sale Securities and Fair Value Measurements Notes 11 false false R12.htm 10501 - Disclosure - Capitalized Fees Paid to a Related Party Sheet http://www.theravance.com/role/DisclosureCapitalizedFeesPaidToRelatedParty Capitalized Fees Paid to a Related Party Notes 12 false false R13.htm 10601 - Disclosure - Stock-Based Compensation Sheet http://www.theravance.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 10701 - Disclosure - Long-Term Debt Sheet http://www.theravance.com/role/DisclosureLongTermDebt Long-Term Debt Notes 14 false false R15.htm 10801 - Disclosure - Shareholders' Deficit Sheet http://www.theravance.com/role/DisclosureShareholdersDeficit Shareholders' Deficit Notes 15 false false R16.htm 10901 - Disclosure - Commitments and Contingencies Sheet http://www.theravance.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 11001 - Disclosure - Income Taxes Sheet http://www.theravance.com/role/DisclosureIncomeTaxes Income Taxes Notes 17 false false R18.htm 11101 - Disclosure - Discontinued Operations Sheet http://www.theravance.com/role/DisclosureDiscontinuedOperations Discontinued Operations Notes 18 false false R19.htm 11201 - Disclosure - Subsequent Events Sheet http://www.theravance.com/role/DisclosureSubsequentEvents Subsequent Events Notes 19 false false R20.htm 20102 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Policies) Sheet http://www.theravance.com/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies Description of Operations and Summary of Significant Accounting Policies (Policies) Policies http://www.theravance.com/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies 20 false false R21.htm 30203 - Disclosure - Net Loss per Share (Tables) Sheet http://www.theravance.com/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.theravance.com/role/DisclosureNetLossPerShare 21 false false R22.htm 30303 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.theravance.com/role/DisclosureCollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.theravance.com/role/DisclosureCollaborativeArrangements 22 false false R23.htm 30403 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Tables) Sheet http://www.theravance.com/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsTables Available-for-Sale Securities and Fair Value Measurements (Tables) Tables http://www.theravance.com/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurements 23 false false R24.htm 30503 - Disclosure - Capitalized Fees Paid to a Related Party (Tables) Sheet http://www.theravance.com/role/DisclosureCapitalizedFeesPaidToRelatedPartyTables Capitalized Fees Paid to a Related Party (Tables) Tables http://www.theravance.com/role/DisclosureCapitalizedFeesPaidToRelatedParty 24 false false R25.htm 30603 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.theravance.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.theravance.com/role/DisclosureStockBasedCompensation 25 false false R26.htm 30703 - Disclosure - Long-Term Debt (Tables) Sheet http://www.theravance.com/role/DisclosureLongTermDebtTables Long-Term Debt (Tables) Tables http://www.theravance.com/role/DisclosureLongTermDebt 26 false false R27.htm 31103 - Disclosure - Discontinued Operations (Tables) Sheet http://www.theravance.com/role/DisclosureDiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.theravance.com/role/DisclosureDiscontinuedOperations 27 false false R28.htm 40101 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Details) Sheet http://www.theravance.com/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails Description of Operations and Summary of Significant Accounting Policies (Details) Details http://www.theravance.com/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies 28 false false R29.htm 40201 - Disclosure - Net Loss per Share (Details) Sheet http://www.theravance.com/role/DisclosureNetLossPerShareDetails Net Loss per Share (Details) Details http://www.theravance.com/role/DisclosureNetLossPerShareTables 29 false false R30.htm 40301 - Disclosure - Collaborative Arrangements (Details) Sheet http://www.theravance.com/role/DisclosureCollaborativeArrangementsDetails Collaborative Arrangements (Details) Details http://www.theravance.com/role/DisclosureCollaborativeArrangementsTables 30 false false R31.htm 40401 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Details) Sheet http://www.theravance.com/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsDetails Available-for-Sale Securities and Fair Value Measurements (Details) Details http://www.theravance.com/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsTables 31 false false R32.htm 40402 - Disclosure - Available-for-Sale Securities and Fair Value Measurements (Details 2) Sheet http://www.theravance.com/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsDetails2 Available-for-Sale Securities and Fair Value Measurements (Details 2) Details http://www.theravance.com/role/DisclosureAvailableForSaleSecuritiesAndFairValueMeasurementsTables 32 false false R33.htm 40501 - Disclosure - Capitalized Fees Paid to a Related Party (Details) Sheet http://www.theravance.com/role/DisclosureCapitalizedFeesPaidToRelatedPartyDetails Capitalized Fees Paid to a Related Party (Details) Details http://www.theravance.com/role/DisclosureCapitalizedFeesPaidToRelatedPartyTables 33 false false R34.htm 40601 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.theravance.com/role/DisclosureStockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.theravance.com/role/DisclosureStockBasedCompensationTables 34 false false R35.htm 40602 - Disclosure - Stock-Based Compensation (Details 2) Sheet http://www.theravance.com/role/DisclosureStockBasedCompensationDetails2 Stock-Based Compensation (Details 2) Details http://www.theravance.com/role/DisclosureStockBasedCompensationTables 35 false false R36.htm 40603 - Disclosure - Stock-Based Compensation (Details 3) Sheet http://www.theravance.com/role/DisclosureStockBasedCompensationDetails3 Stock-Based Compensation (Details 3) Details http://www.theravance.com/role/DisclosureStockBasedCompensationTables 36 false false R37.htm 40701 - Disclosure - Long-Term Debt (Details) Sheet http://www.theravance.com/role/DisclosureLongTermDebtDetails Long-Term Debt (Details) Details http://www.theravance.com/role/DisclosureLongTermDebtTables 37 false false R38.htm 40801 - Disclosure - Shareholders' Deficit (Details) Sheet http://www.theravance.com/role/DisclosureShareholdersDeficitDetails Shareholders' Deficit (Details) Details http://www.theravance.com/role/DisclosureShareholdersDeficit 38 false false R39.htm 40901 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.theravance.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.theravance.com/role/DisclosureCommitmentsAndContingencies 39 false false R40.htm 40902 - Disclosure - Commitments and Contingencies (Details 2) Sheet http://www.theravance.com/role/DisclosureCommitmentsAndContingenciesDetails2 Commitments and Contingencies (Details 2) Details http://www.theravance.com/role/DisclosureCommitmentsAndContingencies 40 false false R41.htm 41001 - Disclosure - Income Taxes (Details) Sheet http://www.theravance.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://www.theravance.com/role/DisclosureIncomeTaxes 41 false false R42.htm 41101 - Disclosure - Discontinued Operations (Details) Sheet http://www.theravance.com/role/DisclosureDiscontinuedOperationsDetails Discontinued Operations (Details) Details http://www.theravance.com/role/DisclosureDiscontinuedOperationsTables 42 false false R43.htm 41201 - Disclosure - Subsequent Events (Details) Sheet http://www.theravance.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.theravance.com/role/DisclosureSubsequentEvents 43 false false All Reports Book All Reports In ''CONDENSED CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS'', column(s) 1, 2, 3 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. thrx-20150930.xml thrx-20150930_cal.xml thrx-20150930_def.xml thrx-20150930_lab.xml thrx-20150930_pre.xml thrx-20150930.xsd true true XML 57 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814

Shareholders' Deficit (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 9 Months Ended

Jul. 24, 2015

Apr. 24, 2015

Feb. 20, 2015

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dividends

Cash dividends declared per common share (in dollars per share) $ 0.25 $ 0.25 $ 0.25 $ 0.25 $ 0.25 $ 0.75 $ 0.25

Dividends paid $ 29.1 $ 87.1

Common Stock

Shareholders' Deficit

Awards exercised (in shares) 111,156 1,127,000

Weighted-average exercise price of awards exercised (in dollars per share) $ 13.75 $ 14.09

Total cash proceeds $ 1.5 $ 15.9

Governance agreement | GSK | Common Stock

Shareholders' Deficit

Common stock purchased (in shares) 424,081

Aggregate purchase price of common stock $ 6.5

X

- Definition
Number of shares issued during the period as a result of private placement to a related party.
+ References
No definition available.
+ Details

Name: thrx_StockIssuedDuringPeriodSharesPrivatePlacementToRelatedParty

Namespace Prefix: thrx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value stock issued during the period as a result of private placement to a related party, net of issuance cost.
+ References
No definition available.
+ Details

Name: thrx_StockIssuedDuringPeriodValuePrivatePlacementToRelatedParty

Namespace Prefix: thrx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate dividends declared during the period for each share of common stock outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_CommonStockDividendsPerShareDeclared

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DividendsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_DividendsCommonStockCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SubsidiarySaleOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=thrx_GovernanceAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=thrx_GSKMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Description of Operations and Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2015

Description of Operations and Summary of Significant Accounting Policies

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In our opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive loss and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2015 or any other period.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (“SEC”) on February 27, 2015.

Business Separation

Business Separation

On June 1, 2014, we separated our biopharmaceutical research and drug development operations from our late-stage partnered respiratory assets by transferring our research and drug development operations into our then wholly-owned subsidiary, Theravance Biopharma, Inc. (“Theravance Biopharma”). We contributed $393.0 million of cash, cash equivalents and marketable securities to Theravance Biopharma and all outstanding shares of Theravance Biopharma were then distributed to Theravance stockholders as a pro-rata dividend distribution on June 2, 2014 by issuing one ordinary share of Theravance Biopharma for every 3.5 shares of our common stock to stockholders of record on May 15, 2014 (the “Spin-Off”). The Spin-Off resulted in Theravance Biopharma becoming an independent, publicly traded company.

The results of operations for the former research and drug development operations conducted by us and by Theravance Biopharma until June 1, 2014 are included as part of this report as discontinued operations for the three and nine months ended September 30, 2014. Refer to Note 11 “Discontinued Operations” for further information.

Variable Interest Entities

Variable Interest Entities

We evaluate our ownership, contractual and other interest in entities to determine if they are variable interest entities (“VIE”), whether we have a variable interest in those entities and the nature and extent of those interests. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. We consolidate the financial results of TRC, which we have determined to be a VIE, because we have the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. The financial position and results of operations of TRC are not material for the periods presented.

Recently Issued Accounting Pronouncements Not Yet Adopted

Recently Issued Accounting Pronouncements Not Yet Adopted

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), requiring an entity to recognize the amount of revenue to which it expects to be entitled to in exchange for the transfer of promised goods or services to customers. The new standard will replace nearly all existing revenue recognition guidance under GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date by one year. Thus, the new standard will be effective for us beginning January 1, 2018, at which time we may adopt the new standard under either the full retrospective method or the modified retrospective method. Early adoption on or after January 1, 2017 would be permitted. We are currently evaluating the effect that the new standard will have on our consolidated financial statements and related disclosures.

In April 2015, the FASB issued ASU 2015-03, Interest — Imputation of Interest, to simplify the presentation of debt issuance costs. This standard amends existing guidance to require the presentation of debt issuance costs associated with term loans in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It will be effective for us on January 1, 2016, with early adoption permitted. We plan to adopt ASU 2015-03 on January 1, 2016. Upon adoption of ASU 2015-03, we will apply the guidance retrospectively to all periods presented and classify our debt issuance costs, which are currently included in other assets in the condensed consolidated financial statements, as a deduction to our long-term debt.

X

- Definition
Disclosure of accounting policy for business separation.
+ References
No definition available.
+ Details

Name: thrx_BusinessSeparationPolicyPolicyTextBlock

Namespace Prefix: thrx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 5A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6759159-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 4

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=52262685&loc=d3e5728-111685

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 2AA

-Subparagraph a

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6759068-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 2A

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6225816-111685

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_ConsolidationVariableInterestEntityPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Discontinued Operations (Details) - USD ($) $ in Thousands	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Components of research and drug development operations presented on the condensed consolidated statements of operations
Net revenues		$ 0	$ 3,129
Loss from discontinued operations		$ 0	(94,934)
Discontinued Operations
Components of research and drug development operations presented on the condensed consolidated statements of operations
Reimbursement of certain research and development costs to the entity	$ 0		$ 100

Subsequent Events (Details) - Subsequent Events - USD ($) $ / shares in Units, $ in Millions	Oct. 30, 2015	Oct. 28, 2015
$150 million share repurchase program
Subsequent Event
Amount approved under share repurchase program		$ 150
Tender offer
Subsequent Event
Amount approved under share repurchase program	$ 75
Tender offer \| Minimum
Subsequent Event
Price per share under share repurchase program	$ 8.50
Tender offer \| Maximum
Subsequent Event
Price per share under share repurchase program	$ 9.25

Net Loss per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
Net Loss per Share (Details) - shares shares in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Anti-dilutive securities
Anti-dilutive securities (in shares)	19,463	20,653	20,101	20,100
Stock options
Anti-dilutive securities
Anti-dilutive securities (in shares)	4,000		4,200
RSUs
Anti-dilutive securities
Anti-dilutive securities (in shares)	300		400
Unvested RSAs
Anti-dilutive securities
Anti-dilutive securities (in shares)	800		1,000
Outstanding options and awards granted under equity incentive plan and ESPP
Anti-dilutive securities
Anti-dilutive securities (in shares)	5,070	6,771	5,459	6,218
Unvested RSAs
Anti-dilutive securities
Anti-dilutive securities (in shares)	1,489	1,782	1,738	1,782
Shares issuable upon conversion of convertible subordinated notes
Anti-dilutive securities
Anti-dilutive securities (in shares)	12,904	12,100	12,904	12,100

Description of Operations and Summary of Significant Accounting Policies (Details) $ in Millions			9 Months Ended
	Jun. 02, 2014	Jun. 01, 2014 USD ($)	Sep. 30, 2015
Business Separation
Cash, cash equivalents and marketable securities contributed to Theravance Biopharma		$ 393.0
Number of ordinary shares of Theravance Biopharma issued for every share of Theravance	0.286
GSK \| LABA collaboration and Strategic Alliance agreements
Description of Operations and Summary of Significant Accounting Policies
Percentage of economic interest in any future payments made under the agreements			15.00%

Available-for-Sale Securities and Fair Value Measurements (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Available-for-sale securities
Amortized Cost	$ 203,512		$ 285,483
Gross Unrealized Gains	15		35
Gross Unrealized Losses	(4)		(122)
Other Than Temporary Impairment Loss			(3,752)
Estimated Fair Value	$ 203,523		281,644
Maturity period for marketable securities
Maximum contractual maturity period	1 year
Average contractual maturity period	3 months
Proceeds from sale of available-for-sale securities	$ 57,098	$ 5,000
Theravance Biopharma
Maturity period for marketable securities
Gain on sale	1,200
Issuer of available-for-securities other than Theravance Biopharma
Maturity period for marketable securities
Proceeds from sale of available-for-sale securities	49,400
Cash and cash equivalents
Available-for-sale securities
Estimated Fair Value	76,077		95,090
Short-term marketable securities
Available-for-sale securities
Estimated Fair Value	127,446		143,698
Marketable securities
Available-for-sale securities
Estimated Fair Value	0		42,856
U.S. government securities
Available-for-sale securities
Amortized Cost	7,503		30,019
Gross Unrealized Gains	3		24
Gross Unrealized Losses	0		0
Other Than Temporary Impairment Loss			0
Estimated Fair Value	7,506		30,043
U.S. government agencies
Available-for-sale securities
Amortized Cost	69,965		34,756
Gross Unrealized Gains	9		6
Gross Unrealized Losses	(2)		(12)
Other Than Temporary Impairment Loss			0
Estimated Fair Value	69,972		34,750
Corporate notes
Available-for-sale securities
Amortized Cost	27,485		80,880
Gross Unrealized Gains	3		5
Gross Unrealized Losses	(2)		(110)
Other Than Temporary Impairment Loss			0
Estimated Fair Value	27,486		80,775
Commercial paper
Available-for-sale securities
Amortized Cost	54,702		34,469
Gross Unrealized Gains	0		0
Gross Unrealized Losses	0		0
Other Than Temporary Impairment Loss			0
Estimated Fair Value	54,702		34,469
Ordinary shares of Theravance Biopharma
Available-for-sale securities
Amortized Cost			10,269
Gross Unrealized Gains			0
Gross Unrealized Losses			0
Other Than Temporary Impairment Loss			(3,752)
Estimated Fair Value			6,517
Money market funds
Available-for-sale securities
Amortized Cost	43,857		95,090
Gross Unrealized Gains	0		0
Gross Unrealized Losses	0		0
Other Than Temporary Impairment Loss			0
Estimated Fair Value	$ 43,857		$ 95,090

Description of Operations and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Description of Operations and Summary of Significant Accounting Policies
Description of Operations and Summary of Significant Accounting Policies	1. Description of Operations and Summary of Significant Accounting Policies Description of Operations Theravance, Inc. (“Theravance”, the “Company”, or “we” and other similar pronouns) is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Theravance’s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Theravance and GSK. Under the Long-Acting Beta 2 Agonist (“LABA”) Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the “GSK Agreements”), Theravance is eligible to receive the associated royalty revenues from RELVAR ® /BREO ® ELLIPTA ® , ANORO® ELLIPTA ® and if approved and commercialized, VI monotherapy. Theravance is also entitled to 15% of any future payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (“TRC”), relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta 2 Agonist (“MABA”) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement (“LABA Collaboration”), which has been assigned to TRC other than RELVAR ®/BREO ® ELLIPTA ® , ANORO® ELLIPTA ® and VI monotherapy. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In our opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive loss and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2015 or any other period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (“SEC”) on February 27, 2015. Business Separation On June 1, 2014, we separated our biopharmaceutical research and drug development operations from our late-stage partnered respiratory assets by transferring our research and drug development operations into our then wholly-owned subsidiary, Theravance Biopharma, Inc. (“Theravance Biopharma”). We contributed $393.0 million of cash, cash equivalents and marketable securities to Theravance Biopharma and all outstanding shares of Theravance Biopharma were then distributed to Theravance stockholders as a pro-rata dividend distribution on June 2, 2014 by issuing one ordinary share of Theravance Biopharma for every 3.5 shares of our common stock to stockholders of record on May 15, 2014 (the “Spin-Off”). The Spin-Off resulted in Theravance Biopharma becoming an independent, publicly traded company. The results of operations for the former research and drug development operations conducted by us and by Theravance Biopharma until June 1, 2014 are included as part of this report as discontinued operations for the three and nine months ended September 30, 2014. Refer to Note 11 “Discontinued Operations” for further information. Variable Interest Entities We evaluate our ownership, contractual and other interest in entities to determine if they are variable interest entities (“VIE”), whether we have a variable interest in those entities and the nature and extent of those interests. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. We consolidate the financial results of TRC, which we have determined to be a VIE, because we have the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. The financial position and results of operations of TRC are not material for the periods presented. Recently Issued Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), requiring an entity to recognize the amount of revenue to which it expects to be entitled to in exchange for the transfer of promised goods or services to customers. The new standard will replace nearly all existing revenue recognition guidance under GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date by one year. Thus, the new standard will be effective for us beginning January 1, 2018, at which time we may adopt the new standard under either the full retrospective method or the modified retrospective method. Early adoption on or after January 1, 2017 would be permitted. We are currently evaluating the effect that the new standard will have on our consolidated financial statements and related disclosures. In April 2015, the FASB issued ASU 2015-03, Interest — Imputation of Interest, to simplify the presentation of debt issuance costs. This standard amends existing guidance to require the presentation of debt issuance costs associated with term loans in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It will be effective for us on January 1, 2016, with early adoption permitted. We plan to adopt ASU 2015-03 on January 1, 2016. Upon adoption of ASU 2015-03, we will apply the guidance retrospectively to all periods presented and classify our debt issuance costs, which are currently included in other assets in the condensed consolidated financial statements, as a deduction to our long-term debt.

Available-for-Sale Securities and Fair Value Measurements (Details 2) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	$ 203,523	$ 281,644
U.S. government securities
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	7,506	30,043
U.S. government agencies
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	69,972	34,750
Corporate notes
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	27,486	80,775
Commercial paper
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	54,702	34,469
Ordinary shares of Theravance Biopharma
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value		6,517
Money market funds
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	43,857	95,090
Recurring basis
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	203,523	281,644
Recurring basis \| U.S. government securities
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	7,506	30,043
Recurring basis \| U.S. government agencies
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	69,972	34,750
Recurring basis \| Corporate notes
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	27,486	80,775
Recurring basis \| Commercial paper
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	54,702	34,469
Recurring basis \| Ordinary shares of Theravance Biopharma
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value		6,517
Recurring basis \| Money market funds
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	43,857	95,090
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	51,363	131,650
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| U.S. government securities
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	7,506	30,043
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| U.S. government agencies
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| Corporate notes
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| Commercial paper
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| Ordinary shares of Theravance Biopharma
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value		6,517
Recurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| Money market funds
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	43,857	95,090
Recurring basis \| Significant Other Observable Inputs, Level 2
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	152,160	149,994
Recurring basis \| Significant Other Observable Inputs, Level 2 \| U.S. government securities
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Other Observable Inputs, Level 2 \| U.S. government agencies
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	69,972	34,750
Recurring basis \| Significant Other Observable Inputs, Level 2 \| Corporate notes
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	27,486	80,775
Recurring basis \| Significant Other Observable Inputs, Level 2 \| Commercial paper
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	54,702	34,469
Recurring basis \| Significant Other Observable Inputs, Level 2 \| Ordinary shares of Theravance Biopharma
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value		0
Recurring basis \| Significant Other Observable Inputs, Level 2 \| Money market funds
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Unobservable Inputs, Level 3
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Unobservable Inputs, Level 3 \| U.S. government securities
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Unobservable Inputs, Level 3 \| U.S. government agencies
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Unobservable Inputs, Level 3 \| Corporate notes
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Unobservable Inputs, Level 3 \| Commercial paper
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Recurring basis \| Significant Unobservable Inputs, Level 3 \| Ordinary shares of Theravance Biopharma
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value		0
Recurring basis \| Significant Unobservable Inputs, Level 3 \| Money market funds
Estimated fair values of entity's financial assets and liabilities
Total assets measured at fair value	0	0
Nonrecurring basis
Estimated fair values of entity's financial assets and liabilities
Total fair value of liabilities	633,889	653,506
Nonrecurring basis \| Convertible subordinated notes due 2023
Estimated fair values of entity's financial assets and liabilities
Convertible subordinated notes due 2023	169,362	197,095
Nonrecurring basis \| Non-recourse notes payable due 2029
Estimated fair values of entity's financial assets and liabilities
Non-recourse notes due 2029	464,527	456,411
Nonrecurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1
Estimated fair values of entity's financial assets and liabilities
Total fair value of liabilities	0	0
Nonrecurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| Convertible subordinated notes due 2023
Estimated fair values of entity's financial assets and liabilities
Convertible subordinated notes due 2023	0	0
Nonrecurring basis \| Quoted Prices in Active Markets for Identical Assets, Level 1 \| Non-recourse notes payable due 2029
Estimated fair values of entity's financial assets and liabilities
Non-recourse notes due 2029	0	0
Nonrecurring basis \| Significant Other Observable Inputs, Level 2
Estimated fair values of entity's financial assets and liabilities
Total fair value of liabilities	633,889	653,506
Nonrecurring basis \| Significant Other Observable Inputs, Level 2 \| Convertible subordinated notes due 2023
Estimated fair values of entity's financial assets and liabilities
Convertible subordinated notes due 2023	169,362	197,095
Nonrecurring basis \| Significant Other Observable Inputs, Level 2 \| Non-recourse notes payable due 2029
Estimated fair values of entity's financial assets and liabilities
Non-recourse notes due 2029	464,527	456,411
Nonrecurring basis \| Significant Unobservable Inputs, Level 3
Estimated fair values of entity's financial assets and liabilities
Total fair value of liabilities	0	0
Nonrecurring basis \| Significant Unobservable Inputs, Level 3 \| Convertible subordinated notes due 2023
Estimated fair values of entity's financial assets and liabilities
Convertible subordinated notes due 2023	0	0
Nonrecurring basis \| Significant Unobservable Inputs, Level 3 \| Non-recourse notes payable due 2029
Estimated fair values of entity's financial assets and liabilities
Non-recourse notes due 2029	$ 0	$ 0

Commitments and Contingencies (Details 2) - Special Long-Term Retention and Incentive Cash Awards Program - USD ($) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	May. 31, 2014	Mar. 31, 2014	Dec. 31, 2011
Special Long-Term Retention and Incentive Cash Awards Program
Timeframe for achievement of performance conditions			6 years
Cash bonus expense recognized		$ 9.1
Total cash bonus paid	$ 9.5
Remaining potential cash bonus expense associated with these cash bonus awards after the modification	$ 0.5

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	230,000	230,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	117,575,000	116,445,000
Treasury stock held	150,000	150,000

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2015
Income Taxes
Income Taxes	10. Income Taxes We did not record a provision for income taxes for the three and nine months ended September 30, 2015. The deferred tax assets remain fully offset by a valuation allowance or uncertain tax position liabilities. As a part of the overall Spin-Off transaction on June 1, 2014, certain assets that were transferred by us to Theravance Biopharma resulted in taxable transfers pursuant to Section 367 of the Internal Revenue Code of 1986, as amended (the “Code”), or other applicable provisions of the Code and Treasury Regulations. The taxable gain attributable to the transfer of the certain assets to Theravance Biopharma was the excess of the fair market value of each asset transferred over our adjusted tax basis in such asset. The U.S. federal income tax gain on transfer of the assets to Theravance Biopharma was approximately $400 million. This taxable income was substantially offset by our net operating loss from 2014 and carryforwards from prior years resulting in a net impact of zero to income tax expenses during the nine months ended September 30, 2014.

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Oct. 30, 2015
Document and Entity Information
Entity Registrant Name	THERAVANCE INC
Entity Central Index Key	0001080014
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		117,425,815
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2015
Subsequent Events
Subsequent Events	12. Subsequent Events On October 28, 2015, we announced the acceleration of our capital return plan with a $150 million share repurchase program effective through the end of 2016 approved by our Board of Directors, replacing our quarterly dividend. As a component of the share repurchase plan, on October 30, 2015, we commenced a “modified Dutch auction” tender offer to purchase up to $75 million of our common stock, at a price per share of not less than $8.50 and not greater than $9.25, which will be contingent upon satisfaction of customary conditions.

Shareholders' Deficit	9 Months Ended
Shareholders' Deficit	Sep. 30, 2015
Shareholders' Deficit
Shareholders' Deficit	8. Shareholders’ Deficit For the nine months ended September 30, 2015, options to purchase 111,156 shares of our common stock were exercised at a weighted-average exercise price of $13.75 per share, for total cash proceeds of approximately $1.5 million. For the nine months ended September 30, 2014, options to purchase 1,127,000 shares of our common stock were exercised at a weighted-average exercise price of $14.09 per share, for total cash proceeds of approximately $15.9 million. During the nine months ended September 30, 2015, GSK purchased 424,081 shares of our common stock pursuant to its periodic “top-up” rights under our Amended and Restated Governance Agreement, dated as of June 4, 2004, as amended, among us, GSK and certain GSK affiliates (the “Governance Agreement”), for an aggregate purchase price of approximately $6.5 million. GSK’s periodic “top-up” rights terminated with the expiration of the Governance Agreement in September 2015. On February 20, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on March 12, 2015. This dividend was paid on March 31, 2015. On April 24, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on June 12, 2015. This dividend was paid on June 30, 2015. On July 24, 2015, our Board of Directors declared a quarterly dividend of $0.25 per share of common stock to stockholders of record as of the close of business on September 10, 2015. This dividend was paid to our stockholders on September 30, 2015. During the three and nine months ended September 30, 2015, we paid an aggregate of $29.1 million and $87.1 million in dividends, respectively. Unvested RSAs and certain unvested RSUs as of the record date are also entitled to dividends, which will only be paid when the RSAs and such RSUs vest and are released. For further information on the impact of the cash dividend payments on the 2023 Notes, refer to Note 7, “Long-Term Debt”.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2015
Commitments and Contingencies
Commitments and Contingencies	9. Commitments and Contingencies Lease Guarantee Upon the Spin-Off, our facility leases in South San Francisco, California were assigned to Theravance Biopharma. However, if Theravance Biopharma were to default on its lease obligations, we would be held liable by the landlord and thus, we have in substance guaranteed the lease payments for these facilities. We would also be responsible for lease-related payments including utilities, property taxes, and common area maintenance, which may be as much as the actual lease payments. As of September 30, 2015, the total remaining lease payments, which run through May 2020, were $29.1 million. The carrying value of this lease guarantee was $1.3 million as of September 30, 2015 and is reflected in other long-term liabilities in our condensed consolidated balance sheet. Special Long-Term Retention and Incentive Cash Awards Program In 2011, we granted special long-term retention and incentive cash bonus awards to certain employees. The awards have dual triggers of vesting based upon the achievement of certain performance conditions over a six-year timeframe from 2011 through December 31, 2016 and continued employment. As of March 31, 2014, we determined that the achievement of the requisite performance conditions for the first tranche of these awards was probable and, as a result, $9.1 million of cash bonus expense was recognized for the three months ended March 31, 2014, the majority of which is included in discontinued operations in the condensed consolidated statements of operations. In May 2014, the total cash bonus of $9.5 million for the first tranche was paid. In connection with the Spin-Off, the Compensation Committee approved the modification of the remaining tranches related to these awards as the performance conditions associated with the remaining portions of these awards were unlikely to be consistent with the new strategies of each company following the Spin-Off. The modification acknowledged the Spin-Off and permitted recognition of achievement of certain of the original performance conditions that were met prior to the Spin-Off, triggering service-based vesting for a portion of the cash awards. The amount due by us under these modified cash bonus awards of $0.5 million was fully paid in June 2015. The remaining tranches of the cash awards were forfeited.

Stock-Based Compensation (Details)		1 Months Ended	3 Months Ended		5 Months Ended	9 Months Ended		12 Months Ended
Stock-Based Compensation (Details)	Jun. 02, 2014	Jun. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) shares	Sep. 30, 2014 USD ($)	May. 31, 2014 USD ($)	Sep. 30, 2015 USD ($) item shares	Sep. 30, 2014 USD ($)	Dec. 31, 2011 shares
Stock-based compensation
Stock-based compensation expense \| $			$ 1,468,000	$ 4,732,000		$ 5,223,000	$ 26,013,000
Number of shares of Theravance Biopharma issued for every share of Theravance	0.286
Employee Stock Purchase Plan
Stock-based compensation
Purchase price as a percentage of fair market value of stock						85.00%
Consecutive and overlapping offering periods						24 months
Number of offering periods \| item						4
Duration of purchase period						6 months
Maximum contributions as a percentage of employee's eligible compensation						15.00%
Maximum number of shares an employee may purchase during any purchase period						2,500
Maximum value of shares an employee may purchase \| $						$ 25,000
Shares remaining available for issuance			278,971			278,971
2012 Equity Incentive Plan
Stock-based compensation
Shares remaining available for issuance			3,200,521			3,200,521
Special Long-Term Retention and Incentive Awards Program \| Unvested RSAs \| Performance-contingent
Stock-based compensation
Shares of common stock approved and authorized for issuance								1,290,000
Timeframe for achievement of performance conditions								6 years
Total stock-based compensation that will be recognized in the year \| $					$ 7,000,000
Stock-based compensation expenses expected to be recognized \| $		$ 3,800,000
RSAs outstanding (in shares)			63,000			63,000

Income Taxes (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 01, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Taxes
U.S. federal income tax gain on distribution of the assets	$ 400,000
Income tax expenses		$ 0	$ (278)	$ 0	$ 0

Shareholders' Deficit (Details) - USD ($) $ / shares in Units, $ in Millions				3 Months Ended		9 Months Ended
	Jul. 24, 2015	Apr. 24, 2015	Feb. 20, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Dividends
Cash dividends declared per common share (in dollars per share)	$ 0.25	$ 0.25	$ 0.25	$ 0.25	$ 0.25	$ 0.75	$ 0.25
Dividends paid				$ 29.1		$ 87.1
Common Stock
Shareholders' Deficit
Awards exercised (in shares)						111,156	1,127,000
Weighted-average exercise price of awards exercised (in dollars per share)						$ 13.75	$ 14.09
Total cash proceeds						$ 1.5	$ 15.9
Governance agreement \| GSK \| Common Stock
Shareholders' Deficit
Common stock purchased (in shares)						424,081
Aggregate purchase price of common stock						$ 6.5

Description of Operations and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Description of Operations and Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In our opinion, the unaudited condensed consolidated financial statements have been prepared on the same basis as audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of our financial position, results of operations, comprehensive loss and cash flows. The interim results are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2015 or any other period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (“SEC”) on February 27, 2015.
Business Separation	Business Separation On June 1, 2014, we separated our biopharmaceutical research and drug development operations from our late-stage partnered respiratory assets by transferring our research and drug development operations into our then wholly-owned subsidiary, Theravance Biopharma, Inc. (“Theravance Biopharma”). We contributed $393.0 million of cash, cash equivalents and marketable securities to Theravance Biopharma and all outstanding shares of Theravance Biopharma were then distributed to Theravance stockholders as a pro-rata dividend distribution on June 2, 2014 by issuing one ordinary share of Theravance Biopharma for every 3.5 shares of our common stock to stockholders of record on May 15, 2014 (the “Spin-Off”). The Spin-Off resulted in Theravance Biopharma becoming an independent, publicly traded company. The results of operations for the former research and drug development operations conducted by us and by Theravance Biopharma until June 1, 2014 are included as part of this report as discontinued operations for the three and nine months ended September 30, 2014. Refer to Note 11 “Discontinued Operations” for further information.
Variable Interest Entities	Variable Interest Entities We evaluate our ownership, contractual and other interest in entities to determine if they are variable interest entities (“VIE”), whether we have a variable interest in those entities and the nature and extent of those interests. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. We consolidate the financial results of TRC, which we have determined to be a VIE, because we have the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. The financial position and results of operations of TRC are not material for the periods presented.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), requiring an entity to recognize the amount of revenue to which it expects to be entitled to in exchange for the transfer of promised goods or services to customers. The new standard will replace nearly all existing revenue recognition guidance under GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date by one year. Thus, the new standard will be effective for us beginning January 1, 2018, at which time we may adopt the new standard under either the full retrospective method or the modified retrospective method. Early adoption on or after January 1, 2017 would be permitted. We are currently evaluating the effect that the new standard will have on our consolidated financial statements and related disclosures. In April 2015, the FASB issued ASU 2015-03, Interest — Imputation of Interest, to simplify the presentation of debt issuance costs. This standard amends existing guidance to require the presentation of debt issuance costs associated with term loans in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It will be effective for us on January 1, 2016, with early adoption permitted. We plan to adopt ASU 2015-03 on January 1, 2016. Upon adoption of ASU 2015-03, we will apply the guidance retrospectively to all periods presented and classify our debt issuance costs, which are currently included in other assets in the condensed consolidated financial statements, as a deduction to our long-term debt.